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ABST‘ACT  
This thesis describes the development and evaluation of a self-monitoring and patient-
initiated follow-up service for people with rheumatoid arthritis (RA) or psoriatic 
arthritis (PsA) on methotrexate. Using a mixed methods approach including a 
randomised controlled trial (RCT) and qualitative semi-structured interviews.  
 
The overall aims of this thesis were to design an alternative model of care which could 
be delivered in rheumatology outpatients by clinical nurse specialists (CNS) in order to 
reduce the burden of established patients in clinic. This is followed by an evaluation of 
intervention effectiveness and safety, along with an exploration of the mechanisms of 
action and patient acceptability.  
 
One hundred patients from University College Hospital London (UCLH) with either RA 
or PsA on methotrexate were recruited into the trial and were followed for six 
consecutive blood tests. Patients randomised to the intervention group were required 
to monitor their symptoms, side effects and laboratory results and use this information 
to initiate care from the CNS. The results indicated that patients were able to 
accurately initiate a consultation with their nurse on approximately 75% of occasions. 
The intervention led to 55% fewer appointments with the CNS (p<0.0001) and 39% 
fewer GP appointments (p=0.07) compared to usual care, with tentative evidence to 
suggest cost savings. There were no significant differences in clinical or psychosocial 
well-being, including function, pain, quality of life and mood. Intervention participants 
were positive about the new model of care, valuing its efficiency and tailored 
approach. The service allowed patients to gain new knowledge and use this 
information along with the skills they obtained to take control of their health and 
arthritis.  
 
This model of care may, therefore, be a viable alternative for established RA and PsA 
patients on methotrexate in order to reduce healthcare utilisation without 
compromising clinical or psychosocial well-being. 
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1. CHAPTE‘ ϭ - INT‘ODUCTION TO ‘HEUMATOID AND 
PSO‘IATIC A‘TH‘ITIS 
1.1 PROLOGUE 
The intention of this thesis is to develop and evaluate the effectiveness and 
acceptability of a self-monitoring and patient-initiated service for patients with 
rheumatoid arthritis (RA) or psoriatic arthritis (PsA) from the patient perspective. The 
specific aims of this thesis were: 
  To establish the current evidence for patient-initiated services in rheumatology 
in comparison to other models of care.  To understand the benefits, to healthcare utilisation and psychosocial well-
being, of formal self-monitoring across a range of long-term conditions.  To design a self-monitoring and patient-initiated service that could be 
delivered in rheumatology outpatients by Clinical Nurse Specialists (CNS).  To evaluate the effectiveness and safety of this intervention in relation to 
usual care.  To identify the mediators and moderators of intervention effectiveness.  To establish patient acceptability and the value placed on this model of care. 
 
This introductory chapter will, therefore, provide an overview of the clinical features of 
both RA and PsA, including diagnostic criteria, the possible causes and risk factors of 
disease onset, prevalence and incidence rates, mortality and co-morbidities, 
pharmacological management and the disease and treatment monitoring 
requirements. It concluded with an assessment of the financial impact of these two 
conditions on the UK National Health Service (NHS).  
1.2 DEFINITION  
RA and PsA are both classified as chronic inflammatory arthritis that primarily affect 
the joiŶts. Both ĐoŶditioŶs aƌe desĐƌiďed as ͞autoiŵŵuŶe͟ ŵeaŶiŶg that ĐeƌtaiŶ Đells 
of the body attack other healthy cells and tissues. The synovial tissue, which maintains 
the nutrition and lubrication of the joints becomes swollen and inflamed and causes 
Chapter 1 – Introduction to Rheumatoid and Psoriatic Arthritis 
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pain, stiffness and disability (Husted, Gladman, Farewell, & Cook, 2001). Both RA and 
PsA have a wide clinical spectrum, from mild joint symptoms to severe inflammation 
and damage but in some cases sustained remission is possible (Gladman, Hing, 
Schentag, & Cook, 2001; Svensson et al., 2013) (Figure 1.1). 
 
 
Figure 1.1. Photograph of the effects of RA and PsA 
 
RA typically affects the small joints of the hands and feet symmetrically, although any 
synovial joints can be involved. Other organs can also be affected including the lungs, 
blood vessels and the haematopoietic system. Many autoimmune diseases also involve 
the skin; the most prevalent in rheumatology is PsA, which is arthritis in association 
with psoriasis. In contrast to RA, PsA not only affects the joints but also the 
surrounding structures such as tendons and ligaments, particularly the enthesis – the 
point where a ligament or tendon joins bone, as well as the skin and nails. Joint 
involvement is asymmetrical and the distal interphalangeal joints of the hands and feet 
are more frequently affected than in RA. Most patients with PsA have mild to 
moderate psoriasis, and there is some evidence to suggest a correlation between total 
joint involvement and the extent of skin disease (Elkayam, Ophir, Yaron, & Caspi, 2000; 
Serarslan, Güler, & Karazincir, 2007). For some the arthritis predates the skin disease 
but can be diagnosed by a family history of psoriasis or PsA (Cantini et al., 2010). 
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1.3 DIAGNOSIS  
There is no single diagnostic test for either RA or PsA; diagnosis involves a series of 
clinical and laboratory observations. In the early stage this relies heavily on the history 
and examination of the patient, with blood and imaging tests helping to confirm the 
most likely diagnosis. The American College of Rheumatology (ACR) and the European 
League Against Rheumatism (EULAR) (Aletaha et al., 2010) classification are now the 
most applied criteria for RA (Table 1.1). 
 
Table 1.1.ACR/EULAR 2010 classification criteria for RA 
Criterion Definition Score 
A. Joint involvement (swollen or tender)  1 large joint  Large refers to shoulders, elbows, 
hips, knees & ankles. Small refers to the joints of the 
hands & feet. 
0  2-10 large joints 1  1-3 small joints (with or without 
involvement of large joints) 
2 
 4-10 small joints (with or without 
involvement of large joints) 
3 
 >10 joints (at least 1 small joint) 5 
B. Serology (at least 1 test result is needed for classification)  Negative RF and negative ACPA tests 0  Low-positive RF or low-positive ACPA 2  High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants (at least 1 test result is needed for classification)  Normal CRP and normal ESR  Normal/abnormal is determined 
by local laboratory standards 
0  Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms (self-report)  <6 weeks 0  шϲ ǁeeks 1 
RF – Rheumatoid Factor; ACPA – Anti-Citrullinated Protein Antibody; CRP – C-Reactive Protein; ESR – 
Erythrocyte Sedimentation Rate 
 
These criteria are applied if the patient has at least 1 joint with definite clinical 
synovitis that cannot be betteƌ eǆplaiŶed ďǇ aŶotheƌ disease. A total sĐoƌe of шϲ is 
Chapter 1 – Introduction to Rheumatoid and Psoriatic Arthritis 
 
26 
needed for classification of definite RA. Although patients with a score of <6 are not 
classifiable as having RA, their status can be reassessed to determine if the criteria may 
be fulfilled at a later date. 
 
PsA was first recognised as a distinct condition in 1964 by the American Rheumatology 
Association (ARA) (Blumberg, Bunim, Calmns, Pirani, & Zvaifler, 1964). Diagnosis of PsA 
is primarily established through the presence of signs and symptoms associated with 
both skin and joint involvement and by eliminating other forms of inflammatory 
arthritis including RA. There is, however, clinical overlap between RA and PsA and, 
therefore, diagnosis is easier if psoriasis is present. In some patients with PsA the 
pattern of joint involvement is very similar to that of RA but the rheumatoid factor, the 
aŶtiďodǇ diƌeĐted agaiŶst the ďodǇ͛s oǁŶ tissue, is usuallǇ Ŷegatiǀe ǁhilst iŶ ‘A it is 
normally positive. The Classification Criteria for PsA (CASPAR) (Taylor et al., 2006) has 
been shown to be highly sensitive to the diagnosis of PsA (Figure 1.2).  
  Inflammatory articular disease (joint, spine or enthesis) AND at least 3 points from the following:
o Current psoriasis (2 points), a personal history of psoriasis (1 point), or a 
family history of psoriasis (1 point)
o Typical nail dystrophy (1 point): onycholysis, pitting, hyperkeratosis
o Negative RF (1 point): ELISA or pephelometry preferred
o Dactylitis (1 point): current dactylitis or a previous episode noted by a 
rheumatologist
o Juxta-articular new bone formation (1 point): on hand or foot radiograph.
RF – Rheumatoid Factor; ELISA – Enzyme-Linked Immunosorbent Assay 
Figure 1.2. Classification criteria for PsA  
 
1.4 PREVALENCE AND INCIDENCE 
It has been almost 50 years since the first age and sex-specific estimates of RA 
prevalence were published in the UK. Using the ARA 1958 criteria, 2.1% of males and 
5.2% of females had probable or definite RA. Rising with age in both sexes, reaching a 
maximum of 6% in males aged 75 years and over and 16% in females aged 65 to 74 
years (Lawrence, 1961). Applying the subsequent 1987 ACR criteria Symmons et al., 
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(2002) were able to capture those who were in remission but had some accumulated 
damage as a result of their RA. In this two stage process Symmons et al., (2002) used a 
screening questionnaire and clinical examination of positive responders, classified as 
participants who reported ever having had swelling of two or more joints (excluding 
the ankles) lasting for 4 or more weeks, or who had ever been told by a doctor that 
they had RA. Although the classification criteria used were different from those in the 
study conducted by Lawrence (1961), there appears to be some change in prevalence 
rates in the last 50 years. A fall in numbers was reported in all women except those 
over the age of 75 for whom there was an 8% increase. This reduction in prevalence 
rates for women has been observed in other studies (Doran, Crowson, O'Fallon, & 
Gabriel, 2004), notably since the 1960s, and has been attributed to the protective 
effect of the oral contraceptive pill. In contrast the prevalence in males had risen by 
27-30% for those aged 45 and older in the study by Doran et al., (2004). A number of 
studies have estimated the prevalence of PsA to be between 1 and 420 cases per 
100,000, depending on the country of the study (Cantini et al., 2010). There are, 
however, currently no accurate figures for the UK. 
 
Several papers have been published over the last 20 years estimating the incidence 
rates of RA in the UK. The most recent study by Humphreys et al., (2012), utilising the 
2010 criteria, reported incidence rates as 40 per 100,000; 54 per 100,000 for women 
and 25 per 100,000 for men. In women the peak age of incidence was younger than in 
men, with highest rates between the ages of 45 and 74 years. In men incidence 
appeared to increase with age, with highest rates in men over 65 years old. A 
systematic review by Alamanos, Voulgari and Drosos (2006) identified 28 studies 
reporting either the incidence and/or prevalence of RA worldwide. Whereas, incidence 
rates in the UK were comparable to other countries for both men and women, 
prevalence estimates were considerably higher in the UK.  
 
The systematic review of PsA by Cantini et al., (2010) found that incidence rates 
ranged between 3 and 23.1 cases per 100,000; however, the review did not include 
any studies from the UK. Harrison, Silman, Barrett, Scott and Symmons (1997) did find 
that in the UK incidence rates for PsA were 3.6 for males and 3.4 for females per 
100,000, less than in other European countries (Alamanos, Voulgari, & Drosos, 2008). 
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In contrast to RA, equal numbers of males and females are affected by PsA and the 
mean age of onset is between 30 and 55 years (Cantini et al., 2010). For approximately 
70% of patients psoriasis develops before the onset of arthritis, for 15% the two 
conditions occur within 12 months of each other and in the remainder arthritis 
precedes the onset of psoriasis by more than 1 year (Cantini et al., 2010).  
1.5 AETIOLOGY 
Both RA and PsA are diseases of unknown cause. A number of risk factors have been 
identified to help explain the development, persistence and outcome of these 
conditions. The general consensus is that they are multi-factorial diseases that occur as 
a result of a combination of genetic and environmental factors. The primary causes will 
now be discussed; however, this is not an exhaustive list. 
1.5.1 Genetic 
There is a lack of consensus on the role of genetics in the development of RA. Whilst 
MacGregor et al., (2000) estimated that the genetic contribution to RA susceptibility is 
around 60%, recent research has suggested that genes are of lesser importance and in 
fact environmental effects may be more important in the development of the 
condition than previously thought (Svendsen et al., 2002). Being able to determine the 
impact of genetics in the development of PsA is complicated by the difficulty in 
discerning whether a genetic marker is specifically associated with skin disease, joint 
disease, or both. Due to the polygenic nature of the disease a number of genes may be 
contributing small effects resulting in the wide range of symptoms. Research has 
suggested that PsA is highly heritable, with heritability far higher than that of psoriasis 
alone and also in comparison to RA (Gladman, Farewell, Pellett, Schentag, & Rahman, 
2003; Bhalerao & Bowcock, 1998; Myers, Kay, Lynch, & Walker, 2005; Rahman & Elder, 
2005). The development of the PsA classification criteria should help to improve our 
understanding of the genetic factors contributing to this condition by having a clear 
definition of what constitutes a case of PsA.  
1.5.2 Hormones 
As noted previously RA is more common in women than men, suggesting that 
reproductive and hormonal factors may play a role in the development of the disease. 
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A large number of studies have identified that the oral contraceptive pill has a 
protective effect, most likely postponing disease onset rather than preventing the 
disease (Silman & Pearson, 2002). In addition, pregnancy can reduce disease activity by 
50-75% and disease onset by 70%. This then increases, however, more than fivefold in 
the first 3 months postpartum (Silman, Kay, & Brennan, 1992). This increase has been 
associated with elevated secretion of the pro-inflammatory hormone prolactin whilst 
breastfeeding. Similarly, pregnancy in the 2 years prior to onset of psoriasis is 
associated with a decreased risk of developing PsA, even after adjusting for the 
influence of age, duration of psoriasis and corticosteroid use (Thumboo et al., 2002). 
Exposure to the oral contraceptive pill or hormone replacement therapy, and 
menopause were, however, not linked to the development of PsA (Thumboo et al., 
2002). 
1.5.3 Smoking 
Smoking has been linked to both the development and course of RA and PsA, but in 
differing ways. In a recent meta-analysis of observational studies Sugiyama et al., 
(2010) concluded that males who had ever smoked were 1.89 times more likely to 
develop RA compared to non-smokers and for females 1.27 times. Smoking 20 or more 
packets a year posed a similar risk for both males and female, with odd ratios of 2.31 
and 1.75 respectively. The review also showed that the risk of developing seropositive 
RA in smokers is greater than the risk of developing seronegative RA (Sugiyama et al., 
2010). Smoking, psoriasis, and PsA have an interesting relationship. Smoking is a risk 
factor for the development of psoriasis on its own (Setty, Curhan, & Choi, 2007) but 
the time to development of PsA decreases with smoking prior to psoriasis onset and 
increases with smoking after psoriasis onset (Rakkhit et al., 2007).  
1.5.4 Socio-economic status 
Although there is no evidence to suggest a link between socio-economic status and 
onset of RA, it does appear to have an impact on the course and outcome of the 
disease. A number of authors have reviewed the literature in this area and patients 
with RA who live in socially deprived areas have been found to experience worse 
physical function and higher mortality rates (Symmons, 2002). Lower formal education 
has also been associated with increased mortality, morbidity, physical function, tender 
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and swollen joint count and more x-ray damage in RA (Symmons, 2003). It is unclear, 
however, why these differences exist; it may in part be due to the lower rates of 
medication adherence in these groups or due to late presentation of symptoms and 
diagnosis. There has been little research exploring the relationship between socio-
economic status and PsA and these potential associations remain to be explored.  
1.5.5 Infection 
There has been a vast amount of interest in the role of infections as the initiators of 
the inflammatory process in RA and PsA. It has been suggested that infection could 
trigger the development of these conditions in a genetically susceptible group. 
Although a number of infections have been implicated, including post-streptococcal 
tonsillitis, parvovirus, rubella, Epstein-Barr virus and Borrelia burgdorferi, there is no 
epidemiological evidence that suggests these infections could explain a significant 
number of cases in either condition (Symmons et al., 1997; Cantini et al., 2010).  
1.5.6 Diet 
In a recent review of 14 studies Pattison, Harrison and Symmons (2004) concluded that 
consumption of olive oil and fish oil were associated with protective effects against RA 
onset, particularly for seropositive RA. A mixed picture was presented for both caffeine 
and alcohol, with some studies reporting an association between increased risk of RA 
and higher consumption and others reporting no significant difference. There was 
more convincing evidence that eating more fruit, cooked vegetables and cruciferous 
vegetables (e.g. cabbage, broccoli, and cauliflower) was associated with a lower risk of 
developing RA. There has been little research exploring the impact of diet on the 
development and course of PsA; however, a generally healthy diet and supplementary 
fish oils have been recommended for psoriasis (Raychaudhuri & Farber, 2001; 
Raychaudhuri & Gross, 2000).  
1.6 MORTALITY  
A number of studies have shown that patients with RA and PsA have an increased risk 
of death compared to the general population. These studies vary in their diagnosis 
criteria, exclusion and inclusion criteria, length of follow-up, duration of disease before 
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recruitment, methods of statistical analysis and the causes of death. Overall, however, 
the findings are consistent. 
 
In the most recent systematic review and meta-analysis of mortality in RA Dadoun et 
al., (2013) synthesized 11 longitudinal studies representing 51,819 patients. The 
review looked at studies pre 1970, from 1970 to 1983 and after 1983, which 
corresponds to the introduction of methotrexate. The meta-analysis suggested a 
significant decrease in incident mortality rates over the 3 periods, starting at 4.7 per 
100 person-years for studies before 1970, 3 per 100 person-years from 1970 to 1983 
and 2 per 100 person-years for those studies conducted after 1983. A significant 
decrease in incidence the mortality rate of 2.84% per year was found over time. These 
rates were significantly higher than in the general population, with higher mortality 
rates associated with older age at diagnosis and longer length of follow-up.  
 
There is some discordance when looking at mortality rates in PsA. Some studies have 
shown no increase in mortality (Shbeeb, Uramoto, Gibson, O'Fallon, & Gabriel, 2000; 
Wilson et al., 2009) whilst others show rates similar to that of the RA population 
(Wong et al., 1997). A UK study found that the leading causes of death in PsA were 
cardiovascular disease (38%), diseases of the respiratory system (27%), and malignancy 
(14%) (Buckley et al., 2010). Mortality was not significantly different from the general 
UK population. This is supported by a more recent systematic review that found no 
increased risk of cardiovascular mortality for patients with PsA (Horreau et al., 2013). 
In a cohort sample of patients with PsA followed prospectively over close to 20 years 
the risk for premature death was related to previously active and severe disease, the 
level of medication and the presence of erosive disease (Gladman, Farewell, Wong, & 
Husted, 1998). It remains to be seen whether modern treatments, such as biological 
agents, will alter these findings in PsA or RA. 
1.7 CO-MORBIDITIES 
1.7.1 Cardiovascular disease 
The prevalence of ischemic heart disease, atherosclerosis, peripheral vascular disease, 
congestive heart failure, cerebrovascular disease, hyperlipidaemia, hypertension, 
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myocardial infarction, stroke, coronary artery disease, along with type II diabetes, are 
significantly higher in patients with RA and PsA than in the general population (Han et 
al., 2006; Horreau et al., 2013). There is however, some evidence to suggest that the 
introduction of methotrexate is associated with a reduced risk of cardiovascular 
disease in patients with RA and PsA, as a result of reduced inflammation (Westlake et 
al., 2010; Horreau et al., 2013). 
1.7.2 Lung problems 
The inflammatory process characteristic of arthritis can affect the membrane lining the 
lungs (the pleura), leading to pleurisy and fluid collection around the lungs. This can 
result in problems such as collapsed lung, coughing up blood, infection, or pleural 
effusion – the accumulation of fluid between the lung and the chest cavity. 
Rheumatoid nodules can also form in the lungs, although in most cases these are 
harmless. Interstitial lung diseases rarely develop as a complication of RA and 
respiratory problems are not generally a feature of PsA. Treatments for both 
conditions can however, cause interstitial lung disease, characterized by shortness of 
breath, cough and fever. These symptoms tend to improve when the drugs are 
stopped.  
1.7.3 Eye complications 
RA and PsA can affect the eyes in several ways. Inflammation of the episclera, the thin 
membrane that covers the sclera is a common complication of RA. It is usually mild, 
but the eye can become red and painful. Scleritis, inflammation of the white of the 
eye, is more serious and can lead to vision loss. Having RA also puts the individual at 
ƌisk of “jogƌeŶ͛s sǇŶdƌoŵe (Ramos-Casals, Brito-Zerón, & Font, 2007), a condition in 
which the immune system attacks the lacrimal glands, which produce tears. This 
causes the eyes to feel gritty and dry. If not treated, dryness can lead to infection and 
scarring of the conjunctiva (the membrane that covers the eye) and to corneal 
ulceration. Eye involvement in RA and PsA occurs in between 2 and 25% of cases 
(Cantini et al., 2010; Matsuo et al., 1997).  
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1.8 PHARMACOLOGICAL MANAGEMENT   
There is no known cure for either RA or PsA; therefore, treatment aims to reduce the 
impact of the disease by limiting the symptoms of pain, stiffness and fatigue. Reducing 
inflammation and the consequent irreversible joint damage that leads to disability, 
maintains or improves quality of life (Pollard, Choy, & Scott, 2005).  
 
Aggressive treatment early in the disease course normally involves a combination of 
drugs. Drug treatment can be broken down into three types. The first is for the relief of 
symptoms, with pain relief being the number one priority for patients. The second 
aims to slow or halt the disease process to prevent progressive functional impairment. 
The latter are often called disease modifying anti-rheumatic drugs (DMARDs). The third 
are the new class of biologic agents which are often used in combination with 
DMARDS. 
1.8.1 Non-steroidal anti-inflammatory drugs  
Non-steroidal Anti-inflammatory Drugs (NSAIDS) have analgesic and fever reducing 
effects, as well as anti-inflammatory properties. NSAIDS are used for symptomatic 
relief only and will not alter the course of the disease in RA or PsA. As these drugs have 
been associated with a number of adverse drug reactions including gastrointestinal 
and renal effects clinicians are cautious in ensuring that there are no contra-indications 
and that the lowest dose is prescribed for the shortest period of time. The success of 
disease modifying anti-rheumatic drugs (DMARDS) has enabled the use of NSAIDS to 
be reduced significantly. If a patient continues to need high doses of NSAIDS for 
symptomatic relief this may reflect inadequate disease control.  
1.8.2 Analgesics  
Analgesics such as paracetamol and codeine, or combinations of these two drugs help 
to control pain and are used by most patients with arthritis at some point in the course 
of their disease. Weak opioids, however, such as codeine, dextropropoxyphene and 
tramadol, despite having short-term benefits for pain management, can cause adverse 
effects that may outweigh the benefits. Therefore, an alternative non-opioid analgesic 
should be considered first (Whittle, Richards, & Buchbinder, 2013). 
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1.8.3 Disease modifying anti-rheumatic drugs  
Any anti-rheumatic drug that ƌeduĐes ƌadiogƌaphiĐ joiŶt daŵage is kŶoǁŶ as ͞disease-
ŵodifǇiŶg͟. The ŵost ĐoŵŵoŶlǇ used DMA‘D“ iŶĐlude ŵethotƌeǆate, sulphasalaziŶe, 
leflunomide and hydroxychloroquine. In the past the care pathway in the UK for a 
patient with RA involved the introduction of DMARDS at a point when there was 
evidence of radiological erosions. It has, however, been argued that these criteria 
often failed to identify recent onset RA as erosions are usually seen on X-rays relatively 
late in the disease and reflect existing and usually irreversible damage. Radiographic 
damage and disease activity are independent contributors to impaired physical 
function in both early and late RA (Ødegård et al., 2006) which has led to the view that 
DMARD therapy should not be delayed but used early in patients with persistent 
synovitis, exhibited by joint swelling and raised inflammatory markers in the blood 
(National Institute for Health and Care Excellence, 2013b). Clinically, the aim of any 
therapeutic intervention is to reduce disease activity to the lowest level possible in the 
shortest period of time. Research suggests that for symptoms, joint damage, function 
and quality of life, any delay in introducing DMARDs is inferior to early commencement 
(Nell et al., 2004). The benefits experienced as a result of this early DMARD therapy 
have been shown to persist for up for 5 years after the drug is introduced when 
compared with a delayed start (Finckh, Liang, van Herckenrode, & de Pablo, 2006).  
 
DMARDS can be used as a monotherapy, but also in combination regimens that include 
one or more DMARDS, usually methotrexate plus another and sometimes with 
glucocorticoids and/or a biologic agent (see section 1.8.4, page 36). Evidence suggests 
that these combination therapies can prolong the period during which patients are in 
remission and do not compromise tolerability (e.g. Breedvald et al., 2006). Current UK 
guidelines for treating RA recommend that methotrexate should be initiated as the 
first DMARD therapy, either as a monotherapy or as part of a combination of other 
drugs, including another DMARD (sulphasalazine or hydroxychloroquine) plus short-
term glucocorticoids (National Institute for Health and Care Excellence, 2013b). Ideally 
this therapy should be within 3 months of the onset of persistent symptoms. Prior to 
this it is important to use NSAIDs and analgesics to control symptoms. Once 
satisfactory disease control has been achieved the number of drugs can be reduced, 
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often stopping corticosteroids first, and the doses of the other drugs reducing to a 
level where disease control is maintained. If a patient fails to respond to at least two 
conventional DMARDS (including methotrexate), in the UK under National Institute for 
Health and Care Excellence (NICE) guidelines, they may be considered for anti-tumour 
necrosis factor (anti-TNF) therapies or other biologic therapies (National Institute for 
Health and Care Excellence, 2013b) (see section 1.8.4, page 36).  
 
Methotrexate is considered to be the gold standard treatment for patients with RA, it 
is also used extensively in patients with PsA and is the most widely used drug in 
patieŶt͛s naïve to DMARDs (Coates L et al., 2012; National Institute for Health and Care 
Excellence, 2013b). Methotrexate is most commonly administered orally and starts as 
a weekly dose of between 7.5 and 15mg, depending on age and the presence of co-
morbidities or co-medication. If disease activity remains unsatisfactory the dose can be 
increased up to a maximum of 25mg over a period of 1-3 months. It can take 6-8 
weeks before the benefits of methotrexate are first seen. As with all drugs any 
potential benefits have to be weighed against the potential for side effects. Adverse 
reactions to methotrexate occur in half of treated patients, but tend to be minor and 
can often be managed without cessation of the drug; these include nausea and 
vomiting, oral ulcers and elevation of liver enzymes (Espinoza et al., 1992; Emery, 
Sebba, & Huizinga, 2013). Rarer but more serious side effects include an effect on the 
bone marrow to lower platelets or neutrophils in the blood. Methotrexate is usually 
prescribed in combination with folic acid or antiemetic drug to reduce gastrointestinal, 
mucosal and haematological side effects (Emery et al., 2013).  
 
As with any medications that suppress the immune system, methotrexate poses some 
increased risk of the bodǇ͛s ǀulŶeƌaďilitǇ to iŶfeĐtioŶs aŶd otheƌ diseases. As a 
consequence before commencing methotrexate, patients are assessed for any 
evidence of tuberculosis. An anti-flu and anti-pneumococcal pneumonia vaccination is 
also given before starting the drug. As a consequence patients should not receive live 
vaccinations whilst taking the drugs and are asked to seek immediate medical 
attention if they develop persistent fever or unexplained symptoms. If an infection 
does develop and patients are required to take antibiotics, methotrexate is stopped. 
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1.8.4 Biologic agents 
In the last decade, there have been significant advances in treating RA and PsA, 
especially for patients whose arthritis does not respond to traditional DMARDs. The 
most important improvement for these patients has been the development of a group 
of drugs called biologic response modifiers or biologic agents. Biologics work by 
blocking specific chemical triggers of inflammation and target specific proteins 
(cytokines) in the immune system known to increase inflammation and cause damage 
in arthritis. By blocking these cytokines these drugs reduce inflammation and have 
relatively few side effects. These agents block the pro-inflammatory cytokine tumour 
necrosis factor (TNF) alpha and are used when a patient has ͞failed͟ oƌ Ŷot ƌespoŶded 
adequately to traditional DMARDs. These anti-TNF agents are often used in 
combination with traditional DMARDs, usually methotrexate, for greater effectiveness. 
This may need to be varied for individual patients because of differences in the 
method of administration and treatment schedules. The self-injecting anti-TNF drugs 
etanercept (trade name Enbrel) and adalimumab (trade name Humira) in combination 
with methotrexate have been found to reduce disease activity and the number of 
swollen and painful joints with a consequent reduction of pain, morning stiffness and 
fatigue (Klareskog et al., 2004; Breedveld et al., 2006). They also lower the blood 
markers of inflammation and in the longer term damage and disability are also 
reduced.  
 
Current NICE guidelines (National Collaborating Centre for Chronic Conditions, 2009) 
recommend that anti-TNF agents are used for patients with active RA, defined as a 
disease activity score (DAS) (Prevoo et al., 1995) greater than 5.1 on at least two 
occasions (1 month apart) and have undergone trials of two DMARDs including 
methotrexate (for at least 6 months) with 2 months at a standard dose. The DAS is a 
measure of disease activity, see section 1.9.2 (page 42) for more detail. According to 
NICE, treatment with anti-TNF agents should only be continued if there is an 
improvement in the DAS28 score of 1.2 or more, 6 months after initiation of 
treatment.  
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Recent NICE guidelines for the use of etanercept and adalimumab in PsA (National 
Institute for Health and Clinical Excellence, 2010) recommend that these drugs are 
introduced when a person has peripheral arthritis (i.e. arthritis in the extremities), with 
three or more tender joints and three or more swollen joints, and they have not 
responded to adequate trials of at least two standard DMARDs, administered either 
individually or in combination. It is recommended that these medications should be 
discontinued in people whose joints do not respond according to the PsARC response 
criteria (Clegg et al., 1996), 12 weeks after the drug is introduced. If the psoriatic skin 
disease responds to treatment at 12 weeks, but PsARC response does not justify 
continuation of treatment the patient should be assessed by a dermatologist to 
determine whether continuing treatment is appropriate on the basis of their skin 
response. 
 
Patients are usually taught to give their own injections of etanercept and adalimumab. 
They are administered under the skin (subcutaneously) once or twice a week 
(etanercept) or once a fortnight (adalimumab). If patients are unwilling or unable to 
inject themselves a family member or caregiver who has been trained may also give 
the injection. Preloaded syringes are available as self-injectable click-pens. In addition 
to pain and inflammation at the injection site, the most common side effects are an 
increased risk of infection, including upper respiratory infections like colds or chest 
infections. These are usually minor but as with methotrexate patients with pre-existing 
lung problems must be carefully assessed and vaccinations should be undertaken prior 
to commencement. Since biologic therapy is in its relatively early stages of use, some 
of the long-term effects of using these medications are not known, prompting regular 
monitoring. Varieties of newer biological agents are also available, for example 
infliximab which is delivered via infusion, and offer hope to those who fail to respond 
to etanercept and adalimumab. 
1.9 DISEASE AND TREATMENT MONITORING 
Monitoring of disease activity in RA and PsA involves the sharing of information 
between patient and healthcare professional about symptoms and side effects, along 
with physical examinations and laboratory tests. Symptoms may indicate a flare of 
arthritis or infection and include pain, swelling and tenderness, length of morning 
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stiffness, fever and weight loss or gain. In addition to this, laboratory tests (see section 
1.9.3, page 44) act as objective measures of the level of inflammation and of some of 
the drug induced side effects before they are apparent clinically, for example any early 
effect on liver function or bone marrow.  
 
For some drugs and drug combinations the adverse effects can be serious and, 
therefore, monitoring using blood tests is required in order to ensure treatment is 
effective and to identify any adverse effects early and before they become serious. 
Guidelines have been established for the prescribing and monitoring of methotrexate 
in NHS Camden (Pang & Malhotra, 2009), the health authority in which this thesis is 
sited and are described in more detail in section 2.6 (page 93).  
1.9.1 Symptoms and side effects 
There are a number of primary symptoms which need to be monitored as part of the 
care of someone with RA or PsA. These symptoms may be directly related to the 
inflammatory process or to drug induced side effects. Reporting of these experiences 
during the consultation process is essential in order for the patient and healthcare 
professional to have a full understanding of disease activity and treatment response. 
The symptoms and side effects described below are not an exhaustive list but are the 
most characteristic and frequently reported by someone with either RA or PsA.  
 Pain  
Pain is described by people with arthritis as the most important symptom, particularly 
early in the disease (Carr et al., 2003). Despite this patients feel that clinicians focus 
more on disease control rather than pain relief (Breivik, Collett, Ventafridda, Cohen, & 
Gallacher, 2006). In a survey of over 11,000 people with a rheumatic condition over 
60% reported severe pain and irritation. Of these almost half said that pain limited 
their daily activities, a large number also reported that the ability to lead a normal life 
was affected because they were always in pain. The proportions were higher for those 
with RA compared with unspecified arthritis, with half of RA patients reporting that 
they were always in pain (Badley & Tennant, 1993).  
 
The impact of pain however, goes beyond the sensation and is associated with 
frequent use of health services (Waltz, 2000) and analgesic use (Blamey, Jolly, 
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Greenfield, & Jobanputra, 2009), with work disability (Wolfe & Hawley, 1998; 
Wallenius et al., 2009), and increased current (Dickens, McGowan, Clark-Carter, & 
Creed, 2002) and future depression (Sharpe, Sensky, & Allard, 2001; Husted, Tom, 
Farewell, & Gladman, 2012) in both RA and PsA. In a recent longitudinal study of over 
15,000 patients with RA Courvoisier et al., (2012) found that pain was the single most 
important predictor of increased quality of life, more important than disease activity 
and functional disability. This suggests that anti-rheumatic drugs are having an 
insufficient effect on pain relief. These results corroborate other studies which suggest 
that two-thirds of people with RA experience inadequate pain relief despite their 
disease being considered well-controlled (Taylor et al., 2010).  
 Fatigue 
The varying definitions and instruments used to measure fatigue are likely to be 
responsible for the variation in the rates of fatigue found in RA and PsA. Moderate to 
severe fatigue is reported by between 42% and 80% of patients with RA or PsA (Belza, 
1995; Belza, Henke, Yelin, Epstein, & Gilliss, 1993; Wolfe, Hawley, & Wilson, 1996; 
Husted, Tom, Schentag, Farewell, & Gladman, 2009). Despite this potentially high 
proportion and confirmation from patients that it is an important problem (Kirwan et 
al., 2007), the clinical mechanisms that cause or exacerbate fatigue are poorly 
understood and are rarely measured in clinical practice. A number of variables have 
been associated with increased fatigue; these include greater disease activity, physical 
limitations, pain and poorer quality of life (Husted et al., 2009); along with depression 
(Huyser et al., 1998), disability (Repping-Wuts, Fransen, van Achterberg, Bleijenberg, & 
van Riel, 2007; Wallenius et al., 2009) and anxiety (Mancuso, Rincon, Sayles, & Paget, 
2006). 
 Synovitis 
Synovitis is inflammation of the joint lining and is usually characterised by pain, 
tenderness and stiffness making movement problematic. Joint swelling is part of the 
DAS28 assessment and examination of joint swelling is achieved through observation 
and palpation; with the examiner looking for soft tissue swelling not bony swelling or 
deformity. Swelling and tenderness of small joints are associated with radiological 
damage (Boers, Kostense, Verhoeven, & Van Der Linden, 2001; Klarenbeek et al., 
2010). In addition an 8 year follow-up of patients with RA found that concomitant joint 
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swelling and tenderness at least once in the first 2 years of diagnosis was 
independently associated with damage in the large joints, as was swelling without 
tenderness. This damage was associated with greater functional disability, as 
compared to those without large joint damage (van den Broek et al., 2013). The 
manifestation may however, be different in patients with RA compared to PsA. People 
with PsA tend to have more tender than swollen joints whereas those with RA have 
more swollen than tender joints (Harty et al., 2012).  
 Joint stiffness 
Joint stiffness, and particularly morning joint stiffness, is a common and clinically 
important complaint for people with arthritis. It is caused by the inflammation found 
around a joint which causes tightness. Although not included in more recent 
classification guidelines, early diagnostic criteria for RA included information on 
duration and location of stiffness (Arnett et al., 1988). It was removed as the criteria 
failed to discriminate between different types of arthritis as morning stiffness was 
found to be present in over 70% of people with PsA, 48% with lupus and 31% with gout 
(Sierakowski & Cutolo, 2011). It seems that morning stiffness, however, may capture 
elements of disease activity not included in the DAS28. Morning stiffness is 
independently associated with pain, patient global assessment, shorter disease 
duration, and younger age (Yazici, Pincus, Kautiainen, & Sokka, 2004). Furthermore, in 
patients with low disease activity, the presence of morning stiffness may indicate 
clinically active disease (Khan et al., 2009) and rheumatologists often use the duration 
of early morning stiffness as one of the primary considerations when changing 
medications in RA (Kirwan, De Saintonge, Joyce, & Currey, 1984; Soubrier et al., 2006).  
 Skin conditions  
Along with psoriatic plaques and damage to nails, PsA is also characterised by 
daĐtǇlitis, also kŶoǁŶ as ͞sausage͟ fiŶgeƌ, ǁheƌe the skiŶ, Ŷail, teŶdoŶ sheathes and 
joints are inflamed. Approximately 5.6-53% of people with PsA during the course of 
their illness will experience dactylitis and this most commonly involves one or two 
digits at a time, with the feet more often affected than the hands (Cantini et al., 2010). 
Patients can also experience enthesitis which is an inflammatory lesion at the insertion 
of a tendon or ligament into bone. The most common site is the Achilles tendon, which 
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presents as a swelling at the back of the heel. Enthesitis is reported in approximately 
25-78% of patients with PsA (Sakkas, Alexiou, Simopoulou, & Vlychou, 2013).  
 
Patients with RA may have rheumatoid nodules – swellings which can occur anywhere 
but are normally found in the dermis around sites of pressure, particularly on the 
elbows, forearms, heels, or fingers. They can develop gradually or appear suddenly. 
Around a 20-30% of patients with RA are affected by these nodules and they are more 
common in men, Caucasians and those who test positive for rheumatoid factor (Kaye, 
Kaye, & Bobrove, 1984). These nodules, although sometimes unsightly, generally do 
not cause the patient any problems and, therefore, do not usually need specific 
treatment unless they ulcerate. Certain DMARDS can shrink rheumatoid nodules 
(Sayah & English, 2005). If they are large and interfere with function, for example 
nodules on the feet can restrict walking, some experts recommend injection with a 
corticosteroid to shrink them. Surgery may also be required if the nodule is causing 
problems such as nerve pain, an open sore or are having a major impact on physical 
functioning.  
 Gastrointestinal problems and oral health 
The gastrointestinal problems reported by patients with RA and PsA are primarily drug 
induced side effects caused by both NSAIDS and DMARDS and, therefore, need 
monitoring to prevent them developing into serious complications. Use of NSAIDS is 
associated with a significant increase in the risk of gastrointestinal clinical events such 
as bleeding, perforation, obstruction and symptomatic ulcers and increase dramatically 
with risk factors such as a priori event, older age and severe RA (Laine et al., 2002). In 
RA 29% of patients experience nausea and 12% diarrhoea, as a result of taking 
methotrexate (Bathon et al., 2000). Research in PsA also indicates that gastrointestinal 
side effects are the most commonly reported adverse effects for patients taking 
methotrexate. Eighty-four percent of patients with PsA reported nausea (41%), 
vomiting (8%), diarrhoea (7%), constipation (3%) or gastritis (25%) (Wollina, Ständer, & 
Barta, 2001).   
 
Present on the palate, underside of the lips or inside of the cheek, oral ulcers or mouth 
sores are a common side effects of drugs such as NSAIDS and methotrexate. Research 
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suggests that 14% of patients with RA who take methotrexate experience mouth ulcers 
(Bathon et al., 2000). This may be due to a lack of folic acid or possibly over dosing due 
to confusion regarding the treatment regimen (Deeming, Collingwood, & Pemberton, 
2005). 
1.9.2 Disease activity and treatment response 
The monitoring of disease activity and treatment response is essential in both RA and 
PsA. The composite scores reported below are now part of routine practice and 
guidelines in RA recommend they are measured monthly until treatment has 
controlled the disease (National Institute for Health and Care Excellence, 2013b).   
 
In RA the DAS (Prevoo et al., 1995) is a combined index designed to measure disease 
activity. It has been extensively validated for use in clinical trials and is now widely 
used in clinical practice to collect valuable information about the condition and 
treatment response. The DAS measures the total number of swollen and tender joints 
out of a total of 44 and the DAS28 is a simplified version (i.e. 28 joints). The joints of 
the shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal 
joints and the knees are examined for tenderness and swelling and this count is then 
combined with either the ESR or C-Reactive Protein (CRP) and patient reported global 
health on a scale of 0 (best) to 10 (worst). The DAS28 scores is interpreted as follows 
(Radboud University Nijmegen, 2014): 
  ‘eŵissioŶ: DA“Ϯϴ ч Ϯ.ϲ.  Loǁ Disease aĐtiǀitǇ: Ϯ.ϲ < DA“Ϯϴ ч ϯ.Ϯ.   Modeƌate Disease AĐtiǀitǇ: ϯ.Ϯ < DA“Ϯϴ ч ϱ.ϭ.   High Disease Activity: DAS28 >5.1.  
 
The DAS28 provides a cross-sectional assessment of disease activity. In order to assess 
how patients with RA change over time two widely applied response criteria have been 
developed by ACR, and EULAR. The ACR criteria (Felson et al., 1995) are referred to as 
the ACR 20, 50 and 70 response criteria, depending on the required percentage of 
improvement (i.e. 20%, 50% or 70%). The EULAR criteria (van Gestel et al., 1996) are 
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based on the DAS or DAS28 and response is defined as none, moderate or good (Table 
1.2).  
 
Table 1.2. EULAR treatment response criteria for RA 
DAS28 at end point 
Improvement in DAS28 from baseline 
>1.2 >Ϭ.ϲ aŶd ≤ ϭ.Ϯ ≤ Ϭ.ϲ 
ч ϯ.Ϯ Good Moderate None 
>3.2 and ч ϱ.ϭ Moderate Moderate None 
>5.1 Moderate None None 
DAS – Disease Activity Score 
 
Unlike the EULAR criteria, the ARC criteria are based on a percentage change only and 
patients are classified as either responders or non-responders (Figure 1.3).  
 
20% improvement in:  Tender joint count.  Swollen joint count. 
And in three of the following:  Patient pain.  Patient global assessment (on a 0–5 Likert scale, with improvement defined 
as a decrease by at least one unit, and worsening defined as an increase by at 
least one unit).  Assessor global assessment (on a 0–5 Likert scale, with improvement defined 
as a decrease by at least one unit, and worsening defined as an increase by at 
least one unit).  Disability.  Acute phase response. 
Figure 1.3. ACR improvement criteria 
 
There is no single point disease activity score in PsA only response criteria. The 
Psoriatic Arthritis Response Criteria (PsARC) (Clegg et al., 1996) is a combination of 
percentage change and global improvement rated by the patient and doctor (Figure 
1.4). The criteria are currently undergoing validation and further development. 
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Achieve two of the following with no worsening of any  Tender joint count improvement of at least 30%.  Swollen joint count improvement of at least 30%.  Patient global improvement by one point on a 5-point Likert scale.  Doctor global improvement by one point on a 5-point Likert scale. 
Figure 1.4. PsA Response Criteria (PsARC) 
 
1.9.3 Blood tests 
NICE guidelines suggest that markers of inflammation need to be checked via blood 
tests every month until treatment has controlled the disease to a level previously 
agreed with the patient (National Collaborating Centre for Chronic Conditions, 2009). 
BSR/BHPR in collaboration with the British Association of Dermatologists (Chakravarty 
et al., 2008) state that patients should also be encouraged to take part in self-
management education so that they can monitor their own therapy. The monitoring 
schedule for methotrexate should include full blood count, urea and electrolytes and 
liver function every 2 weeks until the dose of methotrexate and monitoring is stable 
for 6 weeks and thereafter monthly until the dose and disease is stable for 1 year. The 
monitoring may then be reduced in frequency, based on clinical judgement with due 
consideration for risk factors including age, co-morbidity and renal impairment, when 
monthly monitoring is to continue. The following tests are included;  
 Haemoglobin 
Haemoglobin is the oxygen carrying pigment found in red blood cells. A below normal 
level of haemoglobin is known as anaemia. Anaemia can be a temporary condition, a 
consequence of other health conditions, or it can be a chronic problem. People with 
active RA and PsA can develop anaemia, which may cause symptoms such as fatigue, 
rapid heartbeat, shortness of breath, dizziness, leg cramps and insomnia. There are a 
number of reasons why a person with arthritis may experience anaemia. One cause is 
joint inflammation which can have an effect on iron metabolism, bone marrow, and 
erythropoietin production by the kidneys (a hormone that controls production of red 
blood cells). The other is iron deficiency which could be caused by digestive tract 
bleeding a side effect of some arthritis medications. By monitoring haemoglobin levels 
these can be detected early before they become serious.  
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 White blood cell count and neutrophils 
White blood cells (WBC) are cells of the immune system defending the body against 
both infectious disease and foreign materials. Neutrophils (a sub-set of white cells) are 
the most abundant type of WBC. They are normally found in the blood stream during 
the acute phase of inflammation and are recruited to the site of injury within minutes 
following trauma. Through blood tests, WBC and neutrophil counts are monitored as 
indicators of possible inflammation in arthritis. As people with RA and PsA are also 
more prone to infections, which may be related to the underlying disease or to the 
immune-suppressant medications used to treat them, regular monitoring of WBC is 
required. DMARD therapy can lead to neutropenia, a deficiency in WBC, which can 
lead to an increased susceptibility to infection. In addition treatment with biologic 
agents may greatly increase the risk of serious infections in people with arthritis by 
inducing a certain extent of immunosuppression (Galloway et al., 2011).   
 Platelets 
Platelets or thrombocytes are irregularly-shaped, colourless bodies that are present in 
blood. Their sticky surface lets them, along with other substances, form clots to stop 
bleeding. If platelet levels are too low, excessive bleeding can occur. High platelet 
levels increase the risk of thrombosis, which may result in events such as a stroke, 
heart attack, pulmonary embolism or the blockage of blood vessels to other parts of 
the body, such as the extremities of the arms or legs. Platelets are often elevated in 
active arthritis as a result of enhanced local inflammation; therefore, monitoring of 
platelets, via blood tests, acts as an indicator of possible inflammation. There is also 
accumulating evidence to suggest that DMARD therapy is associated with a possible 
suppression of platelet production in the bone marrow (Gasparyan, Stavropoulos-
Kalinoglou, Mikhailidis, Douglas, & Kitas, 2011); therefore, increasing susceptibility to 
bleeding.  
 Liver function 
The alkaline phosphatase (ALP) test is used to help detect liver disease (or some bone 
disorders). Damaged liver cells release increased amounts of ALP into the blood. A 
raised alanine transferase (ALT) can also reveal liver damage. Although it is probably 
the most specific test for liver damage, it does not reveal the severity of the liver 
damage as the amount of dead liver tissue does not correspond to higher ALT levels. In 
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addition, patients with normal or declining ALP levels may experience serious liver 
damage without an increase in ALT. Lower levels of ALT may indicate any kind of liver 
disease, whereas higher levels generally indicate extensive liver damage from toxins or 
drugs, viral hepatitis, or a lack of oxygen (usually resulting from very low blood 
pressure or a heart attack). Hepatotoxicity is one of the most feared side effects of 
methotrexate. A meta-analysis by Whiting-O'Keefe, Fye and Sack (1991) reported a 
prevalence of advanced histological changes of 2.7% after 4 years on methotrexate. 
This has been associated with cumulative methotrexate dose, duration of treatment, 
drugs or chemicals, such as alcohol; being older; presence of hepatitis B and C virus; 
and a family history of liver disease (Dávila-Fajardo, Swen, Barrera, & Guchelaar, 2013). 
It is important to detect these changes early before irreversible liver damage has 
developed. 
 Markers of inflammation 
ESR and CRP are both markers of inflammation. Generally, ESR does not change as 
rapidly as CRP, either at the start of inflammation or as it goes away. CRP is not 
affected by as many factors as ESR, making it a better marker of inflammation. As ESR, 
however, is an easily performed test, many doctors use ESR as an initial test when they 
think a patient has inflammation. CRP is produced in the liver and is present during 
episodes of acute inflammation or infection. Hence, a high result serves as a general 
indication of acute inflammation. In arthritis changing levels of CRP or ESR can be used 
to assess the effectiveness of treatment and monitor periods of disease flare. Both ESR 
and CRP are, however, non-specific and can rise with any viral or bacterial infection, 
not just arthritis-related inflammation.  
1.10 ECONOMIC IMPACT 
Due to advances in the treatment of RA and PsA, the need for this extensive and 
ongoing monitoring and the potential for long-term damage and disability it is 
unsurprising that the economic impact of arthritis is substantial. The cost of illness is 
said to consist of direct and indirect costs. Direct costs are those for which actual 
payments are made these include treatment costs, social services and private 
expenditure. Indirect costs are those for which no direct payment is made but for 
which resources are lost, for example loss of productivity, earnings or tax revenue.  
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NHS expenditure on musculoskeletal disorders was £5.06 billion in 2010/11, an 
increase of almost 20% since 2008-2009 (Department of Health, 2012a). This is 4.7% of 
the overall NHS budget and is the fifth highest area of spend in the NHS. This 
represents an increase per patient from £80.58 in 2007/2008 to £96.62 in 2010/2011 
(Department of Health, 2012a). Using incidence and prevalence rates the National 
Audit Office estimates that RA costs the NHS in England £557 million annually in 
healthcare costs and an additional £1.8 billion a year on the wider cost to the economy 
including sick leave and work-related disability (National Audit Office, 2009b) this 
equates to £960 per person per year.  
 
McIntosh (1996) conducted one of the most comprehensive surveys in the England 
and found that RA imposed a £1.256 billion burden in 1992. Direct costs accounted for 
£604.6 million and indirect costs £651.5 million. Table 1.3 summarizes the mean 
annual service utilization estimate and annual costs of these services. 
 
Table 1.3. Summary of the mean annual service utilization estimates for RA (£) in 1992 
Service 
Service utilization estimates   
16-64 years 65 years + Annual cost 
GP visits  9.6 (p/a) 8.3 (p/a) 14,917,512 
Hospital Days 5.8 (p/a) 6.2 (p/a) 170,752,014 
Specialist outpatient visits  8.6 (p/a) 4.3 (p/a) 38,901,997 
Nurse visits 0.4 (p/w) 0.8 (p/w) 83,203,184 
Home-help visits 0.2 (p/w) 1.0 (p/w) 60,426,688 
Total   368,201,395 
GP – General Practitioner; p/a – per annum; p/w – per week 
 
Most of the ambulatory visits consisted of GP attendance (at £7.46 per surgery visit) 
and of the £38.9 million cost for specialist outpatient services, the majority of this was 
for visits to the rheumatology unit, which were estimated at £108.75 per person per 
year. This was equivalent to three 20 minute appointments with a rheumatologist. 
Interestingly, the costs of nurse visits were almost double; however, it is unclear what 
percentage of this was specific to nurse specialists in rheumatology, if any.  
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Adapted from (McIntosh, 1996) 
Figure 1.5.The direct costs of RA in the UK in 1992 
 
A majority of the costs associated with RA were hospital days and adults in communal 
establishments (Figure 1.5). The total cost of NSAIDs, DMARDs and steroids was £35.5, 
daily livings aids £10.8 million and laboratory tests for the management of toxicity 
£56.7 million (Table 1.4). The morbidity costs resulting from productivity loss were 
higher in females (£474.3 million) compared to males (£172.2 million), due to the 
higher prevalence rates in women. Although MĐIŶtosh͛s aŶalǇsis ǁas ĐoŶduĐted pƌioƌ 
to the introduction of biologics, which are associated with substantially higher costs 
than those of traditional DMARDS, these figures do reflect more recent international 
estimates (Lundkvist, Kastang, & Kobelt, 2008; Franke, Ament, Laar, Boonen, & 
Severens, 2009). 
 
Table 1.4. Summary of the costs for laboratory tests for the management of toxicity in 
RA (£) in 1992 
Test Times per year Cost per test Total annual cost 
Full blood count 12 8.81 19,027,975 
ESR 12 8.81 19,027,975 
Urea and electrolytes 3 4.89 2,642,774 
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Test Times per year Cost per test Total annual cost 
Liver function test 12 4.89 10,571,097 
Urinalysis 12 0.06 126,853 
X-ray hands and feet 1 29.35 5,285,548 
Total   56,682,222 
ESR – Erythrocyte Sedimentation Rate   
 
Using the most comparable sub-ĐoŵpoŶeŶts of MĐIŶtosh͛s aŶalǇsis aŶd combining 
these with the National Audit Office figures the average direct care costs per person 
with RA in the UK are estimated to be £2,065 per year or £861 million per annum in 
total (Oxford Economics, 2010).  
 
The economic burden associated with PsA may be even greater than RA (Poole, 
Lebmeier, Ara, Rafia & Currie, 2010) found that the total annual health care costs for 
biologic-naïve patients with PsA in the UK ranged from £11 to £20,782, with a mean of 
£1446 per person (SD=£1756). Prescription costs and secondary care episodes 
accounted for more than one-third of the total cost. The average annual cost of 
prescribed medications per person per year was £544 and for secondary care episode 
£497. Consultations with the GP cost on average £226 per year, while the mean annual 
cost of clinical investigations was £135. Costs were significantly higher in people aged 
over 50 years and those experiencing greater disability.  
1.11 SUMMARY 
Chronic inflammatory conditions like RA and PsA are highly prevalent in the UK. Both 
can lead to significant impairments in daily living including pain and fatigue, along with 
potentially debilitating complications to the eyes, lungs, skin, liver, immunological and 
cardiac system and most importantly mortality. Intensive treatment regimens have 
been introduced over recent years in order to ensure tight control of disease activity; 
these include new therapeutic agents and new treatment strategies. Due to the 
potential toxicity of these drugs, however, patients require close monitoring. This 
monitoring is achieved through a combination of patient reported symptoms and side 
effects along with a clinical assessment of disease activity and regular laboratory tests 
to ensure any adverse effects are detected early before they become serious and 
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irreversible. The economic burden of both blood monitoring and regular outpatient 
care is clear. The next chapter will review how the monitoring of patients with RA and 
PsA is undertaken in accordance with UK guidelines and then introduce potential 
alternative methods of managing and monitoring patients with RA and PsA, including 
nurse, community and patient-led services. 
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2. CHAPTE‘ Ϯ - UK SE‘VICE DELIVE‘Y IN ‘HEUMATOLOGY 
2.1 PROLOGUE 
The previous chapter described some of the clinical features of RA and PsA including 
the monitoring requirements of a person receiving DMARD therapy. This chapter will 
begin with a general overview of current UK policy regarding the management of long-
term conditions and the key targets and indicators of success. This will be followed by 
a discussion of the relevance of these policies to patients with arthritis and the 
arthritis-specific policies and guidelines which are now in place, both for the disease 
and also the monitoring of DMARD therapy.  
 
The second part of this chapter will then present data on the current state of 
musculoskeletal outpatient services for established patients in the UK, along with the 
different models of follow-up care that have been implemented and evaluated. This 
includes the evidence relating to consultant-led, nurse-led, community-led and 
patient-led services, as well as telephone consultations. The chapter will then conclude 
with a proposal of how patient-initiated services could be extended to include patients 
taking on a more active role in the monitoring of their conditions leading to a new and 
innovative model of care for managing patients with established arthritis on DMARD 
therapy. Data will then be presented on how University College Hospital London 
(UCLH) and NHS Camden Clinical Commissioning Group (CCG), the local site of this 
thesis, have performed in relation to quality indicators along with the model of care 
adopted by UCLH at the start of this research. 
2.2 MANAGEMENT OF LONG-TERM CONDITIONS IN THE UK 
As a result of the baby boom post Second World War, a reduction in fertility rates, the 
elimination of many acute and occupational illnesses and the success of modern 
tƌeatŵeŶts, the ǁoƌld͛s populatioŶ is agiŶg as life eǆpeĐtaŶĐǇ ĐoŶtiŶues to ƌise. The 
consequence has been that the focus of healthcare has shifted to the burden of long-
term conditions, which increase in prevalence with age. One such condition is arthritis 
for which the prevalence rate in those over the age of 75 has increased by 8% over the 
last 50 years (Symmons et al., 2002). In addition more than half of older adults are now 
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living with three or more long-term conditions (American Geriatrics Society Expert 
Panel on the Care of Older Adults with Multimorbidity, 2012). 
 
In parallel with this the UK population is projected to increase by 3.1 million to 67.2 
million by 2020, which is equivalent to an average annual rate of growth of 0.8%. 
Based on past trends this growth will continue, reaching 72.6 million by 2035.  
Figure 2.1 illustrates the projected age structure of the population and shows the 
disproportionate growth of those aged over 60 years. This is underlined by the 
projected rise in average age from 39.7 years in 2010 to 39.9 years in 2020 and 42.2 
years by 2035 (Office for National Statistics, 2012).  
 
 
  
Source. Office of National Statistics  
Figure 2.1. Estimated and projected age structure of the UK population, 1951, mid-
2011 and mid-2035. 
 
Although the impact on health and social care is hard to predict, the aging population 
is likely to lead to an increase in the demand on GPs, accident and emergency (A&E) 
and hospital in- and out-patient services and, consequently, the annual costs of health 
2035 2014 
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and social care. Figures from 2007/2008 already suggest that retired households cost 
the NHS twice as much (£5,200) as non-retired households (£2,800) (House of 
Commons Library Research, 2010). This is not surprising given the costs associated 
with managing a long-term condition such as arthritis, as highlighted in section 1.10 
(page 46). The NHS has, therefore, had to shift its focus in recent years to provide 
outpatient services that are able to cope with increased demands but at the same time 
achieve this with limited resources. 
 
As a result of these population changes government policy has increasingly focused on 
the needs of those living with one or more long-term conditions. Since 2010 the UK 
Government has introduced a number of key changes to the structure of the NHS and 
the commissioning processes, which aim to meet these demands. In 2010 the White 
Papeƌ ͚EƋualitǇ aŶd EǆĐelleŶĐe: LiďeƌatiŶg the NH“͛ (Department of Health, 2010a) 
outliŶed the ĐuƌƌeŶt CoalitioŶ GoǀeƌŶŵeŶt͛s loŶg-term vision for the future of the 
NHS. This White Paper proposed the abolition of Primary Care Trusts (PCTs) and the 
formation of GP consortia, known as Clinical Commissioning Groups (CCGs), which 
would take over the responsibility of commissioning NHS services in England. The 
premise being that decision making about the allocation of resources should take place 
locally so that services reflect the needs of patients in the local community and the 
clinicians who support them. In addition there should be greater integration of services 
across primary and secondary care. Since 2010 the Department of Health has 
enshrined these principles in the Health and Social Care Act 2012 and published a 
number of national policy documents which add operational detail to these proposed 
changes.  
 
In November 2013 the Department of Health published the NHS Mandate for 2013-
2015 (Department of Health, 2013e) and accompanying 2014/15 NHS Outcomes 
Framework (Department of Health, 2013f). The purpose of the NHS Mandate and 
Outcomes Framework is to provide a national level overview of how well the NHS is 
performing and an accountability mechanism between the Secretary of State and NHS 
England, previously known as the NHS Commissioning Board. From 2013 the Secretary 
of State holds NHS England to account on the basis of the Mandate and NHS England 
holds the CCGs to account for their performance.  
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This framework builds on the three previous frameworks (Department of Health, 
2010c; Department of Health, 2011b; Department of Health, 2012b) and contains 
measures, known as indicators, to help the health system focus on measuring health 
outcomes as opposed to process targets. Indicators within the NHS Outcomes 
Framework are grouped around five domains and set out the high-level national 
outcomes which the NHS should be aiming to improve. Within each domain there are a 
small number of overarching indicators and several improvement domains. The NHS 
Mandate is structured around these five domains and, as such, progress against the 
objectives laid out in the Mandate will be assessed using the NHS Outcomes 
Framework. The most relevant domains to musculoskeletal outpatient services are 
domain 2 and domain 4.  
 
Domain 2 – ͚EŶhaŶĐiŶg the ƋualitǇ of life of people ǁith loŶg-teƌŵ ĐoŶditioŶs͛ 
acknowledges that patient empowerment and support for people with a long-term 
condition, such as arthritis, is vital to enabling them to manage their illness and 
treatment without needing to go into hospital. By March 2015 the Department of 
Health expects NHS England to have made progress in relation to four key areas within 
this domain, one of which is involving people in their own care. Their objective is to 
ensure that the NHS becomes better at involving patients and empowering them to 
manage and make decisions about their own care and treatment in order to improve 
their quality of life. Achieving this objective would mean that by 2015 more people 
with arthritis will have developed the knowledge, skills and confidence to manage their 
own health, so they can live their lives to the full. The Department of Health also wants 
to see improvements in the way that care is coordinated around the needs, 
convenience and choices of patients rather than the interests of organisations that 
provide care. The indicator that is being used to assess the success of this domain is 
the proportion of people who feel supported to manage their condition and is 
measured in the GP patient survey at a general practice level and then aggregated up 
to CCG level (Department of Health, 2013b).  
Domain 4 – ͚EŶsuƌiŶg that people haǀe a positiǀe eǆpeƌieŶĐe of Đaƌe͛. As 80% of 
hospital care is delivered in outpatients, improving the experience for patients was 
identified as a key improvement area in the 2011/12 NHS Outcomes Framework 
(Department of Health, 2010c). The iŶdiĐatoƌ ďeiŶg ͞patieŶt eǆpeƌieŶĐe of outpatieŶt 
Chapter 2 – UK Service Delivery in Rheumatology 
 
55 
seƌǀiĐes͟. “uĐĐess ǁill ďe derived from the Outpatient Survey last conducted in 2011 
aŶd to ďe Đoŵpleted agaiŶ iŶ ϮϬϭϰ. This suƌǀeǇ ĐoŶsists of ƋuestioŶs aďout patieŶts͛ 
experiences prior to attending clinic, waiting on the day of the appointment, the 
hospital environment and facilities, tests and treatments, seeing the doctor and other 
professionals, the overall appointment, leaving the outpatients department and the 
patieŶt͛s oǀeƌall iŵpƌessioŶ.  
 
NHS England is now supporting CCGs to develop and deliver these indicators and 
includes amongst its members a National Clinical Director for Musculoskeletal 
Disorders who will work closely with patients and clinicians to support improvements 
in health outcomes for people with a musculoskeletal condition (Arthritis UK, 2012). 
Figure 2.2 outlines how these national policy documents are linked to arthritis specific 
guidelines, which will reviewed in the following section.
  
5
6
 
 
Figure 2.2. Connection between UK government policy and arthritis-specific guidelines 
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prematurely
Domain 2: Enhancing quality of life for 
people with long-term conditions
Domain 3: Helping people to recover from 
episodes of ill health or following injury
Domain 5: Treating & caring for people in a 
safe environment & protecting them from 
avoidable harm
NICE guidance for the management of RA 
NICE quality standards for RA
Statement 1:
People with 
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persistent synovitis 
affecting the small 
joints of the hands 
or feet, or more 
than one joint, are 
referred to a 
rheumatology 
service within 3 
working days of 
presentation.
Statement 2:
People with 
suspected 
persistent 
synovitis are 
assessed in a 
rheumatology 
service within 3 
weeks of referral.
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People with newly 
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rheumatoid 
arthritis are 
offered short-term 
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and a combination 
of disease-
modifying anti-
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by a rheumatology 
service within 6 
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People with 
rheumatoid 
arthritis are offered 
educational and 
self-management 
activities within 1 
month of diagnosis.
Statement 5:
People who have 
active rheumatoid 
arthritis are 
offered monthly 
treatment 
escalation until the 
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controlled to an 
agreed low disease 
activity target.
Statement 6:
People with 
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arthritis and 
disease flares or 
possible drug 
related side effects 
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People with 
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arthritis have a 
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is coordinated by 
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Outpatient 
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2.3 UK ARTHRITIS GUIDELINES  
The NHS Outcomes Framework is supported by a suite of NICE clinical guidelines which 
provide recommendations on what high-quality care should look like for a particular 
condition or treatment. According to NICE (National Institute for Health and Care 
Excellence, 2013c) their guidance for the management of RA (National Institute for 
Health and Care Excellence, 2013b) can be linked directly to domain 2 of the NHS 
Outcomes Framework; therefore, supporting people to manage their RA should be 
integral to the decision to commission musculoskeletal services throughout England.  
 
NICE guidance for the management of RA were issued in 2009, with minor updates in 
2013 (National Institute for Health and Care Excellence, 2013b). The guidance offers 
best practice advice which is underpinned by the premise of person-centred care. It 
states that a person with RA should have the opportunity to make informed decisions 
about their care and treatment in partnership with healthcare professionals; 
supported by evidence and using information which is tailored to their needs. The 
guidelines indicate that measuring CRP and other key components of disease activity, 
such as the DAS28 should be undertaken monthly for recent-onset patients but once 
treatment has controlled the disease to a level previously agreed with the patient this 
ŵoŶitoƌiŶg should ďe doŶe ͞ƌegulaƌlǇ͟, although ͞ƌegulaƌlǇ͟ is Ŷot defiŶed. The 
frequency and location of appointments can then be organised according to the needs 
and demands of the patient. When a disease flare occurs, patients should have 
additional visits and know when and how to get rapid access to specialist care. An 
annual review should be offered to all people with RA to assess disease activity, 
function and damage, monitor co-morbidities and refer on to other services. Those 
who have a desire to know more about their condition should also be offered the 
opportunity to attend education sessions including self-management.  
 
Full guidelines for managing and treating RA were also published in 2009 (National 
Collaborating Centre for Chronic Conditions, 2009) and recommend that verbal and 
written information need to be provided to patients in order to improve their 
understanding of the condition and its management, and counter any misconceptions 
patients may have. People with RA who wish to know more about their disease and its 
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management should also be offered the opportunity to take part in existing 
educational activities, including self-management programmes. The guidelines also 
state that there is a lack of consistent evidence relating to the most effective 
frequency and location of follow-up appointments for established patients (i.e. primary 
or secondary care). It was noted that no one approach would be suitable for all and, 
therefore, for those in whom patient-initiated follow-up appointments are appropriate 
this method should be offered rather than regular routine reviews. These patients, 
however, need to be well educated about their disease and know about how and when 
to access services, whilst routine drug monitoring continues to take place. The 
guideline reports that in the absence of any evidence, annual reviews are a reasonable 
method to address the disease, complications and co-morbidities. There are currently 
no guidelines for the management of PsA, but in practice the above recommendations 
would be considered appropriate.  
 
NICE has since published the quality standard for RA (National Institute for Health and 
Care Excellence, 2013a), which includes seven quality statements that are aimed at 
high priority areas of health. These are specific, concise and measurable statements 
that act as markers of high-quality, cost-effective patient care. These standards 
contribute to the improvements outlined in the NHS Outcomes Framework 2013/14 
and map directly onto domain 2 (enhancing quality of life for people with long-term 
conditions) and domain 4 (ensuring that people have a positive experience of care). 
The quality statements most relevant to established patients with RA are Quality 
Statements 4, 6 and 7 (Figure 2.2). This includes an offer of self-management 
education within 1 month of diagnosis, receipt of advice within 1 working day of a 
report of disease flare or side effects and the provision of comprehensive annual 
reviews.  
2.4 RHEUMATOLOGY OUTPATIENT SERVICES IN THE UK 
The monitoring requirements of arthritis and DMARD therapy are traditionally and 
most frequently achieved by attending for blood tests either at the local hospital or GP 
practice followed by regular appointments with a rheumatologist and/or a CNS in the 
outpatient setting (Kay & Lapworth, 2004). This means that planned follow-up 
appoiŶtŵeŶts aĐĐouŶt foƌ appƌoǆiŵatelǇ ϳϱ% of the ƌheuŵatologist͛s ǁoƌkload 
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(Kirwan & Snow, 1991) and although exact figures are not available similar estimates 
have been reported for nurses working in rheumatology (Royal College of Nurse 
Rheumatology Forum, 2009). Between 1988 and 2000 however, the number of follow-
up cases seen in rheumatology outpatients increased by 58.3%, an average of 4.9% per 
year and this was dominated by patients with RA (Kirwan et al., 2003a). These follow-
up appointments are not only costly to the NHS, as described in Chapter 1, but are also 
potentially inconvenient and costly for patients as well, particularly for those in 
employment (Gignac, Cao, Lacaille, Anis, & Badley, 2008). These prescheduled 
appointments, which take up the bulk of outpatient time, reduce the flexibility of the 
NHS by increasing waiting times for new referrals and reduce the ability of the 
rheumatology team to respond rapidly to new and urgent cases. Despite this pressure 
on outpatients, follow-up appointments for patients with arthritis who are feeling well 
often result in little or no intervention (Mitchell, 2000). In fact 30% of rheumatologist 
outpatient appointments result in no investigations or other actions (Hehir et al., 
2001). When rheumatologists were asked about the appropriateness of these 
appointments, 10% could have been dealt with by a GP, in 35% of appointments 
patients had no problems and 55% required specialist rheumatology review. Overall 
42% of all visits were deemed completely unnecessary. It is, therefore, likely that a 
considerable amount of time and resources are wasted in rheumatology outpatient 
clinics and unsurprisingly alternative models of care are now being considered.     
 
In order to ensure that everyone receives high quality care in outpatients and to 
support the improvement of services for people of all ages with a musculoskeletal 
condition the Department of Health published the Musculoskeletal Services 
Framework (MSF) (Department of Health, 2006). This was part of the then 
goǀeƌŶŵeŶt͛s stƌategǇ foƌ loŶg-teƌŵ ĐoŶditioŶs, ǁhiĐh iŶĐluded ͚“uppoƌtiŶg people 
with long-teƌŵ ĐoŶditioŶs: IŵpƌoǀiŶg Đaƌe, iŵpƌoǀiŶg liǀes͛ (Department of Health, 
2005a) aŶd the ͚The NatioŶal “eƌǀiĐe Fƌaŵeǁoƌk foƌ loŶg-teƌŵ ĐoŶditioŶs͛ 
(Department of Health, 2005b). As opposed to the clinical guidelines published by NICE 
(National Institute for Health and Care Excellence, 2013b), BSR/BHPR (Coates et al., 
2013; Chakravarty et al., 2008) and EULAR (Smolen et al., 2013) the MSF focuses on 
delivery of services. The MSF sought to address the fragmented and incoherent 
services offered in musculoskeletal care by promoting a redesign. This included the 
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introduction of the 18 week referral-to-treatment target and the need to review all 
patients regularly. It detailed the provision of nurse-led monitoring clinics, support for 
self-management and the use of telephone advice lines. Despite a change in 
government and, therefore, vision for the NHS the MSF remains an important 
document for clinicians and allied health professionals with an interest in 
rheumatology as the NHS Outcomes Framework (Department of Health, 2013f) does 
not make specific reference to rheumatology services.  
 
In 2009 the Arthritis Musculoskeletal Alliance (ARMA) conducted an audit of the 
implementation of the MSF and found a worrying difference between UK trusts in the 
monitoring of follow-up waiting times for patients with RA (Arthritis and 
Musculoskeletal Alliance, 2009). Eighty-nine percent of trusts had not made an 
assessment of the average waiting time for a follow-up appointment, citing the 18 
week referral-to-treatment target as the reason for not doing so. This audit validated 
the Kings Fund report from the Rheumatology Futures Group (The King's Fund, 2009), 
which highlighted that although services had addressed the delays found in referral-to-
treatment time they had lost sight of how they monitored established patients. In 
parallel to the NICE guidance for management of RA (National Institute for Health and 
Care Excellence, 2013b), ARMA suggested that annual reviews should take place to 
ensure that all aspects of the condition, including the physical, psychological and 
educational needs of the patient are addressed.  
 
ARMA then conducted an update of the audit in 2011 to ascertain whether any 
progress had been made since 2009 (Arthritis and Musculoskeletal Alliance, 2012). The 
updated audit found that musculoskeletal services continued to suffer from large-scale 
variation in the way they were delivered. In fact an even worse situation was found in 
ƌegaƌds to a Ŷuŵďeƌ of the M“F͛s ƌeĐoŵŵeŶdatioŶs, iŶĐludiŶg the assessŵeŶt of 
average waiting times for a follow-up RA appointments, which only 9% of trusts had 
achieved, a drop from 11% in 2009 (Arthritis and Musculoskeletal Alliance, 2009). 
Therefore, this indicated that there was a continued focus on initial waiting times for 
treatment rather than the care of established patients.  
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IŶ paƌallel ǁith A‘MA͛s ϮϬϬϵ audit the NatioŶal Audit OffiĐe ;ϮϬϬϵďͿ puďlished a 
report on the services provided for people with RA, which aimed to examine the 
potential for improving the delivery of services. It included a census of all NHS trusts 
with a rheumatology department between November 2008 and January 2009 
(National Audit Office, 2009a), of which 95% of trusts responded. A majority reported 
an increase in the number of new patients with RA, compared to figures from the 
previous financial year and on average 50% of all outpatient appointments were for 
those with RA. In the case of a flare a majority of trusts advised their patients to call 
the nurse telephone advice line or contact their consultant directly. However, 66% of 
trusts did not have the capacity to offer all RA patients who needed them follow-up 
appointments on a timely basis. Sixty-three per cent were able to offer an annual 
review for established patients and only 40% could offer monthly reviews for patients 
with active disease. The primary barriers to not providing these services were lack of 
outpatient capacity, emphasis on referral-to-treatment targets and lack of staffing. The 
report concluded that patients with well-controlled RA should be offered review 
appointments at a frequency and location suitable to their needs but in order to 
address the gap between need and capacity it recommended that services should 
develop new models of delivery.  
 
The following section will now review these new models of care along with the 
traditional service of rheumatologist-led clinics in order to establish possible methods 
via which these issues could be addressed. 
2.5 MODELS OF CARE FOR ESTABLISHED PATIENTS IN RHEUMATOLOGY 
2.5.1 Introduction 
At the time of the MSF being published the Department of Health was also focused on 
the improvement of services more widely and suggested that a reduction in how 
unnecessary new and follow-up outpatient appointments and do not attends (DNAs) 
could substantially reduce costs and streamline services (National Health Service 
Institute for Innovation and Improvement, 2006). Since then a number of strategies 
have been developed with the aim of increasing capacity in rheumatology services 
whilst attempting to maintain high quality care. A report published by Li et al., (2008) 
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synthesized these strategies in order to develop an integrated service delivery 
framework in rheumatology. The authors reviewed the literature in relation to the 
delays found in the various stages of the care pathway, from identification of 
symptoms by the patient and the delay in seeking help, through to referral for 
orthopaedic consultations. Forty-eight articles were found each of which focused on 
one of five potential times of delay in the: community, primary care, secondary care, 
follow-up and referral for orthopaedic review. The evidence in relation to secondary 
care supported the role of allied healthcare professionals in reducing delay, including 
nurses, physiotherapists and occupational therapists in providing tailored education 
and non-pharmacological treatments such as performing musculoskeletal 
examinations, monitoring and recommending changes to medications. The authors 
also recognised the role of patient-centred care in follow-up services and proposed 
that patient-initiated care could be integrated into the framework. Central to all of 
these strategies, however, was the aim to improve the care and management of RA 
and PsA to ensure that the appropriate patients are seen by an appropriate person in 
an appropriate setting and in a timely manner (Hay & Adebajo, 2005). The following 
sections consider each of the models of follow-up care in more detail.  
2.5.2 Consultant-led care 
Rheumatologists are seen as central to the treatment and management of 
inflammatory arthritis (Badley & Davis, 2012; Smolen et al., 2013). Regular reviews are 
ingrained in medical practice (Spence, 2013) and particularly so in rheumatology where 
patients are required to attend ongoing reviews with a rheumatologist and nurse. 
These appointments are customarily managed within a scheduling system that 
arranges appointments well in advance. The frequency of visits does vary but are 
normally scheduled for every 3-6 months (Li et al., 2008) and last for between 10 and 
15 minutes (Royal College of Physicians, 2011). These reviews will customarily include 
an assessment of disease status, damage, function, co-morbidities and a review of 
current needs including medication, education, psychosocial support and referral to 
other services.  
 
As with most other long-term conditions, the delivery of musculoskeletal services is 
within the organisational framework of the local healthcare system and is a balance 
Chapter 2 – UK Service Delivery in Rheumatology 
 
63 
between not only need and demand but also the availability of resources. As a result a 
decision to follow a patient with arthritis up, or the timeframe in which to do this, is 
based not only on the severity and volatility of the condition but also the availability of 
clinic slots (Bukhari, Bamji, & Deighton, 2007). This advanced booking system may, 
therefore, mean that some patients are followed-up by their rheumatologist at a time 
when no help is required, whereas others may not be able to access the 
rheumatologist when they are in most need. The result is that rheumatologist-led 
follow-up appointments for patients with arthritis who are feeling well often result in 
little or no intervention (Mitchell, 2000; Hehir et al., 2001) as previously stated (section 
2.4, page 58).  
 
The organisation and frequency of outpatient visits to the rheumatologist may also be 
iŶflueŶĐed ďǇ the ͚PaǇŵeŶt ďǇ ‘esults͛ sǇsteŵ iŵpleŵeŶted ďǇ the DepaƌtŵeŶt of 
Health (2013c). This payment system implemented in England sees commissioners pay 
healthcare providers for each patient seen or treated; with the amount dependant on 
the ĐoŵpleǆitǇ of the patieŶt͛s healthĐaƌe Ŷeeds. ͚PaǇŵeŶt ďǇ ƌesults͛ iŶĐeŶtiǀises 
hospitals for outpatient attendance. The tariff offered for a new patient in 
rheumatology is more than twice of that of a follow-up patient, £214 versus £100 
(Department of Health, 2013d). This disparity could in part explain why 
rheumatologists are now being driven to reduce their new to follow-up ratios (i.e. 
more new and fewer follow-up patients) or work to fixed ratios that are lower than 
their usual practice. A recent survey of rheumatologists found that 35% had been 
asked to work to a set new to follow-up ratio and this on average was 3.1:1 (Bukhari, 
Dixey, & Deighton, 2011). As noted earlier figures in 1991 suggested that planned 
follow-up appointments accounted foƌ appƌoǆiŵatelǇ ϳϱ% of the ƌheuŵatologist͛s 
workload (Kirwan & Snow, 1991). These more recent data, therefore, suggest an 
attempt to reverse these proportions. This drive to review new patients quickly is 
justified given the evidence for early intervention and tight disease control (Strand & 
Singh, 2007; Grigor et al., 2004; Tanaka et al., 2008) however, a clear and appropriate 
care pathway for established patients would need to be implemented in order to meet 
the needs of this population as well. The findings of Bukhari et al., (2011) sparked 
debate about the influence of the CNS on these new to follow-up ratios and the 
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potential for DMARD monitoring clinics to be run by these nurse, along with moving 
activity out in to the community. 
 
Early evidence suggested that access to specialist rheumatology input resulted in 
better patient outcomes than management by non-rheumatologists alone (Yelin, Such, 
Criswell, & Epstein, 1998; Criswell, Such, & Yelin, 1997). This was attributed to earlier 
intervention with DMARD therapy. The effectiveness of rheumatologist-led services 
has not, in itself, been evaluated in recent years most likely because this is the 
traditional and most established method of reviewing and monitoring patients with 
arthritis. However, it is often employed as a comparator group in trials of what are 
considered more contemporary models of care including nurse-led clinics, 
rheumatology clinics in primary care and patient-initiated services, all of which will be 
reviewed in the following section. This will provide an understanding of how 
consultant-led services compare with more recent developments in service delivery.  
 
As a result of current government policy there is now a significant focus on the 
community and a shift of some hospital-based rheumatology services into primary 
care. This could be achieved either by introducing GP-led services (as reviewed in 
section 2.5.4, page 74) or by moving rheumatologist or CNSs out into the community. 
The former may explain why the number of consultant physicians in rheumatology has 
expanded in the UK by only 3.1% from 2003 to 2011 compared with 5.2% across all 
other general medical specialities (Royal College of Physicians, 2013). The latter may 
explain why the proportion of rheumatology consultants with sessions in primary care 
has increased from 9% in 2007 to 15% in 2009 (Harrison, Lee, Deighton, & Symmons, 
2011). There has also been a growth in the number of musculoskeletal services being 
run in conjunction with clinical assessment and treatment services in England, which 
provide patients with quick and accessible assessment, diagnostics and treatment 
services under one roof, from 13% in 2007 to 17% in 2009 (Harrison et al., 2011). 
These services are, however, yet to be evaluated and BSR has expressed anxiety about 
these changes and the impact they are having on the rheumatology workforce (Royal 
College of Physicians, 2013). 
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Evaluation of these so called outpost clinics, whereby specialist services are run in the 
community by rheumatologists suggests that patients are highly satisfied with the 
service they receive. This is probably due to the proximity and more scheduled time 
with the consultant due to a more rigid booking system. However, this makes the 
ĐoŵŵuŶitǇ settiŶg less ͞effiĐieŶt͟, defiŶed as the Ŷuŵďeƌ of patieŶts seeŶ peƌ ĐliŶiĐ, 
as hospital based systems allow for overbooking. Although the community clinic has 
been found to be cheaper with regard to total staff costs (£114 versus £262), estate 
costs, travel and the higher consultation rate meant that the overall cost per patient in 
the hospital setting was lower (£10.35/patient versus £15.93/patient) (Helliwell, 1996).  
2.5.3 Nurse-led care 
 Face-to-face care 
The introduction of the rheumatology CNS iŶ the ϭϵϴϬ͛s heƌalded aŶ iŵpoƌtaŶt step 
towards developing a multidisciplinary team in the care of patients with arthritis. 
Initially activities included basic disease management and patient education but more 
recently the role of the CNS in rheumatology has been extended to incorporate 
activities traditionally undertaken by the consultant and nurses now lead their own 
clinics separate to that of the rheumatologist (Vliet Vlieland, 2004). A survey 
conducted by the Royal College of Nurse Rheumatology Forum (2009) found that 
rheumatology nurses hold on average 4-5 clinics per week, consisting of 4-10 follow-up 
patients per clinic session and 1-2 emergency patients, with an average slot of 30 
minutes per follow-up appointment, double that of a rheumatologist. For over 70% of 
nurses these clinics consist primarily of patients with RA or PsA. The survey also 
revealed that 44% of rheumatology nurses had been asked to change their usual work 
pattern or take on extra work within the previous 18 months. This was primarily in 
relation to extra clinics and changes in their role or service, described by the nurses 
theŵselǀes as ͞iŶĐƌeased aĐtiǀitǇ ǁithout iŶĐƌeased ƌesouƌĐes͟. Foƌ oǀeƌ ϴϬ% of the 
sample monitoring patients on DMARDs and educating patients about their disease 
and its management were a major, or significant part of their role (Royal College of 
Nurse Rheumatology Forum, 2009).  
 
In the UK nurse-led rheumatology clinics are now a well-established method for 
following up stable patients and reviewing new patients with possible arthritis. As 
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highlighted by the Royal College of Nurse Rheumatology Forum (2009) rheumatology 
nurses play an important role in addressing the unmet needs of patients with arthritis. 
Research both with fellow rheumatology healthcare professionals (Cottrell et al., 2012) 
and patients with arthritis (van Eijk-Hustings et al., 2013) indicate that disease and 
drug monitoring, education, self-management support, emotional support and well 
organised care are essential parts of the rheumatology nurse role. It appears that 80% 
of CNSs in rheumatology are already routinely performing these activities (Goh, 
Samanta, & Samanta, 2006).   
 
Until recently, however, the evidence for the effectiveness of rheumatology nurse-led 
clinics was not robust. A systematic review published by Ndosi, Vinall, Hale, Bird and 
Hill (2011) aimed to analyse the clinical effectiveness of nurse-led rheumatology 
services for people with RA. Seven randomized controlled trials (RCTs) (Hill, Thorpe, & 
Bird, 2003; Hill, Bird, Harmer, Wright, & Lawton, 1994; Hill, 1997; Tijhuis et al., 2002; 
Tijhuis, Zwinderman, Hazes, Breedveld, & Vlieland, 2003; Tijhuis et al., 2003; Ryan, 
Hassell, Lewis, & Farrell, 2006) were found, four of which were conducted in the UK 
(Hill et al., 2003; Hill et al., 1994; Hill, 1997; Ryan et al., 2006). Pooled effects in the 
meta-analyses suggested equivalence between nurse-led care and usual care, which 
tended to be a consultant-led service, with regard to pain, morning stiffness, DAS28 
scores, plasma viscosity, physical or psychosocial functioning. The nurse-led follow-up 
service did, however, lead to significant improvements in joint tenderness, knowledge 
and satisfaction. But as there were so few studies the authors of the review concluded 
that good quality RCTs were still required in order to provide evidence for the 
effectiveness of nurse-led care for people with RA. In addition the review did not 
include the cost-effectiveness analysis reported in the study by Van den Hout, Tijhuis, 
Hazes, Breedveld and Vlieland (2003). This study indicated that although compared 
with inpatient and day patient team care, CNS care led to equivalent quality of life, the 
nurse-led clinic was associated with lower societal and hospital costs. 
 
Since this systematic review a number of good quality RCTs have been conducted. This 
includes a UK based multi-centre pragmatic RCT conducted by the authors of the 
systematic review (Ndosi et al., 2013). In this trial patients with RA had five follow-up 
visits over a 12 month period either in a nurse-led or rheumatologist-led clinic. The 
Chapter 2 – UK Service Delivery in Rheumatology 
 
67 
nurse-led consultations covered a combination of pain control, medication and dosage 
changes, intra-articular or intra-muscular steroid injections, provision of patient 
education and psychosocial support, prescription of splints, non-protocol blood tests 
oƌ ƌadiogƌaphiĐ eǆaŵiŶatioŶ aŶd ƌefeƌƌals. The ƌheuŵatologist pƌoǀided ͞usual Đaƌe͟, 
although exact details were not provided. The analysis indicated that the nurse-led 
clinic was equivalent to a clinic led by a rheumatologist with regards to disease activity 
and in fact led to significant improvements in satisfaction, pain and physical function 
compared with the rheumatologist-led clinic. There was, however, a significant 
worsening in patient fatigue, stiffness and mood in the nurse-led service compared to 
slight improvements in the rheumatologist-led group. Definitive conclusions with 
regards to cost-effectiveness were difficult as the analysis suggested cost benefits 
when disease activity was considered, but when quality-adjusted life-years were used 
the intention to treat (ITT) analyses indicated no significant cost benefits for the nurse-
led clinic.  
 
A number of trials have also been conducted in inflammatory arthritis outside of the 
UK (Koksvik et al., 2013; Larsson, Fridlund, Arvidsson, Teleman, & Bergman, 2013; 
Koksvik et al., 2013; Larsson et al., 2013; Primdahl, Sørensen, Horn, Petersen, & 
Hørslev-Petersen, 2014). In an RCT conducted by Koksvik et al., (2013) in Norway a 
nurse specialist-led clinic was compared to follow-up by a medical doctor for patients 
with inflammatory arthritis who had just started DMARD therapy. The nurse service 
consisted of assessment of disease activity, co-morbidities, medication use, function 
and psychosocial well-being; the ĐoŶteŶt of the doĐtoƌ͛s ĐliŶiĐ ǁas Ŷot desĐƌiďed otheƌ 
than being usual practice. At 21 months post-implementation participants in the nurse-
led service were significantly more satisfied with their care, with the provision of 
information, felt that the service was more empathic and technically competent and 
ǁeƌe ŵoƌe positiǀe aďout the ĐliŶiĐiaŶ͛s attitude toǁaƌds theŵ, the aĐĐess theǇ had 
and the continuity of care. There were also no significant differences in disease 
activity, pain or quality of life suggesting at least equivalence in symptoms and 
psychosocial well-being between the two services.  
 
Similar findings were also been reported in an RCT by Larsson et al., (2013) who 
evaluated an exclusive rheumatologist-led follow-up service with a system which 
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alternated between a rheumatologist-led appointment and a person-centred nurse-led 
clinic for patients with chronic inflammatory arthritis treated with biological therapy. 
In the exclusive rheumatologist-led service patients had a 30 minute appointment 
every 6 months for an assessment of disease activity and medication side effects. 
Patients were also able to contact the rheumatology clinic between these scheduled 
follow-up visits. In comparison participants in the other arm of the trial alternated 
between the nurse-led clinic and a rheumatologist-led appointment. These nurse-led 
appointments were person-centred whereby patients were given the opportunity to 
talk about their illness openly in order to build collaboration between the patient and 
the nurse. Disease activity was also assessed and laboratory tests evaluated the same 
as in the rheumatologist-led clinic. The service aimed to empower patients to take an 
active role in their treatment and find solutions to any problems they encountered; 
however, exact details about how this was achieved was unclear. Over the 12 month 
evaluation there were no statistically significant differences in changes in disease 
activity, tender and swollen joints, pain, disability, satisfaction or confidence in the 
system between the two groups. Qualitative interviews with those in the nurse-led 
service found that patients felt that the nurse was added value and indicated that the 
service made the care pathway more complete (Larsson, Bergman, Fridlund, & 
Arvidsson, 2012).  
 
In a three arm trial conducted in Denmark, Primdahl et al., (2014) compared a control 
group which included consultations with the rheumatologist every 3-12months, with a 
͞shaƌed Đaƌe͟ gƌoup (discussed further in section 2.5.6.1, page 82) and a nursing 
group, which included 30 minute appointments with a specialist nurse every 3 months 
covering medication monitoring, clinical assessment and self-management issues. At 
the 2 year follow-up the nursing group had significantly greater self-efficacy along 
more confidence and satisfaction in the care they received compared with the 
rheumatologist group. There were also no significant differences between nursing care 
and the control group on any of the patient safety measures, including adherence to 
blood monitoring, out-of-range blood tests and the number of side effects. Further 
analysis of this study found that reduced disease activity, a shorter disease duration 
and less fatigue and functional disability at baseline were associated with greater 
improvements in self-efficacy at 3 months (Primdahl, Wagner, Holst, & Hørslev-
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Petersen, 2012). A subsequent qualitative study was undertaken which aimed to 
compare the experiences of patients in each of these three groups (Primdahl, Wagner, 
& Hørslev-Petersen, 2011b). The data indicated that patients valued the continuity of 
care, that their relationship with their nurse was more holistic than with the 
rheumatologist and all patients felt able to contact the service for additional advice if 
they felt it necessary.   
 
A Rheumatology Monitoring Clinic jointly run by Advanced Practice Nurses or 
pharmacists, under the supervision of a rheumatologist has also been implemented in 
Singapore (Chew & Yee, 2013; Chew et al., 2012). These clinics were for established 
patients on a stable dose of DMARDs and inactive or stable disease activity. Monitoring 
of disease activity and side effects were undertaken along with issuing repeat 
prescriptions. In the event of a flare or medication-related complications the 
rheumatologist was approached for their specialist input (Chew & Yee, 2013). Over a 1 
year period 200 patients were seen in the service, a random sample of these patients 
were audited, which indicated that patients remained largely stable (although the 
definition of stability was not provided). Ten percent of sample required either an 
increment, reduction or discontinuation of their DMARD therapy. According to the 
authors these patients were detected early and were seen by a rheumatologist in a 
͞tiŵelǇ ŵaŶŶeƌ͟. “atisfaĐtioŶ ǁas ŵeasuƌed ǀia a suƌǀeǇ of ϵϳ patieŶts seeŶ ǁithiŶ the 
clinic over a 6 month period, 84% of whom had RA (Chew et al., 2012). An 
overwhelming majority of the sample felt more confident in their ability to take their 
medication and adhere to treatment after their appointment. Patients also felt that 
the therapist provided clear and detailed information about their disease and 
medication and hence they had a better understanding of their disease and medication 
and knew what to look out for if their condition deteriorated or if they developed side 
effects. They also felt that their therapist was professional and knowledgeable and 
were willing to come back for follow-up assessment in the clinic. Seven 
rheumatologists and six professionals running the clinic also completed questionnaires 
aŶd all ǁeƌe satisfied ǁith the patieŶts͛ ŵaŶageŵeŶt aŶd ĐoŶtƌol of theiƌ disease. The 
rheumatologists all agreed that the therapists were professional, knowledgeable and 
capable in providing this service and 80% agreed that the clinic freed up time for them 
to see more complex cases. Those running the clinic felt that the referrals were 
Chapter 2 – UK Service Delivery in Rheumatology 
 
70 
appropriate and workflow was acceptable. This study, however, was not an RCT but an 
internal audit conducted by the team one year after implementation of the service. 
The findings, therefore, cannot be assumed to be attributable to the new model of 
care.  
 
In addition to these quantitative trials a number of qualitative studies have been 
undertaken to explore the impact of nurse-led rheumatology clinics from the patient 
perspective. Arvidsson et al., (2006) interviewed 16 patients with RA who had been 
treated with DMARD therapy in a nurse-led rheumatology clinic. The clinic was found 
to have an impact on the empowerment of patients by teaching them about their 
condition and treatment options along with how to adapt their activities and daily life 
in order to live with arthritis. Regular reviews with the same nurse gave patients a 
sense of security and comfort. In these visits the approach was more holistic and as a 
result patients felt respected and listened to. Similarly, Bala et al., (2012) interviewed 
18 people also with RA who had experience of a nurse-led rheumatology clinic and 
found that their experience was one of a person-centred, holistic approach to care.  
 
There is an ongoing RCT being conducted in Sweden (Bergsten, 2014) comparing a 
nurse-led clinic including person-centred care and tight control with usual care in 
patients with RA and moderate or high disease activity. Usual care is described as visits 
to physician every 6 months, whereas the nurse-led clinic will be visits every 6 weeks, 
with structured person-centred care and evaluation of disease activity. If disease 
remission is not reached in the nurse-led group, pharmacological treatment including 
both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs 
and biologics) will be made according to a predefined algorithm. The study will recruit 
120 patients and compare disease activity, quality of life, pain, fatigue, self-
management skills, beliefs about medicines and satisfaction with care over a 6 month 
period. The study is due to complete in 2015 and will provide further evidence either 
for or against the use of nurse-led rheumatology services.  
 
As a result of these studies EULAR (van Eijk-Hustings et al., 2012) have outlined 10 
recommendations for the role of the nurse in the management of chronic 
iŶflaŵŵatoƌǇ aƌthƌitis͛ iŶĐludiŶg ‘A aŶd PsA ;Figure 2.3). In the development of these 
Chapter 2 – UK Service Delivery in Rheumatology 
 
71 
recommendations, the role and capabilities of the nurse in rheumatology services 
were found to vary quite significantly between countries. The recommendations 
acknowledged that the value of a rheumatology nurse was most prominent and 
important in disease monitoring as well as in support for patients across a range for 
ĐhƌoŶiĐ iŶflaŵŵatoƌǇ aƌthƌitis͛. The recommendations also recognised that high-
quality studies, with clear descriptions of nursing roles and interventions needed to be 
conducted as the role of the nurse in care is currently often not clearly stated in many 
studies.  
 
1. Patients should have access to a nurse for education to improve knowledge of 
chronic inflammatory arthritis and its management throughout the course of their 
disease. 
 2. Patients should have access to nurse consultations in order to experience 
improved communication, continuity and satisfaction with care. 
3. Patients should have access to nurse-led telephone services to enhance continuity 
of care and to provide ongoing support. 
4. Nurses should participate in comprehensive disease management to control 
disease activity, to reduce symptoms and to improve patient-preferred outcomes. 
5. Nurses should identify, assess and address psychosocial issues to minimise the 
ĐhaŶĐe of patieŶts͛ aŶǆietǇ aŶd depƌessioŶ. 
6. Nurses should promote self-management skills in order that patients might 
achieve a greater sense of control, self-efficacy and empowerment. 
7. Nurses should provide care that is based on protocols and guidelines according to 
national and local contexts. 
8. Nurses should have access to and undertake continuous education in order to 
improve and maintain knowledge and skills. 
9. Nurses should be encouraged to undertake extended roles after specialised 
training and according to national regulations. 
10. Nurses should carry out interventions and monitoring as part of comprehensive 
disease management in order to achieve cost savings. 
Figure 2.3. EULAR recommendations for rheumatology nursing management of chronic 
inflammatory arthritis 
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In summary, the literature suggests that nurse-led follow-up clinics for patients with 
chronic inflammatory arthritis are at the very least equal to, if not superior to 
rheumatologist-led clinics, in relation to disease activity, symptoms and psychosocial 
outcomes. Despite the evidence regarding the role of nurse-led clinics, problems still 
persist in many services regarding limited access for established patients with acute 
pƌoďleŵs, high ͞Ŷo shoǁ͟ ƌates, aŶd the ƌoutiŶe sĐheduliŶg of folloǁ-up visits often 
well in advance for no defined purpose, all of which are indications of sub-optimal and 
inefficient care (Newman & Harrington, 2007). The development of telephone clinics 
have gone someway to addressing these issues and will be reviewed in section 2.5.3.3 
(page 72).  
 Community 
Community based nurse-led rheumatology services have also been implemented in the 
UK, although evaluations are extremely scare. These services tend to involve 
management of arthritis in the home for people who are housebound. In an audit of 
such a service Douglas et al., (2009) found that over a 3 month period 1510 patient 
contacts were made by the nurse team, which would have been traditionally seen by a 
rheumatologist in clinic. Four percent of patients required a home visit from the nurse, 
11% urgent contact visits (i.e. joint injections), 31% clinic visits and 53% a telephone 
contact. The service, however, was not formally evaluated and it was unclear how 
decisions were made with regards to who entered the service, who was subsequently 
seen and via what method (i.e. at home or in clinic). The evidence for community 
based rheumatology nursing is, therefore, lacking.   
 Telephone care 
Nurse-led telephone clinics are becoming increasingly more popular as an alternative 
to face-to-face clinic visits as they address some of the concerns highlighted by 
Newman and Harrington (2007). Unlike a nurse-led telephone help-line, appointments 
are scheduled like a standard face-to-face visit for the nurse to review and monitor the 
patient. The feasibility and acceptability of this mode of follow-up has been found to 
vary. Whilst Hawley and Quilty (2009) report that only 12% of rheumatology patients 
could be followed-up using a telephone review due to the stage of their illness and 
treatment, Pal (1997) found that 80% of patients would be willing to accept a 
telephone follow-up appointment. This suggests a difference between what clinicians 
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feel is feasible and what patients find acceptable. Pal (1998) reported the results of a 
pilot study that followed rheumatology patients up by telephone rather than face-to-
face. These calls included a review of progress, changes in the disease and its 
treatment, and feedback from test results. Ninety per cent of patients were satisfied or 
very satisfied with the service and most patients felt that the advantages of saving 
time and money, less stress and fewer problems with transport, outweighed the 
disadvantages of telephone clinics being impersonal, the potential for 
misunderstandings and problems that might occur as a result of hearing and language 
issues.  
 
Hennell, Spark, Wood and George (2005) evaluated a nurse-led telephone clinic, aided 
by a consultation proforma which reflected a traditional outpatient consultation, 
covering diagnosis, current medication, monitoring attendance and blood test results. 
Patients were also asked to report any current joint swelling and/or tenderness. At the 
end of the consultation the content was summarized for the patient and the plan of 
action confirmed. During the first month 71 patients who were on the follow-up 
waiting list were allocated a nurse-led telephone appointment, three patients were 
not in or did not answer the telephone. Of the 68 patients surveyed 72% were very 
happy with their consultation and would be happy to use the service again, those that 
were not happy (8%) preferred to see the nurse in person in the future. This telephone 
clinic enabled nurses to review more patients and, therefore, helped reduce follow-up 
wait times by 2 months, down to the recommended 3 monthly interval.  
 
In both studies however, the quality of the methodology and reporting of the 
intervention content and exclusion/inclusion criteria were poor. It is assumed in both 
studies that telephone calls were a replacement for standard face-to-face contact 
although the authors do not clearly state this. There was also no comparison group 
and hence no randomisation of participants, or no details on what clinical care and 
from whom the patients continued to receive. Failure to collect data on clinical 
outcomes makes it difficult to establish if this form of contact had any detrimental 
impact on health and well-being. These studies suggest tentative evidence for nurse-
led telephone consultations in regards to patient acceptability; however, more robust 
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trials need to be undertaken to establish whether this mode of delivery is in any 
clinically or psychologically detrimental to patient well-being.   
2.5.4 GP-led care 
As reported earlier, there is little evidence to support either rheumatologist or CNS-led 
primary care services. Therefore, much of the published literature on rheumatology 
community services focuses on the role of GPs in the management of patients with 
arthritis early in the disease course, either alone or in collaboration with 
rheumatologists, the premise being that this will free up specialist services for those 
with more complex needs such as those with RA and PsA who require DMARD therapy.  
 
This shift is occurring despite the fact that there is little evidence to suggest that GP-
led monitoring of patients with arthritis on DMARD therapy is effective. In fact 
concerns have been raised about the impact that discharging patients with chronic 
inflammatory arthritis back to primary care will have on GP workload (Bukhari et al., 
2011). There are also concerns about the inadequacy of rheumatology education in the 
primary care setting (Wise & Isaacs, 2005). The knowledge of the treating healthcare 
professional is considered by rheumatology patients as one of the most important 
aspects of care (Jacobi, Boshuizen, Rupp, Dinant, & Van Den Bos, 2004). However, 27% 
of patients surveyed by Jacobi et al., ;ϮϬϬϰͿ felt that theiƌ GP͛s kŶoǁledge ǁas 
inadequate for specialist rheumatology care. 
 
MusĐuloskeletal disoƌdeƌs ŵake up appƌoǆiŵatelǇ ϭϴ% of a GP͛s peƌĐeiǀed ǁoƌkload 
(Roberts, Adebajo, & Long, 2002). In this survey of 240 GPs in the UK over one third 
were confident that with advice from a rheumatologist they could manage a patient 
with early RA (Figure 2.4). A further 34% were confident to make a diagnosis but would 
prefer to refer long-term monitoring and management to a rheumatologist (Roberts et 
al., 2002). This lack of confidence may prove problematic as it may generate reluctance 
to provide rheumatological care (Mann, 2006).  
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Figure 2.4. Level of GP self-confidence in managing early RA 
 
In addition population based studies in Canada show that patients with RA managed 
predominantly by primary care physicians are less likely to be prescribed DMARDs 
(Lacaille, Anis, Guh, & Esdaile, 2005; Shipton, Glazier, Guan, & Badley, 2004). Similar 
findings from a UK survey comparing a primary care-led rheumatology service with 
secondary care found that fewer patients with RA or unspecified inflammatory arthritis 
managed in primary care were taking a DMARD compared to those in secondary care 
(Hetthen & Helliwell, 1999). These studies suggest that GPs not only lack confidence in 
their ability to manage established patients with arthritis but the provision of DMARD 
therapy in primary care is poor and in direct contrast to the guidelines which 
recommend treatment to be started as early as possible in order to obtain tight control 
of the condition (National Institute for Health and Care Excellence, 2013b). Evaluations 
of GP-led rheumatology services have been conducted. Schulpen et al., (2003) 
explored the feasibility of referring patients with arthritis back to their GP for 
management. If considered eligible by the rheumatologist, although it was unclear 
what the eligibility criteria were, consenting participants were randomized to either 
remain under the care of their rheumatologist or referred back to the GP. Those 
randomised to referral back to their GP were presented during a joint consultation 
clinic where the rheumatologist explained to the GP how their follow-up care should 
proceed. From that moment on follow-up care was provided by the GP with the 
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opportunity to consult the rheumatologist at any subsequent joint consultation clinic. 
At the start of the study 276 patients were identified as having been originally referred 
from one of the 17 participating GP practices. Of these 276 patients, 45% had been 
subsequently discharged from secondary care without the need for any additional 
medical follow-up, and 32% were deemed to require specialist follow-up. Overall in 
only 10% of cases was it deemed appropriate to refer their care back to the GP 
suggesting that community-led services may not be an acceptable model of care from 
the specialist perspective. This may in part be due to the lack of faith rheumatologists 
had in the ability of the GPs to manage established arthritis and as a result classified 
the patient as needing specialist services. It is unclear, however, what the composition 
of this population was as authors failed to detail the diagnostic status of participants 
and how many patients had chronic inflammatory arthritis. It could be that those 
remaining in specialist services were not established on their treatment or were 
experiencing a period of flare which meant the rheumatologist wanted to review the 
patient more closely. Schuplen et al., (2003) concluded that moving follow-up services 
to primary care does not appear to be the solution as the gap in specialist knowledge 
between rheumatologists and GP is too wide.  
 
Other evaluations of GP-led follow-up clinics from the clinical and patient perspective 
have been undertaken (Hetthen & Helliwell, 1999; Arthur & Clifford, 2004b; Arthur & 
Clifford, 2004a) however, the quality of these studies suggests that there is a lack of 
methodologically robust evaluations within the published literature.  
 
Hetthen and Helliwell (1999) compared 100 patients, with different rheumatological 
diagnosis, seen at a GP-led rheumatology service and 100 patients, seen at a hospital-
based rheumatology outpatient service on both clinical and patient reported outcomes 
(PROMS). Two GP services were commissioned to deliver specialist rheumatology care 
in general practice whilst at the same time acting as clinical assistants in the 
rheumatology outpatient department, working alongside the rheumatologists to 
increase their knowledge and skills. Patients seen in primary care had a median waiting 
time of 0 days compared with 37.5 in secondary care. A majority of patients was 
satisfied with the convenience and length of their appointment and this was similar 
across both groups. Utilisation of support services such as blood tests, radiography, 
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physiotherapy, occupational therapy and podiatry were, however, greater in 
secondary care, as was provision of written information to the patient. Although levels 
of disability were much greater in secondary care, this was likely to reflect the greater 
proportion of patients with established disease attending these clinics. The number of 
patients with RA or inflammatory arthritis on DMARDs was also substantially lower in 
the primary care group (22%) compared with secondary care (69%). This suggests 
either that the GP-led service was being utilised as a substitute for early referral rather 
than for ongoing monitoring and management of established patients who remained 
in secondary care, or established patients in primary were being under prescribed 
DMARDs. This latter hypothesis supports previous findings (Lacaille et al., 2005; 
Shipton et al., 2004) but as the authors failed to describe the sample adequately it is 
not possible to establish the reasons for these discrepancies. In addition the authors 
failed to report the inclusion and exclusion criteria for patients being referred into 
either service.  
 
Arthur and Clifford (2004b) conducted a qualitative study of 10 rheumatology patients 
all taking DMARDs; five being followed up by their GP in primary care and five by a 
rheumatology nurse in a secondary care nurse-led clinic. Participants were asked what 
they expected when they attended their drug monitoring appointment and what they 
would you like to happen in an ideal world. Both groups of participants gave varying 
responses, but those in secondary care tended to provide more examples and spoke 
more about feeling empowered and the psychological care offered by the 
rheumatology nurse whilst those in primary care focused more on the technical 
aspects such as tests. Those cared for in the hospital setting were sceptical about the 
ability of GPs to provide specialist care and knowledge; praising the quality and 
quantity of the information given to them by their nurse as compared to previous 
experiences with their GP.   
 
The same authors also conducted a quantitative assessment of patient satisfaction 
between two cohorts of patients with RA on DMARD therapy (Arthur & Clifford, 
2004a). The first was a group of patients whose drug monitoring was undertaken by 
the GP supplemented by 4 monthly follow-up appointments with the consultant 
rheumatologist in the outpatient department (primary care route). The other group of 
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patients were referred to the rheumatology nurse and attended nurse-led clinics in the 
outpatient department for monitoring, along with 4-6 monthly appointments with 
their rheumatologist (secondary care route). Levels of satisfaction were high in both 
groups but in contrast to the study by Hetthen and Helliwell (1999) who found no 
difference, satisfaction was significantly higher in secondary care across all six 
dimensions of satisfaction (general satisfaction, information provision, empathy, 
technical quality, attitude to patient, continuity of care and overall satisfaction). Those 
managed in secondary care were also more likely to have received information about 
their disease. It was, however, unclear from the published article how patients were 
selected for referral into the primary or secondary care route. The use of a non-
randomized convenience sample also means that these participants may not be 
representative of the larger population and hence the findings cannot be generalised. 
 
A number of trials have evaluated a ͞shaƌed-Đaƌe seƌǀiĐe͟ (Hewlett et al., 2000; Kirwan 
et al., 2003b; Hewlett et al., 2005b; Primdahl et al., 2012; Primdahl et al., 2014) in 
which GPs monitor DMARD therapy but care, either from the GP or rheumatology 
team is initiated by the patient with no regular scheduled appointments. This model of 
care will be reviewed in section 2.5.6.1 (page 82). 
 
Although GPs with a specific clinical interest such as rheumatology are not new, there 
is now recogŶitioŶ of a Ŷeǁ ͞ďƌeed͟ of GP: ͞a GP ǁith a speĐialist iŶteƌest͟ (Hay & 
Adebajo, 2005) and there are now recognised services delivered in primary care by 
these clinicians (Roberts, Dolman, Adebajo, & Underwood, 2003) and associated 
accreditation for the role (Royal College of General Practitioners, 2014). A competency 
framework has also been published specifically for GPs with a special interest in 
musculoskeletal/rheumatology practice (Hay, Campbell, Linney, & Wise, 2007) but as 
yet there is little information or evidence to understand how these new roles are 
impacting on the experience of patients or on the health service. Robust evaluations 
will be required to assess the clinical effectiveness, cost-effectiveness, acceptability 
and sustainability of such services.  
 
Glazier (1996) pƌoposed that ƌatheƌ thaŶ ǁagiŶg a ͞ǁaƌ oǀeƌ tuƌf͟, ƌheuŵatologists 
should take the lead on working with GPs to provide expert training and support to 
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ensure that patients receive high quality specialist care, irrespective of whether that is 
delivered in the community or hospital setting. These studies suggest that there is little 
robust evidence to indicate that either patients or the healthcare system would benefit 
from such a radical change in service delivery particularly in the case of patients with 
established arthritis on DMARD therapy.  
2.5.5 Multidisciplinary teams 
A multidisciplinary team approach which incorporates various healthcare professions is 
often used in the management of patients with arthritis. The composition of the team 
may vary between centres but their general approach aims to bring together the skills 
and knowledge of different disciplines, for both the assessment and management of 
the disease.  
 
Guidelines however, seem to have differing views on the benefits of the 
multidisciplinary team. EULAR recommendations for the management of RA patients 
on DMARDs states that the primary responsibility of caring for a patient should lie with 
the rheumatologist, but a multidisciplinary team approach may sometimes be needed 
when dealing with co-morbidities such as cardiovascular disease, or complications of 
applied therapies, such as serious infections (Smolen et al., 2013). This approach fails 
to acknowledge other members of the rheumatology team, such as specialist nurses, 
physiotherapists and occupational therapists all of whom are cited as key members of 
the rheumatology multidisciplinary team (Cherry, Crossland, Field, Ainsworth, & 
Edwards, 2014). In contrast NICE guidelines for RA state that patients should have 
access to a multidisciplinary team who can provide knowledge and skills to 
complement that of the rheumatologist. These guidelines recommend that people 
with RA should have access to a named member of the multidisciplinary team, for 
example the specialist nurse, who is responsible for coordinating their care. These 
recommendations are, however, ŵade ͞despite the laĐk of deŵoŶstƌated ďeŶefit͟ 
(National Institute for Health and Care Excellence, 2013b).  
 
A systematic review of multidisciplinary team care programs both in outpatient and 
inpatient services for patients with RA by Vliet Vlieland and Hazes (1997) identified 42 
papers reporting on 35 clinical trials. The impact of a multidisciplinary team outpatient 
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care approach was evaluated in two uncontrolled trials and six controlled trials in 
which it was compared with usual outpatient care. The controlled trials found that the 
multidisciplinary team approach was associated with greater improvements in physical 
and social functioning, overall health, disease activity and psychosocial well-being. The 
uncontrolled studies also report significant improvements in disease activity, 
functional status and general health over time. Many of these studies, however, were 
methodologically flawed and in all but one of the controlled studies, multidisciplinary 
team care led to more medical visits. The intensity of other treatment modalities, such 
as the use of NSAIDs, the number of orthopaedic consultations, and hospitalizations, 
appeared similar across groups. Vliet Vlieland (2004) published another review 10 
years later including only controlled clinical trials. The evidence at this time supported 
the role of the CNS in coordinating the multidisciplinary team.  
 
A recent systematic review by Cherry et al., (2014) aimed to identify and synthesise the 
literature relating to the clinical importance of multidisciplinary team working in 
musculoskeletal healthcare. A total of 63 articles were found but only 11 were RCTs. 
Over 80% of these RCTs reported significant clinical benefits for multidisciplinary team 
working compared to minimal team intervention and the remaining reported no effect 
on clinical outcomes. These findings are, however, reported in conference proceedings 
with the full review yet to be published. It is, therefore, not possible to determine the 
quality of these primary research papers, the type of patients included or the exact 
clinical benefits. There does, however, appear to be some positive outcomes in 
relation to this approach.  
2.5.6 Patient-led care 
The models of care described so far in this chapter have sought to redirect care either 
within secondary care or from secondary to primary care. The focus has now begun to 
move towards reducing unnecessary outpatient appointments and follow-up 
appointments altogether (National Health Service Institute for Innovation and 
Improvement, 2006) through the introduction of patient-led services.  
 
The provision of patient-led services in rheumatology is a result of not only the need to 
streamline services but reflects the shift away from a paternalistic model of healthcare 
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where the patient is seen as a passive recipient of care and the clinician in a position of 
dominance and authority. The term patient-led refers to ͞ƌeshapiŶg hoǁ the seƌǀiĐe 
delivers care, based on what patients need aŶd ǁaŶt͟ (Fitzpatrick, 2005). Patients are 
now encouraged to take an active role in knowing and managing their health, in 
expressing their concerns and preferences and participating in medical decisions. This 
is especially important in chronic diseases such as arthritis where the reality of living 
with the condition is demanding, and successful management requires increased 
responsibility on the part of the patient. 
 
A vast body of literature both before and after publication of the NHS White Paper 
͚EƋuitǇ aŶd eǆĐelleŶĐe: liďeƌatiŶg the NH“͛ (Department of Health, 2010a) which 
stƌessed ͞Ŷo deĐisioŶ aďout ŵe ǁithout ŵe͟ has eǆploƌed the ƌole of patieŶt 
involvement in rheumatology. This research emphasises the need for an ongoing 
exchange of information between the clinician and patient, understanding and 
agreement about treatment priorities and objectives and shared decision making 
around future treatment plans (Neame, Hammond, & Deighton, 2005; Renzi, Di, & 
Tabolli, 2011; Garfield, Smith, Francis, & Chalmers, 2007; Ishikawa, Hashimoto, & Yano, 
2006).  
 
Research suggests that people with arthritis have a desire to make their own decisions 
about their health. Neame et al., (2005) found that 78% of patients with RA agreed or 
strongly agreed that they should be free to make decisions about everyday medical 
problems. However, 52% agreed or strongly agreed that if hospitalised they should not 
be making decisions about their own care and 79.5% felt if their illness was to become 
worse they would want the doctor to take greater control. This suggests that when 
patients are well they want to make more autonomous decisions and when unwell 
more collaborative decisions. In a smaller survey of 33 people with PsA only 28% of 
patients preferred to leave treatment decisions entirely to their doctor, whereas 69% 
wanted some level of involvement (Renzi et al., 2011). The desire to participate has 
been linked to a number of factors including being younger, female and of higher 
educational status or social class (Neame et al., 2005; Garfield et al., 2007; Ishikawa et 
al., 2006). 
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Despite this desire, in practice many people with arthritis report only some level of 
involvement and most would like greater collaboration. In a sample of 223 patients 
with RA only 32% felt they had some impact on treatment decisions (Cunha-Miranda, 
Costa, & Ribeiro, 2010). In addition a number of surveys have found that 
approximately 30% of patients with arthritis are not involved in decisions about 
treatment, despite being given the opportunity to ask questions, suggesting that 
involvement is more than just being able to ask questions (Brekke, Hjortdahl, & Kvien, 
2001; Lim, Ellis, Brooksby, & Gaffney, 2007; Kjeken et al., 2006). In comparison, the 
level of involvement in PsA is even lower with only 8.7% of patients actively involved in 
medical decision-making and 76.7% having no participation at all (Leung et al., 2009), 
this could be associated with duality of their condition (i.e. arthritis and psoriasis). 
Actual involvement has been linked to patient characteristics including being female, a 
patieŶt͛s age ;ďeiŶg ǇouŶgeƌ iŶ ‘A aŶd oldeƌ iŶ PsAͿ aŶd a higheƌ leǀel of foƌŵal 
education (Kjeken et al., 2006; Brekke et al., 2001; Leung et al., 2009; Ishikawa et al., 
2006). 
 
Although the direction of causality is unclear there may be potential benefits to having 
greater involvement including higher levels of satisfaction with care (Leung et al., 
2009; Brekke et al., 2001; Kjeken et al., 2006), a more positive attitude about arthritis 
and the impact of treatment, increased adherence to medications (Martin & Johnson, 
2011), better mental health and greater self-efficacy (Brekke et al., 2001). Given that 
patients with RA and PsA have in general a desire for greater involvement more recent 
research has gone beyond involving patients in decisions about treatment and care 
towards patient-led outpatient services; allowing people to take active control of 
initiating aspects of their own care.  
 Patient-initiated services 
The traditional rheumatology system assumes that patients need to be seen on a 
regular basis by a healthcare professional and, when they are seen decisions are made 
by clinicians rather than the patient themselves. Nevertheless, over 40% of patients 
receiving rheumatology services feel they should be able to decide how frequently 
they need a check-up (Neame et al., 2005) and take responsibility for organizing their 
own DMARD monitoring appointments (Kay & Lapworth, 2004), suggesting that 
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patient-initiated services may be acceptable to patients. In fact 30% of outpatient 
appointments result in no investigation or other actions and 42% of all visits are 
deemed completely unnecessary (Hehir et al., 2001) providing further endorsement 
for this model of care. 
 
A number of rheumatology services have been successful in involving patients in 
initiating their own care, much like we all do in primary care. These models include 
varying degrees of patient involvement and involve patients directing their needs to 
either primary or secondary care, or a combination of these services. This section will 
now review the content of these interventions and synthesise the evidence in relation 
to patient-initiated follow-up services in rheumatology. It is important to highlight that 
these services have been labelled differently, some are described as direct access 
others shared care and also patient-initiated. In this section the label given by the 
authors will be used. The common thread throughout these services is that patients 
either alone or in combination with their primary care physicians are able to initiate 
their own arthritis-related reviews, which take place either within primary or 
secondary care.  
 
A priority briefing exercise was undertaken between October 2009 and February 2010 
by the Collaboration for Leadership in Applied Health Research and Care for the South 
West Peninsula (PenCLAHRC, 2010a) in order to guide stakeholders in prioritising 
topiĐs foƌ ƌeseaƌĐh. OŶe of the ϭϮ ƋuestioŶs of iŶteƌest ǁas ͚How can patient-initiated 
clinics be implemented for RA given the demonstration of the acceptability, 
effectiveness and cost-effectiveness of such service organisation?͛ (PenCLAHRC, 
2010b). As a result of this exercise a systematic review was undertaken by Whear et 
al., (2013) synthesising the clinical effectiveness of patient-initiated clinics for patients 
with chronic or recurrent conditions managed in secondary care.  
 
Whear et al., (2013) identified 10 articles describing eight individual studies; seven 
were RCTs and one a retrospective audit. These studies included a total of 1927 
participants, across three conditions, breast cancer (n=3), irritable bowel disease (IBD) 
(n=3) and RA (n=2). All were conducted in the UK and participants were followed-up 
for between 12 and 72 months. The patient-initiated clinics in each of these studies 
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were broadly similar, with the primary access point a telephone helpline through 
which patients could request clinical advice and if necessary arrange an outpatient 
appointment. In three RCTs, two in breast cancer and one in patients with IBD were 
also given written information about how to self-manage their condition and the 
symptoms or events that should initiate the need for a consultation. An initial 
consultation was offered in three RCTs in breast cancer and IBD and an annual review 
in all studies. A broad range of clinical outcomes was measured across studies and 
indicated that patient-initiated clinics do not have a significant detrimental impact on 
relapse in breast cancer and IBD or clinical outcomes over time for patients with RA. 
There was evidence to suggest that the frequency of meaningful medical interventions 
such as change in medications or further investigations for patients with RA was 
greater in those who participated in the patient-initiated clinics. The review also 
suggested savings in relation to healthcare resource use, healthcare costs and 
reductions in clinician time as a result of patient-initiated clinics. The authors 
concluded that UK policy is eager for patient-initiated services, which are evidence-
based, to be implemented and evaluated so that the time of both the patient and the 
healthcare professional is not wasted and costs are minimised without compromising 
clinical or psychosocial well-being. It is important to note, however, that although the 
quality of these studies did vary those in RA had less potential for bias in their results 
than those in breast cancer and IBD as they met more of the quality criteria guidelines 
outlined by the Centre for Reviews and Dissemination (2009). This included 
specification of eligibility criteria, a power calculation, details of the sample at 
baseline, descriptions of co-interventions, they accounted for all participants and 
conclusions were supported by their results.  
 
The authors of this systematic review proposed a logic model for the theory behind 
both traditional and patient-initiated clinic appointments systems (Figure 2.5). The 
model suggests that the traditional review system is more likely to lead to inefficient 
and ineffective use of resources due to people who DNA and because stable, well 
patients are being seen in clinic. Although this may lead to a happier patient in the 
short-term it could lead also to services being less responsive to urgent cases, whereas 
a patient-initiated service would mean unwell patients could be seen more frequently 
and a reduction in DNAs because stable patients are not required to attend 
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unnecessarily. Therefore, resources are being used more efficiently and effectively. 
The model however, does fail to acknowledge the possibility that patient-initiated 
services may lead to unwell patients going unnoticed by the service as they do not 
make contact with the rheumatology team or GP and hence deteriorate further, 
leading to concerns about patient well-being both clinically and psychologically. 
  
8
6
 
 
Source Whear et al., (2013) 
Figure 2.5. Logic model of traditional and patient-initiated clinic systems  
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Examining in more detail the two studies in RA, within Whear et al͛s ;ϮϬϭϯͿ sǇstematic 
review, may shed further light on this issue and provide further evidence in relation to 
the current thesis. Of these two studies, one was a 6 year RCT (Hewlett et al., 2000; 
Kirwan et al., 2003b; Hewlett et al., 2005b) and the other a retrospective audit 
conducted by Chattopadhyay and Hickey (2008).   
 
The long-term follow-up RCT undertaken by Hewlett et al., (2000, 2005b) and Kirwan 
et al., (2003b) Đoŵpaƌed ǁhat authoƌs iŶitiallǇ Đalled ͞a diƌeĐt aĐĐess gƌoup͟, theŶ 
͞shaƌed Đaƌe͟ aŶd lateƌ a ͞patient-iŶitiated seƌǀiĐe͟ ǁith ƌheuŵatologist-initiated care. 
Participants in the patient-initiated service could arrange reviews with a 
rheumatologist, physiotherapist, or occupational therapist through a nurse-led 
telephone helpline. The GPs of patients in this group were already monitoring DMARD 
therapy in this locality, but were also given information to support the day-to-day 
management of patient care and could also initiate reviews with the rheumatology 
team. The control group received traditional routine hospital reviews with their 
rheumatologist every three to six months. Analysis of the self-referrals at the end of 
year one indicated that participants given open outpatient appointments were able to 
appropriately self-refer. There remained a risk, however, that a small percentage of 
patients were not using the system when needed (Hogg, Hewlett, & Kirwan, 1997). 
CoŵpaƌisoŶs ďetǁeeŶ those ǁho ƌeƋuested a hospital ƌeǀieǁ aŶd those that didŶ͛t up 
to 2 years post-implementation indicated that those who did self-refer were 
significantly worse, both physically and psychologically at the start and throughout the 
trial than those who did not self-ƌefeƌ, agaiŶ ĐoŶfiƌŵiŶg the patieŶt͛s aďilitǇ to iŶitiate 
care from their rheumatology team appropriately (Hewlett, Mitchell, & Kirwan, 1999). 
Comparison between the intervention and control group on disease deterioration 
confirmed that there was no difference between the two groups (Mitchell, Hewlett, & 
Kirwan, 1999). 
 
Analysis comparing the patient-initiated group with the control group 2 years after the 
implementation of the programme suggested a 43.8% difference in consultant reviews, 
with the patient-initiated service resulting in fewer visits (Hewlett et al., 2000). Despite 
this, levels of pain were significantly lower in the patient-initiated group at 24 months, 
self-efficacy was also significantly greater in this group at 6, 15, 18 and 21 months into 
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the trial and increases in pain were significantly lower (+0.4) compared to control 
participants (+1.6). There were, however, no significant differences between groups on 
changes in disability, anxiety or depression, although there were trends in favour of 
the patient-initiated group. Participants were also more satisfied with the service when 
asked to look back over the previous 2 years and more confident in the system than 
those in the control group (Hewlett et al., 2000). At 4 and 6 years post-intervention 
patient satisfaction with outpatient care declined in the control group but improved 
significantly in the patient-initiated group. A similar pattern was exhibited for patient 
confidence in the service (Kirwan et al., 2003b; Hewlett et al., 2005b) and after 6 years, 
satisfaction with and confidence in care were significantly greater in the patient-
initiated group, which also had 38% fewer hospital appointments. Importantly there 
were no differences between the traditional review and patient-initiated service on 
either clinical or psychological outcomes, suggesting that this responsive model of care 
is not clinically detrimental and, therefore, warrants further consideration in the 
management of patients with arthritis (Hewlett, 2005). This new system seems to be 
running efficiently as part of standard care for patients with RA at Bristol Royal 
Infirmary and is managed by the existing nurses. This has enabled the system to reduce 
any unnecessary outpatient appointments and fast-track urgent ones. Patients also 
report feeling more empowered to manage their problems for longer at home as they 
know rapid help is available if necessary (Pope, Tipler, Kirwan, & Hewlett, 2005). It is 
unclear, however, how much contact and initiation of services was driven by the 
patient and what was initiated by the GP.  
 
The second study in RA included in Whear et al͛s. (2013) systematic review was an 
audit of one UK hospital in which patient-initiated clinics were standard care. Data 
were compared to that of another hospital which utilized a traditional review system 
(Chattopadhyay & Hickey, 2008). The records of 173 outpatient follow-up 
appointments were reviewed, 113 were traditional reviews and 60 patient-initiated 
appointments. A majority of patients had inflammatory arthritis (61.8%). The patient-
initiated clinic was associated with a significantly higher rate of overall medical 
interventions – 96.7% compared to 52.2%, and higher rates of ͞meaningful͟ 
intervention – 66.7% compared to 30.1%. Time between appointments did not differ 
significantly between the two groups and the authors report no inappropriate 
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accessing of services in the patient-initiated clinic. The authors calculated that the 
patient-initiated service lead to an increase of approximately 25% more new patient 
throughput. This however, was a conference abstract and it is, therefore, unclear what 
the patient-initiated service consisted of. Also, selection bias introduced by comparing 
two hospital settings with potentially very different patient populations and care 
guidelines introduces the possibility that confounding variables may account for these 
differences.   
 
In addition to the aƌtiĐles ideŶtified iŶ Wheaƌ͛s sǇsteŵatiĐ ƌeǀieǁ, theƌe aƌe thƌee 
additional studies which have since been published (Adams & Sands, 2009; Sands & 
Adams, 2009; Primdahl et al., 2014; Primdahl et al., 2012; Primdahl et al., 2011b; 
Symmons et al., 2005; Symmons et al., 2006). These articles evaluated three different 
types of patient-initiated services. Both Primdahl et al., (2014) and Symmons et al., 
(2005; 2006) trialled a shared care service similar to that of Hewlett et al., (2000, 
2003b, 2006b), in which both patients and GPs were able to initiate reviews with the 
rheumatology team and GPs monitored medications according to guidelines written by 
their respective rheumatology departments. Although the description of the service is 
not entirely clear the study by Adams and Sands (2009), appears to be the only true 
patient-initiated service, as only patients are described as being able to initiate reviews 
with their rheumatology team, with no mention of primary care involvement.  
 
The trial conducted by the British Rheumatoid Outcome Study Group compared a 
symptom control and shared care (SCSC) intervention with aggressive treatment in a 
hospital setting (ATH) (Symmons et al., 2006; Symmons et al., 2005). SCSC was 
managed in primary care with the goal of controlling joint pain, stiffness and related 
sǇŵptoŵs fƌoŵ the patieŶt͛s peƌspeĐtiǀe. The patieŶt had Ŷo ƌegulaƌ sĐheduled 
appoiŶtŵeŶt ďut ǁas ͞eŶĐouƌaged͟ to ǀisit the GP if theǇ deǀeloped Ŷeǁ oƌ 
deteriorating symptoms at which point the GP used an algorithm to guide their 
treatment decisions and were asked to contact the rheumatologist if they felt that a 
change in DMARD or steroid therapy was indicated. DMARD therapy was monitored by 
the GP using current guidelines for each centre. The ATH arm was managed 
predominantly in the hospital setting and monitoring of the DMARD therapy continued 
as usual. The patient attended the hospital clinic at least once every 4 months where 
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ESR, CRP and the number of swollen joints were measured. Of the 404 participants 
randomised at baseline, 3 years after implementation there were no significant 
differences between the patient-initiated service and the more aggressive hospital 
based system on levels of disability, disease status, pain, quality of life or patient 
satisfaction. An assessment of healthcare utilisation and cost-effectiveness, however, 
found that SCSC lead to fewer outpatient appointments and GP visits. The differences 
were, however, extremely small and it was unclear if they were statistically significant. 
Despite this SCSC was likely to be more cost-effective than ATH in 60–90% of cases, 
(Davies et al., 2007), suggesting that even this small reduction in healthcare utilisation 
impacted on the cost of care.  
 
As described in section 2.5.3.1 (page 65) Primdahl et al., (2014) compared a 
rheumatologist-led care (n=92) with a nurse-led (n=90) and shared-care service (n=94) 
in a three arm RCT. Shared-care involved no planned consultations with the 
rheumatology team, the GP monitored blood tests and the patient could contact either 
the GP or CNS when required. The GP could also make contact with the rheumatology 
department and use the nurse-led telephone helpline for advice or specialist reviews. 
Comparisons between the rheumatologist and nurse-led service are discussed in 
section 2.5.3.1 (page 65); no comparisons were made between the nurse-led service 
and shared-care. Analysis at the end of the 2 year follow-up period found no significant 
differences in disease activity, self-efficacy, satisfaction or confidence in the service 
between rheumatologist-led and shared care over time. Although significantly fewer 
patients in the shared-care service had their blood tests taken at the planned intervals 
compared to the rheumatologist-led group, there was no difference in the number of 
out-of-range blood tests or alerts, defined as significant changes in RA disease activity 
or functional disability, or any other patient safety measure including death, number of 
telephone consultations and initiation of biological treatments. This suggests that 
shared-care and rheumatologist-led services were equal in regards to psychosocial and 
a majority of clinical outcomes, but there may be concerns about attendance for blood 
tests.  
A comparative pragmatic mixed methods study of a patient- versus physician-initiated 
review service that had been running for 4 years was also evaluated by Adams and 
Sands (Adams & Sands, 2009; Sands & Adams, 2009). Retrospective questionnaire data 
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were collected from 88 patients with RA who were referred into the service, along with 
qualitative data from 12 additional patients. Data from these patients were then 
compared to those receiving conventional follow-up at the same rheumatology unit. 
Participants had only experienced the system from which they were recruited and this 
depended on which rheumatologist was responsible for their care. Comparisons 
between the two groups indicated no significant difference in well-being, mood, 
satisfaction or confidence in the services. Participants in the physician-initiated service 
saw the doctor almost twice as often as those in the patient-initiated group; however, 
it is unclear which doctor the authors are referring to, the GP or rheumatologist. The 
design of this trial, however, introduced significant bias as there was no randomisation 
and hence the variation in the care received from the rheumatologist may have 
significantly affected the results of the trial. The lack of measurement prior to the 
service starting also means that it is unclear whether any changes occurred over time 
or if there were groups differed at baseline which could explain the lack of difference 
found at follow-up. Analysis of the semi-structured interviews, however, suggested 
that patients initiating their own follow-up felt that their appointments were less 
rushed and they were more satisfied with the continuity of their care.  
 
A larger implementation trial is currently being undertaken by Paudyal, Perry, Child 
and Gericke (2012) at Plymouth Hospitals NHS Trust using a stepped-wedge design. 
Researchers are randomising 380 patients who have had RA for more than 2 years and 
are able to initiate telephone contact if needed, to either a patient-initiated service or 
to a regular clinician-initiated review group. The patient-initiated service will include 
patient education about the system prior to their enrolment in the service and patients 
will not have routine clinical reviews with their consultant rheumatologist. Their GP 
will be informed about this and sent a short summary of managing the common 
problems experienced by people with established RA. Clinical advice and requests for a 
review will be managed via a nurse-led telephone advice line. The evaluation will 
compare the groups on patient satisfaction, clinical outcomes and healthcare 
utilisation over a 12 month period, at which point all patients in the control arm will be 
transferred to the patient-initiated service. This will provide further evidence either for 
or against the use of patient-led rheumatology services. 
 
Chapter 2 – UK Service Delivery in Rheumatology 
 
92 
Although the quality of the studies evaluating patient-initiated services are mixed, 
good quality RCTs indicated at least equality, if not significant benefits to patient-
initiated services compared with standard consultant-led care. In support of Whear et 
al., (2013), although UK policy may be eager to implement patient-initiated services, 
robust evaluations are still needed in order to provide an quality evidence base for this 
model of care so that the time of both patients and healthcare professional is used 
efficiently and effectively without compromising clinical care or psychological well-
being.  
 
There are, however, a number of important issues which should be highlighted in 
ƌelatioŶ to the ͞patieŶt-iŶitiated͟ seƌǀiĐes desĐƌiďed aďoǀe. With the eǆĐeptioŶ of 
Adams and Sands (2009), all of these interventions were a combination of both 
patients and GPs initiating rheumatology services and were not wholly patient-
initiated. In addition an important element of any patient-initiated service is the 
information participants are given about the symptoms or events that should trigger 
contact with the clinical team. An implicit or explicit assumption is made within all of 
these trials that patients will use their experience of symptoms and side effects as 
triggers for contacting a healthcare professional. These triggers are vital given that 
their sensitivity could lead to over utilization of services or a potentially dangerous 
situation where a patient does not contact a healthcare professional when they are 
seriously unwell. In some trials more detail is provided about these triggers than 
others; however, most are not described in sufficient detail to be evaluated. Pope et 
al., (2005) reported that after a period of running the patient-initiated service 
evaluated by Hewlett et al., (2000, 2003b, 2006b), a patient education session was 
deemed necessary for those joining the service. A 90 minute session was, therefore, 
developed which sought to address a number of key objectives including 
understanding how and when to request an appointment with the CNS or doctor. This 
iŶĐluded ͞ƌecognising the obvious and less obvious reasons why they may request a 
ĐliŶiĐ appoiŶtŵeŶt͟ ǁhiĐh the authoƌs describe as recognising and managing an 
inflammatory flare of RA. This is likely to include the self-monitoring of symptoms and 
side effects which are persistent and unmanageable, indications of a possible disease 
flare (Hewlett et al., 2012). The service currently being evaluated by Paudyal et al., 
(2012) is also using this approach. Primdahl et al., (2014) delivered a short course to 
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participants in all three arms of their trial, prior to randomisation. This consisted of 
two sessions of 3 hours delivered by a multidisciplinary team. The course aimed to 
enhance patient self-efficacy to manage disease-related problems in everyday life and 
to know when and how to seek help from healthcare professionals. Topics included 
how to detect a flare-up, the medical treatment including how to manage it and 
possible side effects, how to self-manage common problems like pain, fatigue, joint 
stiffness and poor sleep. Details about the remaining studies are unclear. 
 
It is important to describe the active content of any intervention in order to aid 
replicability and identify the active ingredients that bring about a desired change in 
behaviour (Craig et al., 2008). Therefore, future trials of patient-initiated initiated 
services should describe in greater detail the content of any additional education 
sessions or materials along with the specific triggers which patients are required to 
follow when initiating their care. 
2.6 LOCAL SERVICE PROVISION 
At the start of this thesis there were 450 patients with RA or PsA on DMARD therapy at 
UCLH. These patients were managed via a combination of CNS and rheumatologist-led 
appointments with a small number of patients also being monitored by their GP. The 
frequency or combination (i.e. alternate visits to the CNS and rheumatologist) of 
appointments was dependant on the rheumatologist and/or CNS the patient was being 
managed by, but was driven by a combination of clinical need and capacity. A vast 
majority of methotrexate monitoring was undertaken in the CNS-led DMARD 
monitoring clinics. This was despite NH“ CaŵdeŶ͛s puďlished shaƌed Đaƌe guideliŶes 
for methotrexate (Pang & Malhotra, 2009) which invites GPs to participate in these 
activities.  
 
These shared care guidelines are for patients being treated for moderate to severely 
active RA or for the treatment of severe psoriasis and were established in order to 
clarify responsibilities between the specialist team and GP for managing the 
prescribing and monitoring of methotrexate. The guidelines cover:  
 
1. Who will prescribe methotrexate;  
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2. Who will monitor;  
3. How often blood tests will be conducted and in which location;  
4. Which clinician will be responsible for receipt and review of the results;  
5. Who will communicate any necessary changes in dose to the patient and the 
GP;  
6. Who will record test results in the Patient-Held Monitoring and Dosage Record 
booklet  
 
GPs are invited to participate, but if the GP is not confident to undertake these roles, 
total clinical responsibility for the patient remains with the specialist team at UCLH. 
The document is also clear about the importance of patients being consulted about the 
monitoring and treatment plan. The roles and responsibilities for all stakeholders are 
in summarised in (Figure 2.6), the full shared-care guidelines can be found in Appendix 
A. 
 
Consultant and CNS 
1. Perform baseline tests (FBC, LFTs, U&Es, creatinine, chest X-ray).  
2. Initiate and stabilise treatment with methotrexate.  
3. Educate patients about methotrexate.  
4. Invite GP to participate in shared care.  
5. Inform GP of test results, frequency of monitoring, recommended dose and 
changes to treatment  
6. PeƌiodiĐallǇ ƌeǀieǁ the patieŶt͛s ĐoŶditioŶ aŶd eǀaluate adǀeƌse effeĐts  
7. Ensure that clear backup arrangements exist for GPs to obtain advice and 
support.  
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General Practitioner 
1. Reply to the request for shared care. 
2. MoŶitoƌ patieŶt͛s oǀeƌall health aŶd ǁellďeiŶg.  
3. Prescribe methotrexate at the dose recommended.  
4. Ensure that the patient understands dose and adverse effects.  
5. Monitor blood counts, hepatic and renal function at recommended frequencies 
as described, and inform consultant if abnormal.  
6. Offer annual influenza vaccination to the patient.  
Patient 
1. Report to the specialist or GP if he or she does not have a clear understanding of 
the treatment.  
2. Share any concerns in relation to treatment with methotrexate.  
3. Inform specialist or GP of any other medication being taken, including over-the-
counter products.  
4. Report any adverse effects or warning symptoms to the specialist or GP.  
Primary Care Trust 
1. To support GPs to decide whether or not to accept clinical responsibility for 
prescribing.  
2. To support Trusts in resolving issues that may arise as a result of shared care 
Figure 2.6. NHS Camden Shared Care Guideline for methotrexate – roles and 
responsibilities 
 
These shared care guidelines state that regular monitoring should take place in 
accordance with the BSR/BHPR clinical guidelines for monitoring methotrexate 
(Chakravarty et al., 2008). This includes full blood count, urea, electrolytes and liver 
function tests monitored fortnightly until the dose of methotrexate and monitoring is 
stable for 6 weeks, then monthly thereafter until the dose and disease is stable for 1 
year. The monitoring may then be reduced in frequency to every 2 to 3 months, based 
on clinical judgement with due consideration for risk factors for example age, 
comorbidity and renal impairment. The frequency of monitoring advised by the 
specialist to the GP may vary from the above recommendations depending on patient 
factors.  
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Despite this shared care approach at the start of this research a very small proportion 
of the GP practices in Camden PCT had taken on the role of monitoring. As GPs were 
reluctant to take on the monitoring and/or the prescribing of methotrexate these 
activities remained in the CNS-led DMARD monitoring clinics based at UCLH. The 
capacity of these DMARD monitoring clinics continued to be stretched and alternative 
models of care, therefore, needed to be considered to meet the needs of patients. As a 
patient-initiated service is the only model of care designed to reduce overall contact 
with healthcare professionals rather than redirect patients to other services this was 
deemed a viable option which required further exploration.  
 
The most recent evaluation of the local services was provided by the GP patient survey 
conducted between July 2012 and March 2013 (NHS England 2013) and the 2012 
Outpatient Survey (Care Quality Commission, 2012). Fifteen percent of responders to 
the GP survey (NHS England 2013) in NHS Camden CCG had arthritis or other long-term 
joint problem. Of these, 53% felt fairly confident that they could manage their own 
health (compared to 50% at a national level) and 62% had in the last 6 months 
received enough support from local services/organisations to help manage their long-
term conditions (compared to 65% at a national level). Although the local rates appear 
to reflect the national picture, there was clearly a need to either develop new services 
or improve signposting to relevant local organisations in order for a significant 
proportion of patients with arthritis to feel confident in their ability to manage their 
condition, both locally and nationally.  
 
The outpatient survey undertaken at UCLH (Care Quality Commission, 2012) indicated 
that the Trust fell within the worse performing 20% of trusts for: clinic waiting times, 
pƌoǀidiŶg iŶfoƌŵatioŶ oŶ a patieŶt͛s ĐoŶditioŶ aŶd tƌeatŵeŶt, alloǁiŶg patieŶts to fiŶd 
out the results of any tests, the purpose of the medications they were taking, the 
reasons for any changes in medication, as well as receiving contradictory advice from 
different healthcare professionals, and not being treated with respect or dignity. The 
Trust also scored poorly on explaining: the risks and benefits of treatments, the result 
of any tests, who could be contacted if the patient was worried about their condition 
or treatment, any danger signs the patient should watch out for. Confidence and trust 
in the clinical team, sufficient time for the patient to discuss their health and overall 
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satisfaction with their appointment was also poor. Although these results are not 
specific to the rheumatology department they suggest that UCLH were potentially not 
meeting NICE guidelines for RA which state that patients should be offered the 
opportunity to attend education sessions including self-management (National 
Institute for Health and Care Excellence, 2013). Steps, therefore, needed to be taken in 
order to improve the service that was being delivered in outpatients. Only 43% of 
patients who visited outpatients at UCLH in 2011, however, completed the 
questionnaire, this may suggest a possible bias towards those responding who had the 
worst experience. Given these results it is not surprising that one of NHS Camden 
CCG͛s keǇ iŶteƌests is to ƌeǀieǁ the eǆpeƌieŶĐe of people iŶ outpatieŶts aŶd eŶsuƌe 
that patients are seen in the appropriate setting of their choice in a timely manner 
whilst ensuring that best value for money is achieved (Camden Clinical Commissioning 
Group, 2013).  
 
A major part of the CNS-led rheumatology run clinics at UCLH at the start of this thesis 
was the reviewing of blood test results, along with the symptoms and side effects 
patients were experiencing or had experienced since their last appointment. This 
supported the findings of Goh et al., (2006) who found that 82.1% of surveyed nurses 
were frequently undertaking drug monitoring. This raised the question about whether 
patients could be involved in monitoring their own blood tests and use this 
information along with their symptoms and side effects as triggers for initiating care 
from their CNS. This was a way in which the rheumatology service could be more 
responsive to the needs of established patients and offered an opportunity to make 
the services more effective and efficient for all. 
 
As stated above the patient-initiated services outlined in section 2.5.6.1 (page 82) used 
patieŶts͛ eǆpeƌieŶĐes of symptoms and side effects as triggers for initiating care. This 
thesis would, therefore, be the first trial of patients with arthritis formally monitoring 
their own blood test results and symptoms and using this information to initiate their 
own care. As well as being described as patient-initiated services these interventions 
could also be thought of as patient self-monitoring interventions. In concept analyses 
of self-monitoring in chronic illness both Song and Lipman (2008) and Wilde and Garvin 
(2007) identified three closely related components of self-monitoring (i) awareness, (ii) 
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interpretation and (iii) response. In the context of this thesis a self-monitoring and 
patient-iŶitiated seƌǀiĐe ǁould iŶĐƌease a peƌsoŶ͛s aǁaƌeŶess of a disease flaƌe, 
provide them with the knowledge required to understand and interpret these 
indications and allow patients to respond to changes in their health by taking the 
necessary steps to initiate care from their rheumatology team. The transfer of 
monitoring laboratory tests from CNS to patient may seem like a radical step for 
patients with arthritis; however, the use of formal self-monitoring in chronic illness is 
widely implemented in other conditions including diabetes and anti-coagulation 
therapy. A broader synthesis of the literature in relation to formal chronic disease self-
monitoring would establish the potential outcomes of the proposed intervention, the 
results of which are presented in Chapter 3. 
2.7 SUMMARY 
An assessment of the current state of rheumatology services has identified significant 
deficits in the provision of care for patients with arthritis. This includes possible 
unnecessary appointments for those who are feeling well and substantial delays or 
lack of capacity for those who are feeling worse and need faster attention. This has led 
to the development of contemporary models of rheumatology care including patient-
initiated services. These services reflect the move away from the paternalistic model of 
healthcare to one which puts the patient at its centre and are integral to rheumatology 
guidelines. To date this model of care has focused on reducing unnecessary visits to 
the rheumatologist however; since a majority of DMARD monitoring is now performed 
by the CNS an alternative model could look to focus on reducing the demand in these 
clinics. These DMARD monitoring clinics primarily consist of patients with RA and PsA 
for monitoring of symptoms and side effects as well as blood tests, therefore, if these 
subjective and objective markers could be used as triggers for a patient-initiated 
service this would allow established patients to self-monitor at home rather than 
attend for regular monitoring appointments with their CNS. As formal self-monitoring 
is not a technique that has been used extensively in rheumatology the next chapter 
will present a review of the effectiveness of self-monitoring across a range of long-
term conditions with regards to healthcare utilisation, psychosocial well-being and 
clinical outcomes. 
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3. CHAPTE‘ ϯ - THE IMPACT OF SELF-MONITO‘ING ON 
HEALTHCA‘E UTILISATION AND PATIENT ‘EPO‘TED 
OUTCOMES AC‘OSS LONG-TE‘M CONDITIONS: AN 
OVE‘VIEW OF ‘EVIEWS. 
3.1 PROLOGUE 
The first chapter in this thesis described the clinical features and treatment monitoring 
requirements of patients with established RA or PsA who are receiving DMARD 
therapy, along with financial impact of these two conditions on the UK economy. 
Chapter 2 then went on to explore how current UK government policy has influenced 
the delivery of services in rheumatology and how patients with arthritis are involved in 
the care and treatment they receive. These patient-initiated services have been 
successful in reducing the demand placed on outpatient clinics without compromising 
clinical and psychological well-being but currently use informal indicators of disease 
flare as triggers for initiating care. These effects could be enhanced by integrating 
patients formally self-monitoring their symptoms and side effects along with their 
blood test results in order to reduce the demand of established patients with RA or 
PsA on methotrexate in the CNS-led DMARD monitoring clinics. This chapter will 
present the rationale, methods and results of an overview of reviews exploring the 
benefits of formal self-monitoring across a range of long-term conditions in order to 
establish the potential benefits of the proposed service in relation to healthcare 
utilisation, psychosocial well-being and clinical outcomes. 
3.2 BACKGROUND 
3.2.1 Self-monitoring in long-term conditions 
Monitoring of a long-term physical health condition involves the periodic collection of 
data which are used to guide the management of the illness and can be done by 
clinicians, patients or both. Such checks require decisions to be made about what 
needs to be monitored and when and how to adjust treatment. Poor choices in each of 
these can lead to poor disease control, poor use of time and dangerous adjustments to 
treatment (Glasziou, Irwig, & Mant, 2005). The data monitored as part of a long-term 
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health condition may include clinical tests, physiological signs and symptoms, 
behaviour and/or emotions. Patients can now be actively involved in monitoring all 
types of data, enabled by more open access to their own clinical data and the 
introduction of technology.  
 
Self-monitoring is part of best practice in many long-term conditions. The most 
established is that of blood glucose self-monitoring (SMBG) in diabetes. To improve 
glycaemic control patients are advised to undertake regular blood tests and use this 
information to manage their illness effectively, either by changing their lifestyle, 
treatment regimen or seeking help from a healthcare professional. SMBG is now part 
of usual care and is recommended in NICE guidance for the management of type 1 
(National Institute for Clinical Excellence, 2010) and type 2 diabetes (National 
Collaborating Centre for Chronic Conditions, 2008). These recommendations follow 
meta-analysis suggesting significant reductions in HbA1c as a result of SMBG (Sarol Jr, 
Nicodemus Jr, Tan, & Grava, 2005; Welschen et al., 2005b; Allemann, Houriet, Diem, & 
Stettler, 2009; Poolsup, Suksomboon, & Jiamsathit, 2008; Poolsup, Suksomboon, & 
Rattanasookchit, 2009). The involvement of patients in the monitoring of their illness is 
also becoming more widespread in other long-term conditions including respiratory 
conditions such as asthma and COPD, hypertension and in treatments such as 
anticoagulation therapy. As a result of significant reductions in blood pressure 
(Cappuccio, Kerry, Forbes, & Donald, 2004; Bray, Holder, Mant, & McManus, 2010; 
Verberk, Kessels, & Thien, 2011), mortality and severe complications (Christensen, 
Johnsen, Hjortdal, & Hasenkam, 2007).  
3.2.2 Self-monitoring in arthritis 
As outlined in section 1.9 (page 37) DMARD therapy in RA and PsA requires monitoring 
of blood tests, symptoms and side effects. This is commonly undertaken during a 
nurse-led or consultant-led clinic using a combination of patient self-report and clinical 
tests. Together these are interpreted by a healthcare professional and when necessary 
lead to adjustments in treatment, lifestyle or monitoring schedules. However, 30 to 
42% of outpatient visits lead to no adjustments to treatment (Mitchell, 2000; Hehir et 
al., 2001). Consequently, a large proportion of regular monitoring appointments could 
be eliminated to allow greater capacity for new patients and those with established 
Chapter 3 – Self-monitoring: An Overview of Reviews 
 
101 
arthritis who are in need of an urgent appointment. This could be achieved by 
empowering patients to take a more active and formal role in the monitoring of their 
DMARD therapy. This is yet to be implemented in arthritis and hence it is important to 
establish what the benefits are in relation to healthcare utilisation and psychosocial 
well-being across other long-term conditions.  
3.3 AIMS AND OBJECTIVES 
The primary aim of this review was to assess the impact of formal self-monitoring on 
healthcare utilisation and psychosocial outcomes, with a secondary aim of 
summarising the effects on clinical well-being. The primary research questions 
addressed were:  
  Do interventions that include self-monitoring reduce healthcare utilisation for 
patients with a long-term condition?  Do interventions that include self-monitoring improve patient reported 
outcomes for patients with a long-term condition?  To establish whether self-monitoring of blood test results would have any 
additional benefits or harms in comparison to interventions which included 
patients monitoring just their symptoms or side effects. 
3.4 RATIONALE FOR METHODOLOGY 
Due to the amount of literature exploring the effectiveness of self-monitoring in long-
term conditions a number of systematic reviews and meta-analyses have been 
conducted. Therefore, in order to establish whether self-monitoring is associated with 
significant reductions in healthcare utilisation and improvements in patient reported 
outcomes across a range of long-term conditions this review will synthesise the 
evidence from published systematic reviews and meta-analyses, rather than primary 
research studies.  
 
An overview of reviews is a logical and appropriate next step to a systematic review or 
meta-analysis, as it allows the findings of separate reviews to be compared and 
contrasted. The York Centre for Reviews and Dissemination defines an overview of 
ƌeǀieǁs as ͞a sǇsteŵatiĐ ƌeǀieǁ that iŶĐludes oŶlǇ otheƌ sǇsteŵatiĐ ƌeǀieǁs͟ (Centre 
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for Reviews and Dissemination, 2009). This report states that the systematic reviews 
included in the review should have covered most of the primary studies available and 
are particularly helpful when a review question is very broad and a number of 
systematic reviews have already been conducted in the area, as is the case for the 
current review. These overviews aim to provide a summary of evidence from more 
than one systematic review at a variety of different levels, including the combination 
of different interventions, different outcomes, different conditions, problems or 
populations, or the provision of a summary of evidence on the adverse effects of an 
intervention.  
 
The different inclusion criteria adopted by the various reviews can, however, make 
their synthesis problematic. Secondary analysis is beset with inherent limitations, the 
quality of this review will be heavily dependent on the quality of not only the reviews 
themselves and hence quality assessment will be performed, but also the quality of 
reporting. In addition individual primary research studies that appear in several of the 
included reviews will mean that some of the same evidence is included more than 
once. Despite these possible biases, however, a synthesis of this nature in relation to 
these specific outcomes will provide a general overview of the benefits of self-
monitoring across a range of long-term conditions. If found beneficial this would 
suggest that formal self-monitoring merits further investigation for people with 
arthritis. 
3.5 METHODOLOGY 
3.5.1 Terminology  
To clarify, use of the term primary research study refers to the individual studies 
found within each of the included systematic reviews and meta-analyses. Article refers 
to the systematic review or meta-analysis being reviewed within this overview.   
3.5.2 Synthesis 
This overview follows the methodological guidelines outlined by Smith, Devane, Begley 
and Clarke (2011) which reflect that of a standard systematic review. The included 
articles were combined in a systematic review, no statistical analyses or meta-analysis 
were undertaken. Synthesising the results of all reviews in an area could result in 
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incorrect conclusions as many of the primary research studies will be included in more 
than one article potentially biasing the results. In order to measure the degree of 
overlap the Corrected Cover Area (CCA) (Pieper, Antoine, Mathes, Neugebauer, & 
Eikermann, 2014) was calculated. This calculation accounts for articles that include a 
large number of primary research studies and also allows accurate calculation of 
overlap when different articles include completely different primary research studies. 
A CCA of 0-5 is considered slight overlap, 6-10 moderate, 11-15 high and >15 very high 
(Pieper et al., 2014).  
 
A description of the articles is presented, followed by details about the interventions 
evaluated and their effectiveness. In accordance with reporting guidelines for 
systematic reviews, a Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist (Moher, Liberati, Tetzlaff, & Altman, 2009) can be found in 
Appendix B.  
3.5.3 Search strategy 
The following databases were searched in September 2012 and updated in February 
2014. The overall conclusions of the review completed in 2012 did not differ on 
completion of the update in 2014 and, therefore, what is included here is a synthesis 
of the most recent publications. 
  Via EBSCOHost: 
o CINAHL Plus® full text (1937 to 2014) 
o MEDLINE with Full Text (1948 to February 5, 2014) 
o PsycINFO (from 1806 to 2014)  Via OVID Online: 
o EMBASE (1996 to 2014 Week 06) 
o Allied and Complementary Medicine (1985 to February 2014) 
o Evidence Based Medicine Reviews (All)1 
o Health Management Information Consortium (1979 to November 2013) 
                                                     
1 ACP Journal Club 1991 to January 2014; Cochrane Register of Controlled Trials January 2014; Cochrane 
Database of Systematic Reviews 2005 to December 2013, Cochrane Methodology Register 3rd Quarter 
2012, Database of Abstracts of Reviews of Effects 1st Quarter 2014, Health Technology Assessment 1st 
Quarter 2014; NHS Economic Evaluation Database 1st Quarter 2014 
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The basic search terms used are given in Figure 3.1, with the detailed search strategies 
for each database in Appendix C. 
 
[self-care OR self monitor* OR self administer* OR self examin OR self medicat* OR 
self inject* OR self evaluat* OR self test* OR self adjust* OR self measure* OR 
patient participation OR patient monitor* OR patient manage* OR patient adjust* 
OR patient administer* OR patient control* OR patient cent?d OR tele* OR home 
monitOR*] 
[meta-analys* OR systematic review OR overview OR narrative review] 
1 AND 2 
Figure 3.1. Basic search strategy 
 
3.5.4 Inclusion and exclusion criteria 
 Publishing 
Articles must have been published in an academic peer reviewed journal or database 
with an established reporting system (i.e. Cochrane or Health Technology Assessment 
(HTA)). The article must have been written in English. When either a Cochrane or HTA 
review also had an accompanying peer reviewed journal article, only the peer 
reviewed journal article was included unless additional material (i.e. a meta-analysis) 
was provided in which case only the publication with the additional material was 
included.  
 Study design 
Included articles were either a systematic review or meta-analysis which included 
primary research studies only. If these articles contained summaries of qualitative 
studies or secondary data (i.e. other systematic reviews or meta-analyses) this content 
was not extracted. The article had to have a defined research question and show that 
reasonable effort was made to identify all relevant literature.  
 Participants 
All participants were aged 18 and over exclusively and living with a long-term physical 
health ĐoŶditioŶ. DefiŶed as ͞a [phǇsiĐal] ĐoŶditioŶ that ĐaŶŶot, at pƌeseŶt ďe Đuƌed; 
ďut ĐaŶ ďe ĐoŶtƌolled ďǇ ŵediĐatioŶ aŶd otheƌ theƌapies͟ (Department of Health, 
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2010b). Articles which included more than one long-term physical health condition 
were excluded in order for data to be summarised within a long-term condition.  
 Interventions 
The article had to include interventions where patient self-monitoring was the focus of 
the review or be an element of all interventions by virtue of the nature of that 
iŶteƌǀeŶtioŶ ;i.e. teleŵoŶitoƌiŶgͿ. ͞“elf͟ ƌefeƌs to patieŶt, Ŷot Đaƌeƌ oƌ healthĐaƌe 
professional. Self-monitoring was defined as the patient undertaking one or more of 
the following, using the components identified within the concept analyses by Song 
and Lipman (2008) and Wilde and Garvin (2007): 
  Awareness: Measurement of vital signs, symptoms, behaviour or psychological 
well-being, with the implicit or explicit function of interpreting that data in 
order to adjust medication, treatment, lifestyle or help-seeking behaviour by 
either a healthcare professional or the patient.  Interpretation: Interpretation of vital signs, symptoms, behaviour or 
psychological well-being.  Response: Adjustment of medication, treatment, lifestyle or help-seeking 
behaviour as a result of awareness and/or interpretation. 
 
Interventions that included the testing of a monitoring device or comparing for 
example home to office blood pressure monitoring were excluded as these reviews 
tended to focus on accuracy of the monitored data or performance of technology, 
which although important was not the focus of this review.  
 Outcomes 
The article had to report findings for either healthcare utilisation or a patient reported 
outcomes, for example quality of life, mood, satisfaction or acceptability. Articles that 
only included clinical outcomes, cost effectiveness or feasibility outcomes were 
excluded from this review. Articles that included both clinical outcomes, economic or 
feasibility and either patient reported or healthcare utilisation were included in this 
review but the economic and feasibility data were not extracted. Data for clinical 
outcomes were extracted in order to provide an overview of the evidence and a 
context in which the primary outcomes could be discussed. This is because any 
Chapter 3 – Self-monitoring: An Overview of Reviews 
 
106 
benefits in relation to healthcare utilisation or psychosocial well-being should be 
balanced against any potential deterioration in clinical outcomes. 
3.5.5 Procedure 
 Initial assessment 
After the removal of duplicates and articles not published in English, one reviewer 
assessed all titles for relevance. Those clearly not related to the research question or 
inclusion and exclusion criteria were immediately disregarded. Full articles thought to 
be of relevance were retrieved for review. The retrieved articles were assessed for 
inclusion by one reviewer and then those judged to be relevant assessed by a second 
reviewer according to the outlined criteria. Any disagreements were then discussed 
with a third person and resolved by consensus.  
 
In addition to the above literature search the reference lists of all included articles 
were examined for relevant titles and the full articles obtained for inspection. The 
process of second reviewing was then repeated. References were managed in 
Reference Manager 12.  
 Data extraction 
A data extraction form (Appendix D) was designed by the author to assess the 
following characteristics of the article: illness or disease type, level of self-monitoring 
(i.e. awareness/interpretation/response), search strategy, inclusion and exclusion 
criteria, quality assessment, data extraction procedure, total number of studies and 
paƌtiĐipaŶts, authoƌ͛s ĐoŶĐlusioŶs aŶd iŶteƌpƌetatioŶs. The ƌeleǀaŶt data ǁeƌe 
extracted and recorded by one reviewer; independent data extraction was also 
performed on 20% of articles by a second reviewer. Any disagreements were then 
discussed with a third person and resolved by consensus. The following criteria were 
applied when data were extracted: 
  Quantitative pooling (i.e. meta-analysis) was regarded as possessing greater 
validity than qualitative synthesis. 
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 If results were reported inconsistently in different sections of the review, the 
effects were extracted from the main result section or tables, depending on 
which was perceived as being more comprehensive and coherent. 
 Review quality 
The Assessment of Multiple Systematic Reviews (AMSTAR) checklist was used to assess 
the quality of the included articles (Shea et al., 2007). This is a systematically 
developed 11-item measurement tool (Appendix E) which possesses satisfactory inter-
observer agreement, reliability, construct validity and feasibility (Shea et al., 2007; 
Shea et al., 2009). For each criterion, the response is either yes (1 point), no (0 points), 
ĐaŶ͛t aŶsǁeƌ ;Ϭ poiŶtsͿ oƌ Ŷot appliĐaďle ;Ϭ poiŶtsͿ. The ƋualitǇ sĐoƌe is the total 
number of points awarded and, therefore, ranges from 0 (lowest) to 12 (highest). The 
quality of all articles in this review were assessed by one reviewer and 20% of articles 
(a different set of articles than the data extraction) were checked by a second 
reviewer. Any discrepancies were discussed and resolved by consensus with a third 
reviewer.  
3.6 RESULTS 
3.6.1 Identified papers 
Using the search strategy detailed in Appendix C, a total of 2114 references were 
retrieved. Figure 3.2 illustrates the selection of articles at each stage of the search 
strategy. After exclusions based on title alone 320 full articles were then retrieved and 
after screening 25 were selected for possible inclusion. A total of 25 individual articles 
were identified in the search, detailing 23 different systematic reviews or meta-
analyses. Two reviews had been published twice, both as Cochrane reviews and again 
as peer reviewed journal articles (Welschen et al., 2005b; Welschen et al., 2005a; 
McLean et al., 2011; McLean et al., 2012). The papers published by McLean et al., 
(2011; 2012) contained the same data with no additional material in either publication, 
therefore, the peer reviewed article (McLean et al., 2011) was selected. The papers by 
Welschen et al., (2005a; 2005b) did differ as the peer reviewed journal article included 
a meta-analysis and, therefore, this publication (Welschen et al., 2005b) was retained. 
Four additional articles were identified as a result of reference list searches, therefore, 
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a total of 27 articles were included in this overview. Details of the studies excluded and 
reasons can be found in Appendix F. 
 
 
Figure 3.2. Flow chart of article selection 
 
3.6.2 Article characteristics 
All article characteristics can be found in Table 3.1.
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Table 3.1. Article characteristics – systematic review 
Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Hypertension         
Jaana, Pare, & 
Sicotte (2007) 
SR Evaluate the evidence for the 
effectiveness of hypertension 
TM. 
1966 to 2006 Design: Experimental or 
quasi-experimental 
Participants: Chronic 
hypertension 
Intervention: Home TM 
14(1119) BP None 4 
AbuDagga, 
Resnick, & Alwan 
(2010) 
SR & 
MA 
What is the impact of BP TM 
technologies on clinical, 
patient-centred outcomes, 
healthcare utilization & cost?  
1995 to 
September 
2009 
Design: RCT, single group, 
quasi-experimental 
Participants: Established 
diagnosis of uncontrolled  
hypertension  
Intervention: TM 
15(3192) BP None 4 
  
1
1
0
 
Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
COPD 
Turnock, Walters, 
Walters, & Wood-
Baker (2005) 
 
SR & 
MA 
 
Determine whether action 
plans alone, or as part of a 
broader self-management 
intervention, are an effective 
way to manage COPD 
exacerbations. 
 
Not stated 
 
Design: RCT 
Participants: Diagnosed 
primary COPD 
Intervention: Action 
planning 
 
3(367) 
 
Hospital 
admissions 
 
Jadad scale & 
Cochrane 
 
4 
McLean et al., 
(2012) 
SR & 
MA 
To review the effectiveness of 
telehealthcare for COPD 
compared with face-to-face 
usual care in improving 
quality of life & reducing 
accident & emergency 
department visits & 
hospitalisations. 
Inception to 
January 2010 
Design: RCT 
Participants: Diagnosed 
COPD 
Intervention: Telehealthcare 
10(1307) Quality of life, 
healthcare 
utilisation 
Cochrane risk of 
bias 
6 
  
1
1
1
 
Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Heart failure 
Louis, Turner, 
Gretton, Baksh, & 
Cleland (2003) 
 
SR 
 
To present the current 
evidence on TM as a means of 
reducing hospitalisations in 
HF. 
 
1996 to 2002 
 
Design: NR 
Participants: Diagnosed HF 
Intervention: 
TM 
 
24(3643) 
 
Acceptability, 
hospital 
admissions 
 
None 
 
4 
Jovicic, Jolroyd-
Leduc, & Straus 
(2006) 
SR & 
MA 
Determine the effectiveness 
of self-management 
interventions on hospital 
readmission rates, mortality 
& QoL in patients diagnosed 
with HF. 
1966 to Nov 
2005 
Design: RCT  
Participants: 
Hospitalised with diagnosed 
HF 
Intervention: Self-
management 
6(857) Readmissions, 
mortality 
Author designed 7 
Martinez, Everss, 
Rojo-Alvarez, 
Pascual, & Garcia-
Alberola (2006) 
SR To assess the value of home 
monitoring for HF patients. 
1966 to 
April 2004 
Design: Experimental 
studies 
Participants: Not stated 
Intervention: Home 
monitoring 
42(2303) Patient 
acceptability 
Jovell & 
Navarro-Rubio 
scale 
6 
  
1
1
2
 
Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Chaudhry et al., 
(2007) 
SR In-depth examination of a 
wide range of TM 
interventions in HF to find out 
which components are 
effective. 
1966 to 
August 2006 
Design: Randomized study 
design 
Participants: Adults with HF 
Intervention: Home 
monitoring 
9(3582) Hospitalization, 
mortality 
Juni et al & 
York Centre for 
Reviews & 
Dissemination 
5 
Clark, Inglis, 
McAlister, 
Cleland, & 
Stewart (2007) 
SR & 
MA 
To determine whether 
remote monitoring without 
regular clinic or home visits 
improves outcomes for 
patients with CHF. 
Jan 2002 to 
May 2006 
Design: RCT 
Participants: HF, living at 
home 
Intervention: Remote 
monitoring 
14(4264) Hospitalization, 
mortality 
Cochrane 8 
Dang, Dimmick, 
& Kelkar (2009) 
SR Examine the evidence base 
for home telehealth & 
remote monitoring 
interventions in the 
management of HF. 
1966 to 
April 2009 
Design: RCT 
Participants: HF 
Intervention: Home 
telehealth & remote 
monitoring 
9(2017) Hospitalization, 
mortality 
Adapted Hailey 
et al which was 
adapted from 
Jovell & 
Navarro-Rubio 
scale 
5 
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Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Klersy, De 
Silvestri, Gabutti, 
Regoli, & 
Auricchio (2009) 
SR & 
MA 
Assess the effect of remote 
patient monitoring on the 
outcome of CHF patients. 
Jan 2000 to 
October 
2008 
Design: RCT, OB cohort 
studies 
Participants: CHF, living at 
home 
Intervention: Remote 
patient monitoring 
32(8612) Hospitalization, 
mortality 
CONSORT & 
STROBE 
6 
Maric, Kaan, 
Ignaszewski, & 
Lear (2009) 
SR Review studies conducted in 
HF TM, which are not 
telephone based, but utilize 
the concept of patient self-
monitoring in HF. 
Inception to 
August 
2007 
Design: Any 
Participants: HF 
Intervention: Use of 
technology or device to 
assist in self-monitoring 
56(NR) Hospitalization None 2 
Polisena et al., 
(2010) 
SR & 
MA 
Conduct a SR & MA to look at 
clinical outcomes, patient 
QoL & the use of healthcare 
services for home TM 
compared to usual care for 
patients with CHF. 
1998 to 2008 Design: RCT, OB 
Participants: CHF 
Intervention: Home TM 
22(3028) Hospitalization, 
mortality 
Adapted 
version Jovell & 
Navarro- 
Rubio scale 
5 
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Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Inglis et al., 
(2010) 
SR & 
MA 
To review RCTs of STS or TM 
compared to standard 
practice for patients with 
CHF. 
From 2006 
onwards 
Design: RCT 
Participants: CHF, within 
the community 
Intervention: STS or TM 
30(10490) Hospitalization, 
mortality 
Author designed 9 
Clarke, Shah, & 
Sharma (2011) 
MA To assess the effectiveness of 
TM on primary & secondary 
outcomes. 
From January 
1969 to 
October 2009 
Design: RCT 
Participants: CHF 
Intervention: TM 
13(NR) Hospitalization, 
mortality 
None 5 
Ciere, Cartwright, 
& Newman (2012) 
SR To examine whether the 
introduction of telehealth 
leads to an increase in self-
care behaviour or potential 
precursors of self-care 
behaviour (i.e. knowledge, 
self-efficacy) in CHF patients. 
Inception to 
August 2010 
Design: RCT, cohort, case 
controlled trial 
Participants: CHF 
Intervention: Telehealth 
12(943) Knowledge, self-
efficacy, self-care 
Adapted version 
of the Effective 
Public Health 
PƌaĐtiĐe PƌojeĐt͛s 
Quality 
Assessment Tool 
for Quantitative 
Studies & 
additional items 
from Downs & 
BlaĐk͛s ĐheĐklist 
6 
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Authors, year Type 
of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Giamouzis et al., 
(2012) 
SR To assess whether TM 
provides any substantial 
benefit in patients with HF. 
Inception to 
November 
2011 
Design: RCT 
Participants: CHF 
Intervention: TM 
12(3877) Mortality, 
healthcare 
utilisation 
None 3 
Pandor et al., 
(2013) 
SR & 
MA 
To determine whether 
remote monitoring strategies 
improve outcomes for adults 
who have been recently 
discharged (<28 days) 
following an unplanned 
admission due to HF. 
2008 to 
January 2012 
(plus papers 
from 2 earlier 
reviews) 
Design: RCT, OB cohort 
studies  
Participants: Adults, HF, 
discharged from hospital 
with <28days 
Intervention: Remote 
monitoring 
21(6317) All-cause mortality Criteria based on 
The Delphi list & 
The Newcastle-
Ottawa Scale 
6 
Thrombophilia         
Siebenhofer, 
Berghold, & 
Sawicki (2004) 
SR Conduct a SR of controlled & 
RCTs, comparing self-
managed patients to patients 
under routine care provided 
by GPs or a special 
haemostasis care unit. 
1966 to Jan 
2003 
Design: RCT 
Participants: Those taking 
oral anticoagulants 
Intervention: Self-
management 
4(1547) Haemorrhage & 
thromboembolic 
events 
Adapted version 
of 
Cochrane & 
Jadad & Schulz 
6 
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Authors, year Type of 
review 
Aim Period searched Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary outcome/s Quality 
assessment 
tool 
AMSTAR 
score 
Connock et al., 
(2007) 
SR & MA To examine the clinical 
effectiveness & cost-
effectiveness of self-testing & 
self-management of oral 
anticoagulation treatment 
compared with clinic-based 
monitoring. 
1966 to 
September 
2005 
Design: RCT & non-RCT 
Participants: Not stated 
Intervention: Patient self-
testing & self-management 
24(5567) Haemorrhage & 
thromboembolic events 
Authored 
designed 
for RCTs, 
Khan et al., 
(2001) for 
non-RCTs 
6 
Garcia-Alamino 
et al., (2010) 
SR & 
MA 
To evaluate the effects of self-
monitoring or self-
management of oral anti-
coagulation therapy compared 
to standard monitoring. 
1966 to 
Nov 2007 
Design: RCT & cross-over 
trials 
Participants: On oral 
anticoagulation therapy 
Intervention: Self-
monitoring or self-
management 
18(4723) Haemorrhage & 
thromboembolic events 
Cochrane 
& GRADE 
scale 
10 
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Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Bloomfield et al., 
(2011) 
SR & 
MA 
To determine whether 
patient self-testing, alone or 
in combination with self-
management is more 
effective & safer than usual 
care. 
2005 to 
2010 (+ 
references 
from a pre 
2005 review) 
Design: RCT 
Participants: Adult 
outpatients receiving long-
term (>3 months) oral 
anticoagulation therapy 
Intervention: Self-testing 
29(8413) Mortality, 
haemorrhage & 
thromboembolic 
events 
Schulz et al., 
1997 
8 
Diabetes         
Welschen et al., 
(2005b) 
SR & 
MA 
To assess the effects of 
SMBG relative to usual care 
without SMBG on glycaemic 
control, QoL & well-being, 
patient satisfaction & 
hypoglycaemic episodes in 
patients with NID T2DM. 
Inception to 
Sept 
2004 
Design: RCT 
Participants: NID T2DM 
Intervention: SMBG 
6(1285) HbA1c Maastricht- 
Amsterdam score 
list 
8 
McGeoch, Derry, 
& Moore (2007) 
SR Is there evidence to support a 
clinical algorithm for 
identifying T2DM patients 
who will benefit from SMBG? 
Jan 1990 to 
Nov 2006 
Design: RCT (lasting at least 
6 months), OB 
Participants: NID T2DM 
Intervention: SMBG 
17(81901) HbA1c Author designed 5 
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Authors, year Type of 
review 
Aim Period 
searched 
Inclusion/Exclusion criteria n primary 
research 
studies(n 
participants) 
Primary 
outcome/s 
Quality 
assessment 
tool 
AMSTAR 
score 
Kleefstra et al., 
(2009) 
SR Review trials investigating the 
effects of SMBG in NID T2DM 
patients on glycaemic 
control, QoL & satisfaction. 
Inception to 
June 
2009 
Design: RCT 
Participants: NID T2DM 
Intervention: SMBG 
9(2532) HbA1c Maastricht- 
Amsterdam score 
list 
6 
Clar, Barnard, 
Cummins, Royle, 
& Waugh (2010) 
SR & 
MA 
To examine whether or not 
SMBG is worthwhile, in terms 
of glycaemic control, 
hypoglycaemia & QoL in 
patients with T2DM who are 
not treated with insulin or 
who were on basal insulin 
combination with oral agents. 
1996 to 
April 2009 
Design: OB 
Participants: Adults, 
T2DM 
Intervention: Self-testing of 
BG 
66(146148) HbA1c QUOROM & 
CONSORT 
statements 
5 
Malanda et al., 
(2012) 
SR & 
MA 
To assess the effects of SMBG 
in patients with NID T2DM. 
Inception to 
July 
2011 
Design: RCT 
Participants: NID T2DM 
Intervention: SMBG 
12(3170) HbA1c Cochrane 7 
AMSTAR – Assessing the Methodological Quality of Systematic Reviews;  BP – Blood Pressure; CHF - Chronic Heart Failure;  CONSORT - Consolidated Standards of Reporting Trials;  
COPD - Chronic Obstructive Pulmonary Disease;  HF- Heart Failure; MA – Meta-Analysis;  NID – Non-Insulin Dependent;  NR – Not Reported; OB – observational; QoL – Quality of 
Life;  RCT – Randomised Controlled Trial;  SMBG – Self-Monitoring Blood Glucose; SR – Systematic Review;  STROBE - Strengthening the Reporting of Observational studies in 
Epidemiology; STS – structured telephone support; T2DM – Type 2 Diabetes Mellitus; TM – telemonitoring; QUOROM - Quality of Reporting of Meta-analyses; RM – remote 
monitoring
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 Content and structure 
Eleven of the 27 articles were a systematic review only and 16 included a meta-
analysis. The articles were published between 2003 and 2013 and the primary research 
studies between 1986 and 2011. 
 
The articles reviewed interventions in five long-term conditions; heart failure (n=14), 
diabetes (n=5), thrombophilia (n=4), COPD (n=2) and hypertension (n=2). Three 
hundred and twenty-one primary research studies were reviewed across all five 
conditions, within each condition the total number of primary research studies ranged 
from 15 in COPD to 162 in heart failure (Table 3.2). There was no significant correlation 
(p>0.20) between year of publication and number of primary research studies either 
when looking at all articles together or within each long-term condition. 
 
The overall CCA across all five long-term conditions was 2.66%, which represented 
slight overlap. There was variation within each long-term condition. Articles in 
thrombophilia and hypertension had a very high level of overlap according to Pieper et 
al͛s. (2014) criteria, in heart failure the overlap was moderate and in diabetes high. The 
articles in COPD had no duplicate primary research studies as one article was a review 
of action planning and the other telehealthcare (Table 3.2).  
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Table 3.2. Summary of included systematic reviews and meta-analyses 
Condition Articles Total n of primary 
research studies 
Intervention Primary outcomes Monitored data CCA 
Hypertension  2 26 Home blood pressure 
monitoring  
BP  BP  15.38% 
COPD 2 15 Action planning & 
telehealthcare 
Hospitalisation  Symptoms  0% 
Heart failure  14 162 Telemonitoring  Hospitalisation  Symptoms, weight  6.55% 
Thrombophilia  4 38 Self-management Haemorrhage & 
thromboembolic events  
INR  31.58% 
Diabetes  5 80 Self-monitoring  HbA1c  Glucose  13.75% 
BP – Blood Pressure; CCA - Corrected Cover Area; COPD – Chronic Obstructive Pulmonary Disease; FEV - Forced Expiratory Volume; HbA1c - Glycated Haemoglobin; INR - 
International Normalized Ratio
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 Study designs 
Fifteen articles included only RCTs, the remaining articles included a combination of 
study designs including RCTs, experimental or quasi-experimental designs, single 
group, observational and cohort studies and case controlled trials. One article did not 
report study designs (Louis et al., 2003).  
 Outcome measures 
Healthcare utilisation was reported in 17 articles and included a combination of data 
on overall and disease-specific hospital admissions, length of hospital stay, A&E visits, 
GP and outpatient appointments. PROMS such as patient satisfaction, quality of life, 
acceptability and mood were reported in 22 articles. All articles also reported on at 
least one clinical outcome as well.  
3.6.3 Participant characteristics 
The total number of participants included in each article was not always clearly 
reported and due to poor reporting in some cases could not be calculated from the 
sample sizes of each primary research study. From the data that could be extracted, 
within each condition the total number of included participants ranged from 367-1307 
in COPD to 1285-146148 in diabetes. Articles focusing on diabetes and those which 
included a range of study designs tended to include more participants (Table 3.1). 
 
Within each condition there was diagnostic consistency in the type of patients 
included. In hypertension participants were those diagnosed with high blood pressure; 
however, the definition of high blood pressure did differ between primary research 
studies. Articles in heart failure and COPD focused on those with a clinical diagnosis. In 
diabetes, on the whole articles included only patients with non-insulin dependent type 
2 diabetes. In the thrombophilia the participant inclusion criteria were more diverse 
often including patients with any indication, but primarily mechanical heart valve and 
atrial fibrillation. The reporting of participant characteristics, such as the age, gender 
and prescribed medication or treatment was inconsistent across all five long-term 
conditions and in many cases not reported at all.  
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3.6.4 Intervention characteristics 
 Eligibility and completion rates 
Fifteen articles provided detail on the proportion of patients eligible to take part in the 
primary research studies (n=1) and/or the number who completed the studies or 
withdrew (n=12) and two reported both. The proportion of patients eligible to take 
part in these trials were relatively high, as were completion rates (Table 3.3).  
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Table 3.3. Primary research study eligibility and completion rates 
First author, year Intervention n papers (n participants) Follow-up time Results 
Hypertension     
Jaana, 2007 BP TM 14(1119) Study duration 
ranged from 5 
days to 12 
months 
 1 study reported a withdrawal rate of 15% in 
the intervention and 8% in control group. In 
another 50% of the patients were willing to 
stay in the trial to the end of the year.  
COPD     
Turnock, 2005  Action planning 3(367) 6 months & 1 
year 
 87% completed the studies.   Dropout rate ranged from 4.4% to 18.8% 
McLean, 2011  Telehealthcare 10(1307) 3, 6 and 12 
months 
 In 1 RCT only 57% of patients finished the 
intervention arm at 12 months.  
Heart failure     
Clark, 2007  TM or STS 14(4264) Range 2 months 
- 400 days 
 % lost to follow-up ranged from 0-11% 
Polisena, 2010  TM 22(3028) Ranged 30 days - 
1 year 
 The number of patients who withdraw from 
the studies ranged from 0 to 29% 
Inglis, 2010  STS or TM 30(10490) Range 3-18 
months 
 Mean % lost to f/u was 7.6% (range 0 to 26%) 
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First author, year Intervention n papers (n participants) Follow-up time Results 
Thrombophilia 
Connock, 2007 
 
PST or PSM 
 
24(5135) 
 
Range 2-43.6 
months 
  More patients dropped out of the PSM/PST 
group (2-42%) than in the control group (0-
10%) in 10 of the 11 trials that compared 
PSM/PST with usual care.   Patients who withdraw during or after 
training for self-testing tended to be older 
and female.  
Garcia-Alamino, 2010 PST or PSM 26(4723) Duration of 
study 3-19 
months 
 The average % of people that could or would 
not take part in the trials was 68% (range 31-
88%).   24.9% (range 0-57.3%) of the intervention 
group did not complete.   Main reasons for drop-out were: problems 
with the device, physical limitations 
preventing self-testing and problems 
attending the training assessments or failing 
the assessment. 
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First author, year Intervention n papers (n participants) Follow-up time Results 
Bloomfield, 2011 PST or PSM 29(8413) Duration of 
follow-up was 
less than 12 
months in 13 
studies 
 The % of patients who were screened and 
met preliminary eligibility criteria, who 
successfully completed the training and 
agreed to be randomly assigned, was less 
than 20% in 4 studies, between 20-50% in 7 
studies and greater than 50% in 3 studies. 8 
studies did not report this information.   Among participants who were randomly 
assigned, the % continuing the intervention 
ranged from 64-98%.  
Diabetes     
Welschen, 2005b  SMBG 6(1285) Range 6 months-
44  weeks 
 ϱ studies had aŶ ͞aĐĐeptaďle͟ 
withdrawal/dropout rates.   1 study reported a drop-out rate of >40% 
which was considered non-acceptable 
Kleefstra, 2009  SMBG 9(2532) Study duration 
range 6-12 
months 
 Rated as acceptable in 8 RCTs 
Clar, 2010)  SMBG 85(169919) Range 12 weeks-
30 months 
 Ranged from 0-45% in RCTs 
  
1
2
6
 
First author, year Intervention n papers (n participants) Follow-up time Results 
Malanda, 2012  SMBG 16(2795) Study duration 
26 weeks-12 
months 
 Drop-out was rated as low risk of biasing the 
results for 11 articles, high for 3 and unclear 
in 2.  
BP – Blood Pressure; COPD – Chronic Obstructive Pulmonary Disease; PSM – Patient Self-Management; PST- Patient Self-Testing; RCT – Randomised Controlled Trial; SMBG –Self-
Monitoring of Blood Glucose; STS – Structured Telephone Support; TM - Telemonitoring 
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 Type of intervention 
Characteristics of the interventions can be found in Table 3.4. Articles in hypertension 
explored the effects of home-based blood pressure monitoring, all five diabetes 
articles explored the use of blood and/or urine glucose self-monitoring and in 
thrombophilia interventions were either self-testing or self-management. In the 
former patients perform the International Normalized Ratio (INR) test, which is a test 
of how well a particular dose of the anticoagulants are working. If the INR is too high, 
blood clots will not form quickly enough and the patient may experience bruising or be 
at increased risk of bleeding. In this case, the dose of anticoagulants may need to be 
reduced. If the INR is too low, the anticoagulant is not working sufficiently, which 
means that clots could still form unnecessarily and block a blood vessel. In this case, 
the dose of anticoagulants may need to be increased. Self-testing involves patients 
performing the test then any dose adjustments are made by a healthcare professional, 
whereas in self-management the patient makes all dose changes. In COPD one article 
focused on self-management and another on action planning. Similarly, in heart failure 
some articles focused on self-management and others on telemonitoring.  
 Mode of monitoring 
Sixteen of the 27 articles focused specifically on technology to enable patients to 
monitor and transmit data to a healthcare professional. These interventions were 
labelled as telemonitoring, telehealth, telehealthcare, structured telephone support, 
remote monitoring and telephone support. Although the labels varied these 
interventions were either device based monitoring where patients entered data into 
electronic equipment (e.g. mobile phone, personal digital assistant or computer) and 
sent it via telephone line to a monitoring station where it was viewed by a healthcare 
professional; or by using a telephone to either enter data using the touch pad or 
speaking to a healthcare professional on the telephone to report data. Video 
consultations in combination with transmitted data were also used. The remaining 
articles did not state whether data were monitored and recorded using paper based 
formats or other methods. 
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Table 3.4. Intervention characteristics 
First author, year Type of 
intervention 
Level of patient involvement Recommended 
frequency of 
monitoring 
Behaviour/s monitored Follow-up time 
Hypertension      
Jaana, 2007 BP TM Data was given to a HCP. No information on what these 
readings were used for.  
Range 6 a day to 
weekly 
BP, heart rate, 
symptoms, medication 
adherence, stress, ECG, 
weight, sleep quality. 
Study duration 
range 5 days-12 
months 
AbuDagga, 2010 TM Self-measurement & self-transmission of BP. Typically, when 
BP values exceeded predetermined parameters, an alarm 
message was automatically generated & sent to a nurse or 
pharmacist, who contacted patients with disease 
management tips &/or contacted primary care providers for 
action. In other cases, the alarm message was sent directly 
to patients with instructions to contact their physicians.  
Range once a 
week to a few 
times a day 
 
BP (in some studies 
titration decisions, side 
effects). 
Study duration 
range 8 weeks-24 
months 
COPD      
Turnock, 2005  Action planning All studies included patients using an action plan to 
interpret symptoms & make adjustments to their 
medications or seeking HCP advice. 
NR Symptoms. 6 months & 1 year 
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First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
McLean, 2012 Telehealthcare In all studies patients were required to transmit data 
to HCP for personalised feedback. In some studies 
patients were trained to make changes to their 
medication according to an action plan.   
NR NR 3, 6 & 12 
months 
Heart failure      
Louis, 2003  TM NR NR Weight, BP, HR, ECG, 
respiratory rate, body 
temperature, extracellular 
fluid, weight, O2 
saturation. 
Range post 
intervention-12 
months 
Jovicic, 2006 Self-management Patients were taught to recognise when to seek 
medical assistance. 
NR Sign, symptoms, weight. Range 3 
months-1 year 
Martinez-Everss, 
2006  
Home monitoring Data were given to a HCP. There is no information on 
what these readings were used for. 
NR ECG, weight, BP, 
symptoms. 
Range 3-12 
months 
Chaudhry, 2007 TM Data were given to a HCP & was used by a nurse or 
clinician to adjust medication. 
Range twice daily to being 
determined by patient 
status 
Symptoms, weight, 
physiologic measures. 
Range 60 days-
12 months 
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First author, year Type of intervention Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
Clark, 2007 TM or STS Data were given to a HCP. There is no information on 
what these readings were used for. 
Range daily to being 
determined by patient 
status 
Symptoms, weight, pulse, 
BP, electrocardiographic 
data. 
Range 2 
months-400 
days 
Dang, 2009 Home telehealth 
remote monitoring 
Data were given to a HCP. There is no information on 
what these readings were used for. 
Range twice daily to 
weekly 
Weight, BP, HR, O2 
saturation, symptoms, 
ECG, pulse, steps/day, 
medication, pedal 
oedema, respiratory 
effort, facial expressions, 
ankle circumference. 
Range 3-12 
months 
Klersy, 2009 Remote monitoring NR NR Symptoms, weight, BP, 
physical activity, HR, ECG, 
arrhythmias, O2 
saturation, RV pressure. 
RCT: Median 6 
months (range 
2- 
18 months) 
Cohort studies: 
Median 12 
months (range 
2-17 months) 
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First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
Maric, 2009 TM Authors report that changes in weight & symptoms 
were interpreted by a HCP & appropriate action 
taken. But fail to report what happened in each trial. 
NR Signs, symptoms, weight, 
medication, BP, CAD risk 
factors, HR, O2 saturation, 
QoL, blood test results, 
pulse, ECG, steps per day. 
Range 3 
months-1 year 
 
Polinsena, 2010  TM Authoƌs disĐuss patieŶts ďeiŶg ͞eŶĐouƌaged to 
assume a more active role in their disease 
ŵaŶageŵeŶt͟. But fail to ƌepoƌt ǁhat happeŶed iŶ 
each trial. 
NR NR Ranged 30 days-
1 year 
Inglis, 2010  STS or TM It is unclear what happened to the data in a majority 
of studies. In many cases, data were sent to a HCP 
for review but it is unclear what happened as a 
result. 
Range twice daily to 
weekly 
Symptoms, adherence, 
BP, HR, weight, 24hr urine 
output. 
Range 3-18 
months 
Clarke, 2011 TM It is unclear what the data was used for in each trial. 
10 studies included physiological monitoring & data 
were transmitted to HCP to determine if any action 
was required.  
Daily Weight, heart rate. BP, 
ECG, HF symptoms. 
NR 
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First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
Ciere, 2012 Telehealth In all studies patients monitored aspects of the 
disease & transmitted this data. In 4 studies it was 
unclear what the transmitted data were used for, in 
7 studies the data were reviewed by a HCP & 
feedback was given to the participant on 
adjustments to either medication (adherence or 
dose) &/or lifestyle. 
NR Symptoms, medication 
adherence, BP, HR, 
weight, 24hr urine 
output, hear rate, O2 
saturation, self-care 
practices. 
Range 2-12 
months 
Giamouzis, 2012  TM NR NR Weight, BP, heart rate, 
medication dose, 
dyspnoea, asthenia or 
oedema score, blood 
results, changes in 
therapy, pulse oximetry, 
symptoms, 24hr urine 
output, ECG. 
Range 6-26 
months 
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First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
Pandor, 2013  Remote monitoring NR Ranged daily to being 
determined by patient 
status 
Signs & symptoms, 
current medication, 
weight, BP, HR, ECG, fluid 
retention, dyspnoea, 
ankle circumference, 24hr 
urine output, O2 
saturation. 
Study duration 
range 3-15 
months 
Thrombophilia      
Siebenhofer, 2004 PSM In all studies patients monitored their INR values, 
interpreted the results & made adjustments to 
medication. 
Ranged once a week to 
once a month 
INR. Mean 3 months 
Connock, 2007  PST or PSM 5 RCTs looked at monitoring only & 9 monitoring 
with the addition of interpreting & adjusting 
medication. 1 study looked at both. Of the 8 non-
randomised controlled studies, 1 study compared 
monitoring, interpretation & adjustment with just 
monitoring. The remaining studies looked at 
monitoring, interpretation & adjustment. 
Range 0.5 to 4 per week in 
the intervention group & 
from 1 to 4 in the control 
group. 
INR. Range 2-43.6 
months 
  
1
3
4
 
First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
Garcia-Alamino, 
2010  
PST or PSM In 11 trials patients monitored INR levels, 
interpreted the results & made adjustments to their 
medication. In the remaining 6 trials patients just 
monitored their results. 2 reported information on 
both. 
‘aŶge ǁeeklǇ to ͞guided 
ďǇ patieŶt status͟ 
INR. Study duration 
range 3-19 
months 
Bloomfield, 2011  PST or PSM In 19 trials patients monitored INR, interpreted the 
results & made adjustments to their medication. In 5 
trials patients just monitored their results & dose 
adjustment was made by the clinic. In 2 studies it 
was unclear what was taking place. 3 studies 
compared the 2 methods. 
Range 3 times a week to 
at the patients discretion 
INR. Duration of 
follow-up was 
less 
than 12 months 
in 
13 studies 
Diabetes      
Welschen, 2005b  SMBG In 3 trials no standard instructions were provided to 
patients to adjust their behaviour or change their 
lifestyle & medication. No details were provided for 
the 3 other studies. 
Range 6 times a day to 6 
times per week 
BG. Range 
6 months-44 
weeks 
  
1
3
5
 
First author, year Type of 
intervention 
Level of patient involvement Recommended frequency 
of monitoring 
Behaviour/s monitored Follow-up time 
McGeoch, 2007 SMBG 2 RCTs encouraged active modification of behaviour 
based on SMBG readings. 1 of these also used a 
clear management algorithm for changing diabetes-
related medication. There were no details for the 
other studies. 
Range 6 times a day to 
twice every other day 
BG Range 6 
months-6.5 
years 
Kleefstra, 2009  SMBG Glucose values were used for HCP to give advice on 
lifestyle responses. In 4 studies strict algorithms 
were used to adjust BG lowering therapy. But it is 
unclear if this was done by the patient or HCP. 5 
studies were not clear on whether therapy was 
adjusted. 
Range 6 to 42 times per 
week 
BG Study duration 
range 6-12 
months 
Clar, 2010  SMBG/SMUG In 7 RCTs it was unclear if treatment adjustment 
took place. In 2 studies adjustment did not take 
place at all, in 11 trials adjustment was done by a 
HCP, by the patient in 4 trials or a combination. In 2 
further studies adjustment did take place but it did 
not state who did it. 
Range at the patient 
convenience to 36 times a 
week 
BG, UG Range 12 
weeks-30 
months 
Malanda, 2012  SMBG NR Range 6/week to 6/day BG Range 26 
weeks-12 
months 
  
1
3
6
 
BG – Blood Glucose; BP – Blood Pressure; CAD – Coronary Artery Disease; ECG – electrocardiogram; HCP – healthcare professional; HR – heart rate; HF – heart failure; INR – 
international normalized ratio; NR – not reported; PST – patient self-testing; PSM – patient self-management; SMBG – self-monitoring of blood glucose; SMUG – self-monitoring of 
urine glucose; STS – structured telephone support; TM – telemonitoring; UG – urine glucose; RV – right ventricle 
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 Level of patient involvement 
It was important to understand whether all three elements of self-monitoring were 
taking place (i.e. awareness, interpretation, response) according to the concept 
analysis undertaken by Song and Lipman (2008) and Wilde and Garvin (2007). There 
was considerable variation both within and between long-term conditions in the 
degree of involvement patients had in adjusting their behaviour (Table 3.4). In some 
articles participants only undertook the awareness step and data were then passed to 
a healthcare professional or automated system to be interpreted and feedback 
provided on any recommended adjustments to treatment or lifestyle. Other articles 
included participants monitoring, along with interpreting and using this information to 
adjust their treatment regimens, lifestyle and help-seeking behaviour. 
 
In anticoagulation therapy the level of patient involvement differed between articles. 
In all primary research studies patients performed their own INR test. One article in 
this review included only primary research studies in which all intervention 
participants performed an INR test, interpreted the results and adjusted their own 
dose of anticoagulants (Siebenhofer et al., 2004). In the three remaining articles not all 
primary research studies included this level of patient involvement, some only 
required patients to take an INR measurement and then inform a healthcare 
professional of the result for them to decide on the necessary dose adjustment 
(Connock et al., 2007; Garcia-Alamino et al., 2010; Bloomfield et al., 2011).  
 
In both hypertension articles, measurement of blood pressure was undertaken by the 
patient. In the article by Jaana et al., (2007) data were transmitted to a healthcare 
professional but it was unclear what the information was used for. AbuDagga et al., 
(2010) stated that when blood pressure levels were outside of predetermined 
parameters either a healthcare professional would contact the patient or the patient 
received an automated message to contact their healthcare team but it was not 
explicitly clear in all primary research studies.  
 
The article focusing on action planning in COPD involved patients monitoring their 
symptoms and using their action plan to alter their medication regime and/or access 
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relevant medical assistance (Turnock et al., 2005). In the review of telehealthcare by 
McLean et al., (2012) patients were required to transmit data to their healthcare 
professional for personalised feedback or were trained to make their own medication 
changes according to a pre-agreed action plan.  
 
In heart failure four articles failed to report any details on what the monitored data 
were used for and by whom (Giamouzis et al., 2012; Klersy et al., 2009; Louis et al., 
2003; Pandor et al., 2013). Participants appeared to play a more active role in their 
disease management in three articles (Jovicic et al., 2006; Maric et al., 2009; Polinsena 
et al., 2010). Jovicic et al., (2006) included primary research studies that involved 
teaching patients to monitor aspects of their condition and to recognise when to seek 
medical assistance. Maric et al., (2009) reported that patients interpreted changes in 
theiƌ ǁeight aŶd sǇŵptoŵs aŶd took ͞appƌopƌiate aĐtioŶ͟ aŶd PoliŶseŶa et al., (2010) 
stated that patieŶts ǁeƌe ͞eŶĐouƌaged to assuŵe a ŵoƌe aĐtiǀe ƌole in their disease 
ŵaŶageŵeŶt͟. Both Polinsena et al., (2010) and Maric et al., (2009), however, failed to 
report the level of involvement participants had in each of the primary research 
studies. 
 
In heart failure five articles clearly stated that the monitored data were shared with a 
healthcare professional (Chaudhry et al., 2007; Ciere et al., 2012; Clark et al., 2007; 
Dang et al., 2009; Martinez et al., 2006). Martinez et al., (2006), Clark et al., (2007) and 
Dang et al., (2009), however, provided no information on what the monitored data 
were used for. Chaudhry et al., (2007) stated that a healthcare professional used the 
data to alter treatment in all primary research studies. Ciere et al., (2012) combined 
primary research studies in which it was unclear what the data were used for, with 
studies in which data were reviewed by a healthcare professional and feedback 
provided to the participant about adjustments to either medication and/or lifestyle. In 
the remaining articles reporting was inconsistent and definite transmission of data to a 
healthcare professional was reported for only a selection of the primary research 
studies (Clarke et al., 2011; Inglis et al., 2010). Although Inglis et al., (2010) failed to 
detail what the data were used for, Clarke et al., (2011) reported that in a majority of 
the primary research studies physiological monitoring and data were transmitted to 
healthcare professional to determine if any action was required. 
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Despite SMBG being part of standard care in diabetes the level of involvement patients 
had in the interpretation and adjustment of their lifestyle and treatment was poorly 
reported. Malanda et al., (2012) failed to include any information on the level of 
involvement participants had. The four remaining articles included some primary 
research studies that specified the level of patient involvement but in other articles it 
was unclear (Clar et al., 2010; Kleefstra et al., 2009; McGeoch et al., 2007; Welschen et 
al., 2005b).  
 
It is worth noting that use of technology was not associated with patients being more 
actively involved in interpreting and responding to their monitored data. In fact the 
ƌeǀeƌse ǁas tƌue. IŶ oŶlǇ oŶe aƌtiĐle did authoƌs state that patieŶts ǁeƌe ͞eŶĐouƌaged 
to assume a more active role in their disease ŵaŶageŵeŶt͟. No detail was, however, 
provided in how this manifested in the intervention (Polinsena et al., 2010). 
 Behaviour monitored 
The data monitored by participants was in the main consistent within each condition. 
Glucose and INR blood test results were monitored in diabetes and thrombophilia 
respectively. The remaining articles involved monitoring of various symptoms and side 
effects depending on the population. Two articles failed to outline what data patients 
were required to transmit as part of telemonitoring (McLean et al., 2012; Polinsena et 
al., 2010).  
 Additional behaviour change techniques 
In addition to patients self-monitoring many of the primary research studies included 
additional behaviour change components within education and healthcare 
professional feedback. In a majority of cases, however, these details were poorly 
reported and articles either failed to document the specific components or were 
unable to make any conclusions about the effectiveness of these additional techniques 
due to high heterogeneity or too few primary research studies.  
 Control groups 
On the whole the articles that included studies with a control group generally provided 
a poor description of the content. Two articles failed to detail the content of any 
control groups (Chaudhry et al., 2007; Jaana et al., 2007). For a majority there was no 
consistency in what the intervention group was compared to and were a mixture of 
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usual care and/or an active control group. In most cases however, the definition of 
usual or standard care was either not described or was not consistent across primary 
research studies.  
3.6.5 Assessment of review quality 
The methodological quality of the 27 articles varied (Figure 3.3), but was generally 
good (median score = 6). The most common methodological problems were not 
reporting any conflicts of interest either for the authors of the articles or for the 
primary research studies, potential bias in the selection of primary research studies, 
ensuring that there was a search for grey literature and that reports were not excluded 
based on their publication status or language. Appendix G provides detailed scores for 
the AMSTAR checklist for each article. 
 
 
Figure 3.3. Distribution plot of the quality of review articles 
 
3.6.6 Intervention effectiveness 
 Healthcare utilisation 
Healthcare utilisation was reported in 17 articles; 13 in heart failure, 2 in hypertension 
and 2 in COPD (Appendix H). The most frequently reported outcomes were disease-
specific and all-cause hospitalisation. In all but three of these articles did the 
0
1
2
3
4
5
6
7
8
9
2 3 4 5 6 7 8 9 10
N
u
m
b
e
r 
o
f 
a
rt
ic
le
s
AMSTAR quality assessment score
Chapter 3 – Self-monitoring: An Overview of Reviews 
 
141 
intervention consist of self-monitoring aided by technology. In summary, five articles 
failed to find any effect on healthcare utilisation, three found a definite positive 
impact, in three articles it was unclear due to poor reporting and in seven articles the 
results were mixed with a combination of positive effects on some specific outcomes 
and no effect on other aspects of healthcare utilisation. 
3.6.6.1.1 Hospitalisation 
Of these 17 articles, 13 reported the effects of telemonitoring or action planning on 
disease-specific and/or all-cause hospitalisation, 11 in heart failure and 2 in COPD. The 
two meta-analyse both in COPD report conflicting results, whereas Turnock et al., 
(2005) found no significant impact on rates of hospitalisation for action planning, in 
which patients were actively involved in adjusting their treatment or seeking medical 
advice. The meta-analysis by McLean et al., (2012) suggested that the number of 
patients with one or more hospital admissions over a 12 month period was 
significantly greater in the control group compared to telehealthcare in which patients 
used an action plan in only a small proportion of studies.  
 
Of the 11 articles in heart failure six were a meta-analysis of telemonitoring and/or 
structured telephone support and five a systematic review. The level of involvement 
patients had in interpreting and responding to their monitoring data was unclear in all 
these articles. The meta-analyses indicated that telemonitoring and structured 
telephone support were associated with 23% fewer patients being hospitalised for any 
cause (Polisena et al., 2010) and up to 27% fewer total all-cause or disease-specific 
hospitalisations (Pandor et al., 2013; Inglis et al., 2010; Clarke et al., 2011; Klersy et al., 
2009; Clark et al., 2007). 
 
Subgroup analyses were conducted in two of these meta-analyses and suggested that 
telemonitoring with medical support available only during office hours was associated 
with a greater reduction in hospitalisations than when medical support was available 
24/7 (Pandor et al., 2013). Pandor et al., (2013) also found that human-to-human 
structured telephone support led to a 23% reduction in heart failure-related 
hospitalisations, although human-to-machine structured telephone support failed to 
have any effect on either disease specific or all-cause hospitalisation. Klersy et al., 
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(2009) replicated their findings in a subgroup analysis of both low and high quality 
studies and at short- and long-term follow-ups. 
 
Five further systematic reviews included a combination of primary research studies 
that found significant reductions in all-cause and disease-specific hospitalisation rates 
as a result of telemonitoring along with studies that found no significant differences 
between groups (Chaudhry et al., 2007; Dang et al., 2009; Giamouzis et al., 2012; Louis 
et al., 2003; Maric et al., 2009). Te overall conclusions, however, from each of these 
articles suggested a positive trend for a reduction in healthcare utilisation in favour of 
telemonitoring.  
3.6.6.1.2 Readmissions 
One meta-analysis and three systematic reviews all in heart failure reported outcomes 
in relation to readmission rates. The meta-analysis found that self-management, in 
which patients were taught to seek medical assistance in response to symptoms, 
reduced the odds of all-cause and disease-specific readmission by up to 54% of what 
they were in usual care (Jovicic et al., 2006). A majority of the included primary 
research studies in the three systematic reviews reported an association between 
telemonitoring and fewer readmissions to hospital (Louis et al., 2003; Maric et al., 
2009; Martinez et al., 2006). In all three articles, however, it was unclear whether the 
patient or HCP was responding to the monitored data.  
3.6.6.1.3 Length of hospital stay 
The number of days spent in hospital was summarised in eight heart failure systematic 
reviews. The overall findings were mixed, telemonitoring was associated with a 
reduction in the length of hospital stay in many of the primary research studies; both 
within the intervention group over time and when compared to a control group (Louis 
et al., 2003; Maric et al., 2009; Martinez et al., 2006). In many of these studies, 
however, it was unclear if these reductions were statistically significant. The remaining 
articles found that a majority of the included primary research studies failed to 
associate telemonitoring with any reduction in time spent in hospital (Clarke et al., 
2011; Dang et al., 2009; Inglis et al., 2010; Pandor et al., 2013; Polinsena et al., 2010). 
In a majority of these articles it was unclear who was interpreting and responding to 
monitored data. 
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3.6.6.1.4 Accident and emergency attendance  
Seven articles; three meta-analyses and four systematic reviews reported the effects 
of self-monitoring on A&E attendance. The three meta-analyses in COPD and heart 
failure reported conflicting results. Action planning, which involved patients with 
COPD adjusting their own treatment or seeking medical assistance, did not have any 
significant effect on visits to A&E (Turnock et al., 2005). Nor did telemonitoring in heart 
failure, where data were transmitted to a HCP to determine if any action was required 
(Clarke et al., 2011). Telehealthcare in COPD was associated with less attendance at 
A&E compared to the control group; however, the leǀel of patieŶts͛ iŶǀolǀeŵeŶt iŶ 
responding to data did vary (McLean et al., 2012). A majority of the primary research 
studies in the four heart failure systematic reviews did find that telemonitoring 
resulted in fewer visits to A&E for both all-cause and heart failure-related attendance 
(Dang et al., 2009; Louis et al., 2003; Maric et al., 2009; Polinsena et al., 2010). It was 
not possible to examine whether level of patient involvement had an impact on this 
outcome due to poor reporting.  
3.6.6.1.5 Outpatient visits 
Polinsena et al., (2010) included two observational studies, in their systematic review 
of telemonitoring in heart failure, which reported fewer outpatient visits in the 
intervention compared to usual care and two RCTs that found telemonitoring to be 
associated with more outpatient visits. It is unclear, however, if these differences were 
significant and although patients weƌe ͞eŶĐouƌaged to assuŵe a ŵoƌe aĐtiǀe ƌole iŶ 
theiƌ disease ŵaŶageŵeŶt͟ it ǁas uŶĐleaƌ to ǁhat degƌee this ǁas.  
3.6.6.1.6 GP visits 
The impact of self-monitoring on the frequency of GP visits was reported in three 
articles, one meta-analysis and two systematic reviews. The meta-analyses in COPD 
found no significant difference in scheduled or unscheduled GP visits between action 
planning, in which patients made adjustments to their medications and sort medical 
help when required, and usual care (Turnock et al., 2005). These findings were 
substantiated in systematic reviews by Jaana et al., (2007) and AbuDagga et al., (2010) 
in hypertension. In both articles data were transferred to a healthcare professional 
which, in many cases, triggered feedback to the patient.  
3.6.6.1.7 Home visits 
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Two systematic reviews in heart failure report weak and inconsistent effects for 
telemonitoring on the frequency of home visits. One article described a single primary 
research study that found a reduction in home visits from pre- to post-intervention 
(Maric et al., 2009). The second systematic review, however, described two primary 
research studies that found an increase in home care visits in the intervention group 
compared to usual care (Polinsena et al., 2010). But both articles failed to report if 
these changes were statistically significant and it was not possible to determine who 
interpreted and responded to the monitoring, data due to poor reporting.  
 Patient reported outcomes  
Overall the impact of self-monitoring on PROMs was diverse. As a result of incomplete 
reporting it proved difficult to tease out specific findings and hence make overall 
conclusions. This was largely due to the heterogeneity in concept definitions, scales 
and the overall lack of primary research studies which meant only two articles were 
able to perform a meta-analysis (McLean et al., 2012; Turnock et al., 2005), both in 
COPD.  
 
Reporting was particularly poor in regards to detailing the type of measures used, the 
rationale for grouping measures together (e.g. satisfaction combined with anxiety), the 
reporting of significance tests and whether analysis was within or between groups. 
Outcomes for 17 PROMS were summarised in 22 articles (Appendix I). Due to the 
number of outcomes this overview focuses on the most frequently reported and 
relevant variables. Due to the heterogeneity in how terms were grouped within an 
article, data were extracted at primary research study level, where possible. Where 
results for individual primary research studies were not available results are reported 
for each of the outcomes according to the label within the article. In summary, four 
articles found a definite positive impact for self-monitoring on PROMS, three found no 
significant effect, in four article it was unclear primarily due to poor reporting and 11 
articles found positive effects in relation to some PROMS and no significant effect for 
other measures. 
3.6.6.2.1 Quality of life  
Quality of life was the most frequently described PROM and was reported in 18 
systematic reviews; two in COPD, two in hypertension, three in thrombophilia, four in 
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diabetes and eight in heart failure. Quality of life was measured in several ways 
iŶĐludiŶg ǀalidated ŵeasuƌes suĐh as the COPD speĐifiĐ “t Geoƌge͛s ‘espiƌatoƌǇ 
Questionnaire (Jones, Quirk, & Baveystock, 1991) and Minnesota Heart Failure Quality 
of Life (Rector, Kubo, & Cohn, 1987) questionnaire but also using author developed 
questionnaires.   
  
In COPD, the meta-analysis by Turnock et al., (2005) found no significant difference in 
quality of life when patients with COPD undertook self-monitoring and medication 
adjustment based on a pre-agreed action plan, compared to usual care at either the 6 
or 12 month follow-up. Although the meta-analysis of telehealthcare by McLean et al., 
(2012) validated this non-significant result, the mean difference between the 
intervention and control group was greater than the minimally important clinical 
difference on the COPD-speĐifiĐ “t Geoƌge͛s ‘espiƌatoƌǇ QuestioŶŶaiƌe (Jones et al., 
1991). This indicates a clinically significant improvement in quality of life as a result of 
telehealthcare, in which patients changed their medications according to an action 
plan in some of the primary research papers. 
 
In, hypertension, diabetes and heart failure the systematic reviews either found no 
significant impact of quality of life as a result of blood pressure or blood glucose 
monitoring (Clar et al., 2010; Kleefstra et al., 2009; Malanda et al., 2012; Jovicic et al., 
2006) or a combination of primary research studies reporting positive results in favour 
of self-monitoring and others that failed to find any significant impact on quality of life 
(Jaana et al., 2007; AbuDagga et al., 2010; Welschen et al., 2005b; Clark et al., 2007; 
Inglis et al., 2010; Louis et al., 2003; Maric et al., 2009; Martinez et al., 2006; Pandor et 
al., 2013; Polinsena et al., 2010). In the hypertension articles the intervention involved 
data being transferred to a healthcare professional; however, it was not always clear 
what response was taken. In heart failure it was not clear what level of involvement 
patients had in interpreting their monitored data and making the adjustments, 
whereas SMBG was performed by the patient in diabetes; however, it was unclear in a 
majority of cases who was interpreting and responding to the data. 
 
When self-management in thrombophilia was compared to usual care in the article by 
Siebenhofer et al., (2004) two RCTs reported significant differences in quality of life in 
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favour of self-management. These interventions included patients being trained to 
perform an INR test and adjust their dose of anticoagulants. Conversely when primary 
research studies in which dose adjustment was undertaken by either the patient or 
healthcare professional were combined, the results were less clear. Connock et al., 
(2007) and Bloomfield et al., (2011) present a combination of studies that found the 
intervention led to improvements in quality of life and other studies which fail to find 
any significant effects.  
3.6.6.2.2 Mood 
Outcomes in relation to anxiety and depression were synthesised in eight systematic 
reviews; one in COPD, three in diabetes and four in heart failure. In the only article in 
which patients with COPD were taught to interpret their symptoms and make 
adjustments to their medications or seek medical assistance there were no significant 
between group differences in either anxiety or depression (Turnock et al., 2005). The 
systematic reviews in diabetes and heart failure were inconclusive, with some primary 
research studies suggesting significant improvements in mood as a result of self-
monitoring and other primary research studies that found no significant effects for 
anxiety or depression (Clar et al., 2010; Kleefstra et al., 2009; Malanda et al., 2012; 
Clark et al., 2007; Inglis et al., 2010; Maric et al., 2009; Martinez et al., 2006). It is of 
note that one primary research study found a significant increase in depression as a 
result of SMBG (Clar et al., 2010; Malanda et al., 2012). In both diabetes and heart 
failure the level of involvement patients had in adjusting was unclear.  
3.6.6.2.3 Satisfaction, acceptability and ease of use 
Fifteen systematic reviews reported on patient satisfaction, acceptability of the 
intervention or, when the article focused on telemonitoring, how easy the technology 
was to use. Of these 15 articles, one was in COPD, two in hypertension, two in 
thrombophilia, four in diabetes and six in heart failure.   
 
 Jaana et al., (2007) described two primary research studies in hypertension that 
assessed how easy the technology was to use but failed to report any results and two 
other primary research studies in which satisfaction was high. Anecdotal data from 
AbuDagga et al., (2010) suggested high rates of technology acceptance among 
participants. In both articles data were transferred to either an automated system or 
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healthcare professional, the patient did not have any involvement in interpreting the 
data they monitored.   
  
A majority of the primary research studies in thrombophilia and heart failure articles 
reported high levels of satisfaction, both general- and treatment-specific, in the 
intervention group compared to usual care (Bloomfield et al., 2011; Garcia-Alamino et 
al., 2010; Clark et al., 2007; Inglis et al., 2010; Louis et al., 2003; Martinez et al., 2006; 
Pandor et al., 2013; Polinsena et al., 2010). The interventions in both thrombophilia 
articles included a combination of self-testing and self-management. Due to poor 
reporting the heart failure articles can only be assumed to involve patients monitoring 
their symptoms, with no patient interpretation or response to data. There were, 
however, no between group differences in patient or treatment satisfaction when  
SMBG was compared with controls in any of the diabetes systematic reviews (Kleefstra 
et al., 2009; Malanda et al., 2012; McGeoch et al., 2007; Welschen et al., 2005b).  
 Clinical outcomes 
Twenty-six of the 27 articles reported clinical outcomes. The range of clinical outcomes 
was vast and included 25 different variables. Some were disease-specific such as 
HbA1c, in diabetes and thromboembolic events in thrombophilia. In contrast other 
outcomes were reported across conditions such as mortality, blood pressure, weight 
and adherence. In many cases a meta-analysis was not possible because of too few 
primary research studies and high heterogeneity. Due to the large number of clinical 
outcomes this will review will focus on the most frequently reported and relevant. For 
details of all outcomes see Appendix J. Overall the results were generally positive with 
7 of 26 articles finding positive clinical implications as a result of self-monitoring and 
the remaining articles describing a combination of positive effects for some clinical 
variables and no significant effects on other outcomes.  
 
3.6.6.3.1 Generic outcomes 
Mortality 
Twenty articles synthesised the evidence on mortality; two in COPD, two in diabetes, 
three in thrombophilia and 13 in heart failure.  
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Whilst meta-analyses in COPD (McLean et al., 2012; Turnock et al., 2005) and an 
earlier meta-analysis in heart failure found no significant effects on mortality (Jovicic 
et al., 2006) the meta-analyses in thrombophilia  and later meta-analyses in heart 
failure found significant reductions in mortality in favour of self-monitoring 
(Bloomfield et al., 2011; Connock et al., 2007; Garcia-Alamino et al., 2010; Clark et al., 
2007; Inglis et al., 2010; Klersy et al., 2009; Pandor et al., 2013; Polinsena et al., 2010). 
In all articles the level of patient involvement in interpreting and responding to data 
was not consistent. These significant results were maintained across disease 
indications (Connock et al., 2007), when self-monitoring was compared to GP and 
secondary care (Connock et al., 2007; Garcia-Alamino et al., 2010), when studies were 
restricted to RCTs only (Polinsena et al., 2010), those of high quality (Klersy et al., 
2009) and at long and short-term follow-up (Inglis et al., 2010; Klersy et al., 2009). 
Clark et al., (2007), however, found that there was no difference in all-cause mortality 
when structured telephone support was compared to telemonitoring in a subgroup 
analysis. Pandor et al., (2013) found that whereas telemonitoring supported either by 
office hours or 24/7 medical advice had a statistically significant effect on mortality, 
structured telephone support was only effective in reducing mortality rates when the 
support was human-to-human as opposed to human-to-machine.  
 
One primary research study was reported in two diabetes systematic reviews. This 
longitudinal observational study found significant reductions in mortality in those that 
self-monitored despite significantly worse initial fasting glucose and HbA1c (Clar et al., 
2010; McGeoch et al., 2007). A second observational study reported in one of these 
systematic reviews found no change in mortality overtime (Clar et al., 2010). In all 
cases it was unclear who if anyone made changes to treatment.  
Blood pressure 
Four articles reported outcomes in relation to blood pressure (e.g. systolic, diastolic, 
ambulatory, blood pressure within a recommended target range); one in diabetes, one 
in heart failure and two in hypertension. The systematic review in diabetes (Clar et al., 
2010) and another in heart failure (Maric et al., 2009) suggested either no effect or 
very weak evidence to suggest that self-monitoring improved blood pressure. The 
evidence in hypertension was more convincing a majority of the primary research 
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studies found significant reductions in blood pressure when participants were required 
to measure their blood pressure and transmit these readings to a healthcare 
professional (AbuDagga et al., 2007). AbuDagga et al., (2007) suggested that greater 
reductions in blood pressure were found when rates of compliance with 
telemonitoring and self-titration were higher. This, however, was only found in one 
single group study. In a majority of cases patients were not involved in adjusting their 
treatment or lifestyle and data were transferred to a healthcare professional for action 
to be decided upon. 
Weight 
Three articles, one in hypertension and two in heart failure report limited evidence for 
telemonitoring reducing weight. A single primary research study in hypertension found 
significant improvements in weight from pre- to post-intervention (Jaana et al., 2007). 
Similarly, both systematic reviews in heart failure report the results of a single primary 
research study that found self-monitoring to significantly improve weight over time 
(Inglis et al., 2010; Maric et al., 2009). In all cases data were transferred to a healthcare 
professional for review. 
Adherence 
Five systematic reviews, two in hypertension and three in heart failure reported 
outcomes in relation to either adherence to medication or lifestyle recommendations. 
Overall the results were inconclusive. Systematic reviews in both hypertension and 
heart failure reported primary research studies that found significant improvements in 
medication adherence and dietary and exercise recommendations as a result of self-
monitoring whilst other primary research studies found no significant difference either 
within an intervention over time or between intervention and control groups 
(AbuDagga et al., 2007; Inglis et al., 2010; Jaana et al., 2007; Jovicic et al., 2006; Maric 
et al., 2009). Only in the article by Jovicic et al., (2006) were patients taught to 
recognise when medical advice was needed.   
3.6.6.3.2 Disease-specific outcomes 
HbA1c 
All five articles in type 2 diabetes compared the effects of SMBG on HbA1c, primarily 
for non-insulin dependent patients. The results were inconclusive in the two 
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systematic reviews (Kleefstra et al., 2009; McGeoch et al., 2007). Two meta-analyses, 
however, concluded that SMBG significantly reduced HbA1c compared to no self-
monitoring, with a weighted mean difference of between -0.21% and -0.39% (Clar et 
al., 2010; Welschen et al., 2005b). These significant results remained when SMBG was 
undertaken less frequently and for participants who started the trial with HbA1c 
greater than шϴ% the ƌeduĐtioŶ iŶ HbA1c across the trial was greater (Clar et al., 2010). 
When SMBG with an additional educational or feedback component was compared 
with SMBG alone there were no significant differences. In comparison to no SMBG, 
however, this enhanced intervention led to a greater reduction HbA1c (Clar et al., 
2010). In a third meta-analysis Malanda et al., (2012) explored the impact of length of 
follow-up in combination with disease duration. For those who had been living with 
diabetes for more than 1 year SMBG led to a statistically significant decrease in HbA1c 
of 0.3% compared with controls at short-term follow-up (up to 6 months) but there 
were no significant differences at the longer term follow-up (between 6 and 12 
months). For newly diagnosed participants pooled analysis for short term follow-up 
was not possible due to high heterogeneity; however, at the medium-term follow-up 
there was a statistically significant decrease in HbA1c of 0.5%. None of these articles 
explored the impact of level of patient involvement. Welschen et al., (2005b), Clar et 
al., (2010) and McGeoch et al., (2007) included a number of primary research studies 
in which patients adjusted their lifestyle and medication in order to modify their 
glucose values.  
Hypoglycaemia   
The results for hypoglycaemic events were inconsistent, although there was a 
suggestion that occurrence of mild or moderate hypoglycaemia was increased with 
more frequent self-monitoring (Clar et al., 2010).  
Fasting blood glucose  
There were no significant effects for SMBG on fasting blood glucose (Welschen et al., 
2005b).  
Thromboembolic and haemorrhage events  
All four articles in thrombophilia synthesised the effects of self-monitoring on 
thromboembolic and haemorrhage events. Three meta-analyses reported significantly 
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fewer thromboembolic events in the intervention compared to control group, but no 
differences in major haemorrhage events (Bloomfield et al., 2011; Connock et al., 
2007; Garcia-Alamino et al., 2010). A majority of the primary research studies in the 
systematic review by Siebenhofer et al., (2004) reported too few thromboembolic and 
haemorrhage events to draw any conclusions. Connock et al., (2007) also found that 
trials conducted outside of the UK had a greater effect on thromboembolic events than 
those conducted inside the UK (Connock et al., 2007). The type of control group the 
intervention was compared to (i.e. family physician care or anticoagulation clinic) did 
not affect these outcomes (Connock et al., 2007; Garcia-Alamino et al., 2010). Connock 
et al., (2007) also found that there was no difference between patient self-testing and 
patient self-management on thromboembolic events. Garcia-Alamino et al., (2010), 
however, found that patient self-management led to significantly fewer haemorrhage 
events and the relative risk of experiencing a thromboembolic event was also lower 
than in the group that self-monitored. Although the latter finding was not a statistically 
significant interaction. Conversely Connock et al., (2007) found that self-management 
led to significantly more haemorrhage events than patient self-testing.  
International normalized ratio  
The impact of self-monitoring on INR values was reported in four articles, one meta-
analysis and three systematic reviews, either as the percentage of time participants 
spent within the recommended INR range or as the proportion of INR tests within the 
recommended range. One was a meta-analyses and the others systematic reviews. The 
meta-analysis found that self-monitoring, where medication adjustment was 
undertaken by either the patient or healthcare professional, failed to have any 
significant effect on the percentage of time spent within the therapeutic range or the 
percentage of INR tests within range (Bloomfield et al., 2011). Two primary research 
studies in this article compared self-monitoring with self-management and found no 
significant difference in percentage of time in the therapeutic range between the two 
interventions. Two systematic reviews, described primary research studies that found 
significant benefits for self-monitoring on INR values and other studies which failed to 
find any significant effects (Garcia-Alamino et al., 2010; Siebenhofer et al., 2004). 
Whilst another systematic review pooled estimates and found that intervention 
participants spent a greater proportion of time within the recommended INR range 
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compared to control group participants in both RCTs and non-RCTs, no statistical 
comparisons were made (Connock et al., 2007). 
3.7 DISCUSSION 
This overview of systematic reviews and meta-analyses has for the first time examined 
the effectiveness of interventions that include patients self-monitoring their long-term 
condition, on healthcare utilisation, PROMS and clinical variables. It is based on a 
systematic and extensive literature search, combined with an assessment of quality. A 
total of 27 articles were reviewed across five long-term conditions: COPD, 
hypertension, thrombophilia, heart failure and diabetes. 
3.7.1 Healthcare utilisation 
Seventeen of the 27 articles included in this review synthesised the evidence in 
relation to healthcare utilisation, principally in heart failure, COPD and hypertension. 
The results indicated that interventions which involved self-monitoring can lead to 
significant reductions in healthcare usage, with little evidence to indicate an increase 
in healthcare utilisation. 
 
Although the results present a mixed picture in regards to attendance at A&E, 
admission to hospital decreased significantly in patients with heart failure and COPD. 
These findings principally focused on interventions using telemonitoring and 
structured telephone support and suggested that self-monitoring facilitated by 
technology led to significant reductions in both disease-specific and all-cause 
hospitalisation and readmissions. This indicates that in certain long-term conditions 
self-monitoring can impact upon not only on healthcare utilisation relevant to the 
targeted long-term condition but also other areas of health. Both human-to-human 
structured telephone support and telemonitoring interventions that were 
aĐĐoŵpaŶied ďǇ offiĐe houƌ͛s ŵediĐal suppoƌt ǁeƌe fouŶd to be additionally 
advantageous, and in the long- as well as short-term. This suggests that 
communication with another person rather than automated feedback may be 
additionally advantageous. This could be due to the immediate action that can be 
taken or the additional social support offered. Once hospitalised however, the picture 
was mixed in regards to the number of days patients spent in hospital with some 
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reviews suggesting a significant reduction in days both between groups and overtime 
and others that failed to associate self-monitoring with any reduction in time spent in 
hospital. In light of the fall found in hospital admissions, a failure to find a significant 
change in GP attendance is encouraging as this suggests that patients are not diverting 
healthcare usage from secondary to primary care.  
 
The lack of primary research studies exploring the impact of self-monitoring on 
outpatient attendance means that further work is needed in order to establish 
whether the reductions found in other aspects of healthcare usage can be replicated in 
outpatient services. Rather than outpatient attendance not being an important 
outcome for the interventions synthesised within this overview, it was more likely that 
inpatient attendance was a more critical outcome for these patient groups and hence a 
reduction in outpatient attendance was not targeted in these interventions. This does, 
however, remain an important outcome for patients with arthritis who may be less 
likely to be hospitalised than those with heart failure or COPD.  
3.7.2 Patient reported outcomes 
Despite PROMS being synthesised in 22 of the 27 articles, psychosocial well-being and 
patient satisfaction were the most poorly described of all outcomes. This inadequate 
reporting along with heterogeneous measurement tools and concept definitions and 
the limited number of primary research studies made it difficult to draw definitive 
conclusions about the effects of self-monitoring on the patient experience. Overall the 
impact of self-monitoring suggested no detrimental effects on patient well-being or 
satisfaction with care. In fact patients were highly satisfied with self-monitoring when 
investigated within the intervention group, but when compared to usual care many 
articles found no difference in overall or treatment-specific satisfaction. Patient 
acceptability of technology assisted self-monitoring was also high in both hypertension 
and heart failure with very little evidence of rejection.  
 
There was tentative evidence to indicate a possible improvement in quality of life. 
Whilst two meta-analyses reported a statistically non-significant effect on quality of 
life, the actual difference between the intervention and control was clinically 
significant in one article and indicated an improvement in quality of life as a result of 
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self-monitoring in COPD (McLean et al., 2012). In addition both Siebenhofer et al., 
(2004) and Connock et al., (2007) concluded that patient self-management in 
thrombophilia enhanced quality of life, although in these reviews the authors included 
a combination of primary research studies that did find benefits and others that did 
not, suggesting the these findings are not conclusive. The literature was less persuasive 
for mood, with most systematic reviews reporting a combination of primary research 
studies that failed to find any impact on anxiety or depression, other studies which 
found significant improvements and one primary research study which found a 
significant increase in depression as a result of SMBG in type 2 diabetes. These articles 
did not report the hypotheses of the primary research studies in relation to mood; 
therefore, it is unclear whether improvements or equivalence were expected. An 
intervention designed to promote self-monitoring would not necessarily be aimed at 
reducing levels of anxiety and depression, but no detrimental effects or no difference 
between groups could be taken as a positive result.  
 
An increase in any aspect of healthcare utilisation would be particularly important in 
relation to mood as concerns have been raised about the impact that self-monitoring 
may have on levels of anxiety. For instance in diabetes patients have been found to 
feel anxious if blood glucose readings are high and they are unable to understand why 
(Peel, Parry, Douglas, & Lawton, 2004). Intuitively, it may then be expected that 
someone with a long-term physical illness who is more anxious will also exhibit greater 
health-seeking behaviours. There is evidence to suggest that persistently high anxiety 
scores do predict greater hospitalisation (Moser et al., 2011). Implementation of any 
intervention that includes self-monitoring should, therefore, be mindful as to whether 
anxiety could manifest or be exacerbated by self-monitoring and how this could be 
prevented or combated by providing information and guidance on how to interpret 
monitored data and take appropriate action.  
3.7.3 Clinical outcomes 
A wide range of clinical outcomes were measured across reviews reflecting the overall 
aims of the articles and range of long-term conditions. As the aim of this review were 
to explore the evidence in relation to healthcare utilisation and patient reported 
outcomes, many published articles that focused on synthesising the effects of clinical 
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outcomes only were excluded from this review. Despite this there are several 
important conclusions that can be drawn from the findings of this overview which 
mirror other published work, in relation to both general and disease-specific 
outcomes.  
 
Self-monitoring was associated with a significant reduction in mortality, of between 17 
and 52%, primarily in thrombophilia and heart failure. These results support the earlier 
meta-analyses by Heneghan et al., (2006) and Christensen et al., (2007), which found 
significant reductions in mortality in favour of self-monitoring in thrombophilia. A 
more detailed meta-analyses by Heneghan et al., (2011) using individual patient data 
did not see the same reduction in mortality as these previous reviews or the current 
findings, but did find a trend towards significance and a significant effect for those 
aged over the age of 85. This lack of effect is likely due to the larger number of 
participants needed to find a reliable and conclusive treatment effect when conducting 
a review with individual patient data.  
 
With regards to disease-specific measures, blood pressure improved significantly as a 
result of home-based monitoring and HbA1c reduced significantly as a result of SMBG, 
supporting previous meta-analyses in hypertension (Verberk et al., 2011; Cappuccio et 
al., 2004; Bray et al., 2010) and diabetes (Sarol Jr et al., 2005; Allemann et al., 2009; 
Poolsup et al., 2008; Poolsup et al., 2009; Towfigh et al., 2008). Long-term follow-up of 
SMBG was also found to be more beneficial for new-onset patients and for participants 
who began SMBG with poorer glycaemic control, confirming previous meta-analyses 
(Allemann et al., 2009; Jansen, 2006; Poolsup et al., 2009). Self-monitoring and self-
management are also likely to prevent thromboembolic events for patients on 
anticoagulation therapy. Two meta-analyses however, found conflicting results in 
relation to anticoagulation control but this is likely to reflect the additional benefits of 
patients adjusting their own anticoagulant dose as opposed to adjustment by a 
healthcare professional.  
3.7.4 The implementation of self-monitoring 
The manner in which self-monitoring was implemented within each of the 
interventions differed between long-term conditions but was on the whole consistent 
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within each condition likely owing to specific monitoring and treatment requirements. 
In hypertension interventions were home-based blood pressure monitoring, in 
diabetes self-monitoring of blood glucose and in thrombophilia home-based INR 
monitoring. In heart failure and COPD the interventions were more diverse and 
included a combination of self-management which incorporated self-monitoring and 
telemonitoring. Across all conditions participants were required to monitor different 
aspects of disease status, encompassing symptoms and side effects, active use of 
technology to monitor for instance blood pressure or oxygen saturation, along with 
home testing of blood and urine samples to measure glucose levels and INR blood 
testing in anticoagulation therapy. These activities varied from being aspects of disease 
management that are customary in the standard care of any physical health condition 
i.e. reporting of symptoms, to more novel and complex tasks that were likely to 
require skills training and monitoring schedules such as INR testing. Although as 
discussed later in this section, the reporting of the additional behaviour change 
techniques which accompanied self-monitoring were poorly described.  
 
Irrespective of what data patients were required to monitor the integral part of any 
intervention that includes self-monitoring is who has access to the monitored data and 
what the data were used for. The clinical objectives of self-monitoring were in fact 
similar across long-term conditions, those being to help identify early signs of 
deterioration and allow for timely changes to treatment, lifestyle or help-seeking 
behaviour. Although self-monitoring was being used as a tool to aid patient behaviour 
change these objectives were achieved by a decision making process led either by a 
healthcare professional or the patient. By scrutinising the content of these 
interventions, this review has enabled the development of a schematic representation 
of self-monitoring across long-term conditions (Figure 3.4). 
 
The interventions included in this review, involved monitored data either being 
retained by the patient for interpretation and clinical adjustment or transferred to a 
health professional or automated system for review. In this latter case self-monitoring 
was used purely as a tool for clinical monitoring, where the patient was active in 
gathering the data but not in the interpretation of that data or in the decision to adjust 
treatment or lifestyle behaviours, fulfilling only the awareness stage of self-monitoring  
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(Song & Lipman, 2008; Wilde & Garvin, 2007). In the former, which represents chronic 
disease self-management, interventions empowered patients to adjust and hence 
enabled them to manage the consequences of living with their long-term condition 
(Barlow, Wright, Sheasby, Turner, & Hainsworth, 2002). This involved patients 
interpreting their data and adjusting their lifestyle and medication behaviours in order 
to maintain or improve outcomes. These outcomes included clinical and/or 
psychosocial well-being, as well as healthcare utilisation. Other self-monitoring 
interventions, including the one evaluated within this thesis, lie somewhere in the 
middle of these two approaches, whereby patients use their monitored data to make 
decisions about help-seeking in accordance with pre-defined clinical criteria. 
Healthcare professionals then adjust treatment plans or lifestyle behaviours and 
assume that patients then implement these recommended changes.  
  
1
5
8
 
 
Figure 3.4. A diagrammatic representation of self-monitoring in long-term conditions 
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As the articles included in this review suffered from poor reporting it was not always 
possible to establish whether self-monitoring was taking place in the context of chronic 
disease self-management or purely as a tool for clinical monitoring. Allowing patients 
with a long-term condition to make decisions about necessary treatment and lifestyle 
adjustments may engage and empower patients to make changes to their health-
related behaviour. In contrast adjustment decisions made by a healthcare professional 
may allow for a more passive patient and lead to comparatively poorer outcomes due 
to a lack of awareness between behaviour and outcome. Lack of studies and poor 
reporting, however, made it difficult to provide robust evidence to examine this 
hypothesis. Only in anticoagulation therapy were direct comparisons made between 
interventions that included patients adjusting as opposed to healthcare professionals. 
The results were, however, contradictory with evidence to suggest no difference in 
clinical outcomes, a detrimental effect for patients taking control of adjusting and also 
beneficial effects. Inconsistent clinical benefits for patients as opposed to healthcare 
professionals adjusting have also been reported elsewhere in the literature. Whereas 
an early review by Heneghan et al., (2006) failed to find any advantage to patients 
adjusting their own medication in regards to mortality, thromboembolic and 
haemorrhage events, the authoƌ͛s more recent review found significantly fewer 
thromboembolic and haemorrhage events for patients who self-managed as opposed 
to just testing (Heneghan et al., 2011).  
 
Two additional articles in this review that only included interventions in which patients 
made adjustments to their medication or help-seeking behaviour, found either a 
significant decrease in healthcare utilisation and improvements in quality of life 
(Siebenhofer et al., 2004) or no change in healthcare usage (Turnock et al., 2005). The 
interventions in this more recent article would however, fall within the middle ground 
ďetǁeeŶ patieŶt͛s self-management and clinical monitoring as patients were required 
to seek help in respond to abnormal symptoms.   
 
Further investigation and analysis of the primary research studies is needed so that 
definitive conclusions can be made about the additional benefits of patients using their 
monitored data to adjust their own medication, lifestyle and help-seeking behaviours. 
A recently published Cochrane protocol indicates that this is currently being explored 
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in type 2 diabetes (Ng, Liew, Vethakkan, Abdullah, & Teng, 2013). Authors will be 
comparing patient-adjusted versus healthcare professional-adjusted insulin dosing, in 
order to explore whether patient-adjusted insulin dosing is more empowering for the 
patient, leads to better glycaemic control due to a quicker response to high or low 
blood glucose levels and is more cost-effective as fewer contacts with healthcare-
professionals are needed or whether healthcare professional-adjusted insulin is safer. 
As recognised by Clar et al., (2010) in diabetes, but also applicable across other long-
term conditions, self-monitoring is often treated as a diagnostic tool, as an 
intervention in its own right, without acknowledging that in order to change patient 
outcomes self-monitoring needs to include the appropriate education, feedback and 
behavioural adjustment. This could be achieved by returning to the original 321 
primary research studies, classifying them according to level of patient involvement in 
interpreting and responding to data and exploring how this impacts upon study 
outcomes. This was however, outside of the scope of this overview.   
 
Due to poor reporting and study heterogeneity it was not possible to systematically 
extract data on whether additional behaviour change techniques were part of the 
delivered interventions. In the context of self-monitoring it is likely that other 
behaviour change techniques were implemented but this information was often 
missing in the articles and primary research papers; therefore, making it difficult to 
have an accurate and detailed understanding of the intervention delivered. An 
intervention designed to enable participants to monitor and use this information to 
seek help or adjust medication or lifestyle behaviours is likely to include an educational 
and possibly skills training component and it is these additional components that could 
explain the variability found in intervention effectiveness. Lack of detail is common in 
the description of complex interventions and it is, therefore, not surprising that there 
was an absence of detail in the articles included in this overview. This however, 
constrains scientific replication and limits the subsequent introduction of successful 
interventions (Michie, Fixsen, Grimshaw, & Eccles, 2009) because even when 
significant effects are found it is not possible to determine which behaviour change 
techniques were responsible for these observed changes. This review assumes that 
self-monitoring was the integral component of all of the interventions however, 
without a detailed description of the other behaviour change techniques it is not 
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possibly to say unequivocally that this was the key behavioural component. Systematic 
reviews conducted within the general population and in those with a long-term illness 
have however, demonstrated the importance of self-monitoring in behaviour change 
and the significance of combining it with other behaviour change components 
(Dombrowski et al., 2010; Michie, Abraham, Whittington, McAteer, & Gupta, 2009; 
Knittle, Maes, & de Gucht, 2010; Bray et al., 2010). Future work would benefit from 
coding intervention descriptions using the recently developed Behaviour Change 
Technique Taxonomy (BCTTv1) (Michie, Johnston, Abraham, Francis, & Eccles, 2013) 
which enables a detailed description of intervention content according 93 
hierarchically structured behaviour change techniques all derived from theory. This 
would establish the exact content of the intervention and control groups and evaluate 
the impact the content is having on effectiveness.   
 
A majority of the articles in this review evaluated the effectiveness of various point-of-
Đaƌe teĐhŶologies to ŵoŶitoƌ a patieŶt͛s phǇsiologiĐal status aŶd health ĐoŶditioŶ, 
known as telehealth. In the context of this review telehealth involved patients 
monitoring and transmitting their data via telephone or computer, to either receive an 
automated message about any necessary action to take or reviewed by a healthcare 
professional and in some cases feedback provided. The primary advantage to self-
monitoring supported by technology is that it allows patients and healthcare 
professionals to be connected in real time and has become a popular method via 
which self-monitoring is facilitated. There was no consistent evidence within this 
overview that the use of technology was more advantageous than interventions that 
did not use technology nor were there any differences between telemonitoring and 
structured telephone support.  
 
The evaluation of telehealth outside of this review has revealed a complex picture. In 
ϮϬϬϲ, the DepaƌtŵeŶt of Health estaďlished thƌee ͚Whole “Ǉsteŵs DeŵoŶstƌatoƌs͛ 
which recruited over 3,000 patients with diabetes, heart failure or COPD into a large 
RCT (Bower et al., 2011). The results of this trial indicated that telehealth patients were 
less likely to die and needed fewer hospital admissions and bed days in hospital than 
patients receiving usual care, but unexpected patterns that appeared among usual 
care patients suggested that the differences might not be attributable to telehealth 
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but to the detection of unmet need in the intervention group (Steventon et al., 2012). 
There were also no discernable benefits for quality of life or psychosocial outcomes 
(Cartwright et al., 2012). The model of self-monitoring proposed in Figure 3.4 suggests 
that a majority of telehealth is undertaken for clinical monitoring purposes and not 
chronic disease self-management, as in many cases adjustments were made either by 
an automated system or healthcare professional and fed back to the patient for 
implementation. How chronic disease self-management is integrated into telehealth is 
yet to be explored and despite many of these interventions explicitly stating that the 
intervention is one of self-management or aimed to enable self-management patients 
were rarely involved in responding to the data. In fact there is evidence to suggest that 
these interventions may lead to over dependency on technology with negative 
consequences such as an assumption that a healthcare professioŶal is ͞ǁatĐhiŶg oǀeƌ͟ 
them leading to a lack of response to monitored data (Radhakrishnan, Jacelon, & 
Roche, 2012; Ure et al., 2012). As has been underlined in the article by Ciere et al., 
(2012) the mechanisms at work in telehealth interventions have rarely been 
investigated and, therefore, there is little evidence available on which behaviour 
change techniques are included and how they affect outcomes, similarly true of the 
wider self-monitoring literature.  
 
In the context of the current thesis one of the aims of this overview was to establish 
whether self-monitoring of blood test results would have any additional benefits or 
harms, in comparison to interventions which included patients monitoring just their 
symptoms or side effects. It is interesting to highlight that the articles that explored 
the impact of blood test self-monitoring (i.e. in thrombophilia and diabetes) failed to 
explore the impact of the interventions on healthcare utilisation and focused only 
patient reported outcomes and clinical well-being, whilst the articles in heart failure, 
COPD and hypertension all included healthcare utilisation and were focused solely on 
symptoms and side effect monitoring. Where comparisons can be made, there appears 
to be no consistent evidence that blood test monitoring is no more beneficial to clinical 
and psychosocial well-being than symptom monitoring, or detrimental. 
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3.7.5 Strengths and weaknesses of this review 
Reviews of reviews bring together all of the systematic reviews and meta-analyses in 
the area in order to provide an overview of the evidence. By bringing together a large 
number of primary research studies, clinical groups and settings this review provides a 
comprehensive and evidence-based overview of self-monitoring across a range of 
long-term physical health conditions. There are however, several limitations that 
should be acknowledged.  
 
As with any overview of secondary data, this review relies on the quality of the 
reporting found in not only the articles but also the primary research studies. 
Reporting was particularly poor in regards to the content of the intervention and 
control groups, the type of analysis undertaken within the primary research studies 
and in many cases whether between or within group differences were statistically 
significant. It was unclear if some of these reporting issues were due to poor reporting 
within the primary papers or as a result of word limit restrictions placed on the articles 
themselves; although many articles were able to provide this information, as exhibited 
in a number of high quality scores on the AMSTAR checklist. 
 
The overall quality of the systematic reviews and meta-analyses were good, but with 
significant variation with some scoring the minimum possible quality score to some 
with a maximum score. The potential bias introduced by not reporting the sources of 
support and funding for both the review and primary research papers was of particular 
concern, as was the selection of studies for inclusion; by not searching grey literature 
many primary research studies may have been missed. Furthermore, the quality 
checks performed in this review assessed the quality of the article as a whole rather 
than the synthesis performed for each outcome within each article. This is particularly 
problematic for articles which combined a high quality meta-analysis of RCTs with a 
systematic review of varying study designs. For instance data may have only been 
aggregated or publication bias explored for some outcomes within a review and were 
hence given a lower score according to the AMSTAR quality assessment tool. Assessing 
the quality of evidence for each outcome would overcome this but was beyond the 
scope of this review. Despite the quality of the reviews themselves being good, a high 
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quality review may contain poor quality evidence, or even limited evidence, because 
that it all that is available. Therefore, assessment of quality within each article was vital 
however, integration of study quality into conclusions and recommendations was 
undertaken in less than half of all articles. 
 
The inclusion of some primary research studies in more than one systematic review or 
meta-analyses may have unduly influenced the overall conclusions of this review. It is 
however, unlikely given that there was only slight overlap across the review (Pieper et 
al., 2014). This however, did vary quite significantly between long-term conditions with 
no overlap in COPD and a very high level of overlap in thrombophilia. A high degree of 
overlap may reflect an unnecessary duplication of reviews (Pieper et al., 2014). A 
systematic review should only really be performed in the case of an out-of-date review 
or a significantly different research objective. It is however, reassuring that reviews 
appear to reach broadly the same conclusion; that self-monitoring on the whole does 
not have a negative impact on health, psychological well-being or healthcare usage 
and in many cases it is at least, if not more effective in improving these outcomes than 
usual care.  
 
The searches attempted to be comprehensive up to February 2014; however, as this is 
a rapidly evolving field, several primary research papers will have been published since 
the searches were undertaken and the articles may currently be being updated or new 
reviews undertaken. In addition for every review, primary studies will be missed. In 
this paper we have presented brief summaries of all the reviews in the tables, since 
our data extraction was limited to what was contained within the systematic review 
and not the original studies, it is possible that not all minor outcomes were captured. 
Primary or major outcomes for each disease were, however, available in all reviews.  
 
In addition the current review included only articles published in English and those that 
were peer-reviewed. Applying language restrictions is not recommended (Smith et al., 
2011); but was unavoidable due to lack of access to translation services and funds to 
pay for these. Only eight articles, however, were excluded on this basis; therefore, 
suggesting low risk of bias. Although the recommendations encourage the inclusion of 
unpublished studies, the current review did not search grey literature and many of the 
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articles themselves also failed to search these sources. Data suggests that published 
trials generally include more participants and may show an overall greater treatment 
effect than studies published in the grey literature (Hopewell, McDonald, Clarke, & 
Egger, 2007; McAuley, Pham, Tugwell, & Moher, 2000). Therefore, potentially biasing 
the results towards a more positive effect.  
 
A pragmatic decision was taken to structure the overview by outcome measure and 
then by long-term condition. This was due to the amount of data and to ensure a 
coherence to the results. Inevitably an overview of this kind can provide only a 
summary of the major points and conclusions about the reviews. It is, therefore, 
strongly encouraged that readers refer to the original reviews for additional 
information.  
3.8 CONCLUSION  
Despite the limitations of this overview of reviews, it is innovative in that it attempts to 
integrate conclusions across a number of long-term conditions, synthesises both 
systematic reviews and meta-analyses and examines a range of outcomes. The findings 
of this review need to be considered in light of the overall quality of the reviews, which 
varied quite significantly. Nonetheless it provides a useful synthesis of findings on the 
role of self-monitoring in long-term illness.  
 
In summary, self-monitoring can have significant benefits including reductions in 
hospitalisation and readmission to hospital hence reducing the pressure placed on the 
healthcare system whilst at the same time improving, albeit in some cases small 
changes, in mortality, blood pressure, quality of life and adverse events. The impact of 
self-monitoring on outpatient services, GP attendance and other patients reported 
outcomes, however, remains unclear and requires further exploration. Due to 
heterogeneity in concept definitions, utilized scales and an overall low number of 
primary research studies definite conclusions are difficult to make but in the main 
suggest equivalence across all other outcomes. The role of patients in using the self-
monitored data to adjust medication or lifestyle behaviours or seeking help is 
potentially crucial to the outcome of such interventions and requires further 
investigation.  
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3.9 POTENTIAL FOR SELF-MONITORING IN RA AND PSA 
The preceding chapters have described the clinical implications of RA and PsA along 
with the therapeutic regimens and the associated economic burden of both blood 
monitoring and regular outpatient care (Chapter 1). Despite these requirements the 
current state of rheumatology services suggests there are significant deficits in the 
provision of care for patients with RA and PsA. This includes possibly unnecessary 
appointments for those who are feeling well and substantial delays or lack of capacity 
for those who are feeling worse. This has led to the development of patient-initiated 
services which have been shown to be both acceptable to patients and effective in 
increasing capacity without compromising the physical and psychological well-being of 
patients. Nevertheless, the literature recognises the need for further quantitative and 
qualitative research in order to provide a quality evidence base for this model of care 
(Chapter 2).  
 
The potential of formal self-monitoring to reduce healthcare utilisation whilst 
maintaining and in some cases improving quality of life and clinical outcomes suggests 
that integration of these models of care for patients with arthritis could be a suitable 
substitute for usual care but is yet to be trialled (Chapter 2). An intervention of this 
nature would aim to teach patients how to formally self-monitor their symptoms, side 
effects and the blood tests undertaken for DMARD monitoring and provide them with 
the opportunity to use data to initiate their own contact with their CNS. This offers a 
possible avenue to develop a patient-led rheumatology service which is more 
responsive to the needs of established patients and offers an opportunity for more 
effective and efficient care in the CNS-led DMARD monitoring clinics at UCLH. Its 
feasibility and effectiveness would, however, need to be evaluated in order to 
establish effectiveness and acceptability. Therefore, the aim of this thesis is to answer 
these research questions. The following chapter will go on to describe the theoretical 
underpinnings of these types of intervention. 
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4. CHAPTE‘ ϰ - THEO‘ETICAL UNDE‘PINNINGS 
4.4 PROLOGUE 
Chapters 1 to 3 have outlined the context in which this thesis is taking place along with 
the evidence for self-monitoring in long-term conditions and patient-initiated services 
in rheumatology. This chapter will now describe the theoretical underpinnings for 
these interventions, and the applicability of these theories to patients with arthritis.  
4.5 COMPLEX INTERVENTIONS 
Patient-initiated services and self-monitoring interventions can be described as 
complex, as in they consist of a number of interacting components and target a 
number of behaviours which vary in their level of difficulty (Craig et al., 2008). These 
iŶteƌaĐtiŶg ĐoŵpoŶeŶts aƌe the aĐtiǀe iŶgƌedieŶts that ŵake the iŶteƌǀeŶtioŶ ͞ǁoƌk͟ 
i.e. bring about the desired change in behaviour.  
 
Patient-initiated services and self-monitoring interventions can be placed under the 
umbrella of ͞self-management͟. Self-management has been defined by Barlow et al., 
(2002) as aŶ iŶdiǀidual͛s aďilitǇ to manage the clinical and psychosocial consequences, 
along with the lifestyle changes inherent in living with a chronic condition. By enabling 
patients to manage their own DMARD monitoring appointments and access to 
rheumatology services, self-monitoring and patient-initiated services empower 
patients to manage the consequences of living with arthritis, which includes regularly 
attending hospital. Due to this broad definition the content and complexity of self-
management interventions varies quite significantly, not only in terms of their aims 
and the behaviour/s they target, but also in terms of the behaviour change techniques 
they use and their theoretical underpinnings.  
4.6 SELF-MANAGEMENT IN ARTHRITIS 
In response to patients desire for greater involvement in their care and treatment 
decisions, along with the shift in control from clinician to patient, the last 25 years has 
seen a huge growth in self-management interventions particularly in the field of 
rheumatology. This is unsurprising given that arthritis requires daily management 
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outside of the contact had with healthcare professionals. Self-management 
interventions in arthritis aim to facilitate the learning of various behavioural and 
cognitive techniques in order to help patients manage their condition. This could be 
how to deal with pain and fatigue, how to monitor symptoms and side effects, how to 
manage access to healthcare or cope with the emotional and social adjustments 
required.  
 
Guidelines for the management of RA suggest that self-management training is 
essential in order for patients to manage their illness effectively (National Audit Office, 
2009b; National Collaborating Centre for Chronic Conditions, 2009; National Institute 
for Health and Care Excellence, 2013b). The Arthritis Self-management Programme 
(ASMP) developed by Lorig, Lubeck, Kraines, Seleznick and Holman (1985) is by far the 
most well-known program and has undergone extensive evaluation in multiple arthritis 
populations and in different settings. This programme differs from many others in that 
it is community based and delivered by trained lay leaders who themselves have 
arthritis. The ASMP combines elements of patient education and cognitive behavioural 
techniques, such as educating patients about their arthritis and the importance of self-
care, whilst engaging them in goal setting, action planning and self-monitoring, as well 
as other self-management strategies. A majority of other interventions have been 
designed for a single rheumatic disease but ASMP groups can include people with 
different types of arthritis. In a 12 year review of the programme improved behaviour, 
self-efficacy and aspects of health status were reported (Lorig & Holman, 1993). 
Subsequent research in the UK suggested benefits of up to 12 months post-
intervention in terms of mood, self-efficacy and pain for both patients with 
osteoarthritis or RA (Barlow, Turner, & Wright, 2000). Cost-effectiveness analysis of 
the ASMP has also revealed significant savings as a result of decreased physician visits 
(Kruger, Helmick, Callahan, & Haddix, 1998); therefore, suggesting that self-
management interventions should have role in the standard care of patients with 
arthritis. 
 
Due to the vast number of trials evaluating the effectiveness of self-management 
interventions in arthritis there are now a number of systematic reviews and meta-
analyses that have synthesised the evidence. Although the content, delivery and 
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intensity of these interventions differs, there is some consistency in regards to the 
short-term benefits including improvements in pain, functional disability, knowledge, 
coping and psychosocial well-being (Riemsma, Taal, Kirwan, & Rasker, 2004; 
Niedermann, Fransen, Knols, & Uebelhart, 2004; Astin, Beckner, Soeken, Hochberg, & 
Berman, 2002; Knittle et al., 2010; Warsi, LaValley, Wang, Avorn, & Solomon, 2003). 
Although the long-term effects have been questioned by Riemsma et al., (2004), there 
is some evidence to suggest positive benefits in terms of physical activity, pain, 
disability, tender joints, psychological status and coping up to 14 months post-
intervention and across different types of arthritis (Astin et al., 2002; Knittle et al., 
2010; Iversen, Hammond, & Betteridge, 2010). 
 
Although the content of the intervention developed and evaluated within this thesis 
differs to these other self-management interventions in regards to the behaviours 
targeted there is likely to be some consistency in the behaviour change techniques 
adopted within these interventions as a result of the similarities in their theoretical 
underpinnings.   
4.6.1 Theories of self-management 
Whilst a number of theories have informed the move towards and development of 
self-management interventions there is no one theory that encapsulates and 
dominates self-management (Serlachius & Sutton, 2009). A number of theories have 
been proposed by Serlachius and Sutton (2009) and these can be used to inform the 
content of an intervention as well as the framework used to evaluate it, by identifying 
theoretical constructs that could be targeted to change or explain a change in 
behaviour. Within the self-management literature two key theories have been 
discussed and utilised more extensively in people with arthritis: social cognitive theory 
(Bandura, 1986; Bandura, 1997) and self-regulation theory (Leventhal, Meyer, & 
Nerenz, 1980). It important to highlight that the intervention evaluated within this 
thesis was not developed to test a particular theory. Nevertheless, the behaviour 
change techniques which have been employed within the intervention and which are 
described in section 5.8.1.1 (page 204) can be linked to both of these theories. These 
theories were also used to select the psychological constructs measured within the 
evaluation of the intervention and to formulate the hypotheses relating to the 
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mechanisms of effectiveness. These two theories will now be presented alongside 
their applicability to patients with RA or PsA. 
 Social cognitive theory 
Social cognitive theory has become one of the most influential social cognitive models 
in the field of self-management. It proposes that behaviour is determined by an 
interaction between personal factors, environmental influences and behaviour 
(Bandura, 1986). The basic premise is that people learn through a combination of their 
own experiences and by observing the behaviour of others and the consequences of 
those actions (MacAlister, Perry, & Parcel, 2008). There are nine key constructs within 
social cognitive theory (Table 4.1) which can be grouped into five categories (i) 
psychological determinants of behaviour, (ii) observational learning, (iii) environmental 
determinants of behaviour (iv) self-regulation and (v) moral disengagement.  
 
Table 4.1. Constructs of social cognitive theory 
Concept Definition 
Outcome 
expectations 
Beliefs about the likelihood and value of the consequences of 
behavioural choices 
Self-efficacy Beliefs aďout the peƌsoŶ͛s aďilitǇ to peƌfoƌŵ ďehaǀiouƌs that 
bring about desired outcomes 
Collective efficacy Beliefs about the ability of a group to performed concerted 
actions that bring about desired outcomes 
Observational 
learning 
Learning to perform new behaviours by exposure to 
interpersonal or media displays of them, particularly through 
peer modelling 
Reciprocal 
determinism 
Environmental factors influence individuals and groups, but 
individuals and groups can also influence their environments 
and regulate their own behaviour 
Incentive 
motivation 
The use and misuse of rewards and punishments to modify 
behaviour 
Facilitation Providing tools, resources, or environmental changes that make 
new behaviours easier to perform 
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Concept Definition 
Self-regulation Controlling ones-self through self- monitoring, reward & 
instruction, goal setting, feedback & enlistment of social 
support 
Moral 
disengagement 
Ways of thinking about moral behaviours and the people who 
harmed that make infliction of suffering acceptable, by dis-
engaging moral self-regulatory moral standards 
Adapted from (MacAlister et al., 2008), p.171 
 
The psychological determinants of behaviour include outcome expectancies which are 
defined as the beliefs a person holds about the outcomes of performing a behaviour 
and the perceived value of these outcomes. These may be expectations about the 
physical, social or personal outcomes. In the context of the current thesis physical 
outcome expectations could be the perceived pleasant or unpleasant clinical 
consequences of performing self-monitoring, such as poorer control of inflammation 
as a result of not seeing the CNS face-to-face. Social outcomes expectancies might 
include the anticipated reaction of others and the social consequences of contacting 
the CNS for help, whereas personal outcome expectations refer to the anticipated 
feelings a person may have after performing a behaviour, such as a greater sense of 
control. This assumes that people will act to maximise the benefits and minimise the 
costs and work towards distant goals whilst ignoring the immediate costs and short-
term benefits of performing alternative behaviours.  
 
Self-efficacy defined as the confidence a person has about their ability to perform a 
behaviour (Bandura, 1997) is the concept for which social learning theory is most 
widely known and is particularly important when the behaviour is complex or difficult 
to perform. Social learning theory has identified four ways in which self-efficacy can be 
developed (i) mastery experience (ii) social modelling (iii) improving physical and 
emotional states and (iv) verbal persuasion (Table 4.2). Numerous studies have found 
that the performance of a behaviour is determined by both outcome expectancies and 
self-efficacy. Bandura (1997) suggests that people who doubt their self-efficacy will not 
attempt a behaviour, regardless of outcome expectancies.  
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Table 4.2. Methods of increasing self-efficacy 
Concept Method 
Mastery experience  
 
Enabling the person to succeed in 
attainable but increasingly challenging 
behaviours. The experience of 
performance mastery is the strongest 
influence on self-efficacy belief. 
Social modelling  
 
Showing the person that others like 
themselves can do it. This should include 
detailed demonstrations of the small 
steps taken in the attainment of a 
complex objective. 
Improving physical and emotional states Making sure people are well-rested and 
relaxed before attempting a new 
behaviour. This can include efforts to 
reduce stress and depression while 
building positive emotions—as when 
͞feaƌ͟ is ƌe-laďelled as ͞eǆĐiteŵeŶt͟. 
Verbal persuasion Telling the person that he or she can do 
it. Strong encouragement can boost 
confidence enough to induce the first 
efforts toward behaviour change. 
Adapted from (MacAlister et al., 2008), p.171 
 
Although social cognitive theory includes other constructs, a majority of the empirical 
applications of this theory focus on self-efficacy and the concept has been employed 
extensively in rheumatology research. A recent literature review found 74 studies that 
had either reported the association between self-efficacy and arthritis-related disease 
variables or had included self-efficacy as the outcome of a behavioural intervention for 
patients with arthritis. Lower levels of self-efficacy were linked to greater physical 
disability, pain, fatigue and disease duration. The authors were also able to conclude 
that interventions that led to improvements in self-efficacy tended to have a positive 
impact on disease-related variables (Primdahl, Wagner, & Hørslev-Petersen, 2011a). 
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Poor self-efficacy has also been linked to higher levels of anxiety and depression in RA 
(Lowe et al., 2008; Wright et al., 1996). Very little research has been undertaken to 
explore the role of self-efficacy in PsA. Early work suggests, however, that lower self-
efficacy is related to the use of catastrophizing as a coping strategy (Stewart & Knight, 
1991) and more recently self-management interventions which have included patients 
with PsA have led to improvements in self-efficacy (Grønning, Skomsvoll, Rannestad, & 
Steinsbekk, 2012).   
 
Observational learning draws on both outcome expectancies and self-efficacy. 
According to Bandura there are four key process which govern observational learning 
(Bandura, 1986) (i) attention (ii) retention (iii) production and (iv) motivation. People 
will tend to focus on and observe a behaviour which they feel has significant benefits. 
Retention of the behaviour will depend on intellectual capabilities. Performing or 
learning to perform that behaviour will then depeŶd oŶ a peƌsoŶ͛s self-efficacy and 
motivation will also be influenced by outcome expectancies.  
 
However, no matter how much observational learning takes place unless the 
oďseƌǀeƌ͛s environment will support the behaviour or the person is able to influence 
their environment, the behaviour is unlikely to be performed. One basic environmental 
influence on behaviour is reinforcement or punishment, the other is facilitation in 
which the provision of new structures or resources are introduced in order for the new 
behaviour to be performed or to make it easier to be performed.  
 
Self-regulation or self-ĐoŶtƌol ƌefeƌs to a peƌsoŶ͛s aďilitǇ to eŶduƌe shoƌt-term negative 
outcomes in anticipation of long-term positive outcomes. This is achieved through the 
acquisition of skills in order to self-manage. Bandura (1997) identified six ways in which 
self-regulation can be achieved (i) self-ŵoŶitoƌiŶg of oŶe͛s oǁŶ ďehaǀiouƌ ;iiͿ goal 
setting (iii) feedback on the quality of performance and how it can be improved (iv) 
self-reward (v) self-instruction by talking oneself through a behaviour and (vi) social 
support (Table 4.3). These strategies are both similar to and overlap with the 
techniques used to increase self-efficacy (MacAlister et al., 2008) and are the most 
widely used when social cognitive theory is used to develop behaviour change 
interventions.  
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Table 4.3. Methods of achieving self-regulation 
Concept Method 
Self-monitoring The systematic observatioŶ of oŶe͛s oǁŶ 
behaviour—includes observing and 
recording both the behaviour itself and 
the context and cues or events 
accompanying the behaviour.  
Goal setting This is planned behaviour in which 
intentions are formulated in terms of 
both long-term and short-term goals that 
will bring people closer to the changes 
they desire. Gradual steps are needed to 
achieve the successes which will then 
increase self-efficacy. 
Feedback Feedback consists of information about 
the quantity and quality of the 
behaviour, either provided by others or 
fƌoŵ the peƌsoŶ͛s oǁŶ oďseƌǀatioŶs. 
Self-reward Short-term and frequent rewards that 
people give themselves may be more 
effective than rewards that may occur in 
the distant future. 
Self-instruction Effective self-instruction involves 
speaking to oneself about each subtask 
in a complex series of tasks. 
 
 Self-regulatory theory 
Also known as the illness perceptions or common sense-model (Leventhal et al., 1980), 
self-regulatory theory acknowledges that the cognitive determinants of self-regulation 
are important but also proposes that bottom-up processes like the experience of 
health and illness also play an integral role. Health-related behaviours are said to be 
the result of an interaction between cognitions (top-down information) and 
physiological experiences (bottom-up information). Social regulation theory suggests 
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that people develop representations of their condition following five key domains: 
identity, timeline, consequences, cause and control. Identity relates to the symptoms 
or label that an illness is given and timeline is the beliefs about how long the illness will 
last (i.e. acute, chronic or cyclical). Consequences, cause and control related to the 
perceived consequences of living with arthritis, the perceived causes and how much a 
person can influence the outcome of their arthritis. Each of these five components are 
related to both the cognitive and emotional processing of illness information which 
impact upon the type of coping strategies. This in turn influences outcomes, which 
could be emotional or illness-related. The final stage then involves an appraisal of the 
chosen coping strategy and a decision to either continue or chose another strategy, 
this can be achieved either directly or via a change in illness representations (Figure 
4.1).
          
1
7
6
 
 
Source: adapted from Hagger and Orbell (2003) 
Figure 4.1. The self-regulation model of illness representations 
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The five domains of illness representations have been explored extensively in RA and 
PsA and have been found to relate to a number of important outcomes, including 
physical and social functioning, quality of life, depression, functional disability, anxiety 
and pain (Sharpe et al., 2001; Groarke, Curtis, Coughlan, & Gsel, 2005; Carlisle, John, 
Fife-Schaw, & Lloyd, 2005; Scharloo et al., 1998; Graves, Scott, Lempp, & Weinman, 
2009; Murphy, Dickens, Creed, & Bernstein, 1999; van Os, Norton, Hughes, & Chilcot, 
2012; Kotsis et al., 2012). Recent work has also sought to group patients with RA 
according to similarities in their beliefs. Longitudinal data from 227 patients suggested 
that there are two groups of individuals, one that is characterised by a negative 
representation of their arthritis who attributes more symptoms to their condition and 
reports stronger perceptions of the consequences, chronicity and cyclicality of their 
condition, and less control compared to a positive group. Membership of the negative 
representation group was associated with reports of greater pain, functional disability 
and distress, both cross-sectionally and over time (Norton et al., 2013).  
 
A systematic review and meta-analysis of psychological interventions for RA that 
included behaviour change techniques derived from self-regulation theory found 27 
trials. The meta-analysis found positive effects in favour of the interventions based on 
self-regulation theory for outcomes such as mood, physical activity, pain and disability 
immediately post-intervention. At final follow-up, these differences remained 
significant for physical activity, pain, disability and depression. The authors found that 
interventions that included more self-regulation techniques reduced depressive 
symptoms and anxiety significantly more than interventions utilizing fewer self-
regulation techniques (Knittle et al., 2010). This provides further support for this 
theory in the development and evaluation of interventions for patients with arthritis.  
 
A recent extension to self-regulation theory, the Necessity-Concern Framework 
(Horne, 2003; Horne, Weinman, & Hankins, 1999), acknowledges the importance of 
illness representations, but also recognises the importance of treatment beliefs. The 
pƌopoŶeŶts of the fƌaŵeǁoƌk suggest that people͛s ďeliefs aďout theiƌ pƌescribed 
medication can be categorized into perceptions about the necessity of taking the drugs 
and concerns about taking them. As well as having beliefs about specific medications, 
people also have views about medications in general and their harm and overuse. 
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These beliefs have been explored in RA and suggest that concerns about taking 
DMARDS, having a poor understanding of the necessity of DMARDS and a belief that 
medications are harmful and overused are associated with poor adherence to DMARD 
therapy (Neame & Hammond, 2005; Treharne et al., 2005) and more self-reported side 
effects (Nestoriuc, Orav, Liang, Horne, & Barsky, 2010). Research however, has not 
been conducted in PsA. 
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5. CHAPTE‘ ϱ - T‘IAL METHODOLOGY 
5.1 PROLOGUE 
This chapter describes the aims and objectives of the RCT along with a description of 
the methodology. This will include information about study design, recruitment, 
inclusion and exclusion criteria for participants and a detailed description of 
procedures. The intervention is reported in line with the Template for Intervention 
Description and Replication (TIDieR) guidelines (Hoffmann et al., 2014). This is followed 
by a description for each of the quantitative measures and their psychometric 
properties, concluding with the analysis plan.  
5.2 AIMS AND OBJECTIVES OF THE TRIAL 
 To assess whether patients with RA or PsA on DMARD therapy can safely self-
monitor their symptoms, side-effects and blood test results and use data to 
safely initiate a telephone consultation with their CNS.   Identify the factoƌs ǁhiĐh ŵaǇ iŵpaĐt upoŶ a patieŶt͛s aďilitǇ to safelǇ self-
monitor and initiate care.  To establish whether a patient-initiated and self-monitoring service for patients 
with RA or PsA has an effect on healthcare utilisation, psychosocial and clinical 
outcomes in comparison to usual care.  To explore the mechanisms through which the intervention affects healthcare 
utilization and quality of life (mediation).   To explore which baseline variables alter the strength of the relationship 
between trial arm and healthcare utilization and quality of life (moderation).  
5.3 HYPOTHESIS 
These predictions are based on the findings of previous literature outlined in Chapters 
2 and 3, and the theoretical basis of the study outlined in Chapter 4.  
  Participants in the intervention group will attend for fewer CNS outpatient 
visits than those in the control group over the trial period. 
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 There will be equivalence between the intervention and control group on visits 
to the rheumatologist and arthritis-related GP appointments.  Participants in the intervention group will report greater improvements in their 
quality of life and mood than those in the control group.  There will be equivalence between the intervention and control group on 
clinical outcomes.  Participants in the intervention group will report greater improvements in the 
components of social cognitive theory (Bandura, 1986; Bandura, 1997) and self-
regulation theory (Leventhal et al., 1980) than those in the control group.   The components of social cognitive theory (Bandura, 1986; Bandura, 1997) and 
self-regulation theory (Leventhal et al., 1980), will be significant mediators and 
moderators of intervention effectiveness. 
5.4 ETHICS APPROVAL 
The study received full ethics approval from Camden and Islington Community Local 
Research Ethics Committee (Ref. 09/H0722/91).  
5.5 STUDY DESIGN 
This study was a parallel-group, explanatory, superiority RCT designed to assess the 
effectiveness of a self-monitoring and patient-initiated follow-up service in comparison 
to a usual care control group. Figure 5.1 represents the flow of participants in the trial. 
As in many trials of non-pharmacological interventions, participants could not be blind 
to group allocation. In order to obtain the rheumatologists agreement to recruit, each 
rheumatologist was informed when one of their patients were recruited into the trial 
and which arm they had been allocated to. Therefore, treating clinicians were also not 
blind. All psychosocial assessments were self-report and clinical assessments were 
undertaken by either the rheumatologist running the intervention or treating CNS who 
was also aware of group allocation. The final analysis was undertaken by the 
researcher managing the overall trial, who also co-facilitated the training sessions and, 
therefore, was also not blind to group allocation.  
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Figure 5.1. Flow chart of trial procedure
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5.6 PROCEDURE 
5.6.1 Study site  
Participants were recruited from three hospital-based CNS-led DMARD monitoring 
clinics run in the Centre for Rheumatology at UCLH between February 2010 and July 
2011.  
5.6.2 Inclusion and exclusion criteria 
At the beginning of 2010 UCLH had approximately 450 patients with RA or PsA who 
were receiving oral methotrexate either with or without the self-injecting anti-TNF 
ageŶt͛s adaliŵuŵaď oƌ etaŶeƌĐept. These patieŶts ǁeƌe seleĐted foƌ iŶĐlusioŶ iŶ the 
trial as they formed a majority of the monitoring appointments at UCLH and are 
treatments that do not require administration by a healthcare professional, as 
opposed to drugs such as infliximab which require attendance in outpatients for 
regular infusions.  
 Inclusion criteria  All patients with RA or PsA (according to ACR/EULAR/CASPAR criteria) (Aletaha 
et al., 2010; Taylor et al., 2006).   Attending a hospital-based CNS-led DMARD monitoring clinic appointment in 
the Centre for Rheumatology at UCLH.   Aged 18 years or over.  Fluent in written and spoken English.  Patients whose treatment was classified as stable defined as disease 
management with methotrexate for at least 6 months, plus a further 3 months 
if patient were receiving one of two self-injected anti-TNF agents, adalimumab 
or etanercept.   
 Exclusion criteria  Patients with psychosis or dementia, identified by the CNS via electronic 
patient records.  Patients with significant co-morbidity (i.e. their predominant treatment was for 
another illness).  Patients for whom blood tests and monitoring was undertaken by their GP.  
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 Patients whose treatment was classified as unstable. Defined as disease 
management with methotrexate for less than 6 months, or receiving one of 
two self-injected anti-TNF agents, adalimumab or etanercept for less than 3 
months.  Patients prescribed infliximab. 
5.6.3 Identification of participants 
Patients who met the inclusion and exclusion criteria were identified from clinic lists by 
the CNS on a monthly basis. Those identified as eligible were sent an information sheet 
(Appendix K) and consent form (Appendix L) two weeks prior to their outpatient 
appointment, where they were invited to talk further about the study with the CNS 
and/or researcher. 
5.6.4 Consent and randomization procedure 
At the outpatieŶts appoiŶtŵeŶt the CN“ eŶƋuiƌed aďout the patieŶt͛s iŶteƌest iŶ 
participating and introduced them to the researcher who gave a full explanation of the 
study, including what would be involved in each arm of the trial. It was clearly 
explained that each participant would have a 50% chance of being in either the 
intervention or control group. Participants who consented to take part in the study 
were immediately randomised to one of two arms (i) the intervention or (ii) usual care.  
 
Randomization took place using a randomization plan generator (Dallall, 2010). 
Randomly permuted blocks of 10 participants were used; this ensured that for every 
10 participants entering into the study, five were randomized to the control and five to 
the intervention group. This prevented serious imbalance should the study have been 
terminated prematurely. 
5.6.5 Assessment procedure 
Participants were required to complete a questionnaire booklet on three occasions, 
immediately following randomisation and then again after phase one and then phase 
two of the trial (see section 5.8.1, page 199) for intervention participants and after the 
3rd and 6th blood test for control participants. Each administration took approximately 
30-40 minutes to complete.  
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Control group participants took the questionnaire away with them on the day of 
randomisation and were asked to return it in the freepost envelope provided. The 
intervention group could either do the same or bring the completed questionnaire 
along to the intervention training session. All subsequent questionnaires were sent via 
post and returned in a freepost envelope. Those who had not returned their 
questionnaire within 2 weeks of either randomisation or posting (if a follow-up 
questionnaire) received a telephone reminder and then another questionnaire. 
Thereafter, if no response was received, the participant was deemed lost to follow-up 
in regards to the psychosocial variables. Clinical measures and healthcare utilisation 
continued to be collected from the electronic patient records unless the participants 
requested otherwise.  
5.7 MEASURES 
In the evaluation of any complex interventions it is essential to select appropriate 
outcome measures (Medical Research Council, 2000). As health is multi-dimensional 
several different aspects may be relevant to assess the impact of a complex 
intervention. Nevertheless, because of errors that may arise from multiple statistical 
testing, and also because of participant burden and study costs, it is essential that 
investigators make an explicit and strategically considered choice of outcome 
measures (Medical Research Council, 2000).  
 
As the theoretical underpinnings of the intervention lay within social cognitive 
(Bandura, 1986; Bandura, 1997) and self-regulation theory (Leventhal et al., 1980) the 
evaluation framework and selection of measures were, therefore, based on these 
theories. In the UK, the Medical Research Council's (MRC) framework for complex 
interventions places theory at the centre of any evaluation (Craig, Dieppe, Macintyre, 
Michie, Nazareth, & Petticrew 2008). Ideas for complex interventions emerge from 
various sources, including: past practice, existing evidence, theory, an investigator, 
policy makers or practitioners, new technology, or commercial interests (Craig et al., 
2008). As the aim of this intervention was to enable patients to self-monitor their 
symptoms, side effects and blood test results at home and use this information to 
initiate care from their CNS, the content of the intervention was developed in order to 
address gaps in patient knowledge and skills. So although the aim of the current study 
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was not to test a particular theory, the content of the intervention, the selection of 
psychological constructs to measure and the formulation of hypotheses about the 
mechanisms of effectiveness were based on these two theories. The following 
measures were, therefore, selected on the basis that either the intervention would 
have an impact on the variable, or the variable would mediate or moderate the effects 
of the intervention; at the same time considering participant burden (Figure 5.2). A 
copy of the questionnaires can be found in Appendix M. 
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Figure 5.2. Evaluation framework 
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5.7.1 Demographic characteristics 
Details of the paƌtiĐipaŶt͛s seǆ, age, liǀiŶg status ;ŵaƌƌied/liǀiŶg ǁith paƌtŶeƌ, liǀiŶg 
alone or living with relatives/friends) and ethnic background (Bangladeshi, Black-
African, Black-Caribbean, Chinese, Indian, Pakistani, White or other) were self-
reported.  
5.7.2 Clinical variables 
Participants provided information on their year of diagnosis and the date 
methotrexate was started; this was checked against electronic patient records. Clinical 
records were taken as more accurate, when the information could not be found in the 
clinical notes participant self-report was referred to. The dose of methotrexate 
administered at the start of the trial was extracted from the electronic patient records. 
 Response to treatment 
As there is no single-point disease activity score for PsA, a response to treatment score 
was calculated for all participants. For patients with RA the EULAR response criteria 
(Fransen & van Riel, 2005) was used. These criteria are based on the DAS28 (Prevoo et 
al., 1995), a measure of disease activity which incorporates the number of swollen and 
teŶdeƌ joiŶts, E“‘ leǀels aŶd patieŶt͛s gloďal oǀeƌall ǁell-being. To be classified as a 
responder to treatment, there needs to be a significant change in the DAS28 score and 
also low current disease activity. The three categories of good, moderate and non-
responders are based on absolute improvement and the level of disease activity 
achieved (Table 5.1).  
 
Table 5.1. EULAR disease activity criteria for rheumatoid arthritis 
 Improvement in DAS28 from baseline 
DAS28 at end point >1.2 >Ϭ.ϲ aŶd ≤ ϭ.Ϯ ≤ Ϭ.ϲ 
ч ϯ.Ϯ Good Moderate None 
> ϯ.Ϯ aŶd ч ϱ.ϭ Moderate Moderate None 
> 5.1 Moderate None None 
DAS - Disease Activity Score 
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For patients with PsA the Psoriatic Arthritis Response Criteria (PsARC; (Clegg et al., 
1996)) was used. The criterion includes measurement of the following at baseline and 
again after treatment has commenced: 
  Physician global assessment (0-5 scale) – response: reduction by one.  Patient global assessment (0-5 scale) – response: reduction by one.  Tender joint account (76 or 68) – response: reduction of > 30%.  Swollen joint count (76 or 68) – response: reduction of > 30%. 
 
Overall response is defined as improvement in two of the four items, one of which 
must be a joint count and there must not be worsening in any of the four items.  
 
A new variable was then created in order to combine the results of the EULAR criteria 
and PsARC. The EULAR response criteria of moderate and good were recoded as a 
response; and none as no response in order to correspond to the categories within the 
PsARC. Individual items on the DAS28 and PsARC were also retained for analyses. 
 Blood test results 
The blood tests outlined in section 1.9.3 (page 44) were performed as part of the 
routine monitoring of methotrexate and disease activity in RA and PsA for all trial 
participants.  
 Functional disability 
Version 2 of the Health Assessment Question (HAQ-II; (Wolfe, Michaud, & Pincus, 
2004)) is one of the most widely used questionnaires of functional disability in 
rheumatology. The questions ask about the ability of the individual to undertake 
certain activities (e.g. lift heavy objects) over the past week. This 10-item scale has 
responses from without any difficulty (1) to unable to do (4). The scale score ranges 
from 0-3 after appropriate item score reversals and scale adjustments; higher scores 
represent greater levels of functional disability. The HAQ-II possess satisfactory 
ƌeliaďilitǇ ;CƌoŶďaĐh͛s alpha = Ϭ.ϴϴͿ, Đoƌƌelates ǁell ǁith the full version of the HAQ 
(Fries, Spitz, Kraines, & Holman, 1980), quality of life and clinical outcomes (Maska, 
Anderson, & Michaud, 2011) but test–retest reliability is yet to be investigated. 
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 Pain and fatigue 
To reduce participant burden pain and fatigue were measured using a visual numeric 
scale. Participants were asked how much they were affected by pain and fatigue using 
two separate histogram visual numeric scale (see Figure 5.3 as an example). These 
modified scales are easier for participants and result in less missing data and unclear 
responses (Ritter, Gonzalez, Laurent, & Lorig, 2006). The histograms become larger in 
size and darker in colour as the severity of the pain or fatigue increases (from left to 
right). Circling the number below the histogram described the pain or fatigue the 
participant had experienced in the past 2 weeks. Scores ranged from 0 to 10, with the 
higher scores indicating more pain or fatigue.  
  
           
 
  
No 
fatigue  
0 1 2 3 4 5 6 7 8 9 10 
Severe 
fatigue  
 
Figure 5.3. Histogram of visual numeric scale for fatigue 
 
5.7.3 Primary outcome  
 Healthcare utilisation 
The primary outcome was healthcare utilisation. This included outpatient visits to the 
CNS, rheumatologist and arthritis-related GP visits. Data on outpatient visits were 
taken from electronic patients records at the end of the trial period and recorded as a 
cumulative frequency. Data on GP visits were provided by participants at each of the 
assessment points and a cumulative frequency was calculated. 
5.7.4 Psychosocial outcome variables 
The following variables were measured at baseline, after phase one and phase two for 
the intervention group and after the 3rd and 6th blood test for the control group. 
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 Quality of life 
Health-related quality of life was the other primary outcome measure and was 
measured using the 12-item Short-Form Health Survey (SF-12v1®) (Ware Jr, Kosinski, & 
Keller, 1996) which is a shortened version of the 36-item SF-36® (McHorney, Ware Jr, 
& Raczek, 1993; Ware Jr & Sherbourne, 1992). Designed to measure quality of life 
across two component summary scales the Physical Component Summary (SF-12v1® 
PCS) and the Mental Component Summary (SF-12v1® MCS). This 12-item version was 
chosen as opposed to the SF-36® to reduce participant burden. After item aggregation 
and transformation, total scores range from 0-100 with higher scores representing 
better quality of life.  
 
The psychometric properties of the SF-12v1® have been compared to the SF-36® in a 
sample of British patients with RA (Hurst, Ruta, & Kind, 1998). Moderate and strong 
correlations were found between the two component scales. Both SF-12v1® 
component scores were also found to be responsive to change over a 3 month period 
and ICC suggested good test-retest reliability (SF-12v1® MCS = 0.71, SF-12v1® PCS = 
0.75).  
 Mood 
As well as each being important outcomes in their own right, anxiety and depression 
were also considered psychosocial process variables and were measured using the 
Hospital Anxiety & Depression Scale (HADS; Zigmond & Snaith 1983). The HADS is a 14-
item self-screening questionnaire for depression and anxiety in patients with physical 
health problems. The two 7-item subscales, measure how a person has been feeling in 
the past week. The scale scores range from 0-21, with higher scores indicating greater 
levels of anxious or depressed mood. A score of 0–7 on either subscale is regarded as 
being in the normal range, a score of 8–10 is suggestive of the presence of moderate 
levels of anxiety or depression, and a score of 11 or above indicates caseness, a high 
likelihood that a person would be diagnosed with clinical anxiety or clinical depression. 
A systematic review of the HADS has confirmed the factor structure, found the cut-off 
points to be valid against clinical interviews, reports excellent internal consistency 
;CƌoŶďaĐh͛s alpha: aŶǆietǇ Ϭ.ϲϴ-0.93; depression 0.67-0.90) and appropriate 
correlations between the scales and other commonly used questionnaires (Bjelland et 
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al., 2002). High test-retest reliability has also been reported (r=0.86-0.89) (Spinhoven 
et al., 1997). 
5.7.5 Psychosocial process variables 
The following variables were measured at baseline, after phase one and phase two for 
the intervention group and after the 3rd and 6th blood test for the control group.  
 Self-efficacy 
5.7.5.1.1 Generalised self-efficacy 
Self-efficacy is peƌsoŶ͛s belief in their ability to perform a task. There are a number of 
measures of self-efficacy which have been published and utilized within the 
rheumatology literature, some of which are specific to arthritis and others generic. A 
generalised measure of self-efficacy was selected rather than an arthritis-specific 
measure such as the Arthritis Self-Efficacy Scale (ASES) (Lorig, Chastain, Ung, Shorr, & 
Holman, 1989) or Rheumatoid Arthritis Self-Efficacy scale (RASE) (Hewlett, Cockshott, 
Barrett, Stamp, & Haslock, 2001). These measures specify behaviours which were not 
related to the content of the current intervention, such as self-efficacy for pain and 
function, and, therefore, a validated generalized measure of self-efficacy was deemed 
more appropriate to both the intervention and control group. 
 
In a review of three generalised self-efficacy measures (Scherbaum, Cohen-Charash, & 
Kern, 2006) only the General Self-Efficacy Scale (GSES) has been assessed for 
comprehensibility, reliability and validity in patients with arthritis (Barlow, Williams, & 
Wright, 2005). Therefore, the 10 item GSES (Schwarzer & Jerusalem, 1995) was 
selected, which assesses the belief that one can perform a novel or difficult task, or 
cope with adversity in various domains.  
 
Responses are on a 4-point Likert scale from 1 (not at all true) to 4 (exactly true). Total 
scores range from 10-40. Higher scores on this measure indicate higher levels of 
generalised self-efficacy. The scale has been confirmed to be one-dimensional, to 
possess good ƌeliaďilitǇ ǁith CƌoŶďaĐh͛s alpha ƌaŶgiŶg fƌoŵ Ϭ.ϴϴ to Ϭ.ϵϭ, test-retest 
reliability in people with arthritis (r=0.63) and correlates well with other clinical and 
psychosocial variables and in the expected directions (Barlow et al., 2005). These 
Chapter 5 – Trial methodology 
 
192 
findings have been replicated in a systematic review of the measure in a variety of 
populations and countries (Scholz, Doña, Sud, & Schwarzer, 2002). 
5.7.5.1.1 Behaviour-specific confidence 
The Health EduĐatioŶ IŵpaĐt QuestioŶŶaiƌe ;HeiQ™; Osborne, Elsworth, & Whitfield, 
2007) aŶd the MediĐatioŶ EduĐatioŶ IŵpaĐt QuestioŶŶaiƌe ;MeiQ™; Ciciriello, 
Buchbinder, Wicks, & Osborne, 2010) have been developed to assess the impact of 
health education and self-management programs in relation to medication use. The 
HeiQ™ ǀϯ.Ϭ is a shoƌteŶed ǀeƌsioŶ of the oƌigiŶal HeiQ™ ǀϭ.Ϯ aŶd is oƌgaŶised iŶto a 
set of eight constructs. Similarly the MeiQ™ (Ciciriello et al., 2010) consists of 29 items 
making up six constructs (Figure 5.4). The constructs can be administered 
independently; however, item order must be preserved.  
 
IŶ oƌdeƌ to assess a peƌsoŶ͛s ĐoŶfideŶĐe iŶ theiƌ aďilitǇ to ŵoŶitoƌ aŶd ŵaŶage their 
arthritis and communicate with healthcare professionals the self-monitoring and 
iŶsight ĐoŶstƌuĐt ǁas seleĐted fƌoŵ the HeiQ™ aŶd the aĐtiǀe ĐoŵŵuŶiĐatioŶ aŶd self-
ŵaŶageŵeŶt aďilitǇ ĐoŶstƌuĐts fƌoŵ the MeiQ™ ;Figure 5.4). Responses for the self-
ŵoŶitoƌiŶg aŶd iŶsight ĐoŶstƌuĐt of the HeiQ™ aƌe oŶ a ϰ-point Likert scale from 1 
(strongly disagree) to 4 (strongly agree), with a total score ranging from 1-4. Responses 
foƌ the tǁo MeiQ™ ĐoŶstƌuĐts aƌe oŶ a ϲ-point Likert scale ranging from 1 (disagree 
strongly) to 6 (agree strongly), with total scale scores ranging from 1-6. Higher scores 
on all scales indicate stronger beliefs in the concepts represented by the scale. 
 
The original 51-iteŵ HeiQ™ ǀϭ.Ϯ ǁas deǀeloped and validated in a sample of 592 
people with a wide range of chronic diseases and demographic characteristics 
(Osborne et al., 2007). The ƌesults suggest that the HeiQ™ ǀϭ.Ϯ is a ƌeliaďle aŶd 
sensitive measure for assessing the benefits of a broad range of health education 
pƌogƌaŵs. The authoƌs ƌepoƌt CƌoŶďaĐh͛s alphas of Ϭ.ϳϬ foƌ the self-monitoring and 
insight subscale and an intra-class correlation (ICC) of 0.63 which indicates good test-
retest reliability (Schuler et al., 2012). The authors have also demonstrated good 
iŶteƌŶal ĐoŶsisteŶĐǇ foƌ the MeiQ™ ĐoŶstƌuĐts, ǁith CƌoŶďaĐh͛s alphas шϬ.ϳ. The test-
retest reliability also suggests good stability and reliability over time, with ICCs ranging 
from 0.68 to 0.87 (Ciciriello et al., 2010). 
Chapter 5 – Trial methodology 
 
193 
Domain 4 - Self-monitoring and insight – HeiQ™                                                                   
This ĐoŶstƌuĐt Đaptuƌes the iŶdiǀiduals͛ aďilitǇ to ŵoŶitoƌ theiƌ ĐoŶditioŶ, aŶd theiƌ 
physical and/or emotional responses that lead to insight and appropriate actions to 
self-ŵaŶage. AŶ iŵpoƌtaŶt ĐoŵpoŶeŶt of this ĐoŶstƌuĐt is the iŶdiǀiduals͛ 
acknowledgment of realistic disease-related limitations, and the ability and 
confidence to adhere to these limits. This may also relate to the monitoring of 
specific sub-clinical indicators of disease status. 
Domain 2 - Active Communication - MeiQ™                                                                      
This scale measures the capacity of health consumers to communicate effectively 
with health professionals. Active communication includes the ability to understand 
what the health professional is saying, the capacity and confidence to feedback 
beliefs and experiences and discuss the information provided. It also requires the 
confidence and capacity to ask questions clarifying the information given, and to 
gather further information if it is required. 
Domain 4 - Self-management ability- MeiQ™                                                                    
This sĐale ŵeasuƌes health ĐoŶsuŵeƌs͛ ĐoŶfideŶĐe aŶd aďility to perform self-
management tasks. These include the ability to actively participate in decision-
making and perform self-management tasks related to their condition and 
medication. 
Figure 5.4. HeiQ™ aŶd MeiQ™ iŶĐluded ĐoŶstƌuĐt defiŶitioŶs 
 
 Illness and treatment beliefs 
5.7.5.2.1 Illness beliefs 
Illness perceptions are cognitive representations or beliefs that a patient has about 
their illness. These perceptions have been shown to determine not only behaviour but 
have also been associated with a number of arthritis-related outcomes including 
function, depression, psychiatric morbidity and quality of life (Maas, Van Der Linden, & 
Boonen, 2009). Based on self-regulation theory (Leventhal et al., 1980), the original 
Illness Perceptions Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, & Horne, 1996) 
ǁas deǀeloped to pƌoǀide a ƋuaŶtitatiǀe assessŵeŶt of LeǀeŶthal͛s illŶess 
representation component of the self-regulatory model (Leventhal et al., 1980).  
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A revised version of the IPQ, the IPQ-R (Moss-Morris et al., 2002) was developed to 
address the internal consistency problems identified in some of the IPQ subscales. The 
questionnaire assesses each of the components of illness representation: identity, time 
(acute/chronic), consequences, personal control, treatment control, illness coherence, 
timeline cyclical and emotional representations. Table 5.2 provides definitions for the 
five subscales utilised within this trial. Selection of these subscales was based on 
suitability for the study population and the possible mechanisms through which the 
intervention was hypothesised to impact on healthcare utilisation and quality of life.  
 
Table 5.2. Definitions of the IPQ-R subscales 
Subscale A ďelief….. 
Identity …aďout the Ŷuŵďeƌ of sǇŵptoŵs attƌiďutaďle to theiƌ aƌthƌitis 
Consequences …that theiƌ aƌthƌitis ǁill haǀe seƌious ĐoŶseƋueŶĐes 
Personal control …iŶ oŶe͛s aďilitǇ to peƌsoŶallǇ iŶfluence the outcome of their 
arthritis 
Treatment 
control 
…that ŵediĐal tƌeatŵeŶts ǁill ďe effeĐtiǀe iŶ ĐoŶtƌolliŶg theiƌ 
arthritis 
Illness coherence …that aƌthƌitis ͞ŵakes seŶse͟ 
IPQ-R – Illness Perceptions Questionnaire-Revised 
 
The IPQ-R is divided into three sections, with the identity presented first as a list of 12 
commonly experienced symptoms. Respondents are asked to indicate whether they 
have experienced any of these symptoms since starting treatment for their arthritis 
and to subsequently judge whether the symptom is related to their arthritis. The sum 
of this latter question forms the illness identity subscale, with yes scoring 1 and no 0, 
total scores range from 0-12. The remaining subscales are measured by a total of 22 
items. Responses are rated on a 5-point Likert scale, from 1 (strongly disagree) to 5 
(strongly disagree). After the relevant reverse scoring, total scale scores range from 6-
30 for consequences and personal control and 5-25 for treatment control and illness 
coherence. High scores on the identity and consequences dimensions represent 
strongly held beliefs about the number of symptoms attributed to their arthritis and 
the negative consequences of arthritis. High scores on the personal control, treatment 
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control and coherence dimensions represent positive beliefs about the controllability 
of their arthritis and its treatment and a personal understanding of the condition.  
 
The psychometric properties of the IPQ-R have been evaluated in eight illness groups 
including a sample of 76 patients with RA (Moss-Morris et al., 2002). Principal 
CoŵpoŶeŶt AŶalǇsis ;PCAͿ ĐoŶfiƌŵed the stƌuĐtuƌe of the ŵeasuƌes aŶd CƌoŶďaĐh͛s 
alphas ranged from 0.75 to 0.89 indicated good internal consistency. The validity of the 
identity subscale was evaluated using an independent samples t-test which found a 
significant difference between those symptoms experienced versus those participants 
associated with their illness, in addition all the symptoms were endorsed by a 
percentage of the patients, confirming the validity of the range of symptoms included 
in the identity subscale. The 6 month test-retest reliability also confirmed that the IPQ-
R had acceptable consistency overtime (ICC=0.46-0.88). The IPQ-R has been specified 
in this trial, with the questions stating RA oƌ PsA ƌatheƌ thaŶ ͞the illŶess͟. This 
specified ŵeasuƌe has ďeeŶ used suĐĐessfullǇ iŶ a Ŷuŵďeƌ of studies ǁith CƌoŶďaĐh͛s 
alpha ranging from 0.68 to 0.88 on each of the subscales (Sterba et al., 2008; Graves et 
al., 2009).  
5.7.5.2.2 Treatment beliefs 
In addition to the IPQ-R treatment control subscale, beliefs about methotrexate were 
measured using the Beliefs about Medicines Questionnaires (BMQ) (Horne et al., 
1999). The specific concern and specific necessity subscales were selected. Each 
subscale consists of five items assessing concerns about the potential adverse 
consequences of taking methotrexate and the necessity of methotrexate. The scales 
are measured using a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly 
agree). Sum scores range from 5-25 with higher scores suggesting more concerns 
about the adverse consequences of taking methotrexate and viewing methotrexate as 
necessary. The subscales possess acceptable internal consistency for patients with RA 
ǁith ƌepoƌted CƌoŶďaĐh͛s alphas of ďetǁeen 0.81-0.88 for specific necessity and 0.56-
0.66 for specific concern (Treharne, Lyons, & Kitas, 2004; Van De Bemt et al., 2009). 
The authors of the measure also report good test-retest reliability (0.60 to 0.78) and 
correlations between the subscale and other measures of illness and medication 
beliefs and adherence in the expected directions (Horne et al., 1999).  
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An item was also developed to assessment perceived treatment burden. Participants 
were asked to rate how burdensome their treatment had been so far, from 1 (not 
burdensome) to 5 (extremely burdensome).  
5.7.5.2.3 Knowledge about methotrexate 
In addition to the IPQ-‘ illŶess ĐoheƌeŶĐe suďsĐale ǁhiĐh ŵeasuƌes a peƌsoŶ͛s oǀeƌall 
understanding of their arthritis, the Methotrexate in Rheumatoid Arthritis Knowledge 
(MiRAK) (Ciciriello, Wicks, Osborne, & Buchbinder, 2010) and the adapted 
Methotrexate in Psoriatic Arthritis Knowledge (MiPAK) tests were used to assess 
patients overall knowledge of methotrexate in relation to their illness. The MiRAK was 
adapted for the purposes of this thesis, for use in people with PsA. This adaption was 
undertaken by a rheumatologist, two CNSs and the MiRAK authors who include a 
rheumatologist and an epidemiologist/health services researcher. Forty-two of the 
questions remained the same, for 16 questions RA was replaced with PsA and the 
remaining items were deemed inappropriate for patients with PsA. The questions 
͞HaǀiŶg uŶtƌeated RA iŶĐƌeases Ǉouƌ ĐhaŶĐe of haǀiŶg a heaƌt attaĐk͟ aŶd 
͞Methotƌeǆate is ofteŶ ĐoŵďiŶed ǁith otheƌ ŵediĐations that treat RA͟ ǁeƌe 
ƌeŵoǀed. The iteŵs ͞Methotƌeǆate stops ŵost fiŶgeƌŶail pƌoďleŵs iŶ people ǁith 
psoƌiatiĐ aƌthƌitis͟ aŶd ͞Methotƌeǆate ĐaŶ ďe used to ĐoŶtƌol skiŶ diseases͟ ǁeƌe 
added. Both scales consist of 60-items with responses either true, false oƌ doŶ͛t kŶoǁ. 
Total scale scores range from 8-57, with greater scores indicating greater knowledge. 
The authors report excellent internal consistency (0.84) and test-retest reliability 
(ICC=0.894) for the MiRAK (Ciciriello et al., 2010) 
5.7.6 Safety of decision-making2 
The safety with which participants made decisions about the need for a telephone 
consultation with their CNS was recorded within the intervention group after each 
ďlood test, as eitheƌ ͞safe͟ oƌ ͞uŶsafe͟. A deĐisioŶ ǁas deeŵed ͞uŶsafe͟ ǁheŶ the 
participant did not initiate a telephone consultation when either a blood test result 
had significantly changed or was outside the normal range, or there was a new or 
ǁoƌseŶiŶg sǇŵptoŵ oƌ side effeĐt. A deĐisioŶ ǁas deeŵed ͞safe͟ eitheƌ ďeĐause: 
 
                                                     
2 Assessed in the intervention group only 
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a. The participant did not initiate a telephone consultation when either a 
blood test result had remained the same and was within the normal range, 
or there was no new or change in symptoms or side effects, or 
b. The participant initiated a telephone consultation when either a blood test 
result had significantly changed or was outside the normal range, or there 
was a new or worsening symptom or side effect, or 
c. The participant initiated a telephone consultation when either a blood test 
result had remained the same and was within the normal range, or there 
was no new or change in symptoms or side effects. 
 
It was important to distinguish between safe or unsafe decision making as opposed to 
correct or incorrect decision making. The former classification differs from the latter, 
as patients may have made a decision that was incorrect but was not unsafe i.e. 
contacting the CNS when blood tests were normal and there was no new or worsening 
symptoms or side effects. The former could be detrimental to tight disease control and 
well-being. 
5.8 INTERVENTION GROUP 
Figure 5.5 provides a diagrammatic representation of the intervention. 
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Figure 5.5. A diagrammatic representation of the intervention. 
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5.8.1 Intervention procedures 
All participants randomised to the intervention group took part in a training session to 
provide them with the knowledge, skills and resources required to monitor their own 
blood test results, symptoms and side effects and initiate care. This one-off 2 hour 
training session was delivered by a rheumatologist and the researcher with a group of 
between 2-6 participants. These groups were held in the day and evening at UCLH, in 
order to increase participation. The content of this training session was established in 
collaboration with the supervisory team and the CNSs at UCLH. The rheumatologist 
delivering the intervention is an experienced clinician, with a specific interest in the 
social and psychological impact of living with a rheumatic disease. The researcher was 
a Trainee Health Psychologist, with an interest in chronic disease self-management and 
who had received training in how to facilitate and deliver self-management 
interventions. Both were supervised by Professor Stanton Newman an expert in 
designing and delivering self-management interventions. A CNS was also present 
either at the beginning or end of the session to take clinical measurements. 
 
The training session introduced the research team, the purpose and aims of the 
intervention and the ƌatioŶale foƌ paƌtiĐipaŶts͛ seleĐtioŶ iŶ the studǇ. The 
rheumatologist then provided detailed clinical information covering the following 
areas; 
  The cause and symptoms of RA and PsA.   The pharmacological treatment options and their potential side effects.   Information about the blood tests, symptoms and side-effects that would need 
to be monitored.   How to initiate care from the CNS. 
 
PaƌtiĐipaŶts ǁeƌe theŶ tƌaiŶed hoǁ to ideŶtifǇ Ŷoƌŵal oƌ ͞safe͟ ƌaŶges of ďlood leǀels, 
side effects and symptoms and decide if any action was necessary. After a short break 
participants were guided through an example blood test scenario and then practiced 
interpreting example blood test results, symptoms and side effects. The results of 
these practice tasks were then reviewed within the group in a discussion led by the 
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rheumatologist. This enabled the group facilitators to provide tailored feedback to 
each participant in order for them to understand why they had made any errors and 
the potential implication of that error in the real world, highlighting the importance of 
safety and being conservative in their decision making.  
 
The rheumatologist then reviewed, in collaboration with the respective participant, the 
results of their last five blood tests. This enabled the rheumatologist and patient to 
understand and obtain normative ranges. The standard normal ranges applied to most 
participants however, for those whom these ranges were deemed unacceptable 
personalised ranges were set by the rheumatologist. The researcher then guided 
participants through the study documentation and instruction on what would happen 
next. Participants were given the following materials: 
  A file to store all study documentation.  A copy of the training slides (Appendix N).  A table indicating the triggers for patient action (Appendix O).  Contact details for all members of the research team (Appendix P).  A blood record sheet (Appendix Q).  Practice documentation (Appendix R). 
 
The date of the paƌtiĐipaŶt͛s Ŷeǆt ďlood test ǁas Ŷoted at the tƌaiŶiŶg sessioŶ to alloǁ 
the ƌeseaƌĐheƌ to ŵoŶitoƌ the patieŶts͛ atteŶdaŶĐe aŶd ĐheĐk ƌesults. The paƌtiĐipaŶt 
was asked to inform the researcher when any subsequent blood tests had been 
undertaken. The blood test results the participants were expected to assess were 
markers of inflammation (CRP and ESR), plus haemoglobin, WBC, liver function tests 
(ALP and ALT), platelets and neutrophils.  
 
Table 5.3 highlights the normal range and definition of significant change for each of 
the eight tests. These ranges and significant changes were developed and agreed by 
the clinical team at UCLH. From this point on participants in the intervention group 
received routine care from their rheumatologist, defined as outpatient appointments 
every 6 months, and had access to the emergency CNS helpline if requested. All 
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participants attended the hospital for their blood tests every 4-6 weeks depending on 
their dose of methotrexate, as per usual care.  
 
Table 5.3. Normative ranges by blood test 
Test Normal Range Definition of significant change 
Haemoglobin 12.0  - 17.0 Fall of more than 1.0 
WBC 3.0 - 10.0 Two readings in a row each with a fall of more 
than 1.0 
Neutrophils 2.0 - 7.5 A fall of more than 2 
Platelets 150 - 400 Two readings in a row with falls of more than 50 
ALP 40 - 129 A result which doubles from the previous blood 
test or rises 258 
ALT 10 - 50 A results which doubles from the previous blood 
test or rises above 100 
ESR 0 - 20 A rise of more than 20 from the previous blood 
test results 
CRP 0 - 5 A rise of more than 20 from the previous blood 
test results 
WBC - White Blood Count; ALP - Alkaline Phosphatase; ALT - Alanine Transaminase; ESR - Erythrocyte 
Sedimentation Rate; CRP - C-Reactive Protein  
 
The intervention arm consisted of two phases: 
 
Phase One: This phase eŶĐoŵpassed the paƌtiĐipaŶts͛ fiƌst thƌee ďlood tests. Twenty-
four hours after each blood test, participants were sent a copy of their results either 
via email or post, depending on the patieŶt͛s pƌefeƌeŶĐe. IŶĐluded ǁeƌe the patieŶt͛s 
previous blood test results (Appendix S), to enable calculation of change scores by the 
participant. The form required participants to record if the current result was out-of-
range or a significant change had occurred since their last blood test and if any further 
advice was needed. This structured approach allowed participants to work through the 
results methodically. Participants also recorded, using a 17-item checklist, the side 
effects and symptoms they had experienced since their last blood test, indicating if 
they were any new or continuing symptoms. For continuing symptoms participants 
also had to indicate if the symptom had become worse, better or remained the same 
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since their last blood test. The final questions asked participants to record whether 
based on these blood test results, symptoms or side effects if a telephone consultation 
with the CNS was required using the following criteria: 
  A blood test result was outside of the normal range.   A blood test result had changed significantly since their last blood test.   A new symptom or side effect had appeared since their last blood test.   A continuing symptom or side effect had become worse since their last blood 
test.  
 
In between blood tests participants were asked to take immediate action, by 
contacting the CNS helpline, upon the appearance of any of the situations listed in 
Table 5.4. 
 
Table 5.4. Symptoms and side effects to be monitored between blood tests 
Symptom CoŶtaĐt the CNS if…. 
Vomiting persists over 24 hours  
Diarrhoea persists over 48 hours 
Mouth ulcers symptoms, causing discomfort and interference with 
normal eating 
Skin problems unexplained rash or itching occurs 
Bruising unexplained bruising occurs 
Bleeding frequent nose bleeds or excessive bleeding following 
minor injury 
Sore throat if episodes requiring treatment occur within a 4 week 
period 
Fever if fever persist for over 24 hours 
Breathlessness if breathlessness occurs in the absence of physical 
exertion 
Dry cough unexplained dry cough 
Chicken pox/shingles if been exposed to the chicken pox or shingles virus 
Pregnancy if pregnancy is suspected 
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The researcher contacted the participant within 48 hours of receiving their results to 
go through the completed documentation and provide feedback on whether they had 
made the appropriate decision. If any errors were made these were reviewed and 
feedback was provided as to why they were incorrect. This was to ensure that the 
patient fully understood the implications of their decisions and the consequences of 
not reporting this information to their CNS.  
 
If any of the triggers for patient action were present participants contacted the CNS for 
a telephone consultation in order to evaluate whether the issue could be resolved 
remotely. If during this consultation the CNS felt that there was a need for a face-to-
face outpatient appointment an emergency appointment was booked for within the 
subsequent 7 days.  
 
Progression onto Phase Two: If after the 3rd blood test participants had correctly 
identified the need for contact with the CNS on at least two of the three blood tests 
they were able to move onto phase two of the trial. Those who did not meet these 
criteria continued on in phase one until they correctly interpreted two consecutive 
blood tests. If after the fifth blood test a participant had not been able to successfully 
identify when an outpatient appointment was needed, they were removed from the 
trial and returned to usual care as they were deemed unable to self-monitor safely. 
 
Before progression onto phase two of the trial, intervention participants completed a 
follow-up questionnaire, a repetition of the baseline questionnaire, without 
demographic data.  
 
Phase Two: The second phase of the trial encompassed blood tests 4 to 6. As in phase 
one after each blood test the participant was sent their results via post or email 
depending on their preference, along with the same questionnaire. Participants were 
asked to complete the questionnaire on receipt of the results and send it back in the 
freepost envelope provided. Participants did not receive a telephone call from the 
researcher, as this part of the study was to evaluate how participants did when 
interpreting and initiating contact with their CNS independently. By removing the 
additional support provided by the researcher the second phase of the trial aimed to 
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assess the effectiveness of the intervention without attention as a confounder. 
Patients were asked to call or email their CNS using the same criteria described on 
page 201. After the final blood test a third follow-up questionnaire was then 
completed. 
 Behaviour change techniques  
A complex intervention, such as the one evaluated within this trial, is defined by 
several interacting components known as the ͞aĐtiǀe iŶgƌedieŶts͟ (Medical Research 
Council, 2000). As the aim of this intervention was to enable patients to self-monitor 
aspects of their disease at home and use this information to initiate care from their 
CNS, the content of the intervention was developed in order to address gaps in patient 
knowledge and skills, using a number of well-established behaviour change techniques. 
By defining the current intervention in terms of behaviour change techniques this not 
only allows replication and implementation it also provides a link with theory. The 
recently updated BCTTv1 (Michie et al., 2013) contains 93 hierarchically clustered 
techniques many of which can be linked to the published theories of self-management 
described in Chapter 4. A retrospective assessment of the intervention using the 
BCTTv1 was undertaken and Table 5.5 outlines the results of this process. Prior to any 
coding of BCTs it is important to specify the target behaviour/s and target population. 
In the case of this intervention the targeted behaviours were (i) self-monitoring – 
including recording and interpretation and (ii) initiating care (help-seeking). The target 
population were patients with RA or PsA on DMARD therapy. A total of 13 BCTs were 
identified in the intervention. These 13 behaviour change techniques can be linked to 
both social cognitive theory (Bandura, 1997) and self-regulation theory (Leventhal et 
al., 1980) described in Chapter 4 and were used to guide the selection of outcome 
measures for the trial evaluation, as described in section 5.7.5 (page 191).  
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Table 5.5. Behaviour change technique and implementation in the RCT 
Behaviour change technique Definition of the technique Implementation 
Behaviour practice or rehearsal Prompt practice or rehearsal of the performance of the 
behaviour one or more times in a context or at a time when 
the performance may or may not be necessary, in order to 
increase habit and skill.  
Participants were asked to practice the 
monitoring of blood tests (four 
separate scenarios) within the training 
session.  
Credible source Present verbal or visual communication from a credible 
source in favour of or against the behaviour.  
The training session was delivered by 
the rheumatologist and researcher who 
provided information on the benefits of 
undertaking self-monitoring and 
initiating their own care.  
Demonstration of the behaviour Provide an observable sample of the performance of the 
behaviour, directly in person or indirectly e.g. via film, 
pictures, for the person to aspire to or imitate.  
Participants were shown during the 
training session an example scenario of 
how blood test results should be 
interpreted.  
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Behaviour change technique Definition of the technique Implementation 
Discrepancy between current behaviour 
and goal 
Dƌaǁ atteŶtioŶ to disĐƌepaŶĐies ďetǁeeŶ a peƌsoŶ͛s ĐuƌƌeŶt 
behaviour (in terms of the form, frequency, duration, or 
iŶteŶsitǇ of that ďehaǀiouƌͿ aŶd the peƌsoŶ͛s pƌeǀiouslǇ set 
outcome goals, behavioural goals or action plans (goes 
beyond self-monitoring of behaviour).  
At each of the telephone calls for blood 
tests 1-3 the researcher highlighted any 
disĐƌepaŶĐies ďetǁeeŶ the paƌtiĐipaŶt͛s 
current ability to safely self-monitor 
and initiate care and the goal of the 
intervention.    
Feedback on behaviour Monitor and provide feedback on performance of the 
behaviour (e.g. form, frequency, duration, intensity).  
At each of the telephone calls for blood 
tests 1-3 the researcher monitored and 
pƌoǀided feedďaĐk oŶ the paƌtiĐipaŶt͛s 
decision making. Paying particular 
attention to unsafe help-seeking.   
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Behaviour change technique Definition of the technique Implementation 
Framing/reframing Suggest the deliberate adoption of a perspective or new 
perspective on behaviour (e.g. its purpose) in order to 
change cognitions or emotions about performing the 
behaviour.  
If participants made an unsafe decision 
the ƌeseaƌĐheƌ eliĐited the patieŶt͛s 
beliefs about the need for contact with 
the CNS and their understanding of the 
principles of the intervention. Together 
attempts were made to reframe these 
beliefs and address why their response 
was incorrect. 
Goal setting (behaviour) Set or agree a goal defined in terms of the behaviour to be 
achieved.  
During the training session the goal of 
the intervention was defined and 
agreed with each of the participants. 
Information about social and 
environmental consequences 
Provide information (e.g. written, verbal, visual) about 
social and environmental consequences of performing the 
behaviour.  
During the training session information 
was provided on the benefits of 
performing the behaviour and the 
potential reduction in hospital visits.    
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Behaviour change technique Definition of the technique Implementation 
Instruction on how to perform the 
behaviour 
Advise or agree on how to perform the behaviour. The training session and supporting 
documentation provided instruction on 
how to interpret their symptom, side 
effects and blood test results and how 
to initiate care from the rheumatology 
team. 
Self-monitoring of behaviour Establish a method for the person to monitor and record 
their behaviour(s) as part of a behaviour change strategy.  
Participants were provided with 
documentation to record and monitor 
their blood test results, symptoms and 
side effects as well as whether they 
needed to initiate care. 
Social comparison Dƌaǁ atteŶtioŶ to otheƌs͛ peƌfoƌŵance to allow comparison 
ǁith the peƌsoŶ͛s oǁŶ peƌfoƌŵaŶĐe.  
Attention was drawn to the 
performance of other participants after 
practice of the behaviour in the 
education session.  
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Behaviour change technique Definition of the technique Implementation 
Social reward Arrange verbal or non-verbal reward if and only if there has 
been effort and/or progress in performing the behaviour 
Participants were congratulated and 
encouraged when they interpreted 
their symptoms, side effects and blood 
tests safely and made safe decisions to 
initiate care.  
Social support (unspecified) Advise on, arrange or provide social support (e.g. from 
fƌieŶds, ƌelatiǀes, Đolleagues, ͞ďuddies͟ oƌ staffͿ oƌ ŶoŶ-
contingent praise or reward for performance of the 
behaviour. It includes encouragement and counselling, but 
only when it is directed at the behaviour.  
Encouragement was given to all 
participants by the researcher to 
support self-monitoring and the 
initiation of care. 
DMARD – Disease Modifying Anti-Rheumatic Drug 
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5.9 CONTROL GROUP 
Participants in the control group received standard care this typically consisted of a 
blood test every 4-6 weeks, outpatient appointments with the CNS every 3 months and 
rheumatologist every 6 months. Advice was also freely available via the CNS 
emergency helpline when requested.  
5.10 PARTICIPANT SAFETY 
The safety of participants both in the intervention and control groups were of the 
utmost priority to the research team. Phase one of the study was developed in order 
to establish that participants could correctly and safely interpret their blood test 
results, symptoms and side effects with support from the research and clinical team. 
The blood tests of all intervention participants were reviewed both by the researcher 
and CNS independently of the patient. Any serious concerns about the health and care 
of these patients were acted upon immediately. If the participant had any concerns 
about any aspect of their healthcare within the study period they were able to contact 
any member of the research team by email or telephone. This included the CNS 
helpliŶe oƌ theiƌ ĐoŶsultaŶt͛s seĐƌetaƌǇ, ǁheƌe patieŶts ǁeƌe ƌespoŶded to ǁithiŶ Ϯϰ-
48 hours.  
5.11 STATISTICAL ANALYSIS 
All analyses were undertaken in IBM SPSS Statistics Version 21.0.  
5.11.1 Sample size calculation 
An a priori power calculation was conducted using G-Power 3.1 (Faul, Erdfelder, Lang, 
& Buchner, 2007). An initial power calculation was performed using data from Hewlett 
et al., (2005b). This study reported a median of 8 (range 5-13) appointments with the 
consultant rheumatologist in the patient-initiated service and 13 (range 11-17) 
appointments in the control group. These medians and ranges were converted into 
mean and standard deviations using online software (Lowry, 2014) based on 
calculations derived from Hozo, Djulbegovic, & Hozo (2005). This generated a mean 
and standard deviation of 8.5(2.31) and 13.5(1.73) respectively. To conduct an 
independent samples Mann-Whitney U test (two groups), a total sample size of 10 
paƌtiĐipaŶts ǁould ďe ƌeƋuiƌed at ϴϬ% poǁeƌ ;α=Ϭ.ϬϱͿ, ǁith an effect size of 2.45. The 
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magnitude of the effect size and hence sample size were deemed inappropriate for a 
trial of effectiveness and, therefore, a generic sample size calculation was conducted 
with an estimate medium effect size of 0.50, ϴϬ% poǁeƌ aŶd α=Ϭ.Ϭϱ. This ƌeƋuiƌed a 
total sample of 134 participants.  
5.11.2 Missing data 
The authoƌs of the MeiQ™ aŶd HeiQ™ speĐifǇ ŵeaŶ iteŵ ƌeplaĐeŵeŶt as the method 
by which missing data should be dealt with; this was undertaken when calculating 
scale scores. No other scales specify a method for imputing missing data.  
 
Across the entire dataset there was 3.65% missing data and no participant had more 
than 50% missing data (the a priori cut off for exclusion from the analyses). Appendix T 
provides greater detail of missing data levels with indication of which variables had the 
highest amounts of missing data. At baseline the component scores of the SF-12v1® 
had the most missing data (n=30, 30%), at first follow-up the knowledge about 
methotrexate scale had the most missing data (n=10, 11.9%) and at final follow-up the 
DAS28 had the most missing data (n=31, 48.4%). At baseline the missing SF-12v1® data 
was as a result of an administrative error which meant that the questionnaire was 
distributed with a missing page, the knowledge questionnaire is particularly long and 
the poor response at first follow-up may have been a result of questionnaire fatigue 
although the measure was in the middle of the questionnaire booklet and was 
completed at baseline and final follow-up with no problems. At final follow-up due to 
organisational issues difficulty was experienced in gathering disease response data. No 
individual variables had more than 50% missing data (the a priori cut off for exclusion 
from the analyses).  
 
The pattern of missing data was evaluated using the IBM SPSS version 21.0 missing 
data fuŶĐtioŶ. Little͛s MissiŶg CoŵpletelǇ At ‘aŶdoŵ ;MCA‘Ϳ test ǁas ĐoŶduĐted to 
check if there was any systematic differences between the missing values and the 
observed values. A non-significant result (p=0.53) indicated that data was MCAR and as 
the overall dataset had less than 5% missing data multiple imputation methods were 
used. This minimizes the bias found in any further analyses. 
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Missing data was imputed at scale level, but not for an entire time point (i.e. when a 
participant was lost to follow-up). Imputation was performed separately for the 
dataset which included intervention only variables (i.e. data specific to the 
interpretation of symptoms, side effects and blood test results) after imputation of the 
variables which were applicable for both trial arms. Constraints and rounding were 
used to ensure that the imputed scale level data was meaningful and corresponded to 
possible values. Ten scale-level imputation iterations were used to eliminate bias; it 
has been suggested that between three and ten imputations are sufficient, particularly 
for datasets with minimal missing data (Rubin, 2009). All analyses, unless otherwise 
stated, were performed on each of these 10 datasets and then pooled for multiple 
imputation to give a final combined result. 
 
The multiple imputed dataset was, therefore, used for the analysis of baseline 
differences between trial arms, intervention effectiveness in relation to healthcare 
utilisation and the associated economic evaluation. The analysis exploring changes 
over time in the psychosocial variables was undertaken using multi-level modelling 
(MLM) (described in more detail in section 5.11.9.3, page 223) which can be 
undertaken on datasets with missing data. Therefore, these analyses were conducted 
on the original dataset. The analyses of the mediators and moderators of intervention 
effectiveness were conducted using the PROCESS macro developed by Hayes (2013), 
this macro cannot be implemented on multiply imputed datasets; therefore, the 1st 
imputation was analysed. Although this is not ideal as fewer imputations lead to less 
precise confidence intervals and p-values, Bodner (2008) recommends having as many 
imputations as the percentage of missing data which in this case is not far from this 
estimate. 
5.11.3 Internal reliability and validity 
CƌoŶďaĐh͛s alphas ǁeƌe ĐalĐulated to assess the iŶteƌŶal ƌeliaďilitǇ of eaĐh of the 
psychosocial measures at each of the three tiŵe poiŶts. CƌoŶďaĐh͛s alpha of >Ϭ.ϳϬ 
were considered acceptable (Cronbach, 1951); ǀaƌiaďles ǁith CƌoŶďaĐh͛s alpha <Ϭ.ϳϬ 
were explored further and recalculated on removal of each item. An item was 
permanently removed from a scale, across all time points, if the CƌoŶďaĐh͛s alpha 
improved sufficiently to justify its exclusion.  
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The authors of the IPQ-R suggest two methods for assessing the validity and internal 
validity of the identity subscale (Moss-Morris et al., 2002). Firstly, a paired-samples t-
test was coŶduĐted ĐoŵpaƌiŶg paƌtiĐipaŶt͛s sĐoƌes oŶ the sǇŵptoŵs eǆpeƌieŶĐed 
subscale and the identity subscale. A significant difference between the symptoms 
patients experienced versus those they associated with their arthritis, would suggest a 
conceptual difference between somatisation and identity and, therefore, validated the 
measure. Secondly, the frequencies with which different symptoms were endorsed as 
paƌt of patieŶts͛ illŶess ideŶtitǇ ǁeƌe ĐalĐulated. BeĐause the IPQ-R identity subscale 
consists of disparate symptoms and a certain number of these symptoms are more 
relevant to arthritis than others, the internal consistency is less relevant than in the 
otheƌ suďsĐales. Neǀeƌtheless, CƌoŶďaĐh͛s alphas ǁeƌe also ĐalĐulated foƌ eaĐh tiŵe 
point.  
5.11.4 Normality and outliers 
Distributions of responses were examined using histograms and by performing the 
Shapiro-Wilk test (pчϬ.ϬϭͿ. As data tƌaŶsfoƌŵatioŶs ĐaŶ hiŶdeƌ iŶteƌpƌetatioŶ of the 
results (Osborne, 2002) non-parametric statistics were conducted on variables that 
failed to meet the assumptions of normality.  
 
Scatterplots were inspected for outliers, defined as standardised scores in excess of 
±3.29 (Tabachnick & Fidell, 2013). Mahalanobis D² (p<0.001) was also calculated, 
values above or below the critical chi squared value (corresponding to the number of 
included independent variables) identified any multivariate outlieƌs. Cook͛s distaŶĐe 
indicated if these cases were having any undue influence on the results. Values above 
one were of concern and cases were removed and the analyses rerun by means of a 
sensitivity analysis. Any outliers remained in the analysis, as these were viewed as 
legitimate data points that may contain valuable information on the relationships 
between variables (Orr, Sackett, & Dubois, 1991).  
 
The regressions performed as part of this analysis took the form of a Poisson 
distribution and were, therefore, undertaken within the Generalized Linear Models 
(GLM) function in IBM SPSS version 21.0 (further details in section 5.11.8.3, page 218). 
GLM procedures within IBM SPSS version 21.0 do not generate any output in relation 
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to multicolinearity between IVs; therefore, the final regression models were rerun 
using the standard multiple linear regression function within SPSS to obtain the 
tolerance and Variance Inflation Factor (VIF) measures of multicolinearity. Tolerance is 
an indicator of how much of the variability of the specified Independent Variable (IV) is 
not explained by the other IVs in the model, values <0.10 are of concern as this may 
indicate that correlations between the IV are high. The VIF is an inverse of the 
tolerance value and values above 10 would be of concern (Pallant, 2007). The normal 
probability plots (P-P) of the regression standardised residuals were also inspected to 
ensure that the points laid in a reasonable straight diagonal line from bottom left to 
top right. In the scatterplot of the standardised residuals, the residuals should be in 
roughly a rectangular distribution, with most of the scores concentrated in the centre, 
along the 0 y-axis.  
5.11.5 Intention-to-treat analysis 
For those participants who did not complete the first and/or final follow-up 
questionnaires blood test and healthcare utilisation data continued to be collected 
from the electronic patient records. This allowed a comprehensive ITT analysis to be 
performed on these outcomes. ITT is deemed the most suitable way of analysing RCTs 
and compares participants in the groups they were originally assigned irrespective of 
whether they received the intervention or not (i.e. dropped out and returned to usual 
care). A full ITT analysis was not possible for PROMS because if a participant were lost 
to follow-up they had no data to analyse, they did however, remain within the group 
they were allocated to. In order to test the robustness of the findings sensitivity 
analyses were performed for complete (i.e. all three administrations of the 
questionnaire) (n=79) and available case cohorts (n=100). 
5.11.6 Significance level 
A significance level of p<0.01 was set, unless otherwise stated, this was due to the 
large number of tests performed and hence the risk of obtaining a false-positive result 
i.e. rejecting the null hypothesis when it is in fact true (Type 1 error). 
5.11.7 Comparison between trial arms at baseline 
Differences between the intervention and control group on normally distributed 
continuous variables were explored using independent samples t-tests. Equality of 
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ǀaƌiaŶĐes ǁeƌe ĐheĐked usiŶg LeǀeŶe͛s test, if sigŶifiĐaŶt the ǀaƌiaŶĐes of the tǁo 
groups differed and the assumption of equality of variance was violated; the adjusted 
values were then used. Effect sizes were calculated using eta squared (), which 
ƌaŶges fƌoŵ Ϭ to ϭ aŶd aƌe iŶteƌpƌeted as CoheŶ͛s d (Cohen, 1988), whereby 0.01 is a 
small effect, 0.06 moderate and 0.14 large. Differences on non-parametric continuous 
data were explored using the Mann-Whitney U test and the associated median values 
and inter-quartile range for the ranked data were calculated. Effect sizes were 
reported using r aŶd iŶteƌpƌeted usiŶg CoheŶ͛s (1988) criteria as described above. 
 
In order to explore the relationship between categorical variables a chi squared test for 
iŶdepeŶdeŶĐe ǁeƌe peƌfoƌŵed, ǁith Yates͛ CoŶtiŶuitǇ CoƌƌeĐtioŶ ǁhiĐh ĐoŵpeŶsates 
for the overestimate of the chi squared value in a 2 by 2 design. Cell frequencies were 
checked to ensure that at least 80% of cells had an expected frequency of five or more, 
and if it was a 2 by 2 design a frequency of 10 or more. If a 2 by 2 table violated this 
assuŵptioŶ the Fisheƌ͛s EǆaĐt PƌoďaďilitǇ Test ǁas eŵploǇed. IŶ desigŶs ǁheƌe aŶy cell 
contained a frequency of 0, groups were collapsed appropriately. Phi (was used as 
the effeĐt size foƌ Ϯ ďǇ Ϯ taďles, usiŶg CoheŶ͛s ;ϭϵϴϴͿ Đƌiteƌia as desĐƌiďed aďoǀe. Foƌ 
taďles laƌgeƌ thaŶ Ϯ ďǇ Ϯ, Cƌaŵeƌ͛s V ǁas ƌepoƌted as the effeĐt size, as this takes iŶto 
account the degrees of freedom (df). The criteria for a small, medium and large effect 
differs depending on the size of the table. One is subtracted from the number of 
categories in the row variables (R-1) and column variable (C-1) and whichever of these 
values is smaller is the effect size and is evaluated using the following criteria: 
  For R-1 or C-1 equal to 1 (two categories): small = 0.01, medium = 0.30, large = 
0.50.  For R-1 or C-1 equal to 2 (three categories): small = 0.07, medium = 0.21, large 
= 0.35.  For R-1 or C-1 equal to 3 (four categories): small = 0.06, medium = 0.17, large = 
0.29. 
 
In order to explore whether there were any differences in demographic and clinical 
data between trial arms, between those who did and did not receive their allocated 
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group and the interaction between trial arm and receipt of allocation a series of 
factorial analysis of variances (ANOVA), for continuous variables, and factorial logistic 
regressions, for categorical variables, were performed. For the factorial ANOVAs 
hoŵogeŶeitǇ of ǀaƌiaŶĐes ǁeƌe ĐheĐked usiŶg LeǀeŶe͛s test as described above.  
5.11.8 Safety of initiating care 
 Were intervention participants able to safely initiate contact with their CNS? 
Safety of decision making was modelled as the percentage of intervention participants 
who made a safe decision to initiate care at each of the assessment points and also as 
the percentage of safe decisions made by each participant. Percentages rather than 
frequencies are reported as not all participants were in the trial for six blood tests. 
Assessments in relation to blood test results were deemed objective triggers and 
symptoms and side effects subjective triggers. 
 Did safety improve over time?  
In order to assess whether safety improved over time multilevel models were run 
within the general linear mixed model (GLMM) function of IBM SPSS version 21.0. 
MLM, also known as random-coefficient, mixed-effect, hierarchical linear and 
multilevel regression models, deal with nested data – that is, where observations are 
clustered within successive levels of a data hierarchy (Heck, Thomas, & Tabata, 2013). 
In this trial decision making was nested within participants and GLMM provides a 
means of incorporating this categorical repeated measures outcome (i.e. safe or 
unsafe) in situations where there are clustered data structures. Changes in decision 
making over time, as the dichotomous categorical dependant variable were modelled 
as a function of time nested in participant, as illustrated in Figure 5.6. In which safe or 
unsafe decision making was the binomial dependant variable, time was a fixed effect 
and participant identification number a random effect. 
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Figure 5.6. Data structure of the RCT – decision-making 
 
MLM is a relatively new statistical technique within psychology but is gaining 
popularity (Marques & Hamilton, 2014). This is because in comparison to more 
traditional methods of analysis such as ANOVA, it allows the hierarchical structure of 
the data to be taken into account, it is able to include all data despite missingness and 
has the ability to calculate random intercepts and slopes for each participant rather at 
a group level; therefore, enabling a more accurate modelling of the data. The dataset 
was restructured in IBM SPSS Statistics Version 21.0 from a wide to a long format so 
that each variable was represented as a single column. Each participant, therefore, had 
multiple rows of data, one for each longitudinal measurement occasion.  
 
In order to check the assumption that scores within a participant were highly 
correlated the first MLM included no predictors and a scaled identity covariance type 
for both level one and level two in order to calculate the ICC. An ICC of 0.1 are 
classified as small, 0.2 medium and 0.3 large (Maas & Hox, 2005). A large ICC suggests 
that scores within a participant are more similar than between participants; therefore, 
the assumption of independence is violated. In this situation the use of traditional 
analysis methods, such as ANOVA, may lead to biased results as the sample size 
becomes artificially inflated which could lead to overestimate of the effect. ICC for 
safe/unsafe initiation of care based on blood test results was r=0.40 and symptoms 
and side effects r=0.43; therefore, indicating the value of nesting time (first-level unit) 
within participant (second–level unit).  
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 What were the baseline predictors of safe initiation of care? 
In order to explore whether any of the demographic, clinical or psychosocial variables 
ŵeasuƌed at ďaseliŶe pƌediĐted a peƌsoŶ͛s aďilitǇ to safelǇ self-monitor and initiate 
care a series of Poisson regressions were performed. Poisson rather than standard 
hierarchical multiple linear regressions were undertaken as the DV (number of correct 
decisions over the trial period) was count data, a positive integer and on the whole 
negatively skewed with many cases of 0 (Figure 5.7).  
 
 
Figure 5.7. Example of a Poisson distribution 
 
These analyses were performed using the GLM function in IBM SPSS version 21.0. 
Modelling the raw cell counts however, can be misleading because each participant 
had a varying number of blood tests within the trial. Variables of this nature are 
handled within the GLM as offset variables.  
 
In a study with many predictor variables, such as this, it is desirable to reduce the 
number of variables whilst preserving the usefulness of the predictions and power. In a 
traditional multiple linear regression this is achieved through well-known methods 
such as stepwise, forward and backward regressions. These methods are, however, not 
easily implemented when performing a Poisson regression within IBM SPSS version 
21.0. The forward selection algorithm method has, therefore, been proposed and is 
found to be superior to transforming the dependant variable to no longer fit a Poisson 
distribution (Famoye & Rothe, 2003). The method involves running univariate 
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regressions for each IV, selecting the IV with the smallest Akaike's Information 
Criterion (AIC) value, which indicates the best fitting model. If p>0.05 the variable is 
disregarded and the next lowest AIC value is selected and so on. When the first 
significant (p<0.05) IV is found this variable is retained and another Poisson regression 
is performed which incorporates the significant IV with all other IVs. This stepped 
process is continued until there are no remaining significant variables.  
 
In a Poisson regression the  coefficient can be interpreted for continuous IVs as the 
amount that a one-unit change in that IV increases or decreases the DV, holding all 
other IVs in the model constant. For categorical IVs the  coefficient represents an 
increase or decrease in the DV when comparing all groups to the reference group. The 
Exponentiated  Coefficients (Exp()) is interpreted as is an incident rate ratio, so that 
Exp()>1 indicate more safe decisions and Exp()<1 fewer safe decisions. 
5.11.9 Intervention effectiveness 
 Effects of the intervention on healthcare utilisation 
As healthcare utilisation was a cumulative frequency across the trial period, univariate 
Poisson regressions were performed using the GLM function in IBM SPSS version 21.0, 
as described above. Trial arm was the IV and healthcare utilisation (CNS, 
rheumatologist, GP and total) the DV.  
 Effects of the intervention on healthcare costs 
The analyses of cost effectiveness was unplanned a priori and was only considered 
important in light of the results found in relation to healthcare utilisation. Post-hoc 
tests are often considered to be data dredging and, therefore, inferior to a priori 
comparisons (Rothwell, 2005). These additional tests greatly inflated the total number 
of statistical tests performed; therefore, the p-value was adjusted to 0.001 to 
compensate for these additional comparisons. Caution should however, remain when 
interpreting these results. The cost-effectiveness analyses was performed for two 
different models of care: 
 
Model One: The intervention and control group as implemented including the CNS -led 
telephone consultations. 
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Model Two: The intervention and control group as implemented not including the CNS 
-led telephone consultations - replicating the analysis performed by Hewlett et al., 
(2000). This model assumes that the additional telephone contact generated by the 
intervention could be managed by the existing CNSs.  
 
Each of these models was costed using the national average unit cost as well as the 
upper and lower quartiles provided by the Department of Health reference costs for 
2010-2011 (Department of Health, 2011a) and 2012-13 (Department of Health, 2013a) 
and the published Unit costs of Health and Social Care 2012 (Curtis, 2012) (Table 5.6). 
The analysis of cost effectiveness was conducted with all three estimates (upper, 
average and lower) in order to provide a sensitivity analysis, this was followed by the 
analysis of complete cases only. 
  
2
2
1
 
Table 5.6.Source of unit costs 
Usage Source Description in source Average cost 
Face-to-face rheumatology 
nurse outpatient appointment 
Department of Health (2013a) 
Reference costs for 2012-13  
Non-consultant led, non-admitted, face-
to-face, follow-up outpatient 
appointment in rheumatology 
£89 (Lower quartile £52, upper 
quartile £105) 
Telephone consultation with 
rheumatology nurse 
Department of Health (2013a) 
Reference costs for 2012-13  
Non-consultant led, non-admitted, non-
face to face, follow-up outpatient 
appointment in rheumatology 
£80 (Lower quartile £52, upper 
quartile £112) 
Face-to-face consultant 
rheumatologist outpatient 
appointment 
Department of Health (2013a) 
Reference costs for 2012-13  
Consultant-led, non-admitted, face-to-
face, follow up outpatient appointment 
in rheumatology 
£133 (Lower quartile £105, upper 
quartile £150) 
GP appointment Unit costs of Health and Social 
Care 2012 (Curtis, 2012) 
11.7 minute consultation £43 including direct staff costs & 
staff training 
£36 including direct staff costs 
but without training (average 
£39.50) 
  
2
2
2
 
Usage Source Description in source Average cost 
EduĐatioŶ tƌaiŶiŶg sessioŶ† Unit Costs of Health and Social 
Care 2012 (Curtis, 2012) 
One hour of patient contact with a senior 
staff nurse costs £105 excluding 
qualifications and £121 including 
qualifications. The training session was 
2hrs long and included 5-6 patients per 
sessionǂ 
Lower £35 per patient (5 people 
attending) 
Upper £48.40  per patient (6 
people attending) 
Travel to an outpatient 
appointment 
Department of Health (2011a) 
Reference costs for 2010-2011  
Travel to an outpatient appointment £18 
Travel to services other than 
outpatients 
Department of Health (2011a) 
Reference costs for 2010-2011  
Travel to services other than outpatients £5 
Blood tests Local costs Full blood count=£10.33  
ALP & ALT=£7.26  
ESR=£7.26         
CRP=£7.26 
£32.11  
GP – General Practitioner; ALP - Alkaline Phosphatase; ALT - Alanine Transaminase; ESR - Erythrocyte Sedimentation Rate; CRP - C-Reactive Protein  
† Intervention participants only 
ǂ The cost of running the expert patient programme, a chronic disease self-management programme is £298 per patient. This 6 week programme which runs for 2½ hours a week 
and, therefore, equates to £19.87 per patient per hour 
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 Effects of the intervention on clinical and psychosocial outcomes 
As DAS were collected only at baseline and final follow-up exploration of significant 
group by time interaction effects were explored using mixed between-within subjects 
ANOVA rather than MLM. MLM is not recommended for nested data that consists of 
чϮ tiŵe poiŶts as theƌe is oŶlǇ oŶe oďseƌǀaďle ĐhaŶge (Hoffman, 2010). Homogeneity 
of variances were checked using LeǀeŶe͛s test ǁhiĐh iŶdiĐated p-values of greater than 
0.05 and, therefore, the variances for the two trial arms were equal. In addition to 
homogeneity of variances a mixed between-within subjects ANOVA assumes 
homogeneity of inter-correlations. Therefore, for each level of the between-subjects 
variables, the pattern of inter-correlations among the levels of the within-subjects 
vaƌiaďle should ďe the saŵe. This assuŵptioŶ ǁas tested usiŶg Boǆ͛s Test of eƋualitǇ of 
covariance matrices which indicated at the recommended p<0.001 level that the 
assumption was not violated. In order to explore whether there were any differences 
between the intervention and control group on response to treatment, using the 
EULAR treatment response criteria for RA and the PsARC response scale, chi squared 
foƌ iŶdepeŶdeŶĐe ǁith Yate͛s ĐoŶtiŶuitǇ ĐoƌƌeĐtioŶ foƌ a Ϯ ǆ Ϯ taďle, ǁeƌe used.   
 
In order to explore changes overtime on blood test results and psychosocial variables 
MLM was undertaken using the GLMM function in IBM SPSS statistics version 21.0. The 
data collected were nested within participant and hence the dataset was restructured 
from a wide to a long format so that each variable was represented as a single column. 
Each participant, therefore, had multiple rows of data, one for each longitudinal 
measurement occasion.  
 
In order to check the assumption that scores within a participant were highly 
correlated the first MLM included no predictors and a scaled identity covariance type 
for both level one and level two in order to calculate the ICC. ICCs were medium for 
CRP blood tests (r=0.21) and large for all remaining variables (r>0.40); therefore, 
indicating the value of nesting time (first-level unit) within participant (second–level 
unit). The complete case analysis replicated the magnitude of the ICCs found in the 
whole cohort. 
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Trial arm (0=control, 1= intervention), time (0, 1, 2) and the interaction between trial 
arm and time were entered as fixed effects in each model, with participant 
identification number as a random effect. Models were fitted with a first order 
autoregressive (AR1) covariance structure. This covariance structure assumes a type of 
dependence between adjacent observations which dies out between observations 
further apart (Snijders & Bosker, 2012). Restricted Estimate Maximum Likelihood 
(REML) methods were used as these are preferred for small samples (Bryk & 
Raudenbush, 1992).  
 
A significant interaction term was interpreted as evidence for differential treatment 
effectives. The main effects of group and time are reported but were not relevant to 
the primary research question and, therefore, have not been interpreted. Standardized 
adjusted effect sizes for group differences at each time point were calculated using 
Hedges g along with 99% confidence intervals (as p<0.01) using the formula provided 
by Turner and Bernard (2006). Hedges g includes a correction factor for small samples 
which, if absent, may lead to a less accurate and upwardly biased effect size. These 
effect sizes are interpreted in the same way as Cohen͛s d (1988) (small=0.20, 
medium=0.50, large=0.80). 
5.11.10 Mechanisms of effectiveness 
The mechanisms via which the intervention was hypothesised to work are outlined in 
Table 13. 
 
Table 5.7. Hypothesised mechanisms of action 
Measure Mechanism of action Outcome 
Clinical variables 
(i.e. pain, fatigue, 
disease activity) 
Deterioration in health ↓ QualitǇ of life  
↑ HealthĐaƌe utilisatioŶ 
Mood Increased anxiety and depression  ↓ QualitǇ of life  
↑ HealthĐaƌe utilisatioŶ 
Self-efficacy Increased self-efficacy ↑ QualitǇ of life  
↓ HealthĐaƌe utilisatioŶ 
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Measure Mechanism of action Outcome 
Illness & 
treatment beliefs 
More realistic illness and 
treatment beliefs 
↑ QualitǇ of life  
↓ HealthĐaƌe utilisatioŶ 
 
 Mediation analysis 
It was hypothesised that changes in the psychosocial outcome and process variables 
over the trial period may mediate the relationship between trial arm (X) and 
healthcare utilisation (Y), and trial arm (X) and quality of life (Y). The variables that 
were hypothesised to be potential mediators of the relationships between trial arm 
and healthcare utilisation were changes in clinical variables (i.e. pain, fatigue, 
functional disability and disease activity), quality of life, mood, self-efficacy and illness 
and treatment beliefs, from baseline to final follow-up. The variables that were 
hypothesised to be potential mediators of the relationships between trial arm and 
quality of life were changes in clinical variables (i.e. pain, fatigue, functional disability 
and disease activity), mood, self-efficacy and illness and treatment beliefs, from 
baseline to final follow-up.  
 
Figure 5.8 illustrates the total effect (c) which assumes that trial arm causes healthcare 
utilisation or quality of life. It is possible, however, that changes over time in the above 
variables may mediate the relationship between trial arm (X) and healthcare 
utilisation/quality of life ;YͿ. This path ;Đ͛Ϳ is kŶoǁŶ as the iŶdiƌeĐt effeĐt aŶd is a 
product of coefficients of path a and b.  
 
 
Figure 5.8. A simple mediation model depicted as a conceptual diagram 
 
Healthcare utilisation was modelled as the total number of outpatient visits to the 
CNS, rheumatologist and GP individually, as well as overall healthcare utilisation (i.e. a 
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total of all visits). Residualised change scores (standardized) were calculated for each 
of the possible mediators by regressing scores at baseline (IV) onto scores at the final 
follow-up (DV). As all measurement contains some degree of error (i.e. not perfect 
reliability) a change score calculated by subtracting baseline scores from follow-up 
would contain error from both time points. Residualised change scores also remove 
the correlation between pre and post test scores, thereby reducing the problem of 
ƌegƌessioŶ to the ŵeaŶ. A pheŶoŵeŶoŶ iŶ ǁhiĐh aŶ ͞aďŶoƌŵal͟ sĐoƌe ƌetuƌŶs to the 
ŵeaŶ oƌ ͞Ŷoƌŵ͟ iŶ a ƌepeated measures design, this can affect the true magnitude of 
the change scores but is overcome by calculating residualised change scores.  
 
Mediation was assessed using the simple mediation model within the PROCESS macro 
developed by Hayes (2013) and conducted in IBM SPSS version 21.0. This estimates the 
total and direct effect of trial arm on healthcare utilisation/quality of life, as well as the 
indirect effect of trial arm on healthcare utilisation/quality of life through any change 
in the clinical and psychosocial outcomes, and process variables. The macro generates 
bias-corrected 95% bootstrap CIs for the indirect effect using 10,000 bootstrap 
samples. An indirect effect is considered significant when the bias-corrected 95% CI do 
not contain zero. 
 Moderation analysis 
In order to establish if there were subgroups of the population who benefited more 
from the intervention moderation analysis was performed. In order to assess whether 
a variable is a moderator it must have been measured prior to the start of the 
intervention, the moderator and trial arm must also be independent (Kenny, 2013). 
Therefore, all baseline variables were hypothesised as potential moderators, this 
included all demographic, clinical and psychosocial variables (Figure 5.9). 
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Figure 5.9. A simple moderation model depicted as a conceptual diagram 
 
Moderation was assessed using the simple moderation model as part of the PROCESS 
macro developed by Hayes (2013) and implemented in IBM SPSS version 21.0. The 
macro mean centres x and the moderator prior to analysis so that the coefficients for 
the two variables that define the product will be interpretable within the range of the 
data (Hayes, 2012).  
 
For a categorical IV, as in this trial, and a continuous moderator variable, moderation 
means, for example that the difference in the mean number of visits to the CNS 
between the intervention and control group differs according to the level of the 
moderator variable. For two categorical variables, moderation means that the 
difference in the mean number of visits to the CNS between the intervention and 
control group differs depending on group membership on the moderator variable. 
 
Line graphs have been used to provide a visual representation of the significant 
interaction effects. The main effect is plotted on the X axis, the DV on the Y axis, and 
the moderating variable is represented by the lines that are plotted on the graphs.  
 
In order to probe any significant interaction effects PROCESS is able to provide 
information on the conditional effects of X on Y at different values of the moderator. 
This allows an investigation of whether the effects of the intervention were significant 
for different levels of the moderator. Values for dichotomous moderators are for the 
two values of the moderator. Values for quantitative moderators are for the 10th, 
25th, 50th, 75th, and 90th percentiles. The Johnson-Neyman technique was also 
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iŵpleŵeŶted ǁhiĐh pƌoǀides a ͞floodlight͟ aŶalǇsis (Spiller, Fitzsimons, Lynch Jr, & 
McClelland, 2013) of where the significant interaction effect lies. Only applied when a 
moderator is a continuous variable the technique provides values along the continuum 
of the moderator where the conditional effect of X on Y transitions from being 
statistically significant to non-significant (p=0.05). 
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6. CHAPTE‘ ϲ - BASELINE CHA‘ACTE‘ISTICS OF THE SAMPLE 
6.1 PROLOGUE 
This chapter presents the baseline characteristics of the participants approached and 
recruited into the RCT. It begins by presenting the reliability and validity of the 
measurement tools, a description of missing data and an exploration of statistical 
assumptions. This is followed by a description of participation rates and attrition from 
the trial using a consort flow diagram and concludes with participant demographic, 
clinical and psychosocial characteristics at baseline, along with analysis to explore 
differences between trial arms at baseline. It concludes with a comparison between 
the study sample and other available literature with the aim of assessing sample 
representativeness. 
6.2 PARTICIPATION RATES 
6.2.1 Enrolment 
Three hundred and one patients were assessed for eligibility within the recruitment 
period (Figure 6.1). Seventy-four (24.58%) of these were not eligible to take part in the 
trial as they did not meet the inclusion criteria; therefore, 227(75.42%) patients were 
approached to take part. A total of 128(63.05%) gave their consent and were 
randomised into the trial. One (0.49%) participant was already taking part in another 
study which meant they were unwilling to take part in this trial and of the 99(48.77%) 
patients who did not consent the most frequently reported reasons for refusal were 
too busy to participate (n=58, 59.09%), a preference to see their rheumatology face-to-
face (n=31, 31.82%) and two participants felt they were already able to monitor their 
blood tests and did not see the advantage of taking part in the trial (9.09%).  
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Figure 6.1. Consort flow diagram for RCT 
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6.2.2 Allocation 
Of the 128 patients who were randomised, 16(12.50%) failed to complete a baseline 
questionnaire, 9(7.03%) failed to attend the intervention training session despite 
repeated reminders and 3(2.34%) participants were no longer eligible to take part in 
the trial, as they either changed their medication prior to attending the training 
session (n=2) or were found to be monitored by their GP (n=1). A total of 100 
participants, therefore, received their allocated group, 52(85.54%) in the intervention 
arm and 48(73.85%) in the control arm and entered the trial. 
 
In order to explore whether there were any differences in demographic and clinical 
data between those who did (n=100) and did not receive their allocated group (n=28) 
and the interaction with trial arm a series of factorial ANOVA and factorial logistic 
regressions were performed. As participants at this stage of the trial had not 
completed any of the self-report questionnaires or assessments of disease activity the 
only available data were those that could be accessed via the electronic patient 
records (i.e. age, gender, diagnosis, total number of co-morbidities, total number of 
prescribed medications and dose of methotrexate) along with the arm of the trial they 
were allocated to.  
 
Table 6.1. Factorial ANOVAS - trial arm by receipt of allocation (df=1, 128) 
  Trial arm Receipt of 
allocation 
Trial arm*Receipt of 
allocation 
Variable F p F p F p 
Age 3.27 0.07 14.77 <0.001 0.12 0.73 
No. of comorbidities 0.57 0.45 1.04 0.31 0.28 0.60 
No. of ŵediĐatioŶs† 0.19 0.66 0.01 0.92 0.01 0.91 
Dose of methotrexate 0.21 0.65 0.12 0.73 1.22 0.27 
ANOVA – analysis of covariance 
†Ŷot iŶĐludiŶg ŵethotƌeǆate 
 
There were no significant differences in age, total number of co-morbidities or 
medications or dose of methotrexate between participants randomised to the 
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intervention and control group (pшϬ.ϬϳͿ aŶd Ŷo sigŶifiĐaŶt iŶteƌaĐtioŶ effeĐts ďetǁeeŶ 
trial arm and receipt of allocated group (pшϬ.ϮϳͿ ;Table 6.1). Two factorial logistic 
regressions also indicated no significant association between trial arm, receipt of 
allocation and gender (2=8.48, p=0.04) or diagnosis (2=5.49, p=0.14). Those who did 
receive their allocated group were however, significantly older (M=56.71, S.D=11.82, 
n=100) than and those that did not (M=47.07, S.D=14.54, n=28; F1,128=14.77, p=0.0001) 
(Figure 6.2). These results should however, be interpreted with caution as number of 
participants who did not receive their allocated intervention was small in comparison 
to those who did; therefore, breaking one of the assumptions of a factorial ANOVA, 
equal sample sizes in each cell.  
 
 
Figure 6.2. Plot of mean age by trial arm and receipt of allocation 
 
6.2.3 Follow-up 
Of the 100 participants who received their allocated group, and, therefore, completed 
a baseline questionnaire, a proportion failed to complete one or both of the follow-up 
questionnaires. Of the 52 participants who received the intervention 10(19.23%) failed 
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to complete either the first follow-up questionnaire (n=1) or both the first and final 
follow-up questionnaires (n=9). Of the 48 participants who were allocated to the usual 
care control group 12(25.00%) failed to complete either the final questionnaire (n=6) 
or both follow-up questionnaires (n=6). See consort diagram in Figure 6.1. 
 
Analyses were performed on an ITT basis (n=100) and repeated in complete cases only 
(n=79). Healthcare utilisation and clinical variables continued to be collected for the 21 
participants who did not complete a follow-up questionnaire, using electronic patient 
records. Therefore, all 100 participants are included in the analysis of these outcomes. 
As analysis of the questionnaire data used MLM which allows inclusion of participants 
with missing time points the analysis included all 100 participants.  
 
Eight-five (85.00%) participants returned the baseline questionnaire and at least one 
follow-up questionnaire, 82.69% of the intervention group (n=43) and 87.50% of the 
control group (n=42). A chi squared test for independence indicated no significant 
difference between the intervention and control group on the number of participants 
who completed all three time points, 2(1, n=100)=0.20, p=0.65, =0.05.  
 
This resulted in a total of 79(79.00%) participants who returned all administrations 
(known as complete cases), 80.77% (n=42) of the intervention group and 77.08% 
(n=37) of the control group. Analyses comparing complete cases (n=79) with non-
complete cases (n=21) on all continuous demographic characteristics, pre-trial blood 
test results and baseline psychosocial variables also indicated no significant differences 
(pшϬ.ϬϭͿ ďetǁeeŶ the tǁo gƌoups oŶ aŶǇ ǀaƌiaďles ;Appendix U).  
6.3 DATA ASSUMPTIONS 
6.3.1 Internal reliability and validity 
CƌoŶďaĐh͛s alphas iŶdiĐated good iŶteƌŶal ƌeliaďilitǇ foƌ all sĐales at all thƌee tiŵe 
points (Appendix V). Exceptions to this were the IPQ-R treatment control subscale and 
the BMQ specific concern subscale. Deletion of one item from each scale increased the 
CƌoŶďaĐh͛s alpha to gƌeateƌ thaŶ Ϭ.ϲϮ. Theƌefoƌe, these scales were re-calculated 
removing the least reliable items at each of the three time points (Table 6.2). 
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Table 6.2. Measures with poor internal reliability 
Variable Total no. of items Cronbach's alpha Item removed Cronbach's alpha 
Baseline First f/u Final f/u Baseline First f/u Final f/u 
IPQ-R Treatment 
Control 
5 0.48 0.57 0.54 My treatment will be 
effective in curing my RA 
(Item 14) 
0.65 0.71 0.62 
BMQ Specific Concern 5 0.63 0.68 0.70 My methotrexate is a 
mystery to me (Item 6) 
0.67 0.75 0.71 
IPQ-R – Illness Perceptions Questionnaire Revised; BMQ – Beliefs about Medicines Questionnaire; RA – Rheumatoid Arthritis; f/u – follow-up 
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A paired-sample t-test ǁas peƌfoƌŵed ĐoŵpaƌiŶg paƌtiĐipaŶt͛s sĐoƌes oŶ the IPQ-R 
symptoms experienced subscale and the IPQ-R identity subscale. This analysis 
indicated a significant difference between the symptoms patients experienced 
compared to those they associated with their arthritis with the exception of pain, 
fatigue, stiff joints and loss of strength providing support for the conceptual difference 
between somatisation and identity (Table 6.3). As instructed in the guidelines for the 
scale the identity items are used in subsequent analyses (Moss-Morris et al., 2002).  
 
All the symptoms were endorsed by a percentage of the patients, confirming the 
validity of the range of symptoms included in the subscale. Pain was the most 
frequently endorsed symptom, 97% of participants identified it as a symptom specific 
to their arthritis at baseline, 96.3% at the first follow-up and 97.4% at the final follow-
up. Fatigue, stiff joints and loss of strength were also endorsed by at least 68(68%) 
participants at each time point. Wheeziness (17%) and weight loss (27%) were 
endorsed by the fewest number of participants at each of the three time points.  
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Table 6.3. Paired samples t-test for IPQ-R symptoms experienced and IPQ-R identity subscales 
Symptom 
Baseline First follow-up Final follow-up 
M(SD) Statistical test M(SD) Statistical test M(SD) Statistical test 
Pain 0.02(0.20) t(98)=1.00, p=0.32 0.05(0.22) t(79)=2.04, p=0.05 0.04(0.19) t(77)=2.04, p=0.08 
Sore throat 0.38(0.49) t(93)=7.60, p<0.001 0.26(0.49) t(80)=4.72, p<0.001 0.33(0.47) t(77)=2.04, p<0.001 
Nausea 0.19(0.40) t(92)=4.70, p<0.001 0.15(0.39) t(79)=3.41, p=0.001 0.16(0.40) t(76)=2.04, p=0.001 
Breathlessness 0.19(0.39) t(94)=4.69, p<0.001 0.16(0.40) t(81)=3.59, p<0.001 0.14(0.35) t(76)=2.04, p=0.001 
Weight loss 0.13(0.42) t(95)=2.94, p<0.001 0.12(0.33) t(80)=3.36, p=0.001 0.12(0.33) t(75)=2.04, p=0.002 
Fatigue 0.09(0.33) t(96)=2.81, p=0.01 0.14(0.35) t(82)=3.72, p<0.001 0.10(0.31) t(77)=2.04, p=0.004 
Stiff joints 0.02(0.20) t(97)=1.00, p=0.32 0.04(0.19) t(81)=1.75, p=0.08 0.03(0.16) t(78)=2.04, p=0.16 
Sore eyes 0.20(0.40) t(94)=4.85, p<0.001 0.15(0.39) t(81)=3.41, p=0.001 0.15(0.36) t(78)=2.04, p<0.001 
Wheeziness 0.15(0.36) t(92)=4.04, p<0.001 0.11(0.32) t(80)=3.16, p=0.002 0.17(0.38) t(76)=2.04, p<0.001 
Headaches 0.29(0.46) t(93)=6.12, p<0.001 0.28(0.45) t(79)=5.47, p<0.001 0.41(0.50) t(77)=2.04, p<0.001 
Upset stomach 0.20(0.41) t(92)=4.86, p<0.001 0.23(0.45) t(79)=4.48, p<0.001 0.29(0.46) t(74)=2.04, p<0.001 
Sleep difficulties 0.21(0.46) t(95)=4.47, p<0.001 0.27(0.45) t(81)=5.45, p<0.001 0.19(0.40) t(76)=2.04, p<0.001 
Dizziness 0.14(0.35) t(92)=3.87, p<0.001 0.14(0.35) t(79)=3.55, p=0.001 0.19(0.40) t(77)=2.04, p<0.001 
Loss of strength 0.07(0.33) t(97)=2.15, p=0.03 0.08(0.28) t(82)=2.75, p=0.01 0.09(0.33) t(78)=2.04, p=0.02 
IPQ-R – Illness Perceptions Questionnaire Revised; M – Mean; SD – Standard Deviation 
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6.3.2 Normality, linearity and homodasticity 
Inspection of the histograms and Q-Q plots, for the whole sample and within trial arms 
and time points, indicated a more normally distributed population than the Shapiro-
Wilk statistic suggested (p<0.001). Appropriate transformation methods failed to alter 
the most significantly skewed variables; the Shapiro-Wilk test for normality remained 
significant (p<0.001). Transformed variables were not retained as it was reasonable to 
assume some level of non-normality in the population and because transformations 
introduce complexity and confusion in the interpretations of results. This does 
however, mean that statistical inferences become less robust as distributions depart 
more from normality. There are no non-parametric alternatives to multi-level 
modelling and hence these analyses were used despite data being non-normal.  
6.4 PARTICIPANT CHARACTERISTICS 
6.4.1 Demographic characteristics 
The demographic characteristics of the sample can be found in Table 6.4. The 
intervention and control groups did not differ significantly on any of these variables 
and the effect sizes were all small (<0.02). The total sample consisted of 55 females 
and 45 males, with similar proportions in each trial arm. The age of participants ranged 
from 27 to 84 years. Most participants were married or living with their partner and 
identified themselves as being of white ethnicity.
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Table 6.4. Demographic characteristics at baseline 
Variable Total n=100 Intervention n=52 Control n=49 Statistical test 
Age, mean(SD) 56.71(11.82) 54.83(11.22)  58.75(12.22)  t(98.00)=-1.67, p=0.09, 2=0.03 
Female, n(%) 55(55.00) 24(46.15) 31(64.58) 2(1, n =100)=2.72,  p=0.10, =0.19 
Living status, n(%) 
Married or living with partner 
Living alone 
Living with friends or family 
  
70(70.00) 
18(18.00) 
12(12.00) 
  
37(71.15) 
8(15.38) 
7(13.46) 
  
33(68.75) 
10(20.83) 
5(10.42) 
 2(1, n =100)=0.63,  p=0.73, =0.08 
EthŶiĐitǇ,† Ŷ;%Ϳ 
White 
Indian 
Other 
Black-African 
Black-Caribbean 
Chinese 
 
89(89.00) 
4(4.00) 
4(4.00) 
1(1.00) 
1(1.00) 
1(1.00) 
 
46(88.46) 
2(3.85) 
3(5.77) 
0(0.00) 
1(1.92) 
0(0.00) 
 
43(89.58) 
2(4.17) 
1(2.08) 
1(2.08) 
0(0.00) 
1(2.08) 
 
 
 2(1, n =100)=<0.001, p=1.00,=0.02 
SD – Standard Deviation 
†ĐoŵpaƌisoŶ ďetǁeeŶ ǁhite aŶd ŶoŶ-white due to small n 
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6.4.2 Clinical characteristics 
Table 6.5 details the clinical characteristics of the sample by trial arm with the 
associated significance test. There were no significant group differences between the 
intervention and control group on any of these variables (p>0.01). 
 Disease and treatment history 
A majority of the sample had RA and had been living with their diagnosis for between 1 
and 54 years. Thirty-seven per cent of the sample was living with at least one co-
morbidity. The most frequently reported co-morbid conditions were: hypertension 
(14%), hypercholesterolemia (13%), hyperthyroidism (6%) and osteoporosis (6%). The 
medications most frequently prescribed to participants in addition to methotrexate 
were: folic acid (73%), sulphasalazine (27%), diclofenac (22%), hydroxychloroquine 
(20%), adalimumab (17%) and etanercept (14%).  
 Current disease status 
For those with RA, DAS28 scores indicated average to moderate disease activity at 
baseline. There was however, noticeable variation in this with 19(24.05%) participants 
in remission, 13(16.46%) with low disease activity, 33(41.77%) moderate and 6(7.59%) 
high disease activity. These percentages, however, did not differ between the 
intervention and control group (2(1, n =79)=2.70, p=Ϭ.ϰϱ, Cƌaŵeƌ͛s V=Ϭ.ϭϵͿ. Disease 
activity for patients with PsA was low, comparisons between the intervention and 
control group on swollen joints although not statistically significant did have a medium 
to large effect size but clinically the difference of one swollen joint between the trial 
arms was not considered meaningful.   
 Laboratory tests 
The results of the baseline blood tests can be found in Table 6.6 (page 242). A series of 
independent sample t-tests and Mann-Whitney U tests indicated no significant 
differences between the intervention and control group at baseline (p>0.01) with all 
mean and median levels within the normal recommended ranges according to criteria 
outlined in Table 5.3 (page 201).  
  
2
4
0
 
Table 6.5. Clinical characteristics at baseline  
Variable Total   n=100 Intervention  n=52 Control n=48 Statistical test 
Disease type, n(%) 
Rheumatoid arthritis 
Psoriatic arthritis 
  
71(71.00) 
29(29.00) 
  
33(63.46) 
19(36.54) 
  
38(79.17) 
10(20.83) 
2(1, n =100)=2.28, p=0.13,=0.17 
Disease duration in years, median(range) 8(1-54) 8(1-40) 6(1-54) U=1222.75, z=-0.17, p=0.86, r=0.02 
No. of years on methotrexate, median(range) 4(1-20) 4(1-20) 3.85(1-13) U=1205.00, z=-0.30, p=0.77, r=0.03 
Dose of methotrexate, median (range) 15(5-25) 15(5-22.5) 15(5-25) U=11.29.50, z=-0.83, p=0.40, r=0.08 
No. of medications, median(range)ǂ 4(1-11) 4(1-10) 5(2-11) U=1170.00, z=-0.55, p=0.59, r=0.06 
Co-morbidities, n(%) 
Hypertension 
Hypercholesterolemia 
Hyperthyroidism 
Osteoporosis 
Diabetes 
Respiratory 
  
14(14.00) 
13(13.00) 
6(6.00) 
6(6.00) 
4(4.00) 
3(3.00) 
  
9(17.31) 
8(15.38) 
2(3.85) 
2(3.85) 
2(3.85) 
1(1.92) 
  
5(10.42) 
5(10.42) 
4(8.33) 
4(8.33) 
2(4.17) 
2(4.17) 
2(1, n =100)=0.98, p=0.39, =0.10 2(1, n=100)=0.19, p=0.56, =0.07 
p=Ϭ.ϰϮ† 
p=Ϭ.ϰϮ† 
p=ϭ.ϬϬ† 
p=Ϭ.ϲϭ†
No. of comorbidities, n(%) 
None 
One or more 
  
63(63.00) 
37(37.00) 
  
35(67.31) 
17(32.69) 
  
28(58.33) 
20(41.67) 
2(1,n =100)=0.52, p=0.47, =0.09 
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Variable Total   n=100 Intervention  n=52 Control n=48 Statistical test 
DAS28, mean(SD) 3.33(1.27) 3.54(1.36) 3.19(1.23) t(69)=-1.15, p=0.27, 2=0.01 
PsARC 
Physician global assessment, median (range) 
Patient global assessment, median (range) 
Swollen joint count, median (range) 
Tender joint count, mean(SD) 
  
2(1-4) 
2(1-3) 
2(0-13) 
9.02(7.13) 
  
2(1-3) 
1(1-3) 
1(0-13) 
7.79(6.75) 
  
2(1-4) 
2(1-3) 
4(1-10) 
11.34(7.49) 
  
U=75.1, z=-0.98, p=0.39, r=0.18 
U=45.6, z=-0.38, p=0.04, r=0.07 
U=39, z=-2.61, p=0.02, r=0.48 
t(27)=1.29, p=0.24, 2p=0.02 
Fatigue, mean(SD) 4.27(2.66) 4.19(2.69) 4.35(2.65) t(98)=-0.31, p=0.76, 2p=0.001 
Pain, median(range) 3(0-9) 3(1-9) 3(0-9)  U=1226.60, z=-0.15, p=0.88, r=0.01 
Functional Disability, median(range) 0.41(0-0.22) 0.40(0-0.22) 0.46(0-0.22) U=1196.30, z=-0.36, p=0.72, r=0.04 
SD – Standard Deviation; DAS28 – Disease Activity Scores -28; PsARC – Psoriatic Arthritis Response Criteria 
† Fisheƌ͛s EǆaĐt PƌoďaďilitǇ test as the eǆpeĐted fƌeƋueŶĐǇ assuŵptioŶ ǁas ǀiolated; ǂ not including methotrexate 
U = Mann-Whitney test; T=independent samples t-test 
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Table 6.6. Laboratory results for the whole sample (n=100) and by trial arm at baseline 
 Variable 
Recommended 
range Total n=100 Intervention n=52 Control n=48 Statistical test 
Haemoglobin, mean(SD) 12.0 – 17.0 13.66(1.32) 13.91(1.25) 13.40(1.36) t(98)=1.93, p=0.05, 2=0.04 
WBC, mean(SD) 3.0 - 10.0 6.74(1.69) 6.79(1.86) 6.69(1.50) t(98)=0.28, p=0.78, 2=0.001 
Neutrophils, median(range) 2.0 – 7.5 3.73(1.35-8.7) 3.75(2.13-8.7) 3.74(1.35-6.20) U=1160.95, z=-0.60, p=0.56, r=-0.06 
Platelets, median(range) 150 - 400 248.90(130-510) 237(130-372) 260.55(183-510) U=880.20, z=-2.54, p=0.01, r=-0.25 
ALP, mean(SD) 35-104 72.09(20.03) 73.13(22.57) 70.96(17.03) t(94.38)=0.55, p=0.59, 2 =0.003 
ALT, median(range) 10-35 24.55(9-90) 25.5(9-90) 22.80(14-71) U=1131.75, z=-0.80, p=0.43, r=-0.08 
ESR, median(range) 0 – 20 9(4-58) 8(4-58) 11.15(4-56) U=1085.20, z=-1.13, p=0.26, r=-0.11 
CRP, median(range) 0 - 5 2.78(0.6-33.30) 3.2(0.6-33.30) 2.66(0.6-20.4) U=1223.35, z=-0.17, p=0.87, r=-0.02 
SD – Standard Deviation; WBC – White Blood Count; ALP - Alkaline Phosphatase; ALT - Alanine Transaminase; ESR - Erythrocyte Sedimentation Rate; CRP - C-Reactive Protein 
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6.4.3 Psychosocial outcome variables 
Mean scores on each of the psychosocial variables at baseline can be found in Table 
6.9. A series of independent samples t-tests and Mann-Whitney U tests indicated no 
significant differences between the intervention and control group on any of these 
variables (p>0.01) and small effect sizes. Examination of the proportion of patients 
with normal, moderate and clinical anxiety and depression at baseline indicated that 
86% of the sample was experiencing either normal or moderate levels of anxiety at the 
beginning of the trial and 14% were assessed to be clinically anxious (Table 6.7). The 
proportions did not differ significantly between the intervention and control group 
(2(2, n=100)=2.14, p=0.35). Although the effect size did indicate a medium effect 
(=0.35).  
 
Table 6.7. Proportion of sample with normal, moderate and clinical levels of anxiety at 
baseline 
 Group Total n=100 Intervention n=52 Control n=48 
Normal, n(%) 68(68.00) 36(69.23) 32(66.67) 
Moderate, n(%) 18(18.00) 11(21.15) 7(14.58) 
Caseness, n(%) 14(14.00) 5(9.62) 9(18.25) 
 
Ninety-one percent of the sample was experiencing either normal or moderate levels 
of depression and 9% clinical depression (Table 6.8). The proportions did not differ 
significantly between trial arms (2(2, n=100)=0.95, p=0.62). The effect size however, 
was large (=0.62). Two participants were experiencing clinical levels of both anxiety 
and depression (2.0%), one participant in each of the trial arms.  
 
Table 6.8. Proportion of sample with normal, moderate and clinical levels of 
depression at baseline 
 Group Total n=100 Intervention n=52 Control n=48 
Normal, n(%) 82(82.00) 41(78.85) 41(85.42) 
Moderate, n(%) 9(9.00) 5(9.62) 4(8.33) 
Caseness, n(%) 9(9.00) 6(11.54) 3(6.25) 
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Table 6.9. Scores on the psychosocial outcome variables for the whole sample and by trial arm at baseline 
 Variable Possible score Total n=100 Intervention n=52 Control n=48 Statistical significance 
SF-12v1® MCS, mean(SD) 0-100 30.72(5.52) 30.17(6.22) 31.32(4.62) t(98)=-1.03, p=0.30,  2=0.01 
SF-12v1® PCS, mean(SD) 0-100 45.98(9.38) 46.51(9.71) 45.41(9.08) t(98)=0.57, p=0.57,  2=0.003 
Anxiety, median(range) 0-21 5.25(0-17) 5.75(0-16) 5.00(1-17) U=1167.30, z=-0.56, p=0.58, r=0.06 
Depression, median(range) 0-21 3.75(0-12) 4(0-12) 3(0-11) U=1168.55, z=-0.55,   p=0.58, r=0.06 
SD – Standard Deviation; MCS – Mental Component Scores; PCS – Physical Component Scores 
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6.4.4 Psychosocial process variables 
Central tendency scores on each of the psychosocial process variables at baseline can 
be found in Table 6.10. A series of independent samples t-tests and Mann-Whitney U 
tests indicated no significant differences between the intervention and control group 
on any of these variables and small effect sizes. 
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Table 6.10. Central tendency scores on the psychosocial process variables at baseline for the whole sample and by trial arm 
 Variable 
Possible 
score Total n=100 Intervention n=52 Control n=48 Statistical significance 
Generalised self-efficacy, mean(SD) 10-40 31.80(3.78) 31.79(3.79) 31.82(3.80) t(98)=-0.04, p=0.97, 2<0.001 
HeiQ™ “elf-monitoring & insight, mean(SD) 1-4 3.07(0.42) 3.00(0.41) 3.15(0.41) t(98)=-1.81, p=0.07, 2=0.03 
MeiQ™ AĐtiǀe CoŵŵuŶiĐatioŶ, ŵediaŶ;ƌaŶgeͿ 1-6 5(1-6) 5(2.5-6) 5.25(1-6)  U=1204.00, z=-0.31, p=0.75, r=0.03  
MeiQ™ “elf-management ability, 
median(range) 
1-6 4.83(2.5-6) 4.67(2.5-6) 4.92(3-6)   U=1061.50, z=-1.29, p=0.20, r=0.13  
IPQ-R Identity, mean(SD) 0-12 5.19(2.31) 5.23(2.13) 5.15(2.51) t(98)=0.18, p=0.85, 2=0.0003 
IPQ-R Consequences, mean(SD) 6-30 19.87(4.66) 19.69(4.78) 20.07(4.57) t(98)=-0.40, p=0.69, 2=0.002 
IPQ-R Personal control, mean(SD) 6-30 20.86(4.22) 20.70(4.13) 21.03(4.34) t(98)=-0.39, p=0.70, 2=0.002 
IPQ-R Treatment Control, mean(SD) 5-25 15.82(2.21) 15.66(2.17) 15.98(2.26) t(98)=-0.71, p=0.48, 2=0.01 
IPQ-R Illness Coherence, mean(SD) 5-25 18.73(4.35) 18.54(4.35) 18.93(4.38) t(98)=-0.45, p=0.66, 2=0.002 
BMQ Specific Concern, mean(SD) 5-25 12.33(2.90) 12.13(2.83) 12.54(2.99) t(98)=-0.69, p=0.49, 2=0.01 
BMQ Specific Necessity, mean(SD) 5-25 16.65(2.94) 16.13(2.96) 17.20(2.86) t(98)=1.83, p=0.07, 2=0.03 
Treatment burden, median(range) 1-5 2(1-5) 2(1-5) 1.75(1-4)  U=1043.60, z=-1.47, p=0.14, r=0.15 
Knowledge about methotrexate, mean(SD) 8-57 18.16(4.74) 18.37(4.73) 17.94(4.78) t(98)=0.45, p=0.65, 2=0.002 
SD – StaŶdaƌd DeǀiatioŶ; HeiQ™ – Health EduĐatioŶ IŵpaĐt QuestioŶŶaiƌe; MeiQ™ – Medication Education Impact Questionnaire; IPQ-R – Illness Perceptions Questionnaire 
Revised; BMQ – Beliefs about Medicines Questionnaires  
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6.5 DISCUSSION 
6.5.1 Acceptability of the intervention 
The acceptability of an intervention can be assessed in a number of ways including the 
ability to consent patients into a trial, reasons for refusal, along with rates of attrition. 
In the current study all methods were utilized. Overall it would be expected that a ͞one 
size fits all͟ approach is not appropriate (Trappenburg et al., 2013) and consideration 
must be made for those who would prefer the more traditional model of care. 
 
Refusing to participate may be a rejection of research in general or a rejection of the 
intervention itself. This may not only be because the intervention is not acceptable to 
the participant but the threat of being randomized to a non-preferred group may not 
be acceptable and, therefore, the participant refuses to take part. In addition some 
participants may not wish to experience a perceived disruption to their care. In 
common with all studies that require consent the sample recruited may not be 
representative of the population under examination. This would compromise the 
external validity of the findings (Britton et al., 1999). It can however, be difficult to 
disentangle the true reasons for rejection.  
 
Over 40% of patients receiving rheumatology services feel they should be able to 
decide how frequently they need a check-up (Neame et al., 2005) and take 
responsibility for organizing their own DMARD monitoring appointments (Kay & 
Lapworth, 2004). The 63% participation rate in this trial suggests that in practice more 
patients may be willing to take on these responsibilities. This rate is similar to the 68% 
reported in the trial of shared care by Hewlett et al., (2000, 2003, 2005b) but greater 
than the 26% in the shared-care trial by Primdahl et al., (2012; 2014). The participation 
rates found within this trial also reflect the findings of Garcia-Alamino et al., (2010) 
who reviewed the literature on self-monitoring in thrombophilia and found that the 
average proportion of patients that could or would take part in the trials was 68% 
(range 31-88%). These figures are also comparable to van der Vaart, Drossaert, Taal 
and van de Laar (2011) who found that 68% of patients with arthritis would like access 
to their electronic patient records, 63% would be interested in performing online 
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symptom monitoring with their care provider and 51% would be interested in 
autonomous symptom monitoring.  
 
Due to ethical constraints in accessing patient data, an analysis comparing the 
characteristics of those who did and did not consent was not possible. The patients 
approached did however, provide reasons for refusal. The primary reason was a 
peƌĐeptioŶ of ďeiŶg ͞too ďusǇ͟ to paƌtiĐipate. It is uŶĐleaƌ if this ǁas due to the 
perceived demands of being in a research study or because of the nature of the 
intervention. Trials of self-management interventions in rheumatology have also found 
that patients report being too busy as reason for non-participation (Yip et al., 2007; 
Bair et al., 2009; Wu, Kao, Wu, Tsai, & Chang, 2011). It may be reasonable to think that 
this model of care could be burdensome to time but as opposed to the disease 
management skills learnt in generalised self-management programmes this 
intervention specifically aimed to reduce the time burden of attending clinic visits. On 
reflection the potential for patients to save time in the long-term by taking part in the 
intervention could have been emphasised more in the recruitment process. The design 
and provision of future models of care in rheumatology, therefore, need to consider 
the intensity of patient involvement and the time required of patients in order to 
increase acceptability of services to the patient.   
 
Thirty-two percent of the patients approached to take part in the trial declined to 
participate because they preferred to attend the outpatient clinic to see their 
rheumatology CNS face-to-face. This was also reported as a reason for refusal in the 
trial by Primdahl et al., (2012; 2014), which evaluated a shared care approach between 
the patient and general practice but far exceeds the rate reported by Hennell et al., 
(2005) who found that 8% of patients preferred to see their nurse in person although 
this was in comparison to a nurse-led rheumatology telephone clinic. The increased 
level of involvement and the additional responsibility for self-monitoring blood tests in 
this trial may explain this difference. Refusal to participate in trials that increase 
patient involvement in healthcare have been linked to a reluctance to disrupt services 
and relationships that are working well and are highly valued (Sanders et al., 2012) 
which may go some way in explaining the rates found within the current trial.  
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Many of the patients who refused on this basis also spoke about their own ability to 
self-monitor and the concern they had about their numeracy skills. Although these are 
anecdotal data it is reasonable to assume that the perceived intellectual requirements 
of this model of care, and in particular numeracy skills, may have influenced an 
iŶdiǀidual͛s likelihood of paƌtiĐipatiŶg. Theƌe is a peƌĐeptioŶ that patieŶts ǁith pooƌeƌ 
literacy or numeracy skills may have difficulty interpreting and acting on abstract or 
complex health information related to their chronic illness (Ad Hoc Committee on 
Health Literacy for the Council on Scientific Affairs & American Medical Association, 
1999). Recent evidence in diabetes suggests that despite low health literacy and 
numeracy being related to poor knowledge there is little sufficient or consistent 
evidence to suggest a link between literacy or numeracy skills and diabetes self-care, 
including self-monitoring and clinical outcomes (Al Sayah, Majumdar, Williams, 
Robertson, & Johnson, 2013). The inclusion criteria of this trial did not specify a 
particular level of literacy or education. 
 
Attrition is another indication of intervention acceptability. Of the 128 participants 
who were consented into the study, 22% did not proceed onto the trial. In a majority 
of cases this was because, despite reminders, participants either failed to complete a 
baseline questionnaire or did not attend the intervention training session. Although 
participants had already consented into the trial, these drop outs also reflect 
participants declining to take part in the trial, as they were yet to receive their 
allocated intervention. The analysis suggested that those who did not receive their 
allocated intervention were significantly younger than those that did. This is in 
opposition to both Hogg et al., (1997) and Primdahl et al., (2012; 2014) who found that 
those who declined to participate in an evaluation of a shared cared approach to 
rheumatology services were significantly older than those who took part in the trial. In 
the trial by Hewlett et al., (2000) attrition was linked to greater disease activity and 
disability. Although levels of functional disability were not available for those who did 
not receive their allocated intervention in the current trial, the overall level of 
functional disability was significantly lower than that found within the trial by Hewlett 
et al., (2000) possibly indicating the population as a whole were less disabled.  
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The dropout of younger participants in the current trial also supports the notion that 
the perceived requirements of taking part in the research and/or intervention placed 
additional time demands on younger patients who may be more likely to be working 
than their older counterparts. In the design of the trial consideration was given to 
delivering the education training session at times outside of working hours, which 
aimed to provide an opportunity, for patients who would otherwise be unable to 
attend due to work commitments, to participate. As randomisation was undertaken 
prior to the collection of baseline data it was not possible to include these participants 
in any subsequent analysis. Although this means the integrity and validity of the ITT 
analysis is somewhat threatened, the drop-out rate was equal across the trial arms. 
The decision was taken during the design of the trial to randomise prior to baseline 
assessment in order for participants randomised to the intervention group to be 
allocated to a particular training session. It was felt that commitment to a particular 
session at the time of consenting would reduce drop-outs from the intervention group. 
This was not necessarily the case given that 9(7.03%) intervention participants did not 
attend the training session.  
 
Of the 100 participants who received their allocated intervention, 15% did not 
complete one of the follow-up questionnaires. Other patient-initiated services in 
rheumatology and systematic reviews of self-monitoring interventions report similar 
dropout rates (Hewlett et al., 2000; Jaana et al., 2007; Turnock et al., 2005; Clark et al., 
2007; Polisena et al., 2010), whilst some have dropout rates as low as 5% (Primdahl et 
al., 2014; Inglis et al., 2010). It is reassuring however, that there were no significant 
difference in demographic characteristics, pre-trial blood test results or baseline 
psychosocial variables between those who did not complete both follow-up 
questionnaires and those who did, particularly as other trials of self-monitoring 
intervention have found that patients who withdraw during or after training tended to 
be older and female (Connock et al., 2007). Due to these dropouts, however, the study 
did not achieve the planned numbers and was, therefore, not adequately powered to 
find an effect.  
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6.5.2 Representativeness of the study sample 
Baseline differences between the intervention and control group on all measures 
suggest no significant differences; therefore, indicating that randomisation of 
participants was successful.  
 Demographic characteristics 
In terms of the demographic composition of the study population, overall the sample 
was similar to that of the general arthritis population and to other evaluations of 
patient-initiated services in arthritis. Although the higher proportion of females found 
within this trial is typical of the population, the actual percentage is lower than that of 
the general UK arthritis population (Humphreys et al., 2012) and those recruited to 
other intervention studies, which report approximately 65-74% of the population being 
female (Primdahl et al., 2014; Hewlett et al., 2000; Sands & Adams, 2009), as opposed 
to the 55% found within the current trial. Although some intervention studies have 
recruited older patients with arthritis (Primdahl et al., 2014) the current study is 
comparable to other trials of patient-initiated services in regards to age (Hewlett et al., 
2000; Mitchell et al., 2001; Hewlett et al., 2005b; Sands & Adams, 2009). The ethnic 
composition of study samples is often not reported in intervention trials, this may 
reflect a bias towards white participants. The current study demonstrates a more 
ethnically diverse sample than the general intercity UK rheumatology population 
(MacGregor, Riste, Hazes, & Silman, 1994) but does more closely represent the London 
Borough of Camden in which the site of recruitment is located (Greater London 
Authority, 2012). The living status of participants was also found to be comparable to 
other trials (Primdahl et al., 2014). 
 Clinical characteristics 
Overall the clinical status of participants in this trial was as expected of the general 
arthritis population and reflected other arthritis intervention studies, with some minor 
variations. The longer disease duration of 8 years reflected that of other trials of 
patient-initiated follow-up services (Hewlett et al., 2000; Kirwan et al., 2003b; Hewlett 
et al., 2005b; Primdahl et al., 2014) but these were all significantly longer than the trial 
conducted by Sands and Adams (2009) in which the average disease duration was 23-
26 months. A majority of the sample had no other co-morbidities which reflects the 
general arthritis population (Cumming, Stannett, & Hull, 2013) and those who take 
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part in trials of this nature (Primdahl et al., 2014). For those who did have another co-
morbidity the most frequently reported were hypertension and hypercholesterolemia. 
These proportions were significantly lower than prevalence rates reported for 
hypertension in the overall arthritis population (Panoulas et al., 2007) and are in fact 
more similar to those found within the general population (Standing, Deakin, Norman, 
& Standing, 2005; Boyer, Gourraud, Cantagrel, Davignon, & Constantin, 2011; Tolonen, 
Keil, Ferrario, Evans, & for the WHO MONICA Project, 2005).  
 
Levels of self-reported pain and fatigue vary in other trials of self-management and 
patient-initiated rheumatology services. When comparing the same visual numeric 
scale, self-reported pain and fatigue were slightly lower in the trials by Lorig et al., 
(2008) and Lorig, Ritter, Laurent and Plant (2008) of the ASMP, whereas comparisons 
with similar interventions but different measurement tools indicate either similar 
levels of pain (Hewlett et al., 2000; Kirwan et al., 2003b; Hewlett et al., 2005b) or 
greater levels of pain and fatigue (Primdahl et al., 2014). Levels of functional disability 
were slightly lower than that of the general arthritis population (ten Klooster, Taal, & 
van de Laar, 2008; Wolfe et al., 2004) and that reported in other patient-initiated trials 
(Hewlett et al., 2000; Kirwan et al., 2003b; Hewlett et al., 2005b) but higher than other 
trials of this nature (Primdahl et al., 2014). The sample were, therefore, fairly 
unremarkable on these measures.  
 Psychosocial well-being 
Baseline scores for the study sample on the SF-12v1® can be compared to US 1998 
normative data for healthy people (Ware et al.,2007), data from a psychometric 
evaluation of the measure in a population of patients with RA (Gandhi et al., 2001) and 
other trials of patient-initiated services (Primdahl et al., 2014). There are currently no 
UK normative data for this version of the SF-12v1®. With higher scores on the SF-12v1® 
indicating better quality of life, this suggests the physical quality of life of participants 
in this trial is almost the same of the healthy US population (Ware et al.,2007) and 
better than norms for patients with RA or PsA (Gandhi et al., 2001; Fernández-Sueiro 
et al., 2010). But despite being able to maintain their physical health quality of life 
participants in this trial were experiencing considerably impaired mental quality of life, 
significantly lower than US norms for both healthy participants (Ware et al.,2007) and 
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those with RA or PsA (Gandhi et al., 2001; Fernández-Sueiro et al., 2010). Scores were 
however, similar to other trials of shared care services in RA (Primdahl et al., 2014). 
 
The HADS is a widely used measure in patients with arthritis and, therefore, baseline 
scores in this trial can be compared to other trials of patient-initiated services and 
normative scores for the general arthritis population. Mean levels of anxiety were 
within one standard deviation of scores found within the trial of patient-initiated 
services by Hewlett et al., (2000; 2003b; 2005b), as were levels of depression. Similar 
scores have also been reported for participants entering trials of arthritis self-
management interventions (Buszewicz et al., 2006; Barlow et al., 2009). Mean levels 
and the proportion of participants with clinical levels of depression and anxiety also 
reflected the general RA and PsA populations (Covic et al., 2012; Cauli et al., 2011; 
Williamson et al., 2004). Higher scores on the anxiety and depression subscales of the 
HADS represented greater anxiety and depression; therefore, suggesting that patients 
with RA or PsA experience greater levels of anxiety and depression compared to the 
general population.  
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7. CHAPTE‘ ϳ – PATIENTS͛ ABILITY TO INITIATE CA‘E 
7.1 PROLOGUE 
As reported in Chapter 2 patient-initiated follow-up services have so far involved 
patients successfully understanding what symptoms and side effects should trigger 
contact with the rheumatology team. By integrating the interpretation of laboratory 
tests as additional triggers it was important to establish whether patients could be 
taught how to interpret these blood tests and use this information along with their 
symptoms and side effects to safely initiate care from the CNS. The following analyses 
includes only those participants randomised to the intervention group (n=52) 
7.2 DID INTERVENTION PARTICIPANTS INITIATE THEIR OWN CARE SAFELY? 
Receipt of the laboratory results triggered a series of decisions for intervention 
participants about their need to seek help from their CNS and initiate a telephone 
consultation. These decisions were made in relation to (i) laboratory tests and (ii) any 
associated symptoms and side effects that the patient recorded at the time of 
receiving these results. As described in section 5.7.6 (page 196) safety of help-seeking 
was assessed according to: 
 
a) Whether patients could safely decide if a telephone consultation was needed 
as a result of their laboratory results;  
b) Whether patients could safely decide if a telephone consultation was needed 
as a result of their symptoms and side effects.  
 
On each of the six occasions the decision was coded as: 
 
a) Safe either because:  The participant did not initiate a telephone consultation when either a 
laboratory result had remained the same and was within the normal 
range, or there was no new or change in symptoms or side effects. 
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 The participant initiated a telephone consultation when either a 
laboratory result had significantly changed or was outside the normal 
range, or there was a new or worsening symptom or side effect.  The participant initiated a telephone consultation when either a 
laboratory result had remained the same and was within the normal 
range, or there was no new or change in symptoms or side effects. 
b) Unsafe because the participant did not initiate a telephone consultation when 
either a laboratory result had significantly changed or was outside the normal 
range, or there was a new or worsening symptom or side effect. 
 
Across the entire trial period 77% of all decisions made in response to laboratory 
results were safe and 23% were unsafe (Figure 7.1). On average participants made 
unsafe decisions in response to laboratory results on 23.94% of occasions. Three 
(5.77%) participants were in phase one of the trial for an addition 2 or 3 blood tests as 
they were unable to correctly interpret two of their first three blood tests within the 
trial. They did however, manage to interpret two consecutive blood tests after this 
point and entered phase two of the trial. An additional 2(3.84%) participants were 
removed from the trial in phase one of the trial for safety reasons as they were 
deemed unable to self-monitor their laboratory results safely. These two participants 
were in the trial for four and five blood tests respectively and despite receiving the 
same training and feedback as other intervention participants they were unable to 
accurately initiate care on any of these occasions.  
 
In response to symptoms and side effects 73% of decisions across the entire trial 
period were deemed safe and 27% unsafe (Figure 7.2). On average participants made 
unsafe decisions in response to their symptoms and side effects on 29.95% of 
occasions.   
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Figure 7.1. Safety of participant decision making in relation to laboratory results. 
 
 
Figure 7.2. Safety of participant decision making in relation to symptoms and side 
effects. 
 
7.3 DID SAFETY OF HELP-SEEKING IMPROVE OVERTIME?  
Statistically significant effects for time were found in regards to laboratory results 
(F1,278=9.24, p=0.003) and for symptoms and side effects (F1,278=5.00, p=0.03) (Table 
7.1), iŶdiĐatiŶg that paƌtiĐipaŶts͛ aďilitǇ to safely initiate care from their CNS improved 
significantly over time.  
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Table 7.1. Estimates of the fixed effects for safe decision making overtime in the 
intervention group 
Model term β SE t p Eǆp;βͿ ϵϱ% CI for Eǆp;βͿ 
Laboratory results 
Intercept 
Time  
0.44 
0.24 
0.28 
0.08 
1.57 
3.04 
0.12 
0.003 
1.56 
0.27 
0.90, 2.71 
1.09, 1.48 
Symptoms and side-effects 
Intercept 
Time 
0.27 
0.20 
0.29 
0.09 
0.92 
2.24 
0.36 
0.03 
1.30 
1.22 
0.74, 2.30 
1.02, 1.45 
SE – Standard Error; CI – Confidence Interval 
 
7.4 WHAT ARE THE BASELINE PREDICTORS OF SAFE HELP-SEEKING? 
In order to explore whether any of the demographic, clinical or psychosocial variables 
were associated with the number of safe decisions made within the trial period 
Poisson regressions were performed using the forward selection algorithm (Famoye & 
Rothe, 2003) described in section 5.11.8.3 (page 218).  
 
The final model in the Poisson regressions revealed a significant effect for age, co-
ŵoƌďiditǇ aŶd the MeiQ™ suďsĐales of self-management ability and active 
communication (Table 7.2 and Table 7.3). The models were identical for decision 
making in relation to laboratory tests and decision making in relation to symptoms and 
side effects. The eǆpoŶeŶtiated β statistiĐ iŶdiĐated that those ǁith a Đo-morbid 
medical condition made more safe decisions in relation to both their laboratory tests 
and symptoms, as did younger participants and those who felt they had a greater 
ability to self-manage their arthritis at baseline. In contrast to what might be expected 
those who felt less confident in their ability to communicate with their healthcare 
team at baseline made more safe decisions. 
  
2
5
8
 
Table 7.2. Predictors of safe decision-making in response to laboratory tests 
Step Variable β SE 
95% Wald CI Hypothesis Test 
Eǆp;βͿ 
95% Wald CI 
for Eǆp;βͿ 
AIC Lower Upper 2 df p Lower Upper 
1 
  
(Intercept) 
MeiQ™ self-management ability 
-4.65 
0.38 
0.08 
0.11 
-4.81 
0.16 
-4.49 
0.60 
3501.35 
11.55 
1 
1 
<0.0001 
0.0009 
0.01 
1.46 
0.01 
1.17 
0.01 
1.82 
251.96 
2 
  
 
(Intercept) 
MeiQ™ aĐtiǀe ĐoŵŵuŶiĐatioŶ 
MeiQ™ self-management ability 
-4.59 
-0.38 
0.50 
0.07 
0.10 
0.11 
-4.72 
-0.57 
0.29 
-4.45 
-0.18 
0.72 
4734.31 
15.25 
21.95 
1 
1 
1 
<0.0001 
0.0001 
<0.0001 
0.01 
0.69 
1.66 
0.01 
0.57 
1.34 
0.01 
0.83 
2.05 
241.32 
3 
  
  
 
(Intercept) 
Age 
MeiQ™ self-management ability 
MeiQ™ aĐtiǀe ĐoŵŵuŶiĐatioŶ 
-4.61 
-0.02 
0.46 
-0.29 
0.07 
0.00 
0.10 
0.09 
-4.74 
-0.03 
0.26 
-0.48 
-4.48 
-0.01 
0.65 
-0.11 
4921.50 
11.21 
21.72 
10.15 
1 
1 
1 
1 
<0.0001 
0.001 
<0.0001 
0.002 
0.01 
0.98 
1.58 
0.75 
0.01 
0.97 
1.30 
0.62 
0.01 
0.99 
1.91 
0.89 
237.07 
4 
  
  
  
  
(Intercept) 
Has a co-morbid medical condition 
MeiQ™ self-management ability 
MeiQ™ aĐtiǀe ĐoŵŵuŶiĐatioŶ 
Age 
-4.76 
0.42 
0.44 
-0.24 
-0.02 
0.09 
0.13 
0.07 
0.08 
0.01 
-4.94 
0.16 
0.29 
-0.40 
-0.03 
-4.58 
0.69 
0.58 
-0.07 
-0.01 
2772.74 
9.96 
36.78 
8.56 
22.51 
1 
1 
1 
1 
1 
<0.0001 
0.002 
<0.0001 
0.004 
<0.0001 
0.01 
1.52 
1.55 
0.79 
0.98 
0.01 
1.17 
1.34 
0.67 
0.97 
0.01 
1.98 
1.78 
0.92 
0.99 
231.80 
MeiQ™ – Medication Education Impact Questionnaire; SE – Standard Error; CI – Confidence Interval; AIC - Akaike Information Criterion 
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Table 7.3. Predictors of safe decision-making in response to symptoms and side effects 
Step Variable β SE 
95% Wald CI Hypothesis Test 
Eǆp;βͿ 
95% Wald CI 
for Exp(βͿ 
AIC Lower Upper 2 df p Lower Upper 
1 (Intercept) 
MeiQ™ “elf-management ability 
-4.64 
0.38 
0.08 
0.11 
-4.79 
0.15 
-4.48 
0.60 
3451.90 
11.29 
1 
1 
<0.0001 
0.001 
0.01 
1.46 
0.01 
1.17 
0.01 
1.82 
248.09 
2 (Intercept) 
MeiQ™ AĐtiǀe CoŵŵuŶiĐatioŶ 
MeiQ™ “elf-management ability 
-4.57 
-0.43 
0.52 
0.07 
0.10 
0.11 
-4.70 
-0.63 
0.31 
-4.44 
-0.23 
0.74 
4697.08 
18.10 
23.05 
1 
1 
1 
<0.0001 
<0.0001 
<0.0001 
0.01 
0.65 
1.69 
0.01 
0.53 
1.36 
0.01 
0.79 
2.09 
233.19 
3 (Intercept) 
Age 
MeiQ™ “elf-management ability 
MeiQ™ AĐtiǀe CoŵŵuŶication 
-4.59 
-0.02 
0.47 
-0.34 
0.07 
0.00 
0.10 
0.09 
-4.72 
-0.03 
0.28 
-0.53 
-4.46 
-0.01 
0.67 
-0.16 
4897.00 
11.41 
23.24 
13.83 
1 
1 
1 
1 
<0.0001 
0.0009 
<0.0001 
0.0003 
0.01 
0.98 
1.61 
0.71 
0.01 
0.97 
1.32 
0.59 
0.01 
0.99 
1.95 
0.85 
228.66 
4 (Intercept) 
Has a co-morbid medical condition 
MeiQ™ “elf-management ability 
MeiQ™ AĐtiǀe CoŵŵuŶiĐatioŶ 
Age 
-4.73 
0.40 
0.45 
-0.29 
-0.02 
0.09 
0.14 
0.08 
0.09 
0.01 
-4.91 
0.13 
0.31 
-0.46 
-0.03 
-4.56 
0.66 
0.60 
-0.13 
-0.01 
2789.80 
8.54 
37.28 
12.51 
21.14 
1 
1 
1 
1 
1 
<0.0001 
0.004 
<0.0001 
0.0005 
<0.0001 
0.01 
1.49 
1.57 
0.75 
0.98 
0.01 
1.14 
1.36 
0.63 
0.97 
0.01 
1.94 
1.82 
0.88 
0.99 
224.19 
MeiQ™ – Medication Education Impact Questionnaire; SE – Standard Error; CI – Confidence Interval; AIC - Akaike Information Criterion 
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7.5 DISCUSSION 
These results suggest that overall patients with RA and PsA on methotrexate are able 
to learn the knowledge and skills required to understand and interpret their 
symptoms, side effects and blood test results and use this information to safely initiate 
care from their CNS. It is important to firstly distinguish between correct or incorrect 
decision making as opposed to safe/unsafe. The latter classification differs from the 
correct/incorrect groupings, as patients may have made a decision that was incorrect 
but was not unsafe i.e. contacting the CNS when blood tests were normal and there 
was no new or worsening symptoms or side effects. It was important to single out 
unsafe decisions as these could threaten the aim of tight control over the arthritis and 
lead to potentially serious consequences. Although a safe decision to initiate care does 
not represent more help-seeking, it does represent more appropriate help-seeking. In 
a systematic review of help-seeking in early RA Stack et al., (2012) concluded that the 
key challenge facing the development of interventions in this area was that 
appropriate help-seeking must be encouraged, which the current intervention was 
able to foster. 
7.5.1 Discrepancy between objective and subjective triggers 
It is important to establish whether patients were able to safely self-monitor and use 
this information to seek appropriate help from their CNS via initiation of a telephone 
consultation. Across the entire trial period 77% of all decisions made in response to 
ďlood test ƌesults ;deeŵed ͞oďjeĐtiǀe tƌiggeƌs͟Ϳ ǁeƌe safe aŶd Ϯϯ% uŶsafe. IŶ ƌespoŶse 
to sǇŵptoŵs aŶd side effeĐts ;deeŵed ͞suďjeĐtiǀe tƌiggeƌs͟Ϳ ϳϯ% of all deĐisioŶs 
across the entire trial period were safe and 27% unsafe. On average participants made 
unsafe decisions in response to blood test results on 23.94% of occasions and on 
29.95% of occasions when responding to symptoms and side effects, suggesting that 
participants were more able to accurately judge when contact with the CNS was 
required in response to objective rather than subjective triggers. This is particularly 
interesting considering patients would in usual care be encouraged to report 
symptoms and side effects to their healthcare team.  
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The discrepancy between patients ability to safely monitor their blood tests as 
opposed to symptoms could be attributed to a combination of reasons. Theoretical 
explanations could illuminate on the discrepancy between the objective and subjective 
triggers for contact with the services. According to social cognitive theory, outcome 
expectancies are the beliefs a person holds about the positive or negative 
consequences of performing the behaviour (Bandura, 1986). These expectations could 
be physical, social or personal outcomes. In the context of the current trial the physical 
outcome expectancies of not contacting the CNS in response to abnormal blood test 
results may have been perceived as being more serious than compared with abnormal 
symptoms, which could be a legitimate concern. Hence accuracy was higher for blood 
test results. There is little research to indicate when rapid access in response to 
symptoms and side effects is clinically necessary and what the appropriate tipping 
point is from self-managing symptoms to help-seeking. From the patient perspective 
research by Flurey (2014) indicates that the tipping points of help-seeking in 
established RA are increased pain, lack of control and longevity of the flare. This lack of 
speĐifiĐitǇ ŵaǇ haǀe led to ŵoƌe ͞uŶsafe͟ deĐisioŶs ďeiŶg ŵade iŶ ƌespoŶse to 
symptoms.  
 
It is also possible that social outcomes expectancies, such as the anticipated reaction 
of healthĐaƌe pƌofessioŶals, ŵaǇ haǀe iŶflueŶĐed a peƌsoŶ͛s deĐisioŶ to ĐoŶtaĐt theiƌ 
CNS, such as a fear that they ǁeƌe ǁastiŶg the ĐliŶiĐiaŶ͛s tiŵe, as suggested by Flurey 
(2014). It is also possible that patients felt that subjective indicators such as self-
reported symptoms and side effects may not be taken as legitimate markers of disease 
status; which Đould haǀe iŶflueŶĐed paƌtiĐipaŶts͛ ďehaǀiouƌ. The legitiŵisatioŶ of 
symptoms in arthritis has been found to be an important part of successful 
communication with healthcare professionals (Paskins, Sanders, & Hassell, 2014). 
Research in chronic disease indicates that when objective measures are absent or if 
subjective reports are incongruent to objective markers patients can perceive their 
communication with healthcare professionals as discrediting their symptoms. When 
biomarkers exist and these are in line with subjective experiences this adds credibility 
(Thorne, Harris, Mahoney, Con, & McGuinness, 2004). Assessment of both RA and PsA 
involves a combination of objective and subjective markers; therefore, healthcare 
professionals should be aware of the impact of this incongruence and how this could 
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hinder communication. While biomarkers and other objective indicators may play a 
useful role in disease monitoring and management it is also important for healthcare 
professionals to be responsive to subjective reports along with the interpretation 
patients make of these symptoms.  
 
Another possible reason for this disĐƌepaŶĐǇ Đould ďe ƌelated to a patieŶt͛s peƌĐeiǀed 
ability to self-manage symptoms and side effects without the need to seek help. In this 
trial participants were asked to contact the team when they had a new symptom or a 
continuing symptom had worsened since their last blood test; however, self-managing 
these symptoms is now part of living with arthritis. Therefore, by asking people to 
initiate care in circumstance which they felt they could manage themselves the criteria 
in this study may have been too rigid and in direct opposition to how participants were 
managing their arthritis prior to starting the study. This may have left them feeling 
either confused or that contact was unnecessary, hence leading them to make more 
unsafe decisions according to the study criteria. The decision was taken by the clinical 
team to use individual symptoms as triggers for patients initiating care. This was 
pƌiŵaƌilǇ takeŶ as a pƌeĐautioŶaƌǇ deĐisioŶ as theƌe ǁas ĐoŶĐeƌŶ that ĐoŶtaĐt ǁouldŶ͛t 
be made in the presence of serious symptoms or side effects. Increasing symptoms, 
which are unmanageable and persistent, are more commonly known as periods of 
disease flare (Hewlett et al., 2012) and incorporate not just the symptoms reported in 
the current trial (e.g. pain, fatigue, nausea) but also use of medications, physical 
functioning and emotional well-being. Had measures such as The FLARE instrument 
(Berthelot et al., 2012) - a tool to identify recent or present RA flare, been published 
prior to the start of this trial it may have been more appropriate for the criteria for 
patient action to be the experience of a disease flare rather than the experience of 
individual symptoms. There would still however, need to be an agreed cut-off point for 
contact with the clinical team.  
7.5.2 Ability to safely seek help 
The clinical care and safety of participants in the intervention group was of high 
priority; therefore, criteria for the return of participants back to usual care if they 
continually made unsafe decisions were decided a priori. Of the 52 participants 
randomised to the intervention group two participants returned to usual care due to 
Chapter 7 – PatieŶts’ AďilitǇ to IŶitiate Caƌe 
 
263 
concerns about safety. Despite receiving the standardised training session and support 
from the research team, which included a CNS and rheumatologist, these patients 
were unable to accurately initiate care when their blood test results were either 
outside of the normal range or had changed significantly since their last blood test. 
Concerns for participant safety, specifically in relation to deterioration of disease 
status, was reported within the trial by Hewlett et al., (2000; 2003b; 2005b). At the 2 
year follow-up 12.5% of participants either withdrew or were withdrawn because of 
non-compliance with the safety monitoring procedures, which included 3-monthly 
questionnaires assessing clinical status (Hewlett et al., 2000). Primdahl et al., (2014) 
also reported incidences of missing out-of-range blood tests, but these situations were 
largely in the control of GP who took on the monitoring of patients in the evaluation of 
a shared-care service, as opposed to the patient undertaking these tasks within the 
current trial.   
 
It was not possible to determine whether any of the baseline variables could 
distinguish these participants from the rest of the intervention group due to too small 
a sample size. Of particular concern to the clinical team were situations in which blood 
test results were out-of-range or had changed significantly since their last blood test. 
These situatioŶs ǁeƌe deeŵed poteŶtiallǇ ͞uŶsafe͟ if the patieŶt did Ŷot ƌespoŶd 
correctly, as signs of inflammation or liver damage can have serious consequences. At 
the fiƌst ďlood test ϯϰ.ϲϮ% of the saŵple ŵade aŶ ͞uŶsafe͟ deĐisioŶ to Ŷot seek help 
from their CNS when their blood test results were either outside of their specified 
range or had changed significantly since their last blood test, this decreased to 10.87% 
of the sample at the final blood test. As part of the design of the trial the initial phase 
of self-monitoring was undertaken in collaboration with the researcher, with support 
from the CNS, this enabled ongoing training for the patient and feedback about 
incorrect help-seeking. The feedback given to participants, therefore, provided an 
opportunity for accuracy to improve over time which was demonstrated in the 
significant time effect found in the MLM analysis, lending support for the fact that a 
majority of patients knew when they needed to seek medical help. Only 9.81% of the 
sample, however, made safe decisions on every occasion. Therefore, in order to 
implement such a service and allow patients to independently self-monitor and initiate 
care clinicians would need to be sure that patients could undertake these tasks safely 
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and accurately. It appears that six blood tests were not a sufficient number of 
opportunities for all participants to grasp the knowledge and skills required, if the trial 
had been extended to encapsulate more blood tests accuracy may have improved 
further. This may mean that any service implemented would need to have a pilot 
phase for each patient to ensure a high level of accuracy is achieved prior to 
independent self-monitoring.   
7.5.3 Drivers of safe help-seeking 
Results from the current trial found that patients made more safe decisions to initiate 
care if they had additional co-morbidities, were younger and felt more confident in 
their ability to self-manage their arthritis, but less confident in their ability to 
communicate with their healthcare team at baseline. Interestingly no clinical variables, 
including pain, fatigue, physical functioning or disease activity, were found to be 
significant predictors in this model, indicating that rather than the symptoms or 
laboratory results driving help-seekiŶg it ǁas paƌtiĐipaŶts͛ ĐoŶfideŶĐe which was 
primarily important.   
 
Results from the current trial found that patients who made more safe decisions to 
initiate care from their CNS were more confident in their ability to self-manage their 
arthritis at baseline. These findings could suggest that seeking help is seen as part of 
the self-management process rather than as a consequences of failed self-
management strategies as suggested by Hewlett et al., (2012). Hewlett et al., (2012) 
propose that as the intensity of a flare increases efforts to self-manage also increase, 
but if symptoms remain uncontrollable this leads patients to seek help. Over this 
peƌiod a patieŶt͛s uŶĐeƌtaiŶtǇ aďout the likelihood of the sǇŵptoŵs ďeiŶg a flaƌe 
decreases, which together increases the likelihood of a patient seeking medical help, 
which is often seen as a last resort (Flurey, Morris, Richards, Hughes, & Hewlett, 2014). 
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Source: Hewlett et al., (2012) 
Figure 7.3. Cycles of self-managing flare symptoms on the patient journey to seeking 
help  
 
As well as the fear of time wasting identified by Flurey (2014) in established RA, the 
systematic review by Stack et al., (2012) found that help-seeking behaviours in early 
RA are iŶflueŶĐed Ŷot oŶlǇ ďǇ a peƌsoŶ͛s ďeliefs aďout their illness and treatment but 
also by the relationship they have with their healthcare team. Stack et al., (2012) 
suggested that having a good relationship with your healthcare professionals was a 
driver for help-seeking, but when a patient anticipated negative communication or 
attitudes this contributed towards delayed help-seeking. In the current trial safer help-
seeking was associated with lower scores on the active communication subscale of the 
MeiQ™ at baseline. Although this was a trial in which help-seeking behaviour was 
manipulated, this suggests that those who felt less confident in their ability to 
communicate with their rheumatology team about their beliefs, knowledge and 
capabilities made a greater number of safe help-seeking decisions. One explanation for 
this negative relationship could be that providing a structured approach to help-
seeking and clear guidelines on the triggers for contacting the CNS could have provided 
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participants who were experiencing poor self-efficacy for communicating with their 
healthcare team, with the ͞peƌŵissioŶ͟ theǇ Ŷeeded to ŵake ĐoŶtaĐt, ǁithout the feaƌ 
of time wasting. This Đould highlight a ǁideƌ issue aďout healthĐaƌe pƌofessioŶals͛ 
ĐoŵŵuŶiĐatioŶ stǇles aŶd the possiďilitǇ of pƌeǀious eŶĐouŶteƌs affeĐtiŶg patieŶts͛ 
future help-seeking behaviour (Stack et al., 2012).  
 
These findings tentatively suggest a possible extension to the cycle of managing a flare 
(Figure 7.3) proposed by Hewlett et al., (2012) by incorporating self-efficacy for self-
management and self-efficacy for communicating with the rheumatology team in this 
process. The findings from this trial could indicate that in a similar pattern to 
uŶĐeƌtaiŶtǇ a peƌsoŶ͛s ĐoŶfideŶĐe iŶ theiƌ aďilitǇ to self-manage their arthritis could 
decrease over time as an increasing number of failed self-management attempts are 
made, whilst self-efficacy for communicating with healthcare professionals could have 
a moderating effect on help-seeking. These relationships would, however, require 
further exploration.  
 
In addition to self-efficacy for self-management ability and active communication, 
those with a co-morbid medical condition made more safe decisions, as did younger 
participants. Living with more than one chronic condition may lead someone to 
become acutely aware of the importance of clinical indicators and seeking appropriate 
medical assistance in order to prevent deterioration. In contrast to the current study 
help-seeking in chronic illness has typically been associated with older age, for instance 
in a review of help-seeking in chronic pain by Cornally and McCarthy (2011) 8 of the 17 
quantitative studies found that increasing age was a significant predictor of help-
seeking behaviour.   
7.5.4 Alternative explanations for unsafe help-seeking 
The first and most obvious reason why patients made decisions not to contact the CNS 
when either their blood test results were abnormal or when they experienced a new or 
ǁoƌseŶiŶg sǇŵptoŵ Đould haǀe ďeeŶ people͛s iŶaďilitǇ to uŶdeƌstaŶd aŶd iŶteƌpƌet 
the information they were given during the training session. The tasks required of 
participants in the intervention group required basic numeracy skills – calculating 
change scores from one blood test to another and using this information to 
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understand whether there had been a significant change since there last blood test or 
if the results remained abnormal.  
 
Health numeracy skills have been found to impact upon clinical outcomes in the 
context of self-monitoring interventions (Estrada, Martin-Hryniewicz, Peek, Collins, & 
Byrd, 2004; Cavanaugh et al., 2008) and was one of the potential reasons why patients 
refused to take part in the current trial (see section 6.5.1, page 247). A recent 
systematic review of health literacy in patients with a musculoskeletal disorder 
suggests that between 7 and 42% of the population experience low health literacy, 
dependant on the measure of literacy used (Loke et al., 2012). With 1 in 6 people with 
RA in UK deemed functionally illiterate (Gordon, Hampson, Capell, & Madhok, 2002). 
These patients struggle to understand patient education materials or prescription 
labels and attend three times more often for hospital visits compared with disease, age 
and sex matched controls (Gordon, Hampson, Capell, & Madhok, 2002). Since this 
review multivariate analysis by Caplan, Wolfe, Michaud, Quinzanos and Hirsh (2014) 
found that limited health literacy in RA was a stronger predictor of functional disability 
than prednisolone use, smoking history and biologic agent use, independent of 
educational attainment; therefore, confirming that health literacy could have been a 
legitiŵate ƌeasoŶ ǁhǇ paƌtiĐipaŶts ŵade ͞uŶsafe͟ deĐisioŶs to ĐoŶtaĐt the CN“.  
  
Another potential reason for the inaccuracies made by participants in relation to their 
blood test results could come from evidence that suggests that when patients self-
monitor aspects of their clinical well-being, such as blood test results, an assumption is 
ŵade that ͞soŵeoŶe is ǁatĐhiŶg͟ oǀeƌ theŵ, ͞iŶ the ďaĐkgƌouŶd͟ ŵoŶitoƌing their 
clinical readings. Qualitative studies in telehealth suggest that this gives people a sense 
of security and peace of mind as they feel that if their results are dangerously high or 
low a healthcare professional would contact them (Fairbrother et al., 2014; Liddy et al., 
2008; Rogers, Kirk, Gately, May, & Finch, 2011). One of the objectives of this trial was 
to establish whether patients had the ability to accurately self-monitor and initiate 
care, but in order for these activities to be achieved safely and within the ethical 
constraints of the trial, measures were put in place which involved the researcher and 
CNS checking blood test results in order to ensure that potentially serious 
abnormalities were picked up and the patient contacted when necessary. This was 
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communicated to participants during the training session, providing credibility to the 
hypothesis that participants knew someone was ͞watching over them͟ and were, 
therefore, more complacent about seeking help in relation to abnormal blood test 
results. Although the procedure of cross checking results was deemed necessary by the 
clinical team and was a condition of the local ethics board, whether this level of 
healthcare professional monitoring would be expected or feasible if this model of care 
was rolled out across the service is unclear. These beliefs would need to be considered 
and addressed prior to any implementation in order to avoid dangerous clinical 
situations. Self-monitoring in for example diabetes and anti-coagulation therapy do not 
have this level of cross checking and may, therefore, not be necessary or feasible in 
arthritis either.   
 
Recent research into the experience of flare in established RA may also provide clarity 
on the inaccuracies made by intervention participants. Reflecting on the telephone 
conversations had between the researcher and participants during phase one of the 
trial, despite acknowledging that a new symptom had developed or a blood test result 
was outside the advisable range, participants who made incorrect decisions tended to 
normalise their clinical status. In many cases they would report that a symptom had 
worsened but were able to provide a reason for this, for example increased pain was 
due to increased activity. This may have been a legitimate explanation but under the 
conditions of the trial, all worsening or new symptoms had to be discussed with the 
CNS to ensure that serious events were dealt with appropriately.  
 
Being able to regain and maintain a normal lifestyle is regarded as an important 
outcome for people living with arthritis (Hewlett et al., 2005a; Kristiansen et al., 2012; 
Kristiansen et al., 2012). Normalisation is a common coping mechanism for people 
living with a long-term condition and involves separating the impact of the illness so 
that its effeĐts oŶ the peƌsoŶ͛s ideŶtitǇ aƌe ŵiŶiŵised. Qualitatiǀe ƌeseaƌĐh ďǇ Hewlett 
et al., (2012) found that patients with RA initially normalise their symptoms early in the 
cycle of managing a flare, when symptoms are less severe. Sanderson, Calnan, Morris, 
Richards and Hewlett (2011) also found that in an attempt to maintain a normal life 
symptoms can be ignored even when severe or fluctuating, which may have serious 
and devastating consequences. The training session delivered to intervention 
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participants in this trial looked to emphasise the importance of seeking clinical care 
when blood tests or symptoms were abnormal even if the patient felt they could 
provide an explanation, this clearly did not resonate with all participants. Although the 
training did Ŷot aiŵ to eǆploƌe paƌtiĐipaŶts uŶdeƌstaŶdiŶg of ͞Ŷoƌŵal͟ the suďseƋueŶt 
feedback sessions with the researcher did endeavour to address these attitudes; 
however, not in a systematic or explicit way. Eliciting these attitudes in the training 
session using a structured approach could have provided an opportunity to address 
issues around normalisation prior to the start of the intervention which may have 
improved the accuracy and safety of participant decision making. 
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8. CHAPTE‘ ϴ – INTE‘VENTION EFFECTIVENESS 
8.1 PROLOGUE 
As previously reported, patient-initiated follow-up services have been found to be an 
effective model of care for people with RA (section 2.5.6.1, page 82). This type of 
service has not been trialled in a nurse-led DMARD monitoring clinic; and has not been 
implemented in conjunction with patients self-monitoring their own laboratory results 
and using this information along with their symptoms and side effects to initiate their 
own rheumatology care. This RCT has, therefore, evaluated of this service as compared 
to usual care.  
 
As the timing of the data collection points were dictated by the frequency with which 
participants had their scheduled blood tests participants spent varying times within the 
trial. An independent samples t-test was undertaken to explore whether there were 
any significant differences between the intervention and control group on the number 
of laboratory tests participants had within the trial and the length of time (in days) 
participants spent within the study. There was no significant difference in the number 
of laboratory tests participants spent within the trial (Intervention: M=5.75, SD=1.31; 
Control: M=5.58, SD=1.07; t(98)=-0.69, p=0.49, 2=0.004) or the length of time in days 
participants were in the study for (Intervention: M=256.02, SD=86.48; Control: 
M=257.48, SD=113.33; t(98)=0.07, p=0.94, 2<0.001). Therefore, the following analysis 
did not need to control for these factors.  
 
A full description of analytical methodology can be found in section 5.11.9.3 (page 
223). Analyses were conducted in the whole sample and again in only those 
participants who completed all three time points, as a means of sensitivity analysis. 
The results presented were for the whole sample (n=100) as there were no differences 
in the results of the significance test. The results of the complete case analysis can be 
found in Appendix W. 
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8.2 WHAT WERE THE EFFECTS OF THE INTERVENTION ON HEALTHCARE UTILISATION? 
As frequency of healthcare utilisation was count data a series of univariate Poisson 
regressions were performed in order to explore whether trial arm (IV) was associated 
with healthcare utilisation (DV). The total number of appointments attended by 
intervention and control group participants varied (Table 8.1). 
 
Table 8.1. Total number of face-to-face arthritis-related healthcare visits by trial arm 
for whole sample  
Healthcare professional 
Total 
n=100 
Intervention  
n=52 
Control  
n=48 
Difference between 
groups  
(Control – 
Intervention) 
CNS 96 30 66 36 
Rheumatologist 199 96 103 7 
GP 76 29 47 18 
Overall 371 155 216 61 
GP – General Practitioner 
 
Overall the intervention group had 54.55% fewer appointments with their CNS 
compared to control participants (Figure 8.1). A majority of participants in the 
intervention group had no visits (Median=0; range 0-4, mean=0.58, SD=0.80) and a 
majority of control group participants had one (Median=1; range 0-4, mean=1.38, 
SD=1.00); very few participants in the intervention had more than one visit over the 
trial period compared with control group participants who had up to four visits. The 
Poisson regression indicated that group was a significant predictor of outpatient visits 
to CNS ;Eǆp;βͿ=Ϯ.ϯϳ, 2(1, n=100)=15.48, p<0.0001). Control group participants 
attended the CNS 2.37 times more than those in the intervention group. 
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Figure 8.1. Frequency of visits to the CNS by trial arm 
 
Overall the intervention group had 6.80% fewer reviews with their rheumatologist 
over the trial period compared to control group participants (Figure 8.2). A majority of 
participants in the intervention group had two visits (Median=2; range 0-4, mean=1.85, 
SD=1.00) and a majority of control group participants also attended twice. The 
distribution in the control group (Median=2; range 0-7, mean=2.15, SD=1.58) did 
indicate that a number of these participants did have more than four visits over the 
trial period. Poisson regression indicated that group was not a significant predictor of 
outpatient visits to the ƌheuŵatologist ;Eǆp;βͿ=ϭ.Ϭϰ, 2(1, n=100)=1.16, p=0.23) 
indicating that participants in the intervention and control group did not differ in the 
number of visits they had to their rheumatologist.  
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Figure 8.2. Frequency of visits to the rheumatologist by trial arm 
 
Overall the intervention group had 38.80% fewer appointments with their GP in 
relation to their arthritis than control group participants (Figure 8.3). A majority of 
participants in both trial arms did not visit their GP about their arthritis at all 
(Intervention: Median=0; range 0-3, mean=0.56, SD=0.87; Control: Median=0.05; range 
0-5, mean=0.94, SD=1.30). In the regression, participants in the control group had 1.78 
times as many arthritis-related GP visits than those in the intervention group, although 
this difference was not statistically significant ;Eǆp;βͿ=ϭ.ϳϴ, 2(1, n=100)=3.64, p=0.07).  
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Figure 8.3. Frequency of visits to the GP by trial arm 
 
When analysing the total number of visits to the GP, CNS and rheumatologist together, 
participants in the control group had 28.44% more appointments with their healthcare 
team compared to those in the intervention group. The Poisson regression indicated 
that gƌoup ǁas a sigŶifiĐaŶt pƌediĐtoƌ of total healthĐaƌe utilisatioŶ ;Eǆp;βͿ=ϭ.ϰϵ, 2(1, 
n=100)=12.54, p<0.001). Control group participants used for 1.49 times more health 
services than those in the intervention group.  
 
Out-of-range blood tests in the intervention group triggered a total of 231 telephone 
consultations, with a mean per participant of 4.43(SD=1.43). All intervention 
participants required at least one telephone consultation during the trial period, 
15(29.23%) participants required a telephone consultation at each of the six blood 
tests (Figure 8.4). These 231 telephone consultations led to 96(41.56%) face-to-face 
outpatient appointments with the CNS. Therefore, for approximately every five 
telephone consultations, two outpatient appointments were requested.   
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Figure 8.4. Frequency of telephone consultations in the intervention group 
 
When these telephone consultations were added to the total number of face-to-face 
visits patients had with their healthcare team (including CNS, rheumatologist and GP) 
the intervention group had 55.84% more contact with healthcare professionals about 
their arthritis than participants in the control group. Poisson regression indicated that 
group was a significant predictor ;Eǆp;βͿ=Ϭ.ϲϬ, 2(1, n=100)=27.08, p<0.0001) 
indicating that participants in the control group attended 40% fewer (0.60 times more) 
healthcare visits than those in the intervention group. 
8.3 WHAT WERE THE EFFECTS OF THE INTERVENTION ON HEALTHCARE COSTS? 
The analysis of healthcare utilisation indicated that there were significant reductions in 
relation to the number of outpatient visits participants had with their CNS and overall 
healthcare utilisation. However, when taking into account the number of telephone 
consultations as a result of new or worsening symptoms or out-of-range blood tests, 
the reverse was found (i.e. the intervention group had significantly more contact with 
their healthcare team). It was, therefore, important to assess whether there were any 
cost savings attached to a telephone consultation as opposed to face-to-face contact. 
Therefore, the following analyses looked at the economic impact of the intervention 
using the Department of Health Reference costs (Department of Health, 2011a; 
Department of Health, 2013a) and the Unit Costs of Health & Social Care 2012 (Curtis, 
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2012) as described in section 5.11.9.2 (page 219). As stated in Chapter 5 these analyses 
were post-hoc and, therefore, results should be interpreted with caution, p-values 
were adjusted to 0.001 to compensate for these additional tests.  
 
Table 8.2 indicates that irrespective of the model or unit price the cost of providing 
face-to-face rheumatology nursing care for patients in the intervention group was 
significantly cheaper than that of the control group (U=652.50, z=-4.36, p<0.001, r=-
0.44) but there were no significant differences between the intervention and control 
group on the cost of providing rheumatologist outpatient visits (U=1194.50, z=-0.39, 
p=0.70, r=-0.04), arthritis-related GP care (U=1070.45, z=-1.39, p=0.18, r=-0.14), travel 
(U=992.00, z=-1.78, p=0.08, r=-0.18) or laboratory tests (U=1112.00, z=-1.40, p=0.16, 
r=-0.14). No statistical comparisons can be made between the intervention and control 
on the cost of training or telephone consultations as these did not take place in the 
control group. 
  
2
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Table 8.2. Group comparisons between trial arms on healthĐaƌe Đosts foƌ eaĐh ŵodel peƌ paƌtiĐipaŶt ;ǁhole saŵpleͿǂ 
 Healthcare professional Intervention n=52 Control n=48 Significance statistic 
CNS, median(range) 
Lower 
Average 
Upper 
£0(£0-208) 
£0(0-356) 
£0(£0-420) 
£52(£0-208) 
£89(£0-356) 
£105(£0-420) 
 
U=652.50, z=-4.36, p<0.001, r=-0.44 
Rheumatologist, median(range) 
Lower 
Average 
Upper 
£210(£0-420) 
£266(£0-532) 
£300(£0-600) 
£210(£0-735) 
£266(£0-931) 
£300(£0-1050) 
  
U=1194.50, z=-0.39, p=0.70, r=-0.04 
GP, median(range) 
Lower 
Average 
Upper 
£0(£0-108) 
£0(£0-118.50) 
£0(£0-129) 
£1.80(£0-180) 
£1.98(£0-197.50) 
£2.15(£0-215) 
 
U=1070.45, z=-1.39, p=0.18, r=-0.14 
Telephone consultations, median(range) 
Lower 
Average 
Upper 
£241.80(£52-312) 
£372(£80-480) 
£520.80(£112-672) 
- 
 
n/a 
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 Healthcare professional Intervention n=52 Control n=48 Significance statistic 
Travel, median(range) £41(£5-113) £54(£0-126) U=992.00, z=-1.78, p=0.08, r=-0.18 
Laboratory tests, median(range) £192.66(£32.11-256.88) £192.66(£64.22-192.66) U=1112.00, z=-1.40, p=0.16, r=-0.14 
Education, mean(SD) 
Lower 
Average 
Upper 
£35(£0) 
£41.70(£0) 
£48.40(£0) 
- 
 
n/a 
Total costs (Lower quartile unit cost) 
Model One, mean(SD) 
Model Two, mean(SD) 
  
£743.17(£209.58) 
£512.17(£178.85) 
  
£574.72(£232.89) 
£574.72(£233.98)  
  
t(98)=-3.84, p<0.001, =0.16 
t(85.99)=1.48, p=0.14, =0.02 
Total costs (National average unit cost) 
Model One, mean(SD) 
Model Two, mean(SD) 
  
£949.25(£271.51) 
£593.86(£222.53) 
  
£689.10(£282.65) 
£689.10(£285.58) 
  
t(98)=-4.68, p<0.001, =0.23 
t(86.78)=1.83, p=0.07, =0.03 
Total costs (Upper quartile unit cost) 
Model One, mean(SD) 
Model Two, mean(SD) 
  
£1140.67(£319.99) 
£650.15(£246.75) 
  
£751.01(£304.28) 
£751.01(£315.90) 
  
t(98)=-6.10, p<0.001, =0.41 
t(86.76)=1.87, p=0.06, =0.04 
GP – General Practitioner; SD – Standard Deviation 
ǂ The results of the significance tests remain the same irrespective of whether the task was costed at lower, national or upper rates 
Model One – Total costs including nurse-led telephone consultations. Model Two – Total costs excluding all nurse-led telephone consultations 
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Model One: When including the cost of the telephone consultations the overall cost of 
a self-monitoring and patient-initiated follow-up service for patients with RA or PsA on 
DMARD therapy was between 29.31% and 51.88% more expensive per patient than 
usual care (Table 8.3) and this difference was statistically significant for each of the 
three unit costs (Lower quartile: t(98)=-3.84, p<0.001, =0.16; National average: 
t(98)=-4.68, p<0.001, =0.23; Upper quartile: t(98)=-6.10, p<0.001, =0.41) (Table 
8.2).  
 
Model Two: Excluding the cost of telephone consultations meant that the intervention 
was between 10.88% and 13.88% cheaper to run than the control group (Table 8.4). 
This difference, however, remained statistically non-significant (Lower quartile: 
t(85.99)=1.48, p=0.14, =0.02; National average: t(86.78)=1.83, p=0.07, =0.03; 
Upper quartile: t(86.76)=1.87, p=0.06, =0.04). 
 
 
 
Figure 8.5. Overall cost difference between the intervention and control group (whole 
sample) 
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Table 8.3. Model One: Healthcare utilisation usage and costs across the trial period and the associated costs (whole sample) 
 Healthcare usage Trial arm No. of visits Lower quartile National average Upper quartile 
Unit cost Total cost Unit cost Total cost Unit cost Total cost 
CNS Intervention 30 £52 £1,560 £89 £2,670 £105 £3,150 
Control 66 £3,432 £5,874 £6,930 
Rheumatologist Intervention 96 £105 £10,080 £133 £12,768 £150 £14,400 
Control 103 £10,815 £13,699 £15,450 
GP Intervention 29 £36 £1,044 £39.50 £1,146 £43 £1,247 
Control 47 £1,692 £1,857 £2,021 
Training session Intervention 52 £35 £1,820 £41.70 £2,168 £48.40 £2,517 
Control 0 £0 £0 £0 
Transport to outpatients Intervention 126  £18 £2,268 £18 £2,268 £18 £2,268 
Control 169  £3,042 £3,042 £3,042 
Transport to training session Intervention 52 £5 £260 £5 £260 £5 £260 
Control 0 £0 £0 £0 
Telephone Intervention 231 £52 £12,012 £80 £18,480 £112 £25,872 
Control 0 £0 £0 £0 
Laboratory tests Intervention 299 £32.11 £9,600.89 £32.11 £9,600.89 £32.11 £9,600.89 
Control 268 £8,605.48 £8,605.48 £8,605.48 
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 Healthcare usage Trial arm No. of visits Lower quartile National average Upper quartile 
Unit cost Total cost Unit cost Total cost Unit cost Total cost 
Total cost per group Intervention - £38,644.89 £49,360.79 £59,314.69 
Control £27,586.48 £33,076.98 £36,048.48 
Cost per patient Intervention - £743.17 £949.25 £1,140.67 
Control £574.72 £689.10 £751.01 
GP – General Practitioner 
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Table 8.4. Model Two: Healthcare utilisation usage and costs across the trial period and the associated costs (whole sample) 
 Healthcare usage Group No. of visits Lower quartile National average Upper quartile 
Unit cost Total cost Unit cost Total cost Unit cost Total cost 
CNS Intervention 30 £52 £1,560 £89 £2,670 £105 £3,150 
Control 66 £3,432 £5,874 £6,930 
Rheumatologist Intervention 96 £105 £10,080 £133 £12,768 £150 £14,400 
Control 103 £10,815 £13,699 £15,450 
GP Intervention 29 £36 £1,044 £39.50 £1,146 £43 £1,247 
Control 47 £1,692 £1,857 £2,021 
Training session Intervention 52 £35 £1,820 £41.70 £2,168 £48.40 £2,517 
Control 0 £0 £0 £0 
Transport to outpatients Intervention 126  £18 £2,268 £18 £2,268 £18 £2,268 
Control 169  £3,042 £3,042 £3,042 
Transport to training session Intervention 52 £5 £260 £5 £260 £5 £260 
Control 0 £0 £0 £0 
Laboratory tests Intervention 299 £32.11 £9,600.89 £32.11 £9,600.89 £32.11 £9,600.89 
Control 268 £8,605.48 £8,605.48 £8,605.48 
Total cost per group Intervention   
 -  
£26,632.89 £30,880.79 £33,807.69 
Control £27,586.48 £33,076.98 £36,048.48 
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 Healthcare usage Group No. of visits Lower quartile National average Upper quartile 
Unit cost Total cost Unit cost Total cost Unit cost Total cost 
Cost per patient Intervention - £512.17 £593.86 £650.15 
Control £574.72 £689.10 £751.01 
GP – General Practitioner
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8.4 WHAT WERE THE EFFECTS OF THE INTERVENTION ON CLINICAL OUTCOMES? 
8.4.1 Disease activity 
In order to explore if there were any significant interaction effects between group and 
time on disease activity a mixed between-within participants ANOVA was undertaken 
to look at changes over time in the intervention and control on the DAS28 and the 
individual subscales of the PsARC (Table 8.5). This test was chosen instead of MLM as 
there were only two time points (baseline and final follow-up). There was an 
improvement in DAS28, PsARC patient global health scores and PsARC tender joint 
count in both the intervention and control group. Physical PsARC global health scores 
remained the same over time in both groups and there was an increase in the number 
of swollen joints in both the intervention and control groups. The mixed between-
within participants ANOVAs revealed that none of these differences were statistically 
significant for the DAS28 (Wilks͛s lambda=0.99, F1, 69=0.42, p=0.63, 2p=0.02), PsARC 
physician global score (Wilks͛s lambda=0.99, F1, 69=0.43, p=0.70, 2p=0.04), PsARC 
patient global score (Wilks͛s lambda=0.97, F1, 69=0.66, p=0.58, 2p=0.13), PsARC 
swollen joints (Wilks͛s lambda=0.93, F1, 69=2.11, p=0.27, 2p=0.04) or PsARC tender 
joints (Wilks͛s lambda=0.97, F1, 69=0.88, p=0.50, 2p=0.05).  
 
Table 8.5. Disease activity scores by trial arm across the 2 time points, mean(SD) 
 Variable 
Intervention Control         
Baseline Final f/u Baseline Final f/u 
DAS28† 3.54(1.36) 3.29(1.46) 3.19(1.23) 3.09(1.34) 
PsARCǂ physician global 2.05(0.71) 2.00(1.46) 2.40(0.74) 2.40(1.46) 
PsARCǂ patient global 1.43(0.61) 2.03(1.32) 2.15(0.67) 2.41(1.36) 
PsARCǂ swollen joints 1.84(3.00) 6.11(6.10) 4.64(3.20) 5.98(5.34) 
PsARCǂ tender joints 7.79(6.75) 6.41(7.12) 11.34(7.49) 7.38(6.90) 
SD – Standard Deviation; DAS28 – 28-Item Disease Activity Score; PsARC – Psoriatic Arthritis Response 
Criteria; f/u – follow-up 
† n=71 whole sample (33 intervention, 38 control); ǂ n=29 whole sample (19 intervention, 10 control) 
 
A majority of participants did not respond according to the EULAR treatment response 
criteria for RA or on the PsARC (Table 8.6). When the frequency of responders was 
compared to none responders at the end of the trial period, there was no significant 
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association between trial arm and disease response, 2(1, n=100)=0.35, p=0.77, =-
0.03.  
 
Table 8.6. Disease response over the trial period by trial arm, n(%) 
Variable Whole n=100 Intervention n=52 Control n=48 
DAS28 response 
None 
Moderate 
Good 
 
52(73.24) 
7(9.86) 
12(16.90) 
 
25(75.76) 
3(9.09) 
5(15.15) 
 
27(71.05) 
4(10.53) 
7(18.42) 
PsARC response 
No response 
Response 
22(75.86) 
7(24.14) 
14(73.68) 
5(26.32) 
8(80.00) 
2(20.00) 
DAS28 – 28-item Disease Activity Score; PsARC – Psoriatic Arthritis Response Criteria 
 
8.4.2 Time between laboratory tests 
An independent samples t-test was conducted in order to explore whether there was a 
significant difference between the intervention and control group on the time 
between laboratory tests. Analysis indicated that intervention participants attended 
for their laboratory tests more frequently (M=39.35 days, SD=9.12 days) than control 
group participants (M=47.88 days, SD=13.50 days; t(79.84)=3.63, p=0.001, =0.12). 
8.4.3 Laboratory tests  
Data were entered for the pre-trial blood test and the six laboratory tests within the 
trial period (Table 8.8). There were no statistically significant interaction effects 
between group and time on any of the laboratory results (Table 8.7). See Appendix X 
for a graphical representation of the laboratory tests over time. A majority of the 
effect sizes were also small .
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Table 8.7. MLM analysis for laboratory tests (n=100) 
Test Group Time Group*Time 
Haemoglobin F1,92.59 = 4.74, p=0.03 F6,302.56= 1.51, p=0.18 F6,302.56 = 0.75, p=0.61 
WBC F1,88.79 = 0.02, p=0.90 F6,290.87= 0.86, p=0.53 F2,290.87= 0.39, p=0.89 
Neutrophils F1,89.72 = 0.08, p=0.78 F6,288.13 = 0.71, p=0.64 F6,288.13 = 1.33, p=0.25 
Platelets F1,92.19 = 9.00, p=0.003 F6,299.34= 1.09, p=0.37 F6,299.34 = 1.00, p=0.43 
ALP F1,92.65 = 0.02, p=0.90 F6,297.91 = 1.22, p=0.30 F6,297.91 = 1.19, p=0.31 
ALT F1,93.46 = 1.37, p=0.25 F6,307.46 = 1.08, p=0.37 F6,209.46 = 1.58, p=0.15 
ESR F1,94.06 = 0.28, p=0.60 F6,300.96 = 0.41, p=0.87 F6,300.96 = 0.35, p=0.91 
CRP F1,88.59 = 0.88, p=0.35 F6,279.19 = 1.13, p=0.34 F6,279.19 = 0.53, p=0.78 
MLM – Multi-Level Modelling; WBC – White Blood Count; ALP – Alkaline Phosphatase; ALT – Alanine Transaminase; ESR – Erythrocyte Sedimentation Rate; CRP – C-Reactive 
Protein 
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Table 8.8. Descriptive statistics adjusted mean(SD) for laboratory tests over time by trial arm (n=100) 
 Test Trial arm Pre-trial  1 2 3 4 5 6 
Haemoglobin Intervention 13.91(1.37) 14.01(1.37) 13.96(1.38) 13.88(1.33) 13.88(1.33) 13.95(1.34) 13.82(1.40) 
Control 13.35(1.53) 13.29(1.53) 13.25(1.47) 13.23(1.47) 13.39(1.49) 13.54(1.55) 13.29(1.56) 
Effect size (99% CI) 0.49(0.00,0.98) 0.49(0.00,0.99) 0.46(-0.03,0.95) 0.34(-0.15,0.84) 0.28(-0.22,0.78) 0.36(-0.15,0.86) 
WBC Intervention 6.79(1.77) 6.76(1.77) 6.93(1.78) 7.11(1.73) 6.73(1.74) 6.99(1.75) 6.80(1.85) 
Control 6.65(1.96) 6.88(1.98) 7.00(1.90) 6.97(1.92) 7.00(1.95) 7.01(2.04) 6.86(2.05) 
Effect size (99% CI) 0.06(-0.57,0.69) 0.04(-0.60,0.68) 0.08(-0.57,0.72) 0.14(-0.50,0.79) 0.01(-0.64,0.67) 0.03(-0.63,0.69) 
Neutrophils Intervention 4.28(1.53) 3.96(1.53) 4.04(1.55) 4.26(1.50) 3.96(1.50) 4.15(1.54) 3.93(1.62) 
Control 3.84(1.70) 4.23(1.71) 4.20(1.65) 4.30(1.66) 4.13(1.70) 4.22(1.77) 4.16(1.78) 
Effect size (99% CI) 0.16(-0.38,0.71) 0.10(-0.45,0.66) 0.02(-0.53,0.58) 0.11(-0.46,0.67) 0.04(-0.53,0.61) 0.13(-0.44,0.71) 
Platelets Intervention 241.27(57.39) 238.27(57.39) 239.51(57.66) 240.82(55.59) 242.74(55.76) 245.19(56.32) 239.34(58.87) 
Control 273.81(63.86) 277.70(64.06) 279.82(61.60) 278.44(61.79) 270.92(62.39) 273.21(62.05) 264.31(65.28) 
Effect size (99% CI) 0.64(-19.89,21.18) 0.67(-19.96,21.30) 0.64(-20.06,21.34) 0.47(-20.29,21.24) 0.46(-20.57,21.43) 0.40(-20.66,21.46) 
ALP Intervention 73.13(20.60) 75.10(20.60) 72.71(20.71) 72.80(19.93) 70.87(19.99) 73.14(20.08) 73.20(20.97) 
Control 70.81(22.92) 72.83(22.98) 73.20(22.10) 73.03(22.15) 74.46(22.44) 75.68(23.36) 74.56(23.38) 
Effect size (99% CI) 0.10(-7.27,7.47) 0.02(-7.39,7.43) 0.01(-7.41,7.43) 0.17(-7.27,7.61) 0.12(-7.36,7.59) 0.06(-7.44,7.56) 
ALT Intervention 28.88(16.51) 29.08(16.51) 31.75(16.70) 32.27(16.11) 30.10(16.28) 31.59(16.40) 31.59(17.21) 
Control 26.93(18.37) 26.02(18.70) 28.34(17.77) 25.05(17.96) 29.85(18.51) 26.93(19.37) 28.70(19.22) 
Effect size (99% CI) 0.17(-5.73,6.08) 0.20(-5.78,6.17) 0.42(-5.58,6.42) 0.01(-6.05,6.08) 0.26(-5.85,6.37) 0.16(-6.00,6.31) 
ESR Intervention 13.54(12.63) 13.15(12.69) 13.09(12.77) 12.21(12.60) 12.63(12.49) 13.04(12.63) 12.17(13.23) 
Control 13.55(14.06) 15.69(14.51) 13.88(13.69) 12.68(13.96) 14.17(14.19) 13.36(14.58) 14.36(14.80) 
Effect size (99% CI) 0.19(-4.35,4.72) 0.06(-4.51,4.63) 0.04(-4.66,4.73) 0.11(-4.53,4.76) 0.02(-4.68,4.73) 0.16(-4.58,4.89) 
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 Test Trial arm Pre-trial  1 2 3 4 5 6 
CRP Intervention 5.07(8.34) 4.60(8.41) 4.87(8.62) 5.89(8.23) 4.73(8.46) 4.52(8.55) 5.23(8.91) 
Control 4.26(9.28) 5.89(9.47) 6.96(9.11) 7.50(9.21) 5.80(9.65) 4.23(9.96) 7.17(9.96) 
Effect size (99% CI) 0.14(-2.86,3.15) 0.23(-2.85,3.32) 0.18(-2.88,3.25) 0.12(-3.03,3.27) 0.03(-3.15,3.22) 0.21(-2.98,3.39 
SD – Standard Deviation; WBC – White Blood Cell; ALP – Alkaline Phosphatase; ALT – Alanine Transaminase; ESR – Erythrocyte Sedimentation Rate; CRP – C-Reactive Protein; CI – 
Confidence Interval 
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8.4.4 Functional disability, pain and fatigue 
Scores at the first and final follow-up indicated that participants in the intervention 
group experienced less pain, functional disability and either more or the same levels of 
fatigue as participants in the control group (Appendix Y). Over time, however, levels of 
fatigue, pain and functional disability remained stable and effect sizes were small at 
both time points (Table 8.9). 
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Table 8.9. Descriptive statistics adjusted mean(SD) and MLM analysis for pain, fatigue and functional disability (n=100) 
Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group 
Fatigue Intervention 4.20(2.74) 4.53(2.87) 4.30(2.90) 
F1,97.20=0.11,  
p=0.74 
F2,115.21=0.68,   
p=0.51  
F2,115.21=0.45,  
p=0.64  
Control 4.35(2.70) 4.50(2.79) 4.69 (2.93) 
Effect size(99% CI) 0.01(-0.97, 0.99) 0.13(-0.90, 1.16) 
Pain Intervention 3.64(2.46) 3.56(2.70) 3.68(2.60) 
F1,95.62=0.24,  
p=0.63  
F2,159.60=0.65,   
p=0.53 
F2,159.60=0.84,  
p=0.43 
Control 3.50(2.43) 4.12(2.56) 3.86(2.70) 
Effect size(99% CI) 0.21(-0.67, 1.09) 0.07(-0.90, 1.03) 
Functional Disability Intervention 0.59(0.62) 0.55(0.64) 0.56(0.63) 
F1,95.18=1.12,  
p=0.29 
F2,110.04=0.51,   
p=0.60 
F2,110.04=2.01,  
p=0.14 
Control 0.64(0.62) 0.74(0.63) 0.70(0.64) 
Effect size(99% CI) 0.29(0.07, 0.51) 0.22(0.00, 0.45) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI – Confidence Interval; f/u – follow-up 
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8.5 WHAT WERE THE EFFECTS OF THE INTERVENTION ON PSYCHOSOCIAL OUTCOMES? 
Table 8.10 illustrates the descriptive statistics for the intervention and control group at 
each of the three time points for quality of life and mood, along with the associated F-
tests for the MLM analyses. The associated graphs (Appendix Z) indicate very little 
change in any of these outcomes either in the intervention or control group. None of 
the interaction effects were significant, in either the whole sample or for complete 
cases only (Appendix W).  
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Table 8.10. Descriptive statistics mean(SD) and MLM analysis for quality of life and psychosocial well-being (n=100) 
Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group  
Anxiety Intervention 5.73(4.22) 5.84(4.39) 5.06(4.38) 
F1,98.61=2.51,  
p=0.12 
F1,107.47=1.28,   
p=0.28 
F1,107.47=1.85,  
p=0.16 
Control  6.46(4.21) 7.01(4.34) 6.97(4.45) 
Effect size(99% CI) 0.26(-1.25,1.78) 0.43(-1.14, 2.00) 
Depression Intervention 4.63(3.33) 4.44(3.49) 4.11(3.46) 
F1,97.24=0.001, 
p=0.98 
F1,132.01=0.22,  
p=0.81 
F1,132.01=1.20,  
p=0.31 
Control  4.25(3.33) 4.50(3.42) 4.51(3.52) 
Effect size(99% CI) 0.02(-1.18, 1.21) 0.11(-1.14, 1.36) 
SF-12v1® MCS Intervention 30.15(7.48) 29.18(7.72) 30.99(7.80) 
F1,89.00=0.02,  
p=0.89 
F2,84.85=1.49,  
p=0.23 
F2,84.85=1.48,  
p=0.23 
Control  30.91(8.36) 29.60(7.62) 29.26(8.22) 
Effect size(99% CI) 0.05(-2.62, 2.73) 0.21(-2.55, 2.97) 
SF-12v1® PCS Intervention 46.82(11.41) 46.34(11.83) 45.26(11.71) 
F1,90.22=0.28,  
p=0.60 
F2,99.16=0.07,  
p=0.94 
F2,99.16=1.02,  
p=0.36 
Control  44.30(12.57) 45.22(11.73) 45.59(12.38) 
Effect size(99% CI) 0.09(-3.99, 4.18) 0.03(-4.20, 4.26) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI – Confidence Interval; MCS – Mental Component Score; PCS – Physical Component Score; f/u – follow-up 
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8.5.1 Quality of life 
There were no statistically significant interaction effects between group and time on 
either the mental (F2,84.85=1.48, p=0.23) or physical health (F2,99.16=1.02, p=0.36) SF-
12v1® component scores. At first follow-up participants in the intervention group had 
slightly poorer mental health quality of life and marginally better physical quality of life 
than those in the control group, and the reverse was found at final follow-up; 
however, effect sizes were very small (Table 8.10).  
8.5.2 Mood 
There were no statistically significant interaction effects between group and time for 
depression (F1,132.01=1.20, p=0.31) or anxiety (F1,107.47=1.85, p=0.16). At both follow-ups 
participants in the intervention group had lower levels of anxiety and depression, the 
effect sizes were all small except for anxiety at final follow-up when the difference 
between the intervention and control group suggested a medium size effect (Table 
8.10). 
8.6 WHAT WERE THE EFFECTS OF THE INTERVENTION ON PSYCHOSOCIAL PROCESS 
VARIABLES? 
Table 8.11 illustrates the descriptive statistics for the intervention and control group at 
each of the three time points on all psychosocial process variables, along with the 
associated F-tests for MLM analyses. There were no significant interaction effects for 
any of the psychosocial process variables, in either the whole sample or for complete 
cases only (Appendix W).  
8.6.1 Self-effficacy 
 Generalised self-efficacy 
There was no statistically significant interaction effects between group and time for 
generalised self-efficacy (F1,130.49=1.50, p=0.23). At both follow-ups participants in the 
intervention group exhibited greater levels of self-efficacy than control group 
participants, although not significant and effect sizes indicated these differences were 
small (Table 8.11). 
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Table 8.11. Descriptive statistics adjusted mean(SD) and MLM analysis for self-efficacy (n=100) 
 Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group  
Generalised 
self-efficacy 
Intervention  31.78(4.57) 31.60(4.83) 32.33(4.76) F1,94.97=0.85,  
p=0.36 
F1,130.49=0.26,  
p=0.77 
F1,130.49=1.50,  
p=0.23 Control 31.42(4.57) 31.13(4.67) 30.82(4.85) 
Effect size(99% CI) 0.10(-1.54, 1.73) 0.31(-1.42, 2.04) 
HeiQ™ “elf-
monitoring & 
insight 
Intervention 3.00(0.41) 3.07(0.44) 3.10(0.44) F1,99.05=1.57,  
p=0.21 
F2,121.44=0.87,  
p=0.42 
F2,121.44=1.36,  
p=0.26 Control  3.15(0.41) 3.18(0.43) 3.11(0.45) 
Effect size(99% CI) 0.26(0.11, 0.40) 0.03(-0.13, 0.18) 
MeiQ™ AĐtiǀe 
communication 
Intervention 5.16(0.87) 5.08(0.92) 5.10(0.93) F1,95.43=0.35,  
p=0.56 
F2,121.77=0.14,  
p=0.87 
F2,121.77=0.99,  
p=0.37 Control  5.16(0.87) 5.28(0.90) 5.18(0.95) 
Effect size(99% CI) 0.22(-0.09, 0.53) 0.09(-0.24, 0.42) 
MeiQ™ “elf-
management 
ability 
Intervention 4.69(0.74) 4.80(0.77) 4.80(0.77) F1,100.52=0.37,  
p=0.54 
F2,131.50=0.52,  
p=0.60 
F2,131.50=0.78,  
p=0.46 Control  4.85(0.74) 4.82(0.76) 4.87(0.79) 
Effect size(99% CI) 0.02(-0.24, 0.29) 0.09(-0.19, 0.36) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI Confidence Interval; HeiQ™ – Health EduĐatioŶ IŵpaĐt QuestioŶŶaiƌe; MeiQ™ – Medication Education Impact 
Questionnaire; f/u – follow-up
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 Confidence in ability to self-monitor, communicate with healthcare 
professionals and self-manage 
There were no statistically significant interaction effects between group and time on 
aŶǇ of the HeiQ™ oƌ MeiQ™ suďsĐales iŶ eitheƌ the ǁhole saŵple ;Table 8.11) or for 
complete cases only. The effect sizes at both follow-ups were small.  
8.6.2 Illness and treatment beliefs 
 Illness beliefs 
There were no statistically significant interaction effects between group and time on 
any of the IPQ-R subscales (Table 8.12). All effect sizes were small at both follow-ups, 
except IPQ-R illness identity at final follow-up, which suggested that the difference 
between the intervention and control group was medium, with control group 
participants identifying more symptoms associated with their arthritis than those in 
the intervention group.  
 Treatment beliefs 
There were no statistically significant interaction effects between group and time on 
BMQ specific necessity or concern subscale or perceptions of treatment burden (Table 
8.12). All effect sizes were also small at both follow-ups.  
 Knowledge about methotrexate 
There was no statistically significant interaction effect between group and time on 
knowledge about methotrexate (F1,76.84=1.67, p=0.20) (Table 8.13) the effect size was 
also small at both follow-ups. 
   
2
9
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Table 8.12. Descriptive statistics adjusted mean(SD) and MLM analysis for illness beliefs (n=100) 
 Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group  
IPQ-R Identity Intervention  5.23(2.40) 4.60(2.58) 4.28(2.56) 
F1,92.81=1.21,  
p=0.28 
F2,140.83=1.77,  
p=0.17 
F2,140.83=2.75,  
p=0.07 
Control  5.15(2.40) 5.01(2.51) 5.32(2.63) 
Effect size(99% CI) 0.16(-0.70, 1.02) 0.40(-0.53, 1.32) 
IPQ-R Consequences Intervention  19.54(4.99) 18.63(5.17) 18.45(5.15) 
F1,98.58=1.32,  
p=0.25 
F2,113.04=4.06,  
p=0.02 
F2,113.04=0.25,  
p=0.78 
Control  20.40(5.04) 19.95(5.13) 19.56(5.28) 
Effect size(99% CI) 0.25(-1.53, 2.04) 0.21(-1.64, 2.06) 
IPQ-R Personal Control Intervention  20.78(4.34) 21.44(4.52) 21.45(4.53) 
F1,97.10=0.04,  
p=0.84 
F2,116.26=2.04,  
p=0.14 
F2,116.26=0.04,  
p=0.96 
Control  21.00(4.42) 21.51(4.57) 21.67(4.64) 
Effect size(99% CI) 0.01(-1.54, 1.57) 0.05(-1.57, 1.67) 
IPQ-R Treatment Control Intervention  15.61(2.28) 15.56(2.43) 16.05(2.43) 
F1,94.26=0.13,  
p=0.72 
F2,117.43=1.03,  
p=0.36 
F2,117.43=1.95,  
p=0.15 
Control  15.98(2.25) 15.43(2.40) 15.39(2.51) 
Effect size(99% CI) 0.05(-0.76, 0.87) 0.26(-0.61, 1.13) 
IPQ-R Coherence Intervention  18.40(4.22) 19.58(4.46) 19.42(4.46) 
F1,97.10=0.28,  
p=0.60 
F2,112.73=2.76,  
p=0.03 
F2,112.73=2.76,  
p=0.07 
Control  18.94(4.20) 19.27(4.34) 17.97(4.58) 
Effect size(99% CI) 0.07(-1.44, 1.58) 0.32(-1.28, 1.92) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI Confidence Interval; IPQ-R – Illness Perceptions Questionnaire-Revised; f/u – follow-up 
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Table 8.13. Descriptive statistics mean(SD) and MLM analysis for treatment beliefs and knowledge (n=100) 
 Variable Trial arm Baseline First f/u Final f/u Group Time Time*Group  
BMQ Specific Necessity 
Intervention  16.13(2.99) 16.56 (3.17) 16.68(3.21) 
F1,99.28=1.56,  
p=0.21 
F2,113.51=0.77,  
p=0.47 
F2,113.51=1.19,  
p=0.31 
Control 17.22(3.05) 17.37(3.14) 16.80(3.33) 
Effect size(99% CI) 0.26(0.81, 1.32) 0.03(-1.10, 1.17) 
BMQ Specific Concern 
Intervention  12.14(3.05) 12.01(3.22) 11.47(3.26) 
F1,99.08=0.92,  
p=0.34 
F2,109.62=1.56,  
p=0.22 
F2,109.62=0.14,  
p=0.87 
Control 12.56(3.08) 12.47(3.21) 12.18(3.37) 
Effect size(99% CI) 0.14(-0.95, 1.23) 0.21(-0.94, 1.37) 
Treatment burden 
Intervention  2.25(1.02) 1.97(1.11) 2.12(1.08) 
F1,95.53=0.46,  
p=0.50 
F2,144.13=0.71,  
p=0.50 
F2,144.13=1.91,  
p=0.15 
Control 1.98(1.03) 2.06(1.06) 1.92(1.11) 
Effect size(99% CI) 0.09(-0.28, 0.45) 0.17(-0.22, 0.57) 
Knowledge about 
methotrexate 
Intervention  18.49 (5.29) 19.86(5.47) 20.45(5.53) 
F1,96.35=2.10,  
p=0.15 
F2,95.06=5.13,  
p=0.01 
F2,95.06=1.28,  
p=0.28 
Control  17.78 (5.50) 17.98(5.63) 18.65(5.81) 
Effect size(99% CI) 0.34(-1.56, 2.23) 0.32(-1.64, 2.27) 
SD – Standard Deviation; MLM – Multi-Level Modelling; CI Confidence Interval; BMQ – Beliefs about Medicines Questionnaire; f/u – follow-up
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8.7 WHAT WERE THE MECHANISMS OF EFFECTIVENESS? 
8.7.1 Mediators of intervention effectiveness 
It was hypothesised that changes in the clinical and psychosocial variables would 
mediate the relationship between trial arm and healthcare utilisation, and trial arm 
and quality of life. The psychosocial outcomes variables which were identified as 
possible mediators were mood and quality of life (for healthcare utilisation only). The 
potential psychosocial processes which were identified as possible mediators were 
self-efficacy, illness and treatment beliefs and knowledge. 
 
As described in section 5.11.10.1 (page 225) residualised change scores were 
computed for each process variable and mediation analysis was performed using these 
changes scores and the PROCESS macro designed by Hayes (2013). This macro tests the 
statistiĐal sigŶifiĐaŶĐe of the iŶdiƌeĐt effeĐt Đ͛, ǁhiĐh is a pƌoduĐt of ĐoeffiĐieŶts of path 
a and b (Figure 8.6). The following analysis includes only those participants with 
complete cases (n=79). Multiply imputed datasets cannot be used with this macro and 
hence participants with missing data on either the outcome or mediator are not 
included in the analysis. Traditionally mediation analysis would only be recommended 
if the intervention was found to have an effect the study outcome. More recently, 
however, it has been argued this is no longer necessary for mediation to be possible 
(Hayes, 2009; Collins, Graham, & Flaherty, 1998). Therefore, mediation analysis was 
performed on healthcare utilisation and quality of life as DVs. 
 
Changes in the clinical, psychosocial process and outcome variables from baseline to 
final follow-up did not mediate the relationship between trial arm and healthcare 
utilisation, for CNS, GP, rheumatologist or overall visits as the a bias-corrected 
bootstrap CI for the indirect effect based on 10,000 bootstrap samples contained zero.  
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Figure 8.6. Simple mediation model for anxiety in the form of a statistical diagram 
 
The only significant mediator of the relationship between trial arm and quality of life 
was change in anxiety. From a simple mediation analysis conducted using ordinary 
least squares path analysis, trial arm indirectly influenced mental health quality of life 
at final follow-up through its effect on changes in anxiety over the trial period. As can 
be seen in Figure 8.6 and Table 8.14, participants in the intervention arm experienced 
greater decline in anxiety than those in the control group (a=-0.40), and participants 
who experienced greater decline in anxiety over the trial period also experienced 
increased quality of life at final follow-up. A bias-correct bootstrap CI for the indirect 
effect (ab=0.89) based on 10,000 bootstrap samples was entirely above zero (0.12 to 
2.52). There was no evidence that trial arm influenced mental health quality of life 
iŶdepeŶdeŶt of its effeĐts oŶ aŶǆietǇ ;Đ͛=-0.19, p=0.90).  
 
Table 8.14. Model coefficients for anxiety  
 Consequent 
M (anxiety)  Y (SF-12v1® MCS) 
Antecedent  Coeff. SE p  Coeff. SE p 
         
X (trial arm) a -0.40 0.22 0.07 Đ’ -0.19 1.44 0.90 
M (anxiety)  - - - b -2.23 0.73 0.003 
Constant i1 0.22 0.16 0.19 i2 30.73 1.05 <0.001 
 R2=0.04  R2=0.11 
F1,77=3.28, p=0.07 F2,76=4.85, p=0.01 
MCS – Mental Component Score; SE – Standard Error 
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8.7.2 Moderators of the relationship between intervention and healthcare 
utilisation 
Moderation analysis was performed in order to establish whether any baseline 
demographic, clinical or psychosocial variables moderated the effect of the 
intervention on healthcare utilisation or quality of life (Figure 8.7). 
 
 
Figure 8.7. Moderation model 
 
 CNS visits 
The SF-12v1.0® MCS (β= Ϭ.ϭϬ, t=ϯ.Ϭϯ, p=0.003, R2 change=0.07, F1,96=9.15) was the 
only significant moderator of CNS outpatient visits. As SF-12v1.0® MCS increased by 
one unit, the difference in the number of appointments had with the CNS between the 
intervention and control group increased by 0.10 units. The Johnson-Neyman 
technique indicated that there was a conditional effect of trial arm on healthcare 
usage only when participants scored below 34.64 on the SF-12v1.0® MCS (β=-0.43, t=-
1.99, p=0.05). Specifically, when mean SF-12v1.0® MCS scores were below 34.64 at 
baseline, the intervention decreased the number of visits to the CNS, as participants 
with a SF-12v1.0® MCS of less than 34.64 at the start of the trial assigned to the 
intervention group made fewer visits to their CNS over the trial period than those in 
the control group (Figure 8.8). 
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Figure 8.8. Moderating effect of mental health QoL on visits to the CNS 
 
 Rheumatologist visits 
There were no significant moderators of the relationship between trial arm and the 
number of outpatient visits participants had with their rheumatologist.  
 GP visits 
The only significant moderator of self-reported GP ǀisits ǁas geŶdeƌ ;β=-1.28, t=-2.84, 
p=0.01, R2 change=0.07, F1,96=8.08). Probing of the significant moderating effect of 
gender (Figure 8.9) indicated that for female participants the relationship between 
intervention arm and arthritis-related GP appointments was negative and statistically 
sigŶifiĐaŶt ;β=-0.97, t=-3.24, p=0.002) but was positive and non-significant for male 
paƌtiĐipaŶts ;β=Ϭ.ϯϮ, t=Ϭ.ϵϯ, p=0.35), meaning that females randomised to the control 
group attended more visits than females randomised to the intervention group. There 
were no differences between trial arms for male participants. 
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Figure 8.9. Moderating effect of gender on visits to the GP 
 
 Overall healthcare utilisation 
The only significant moderator of overall healthcare utilisation was baseline 
haeŵogloďiŶ leǀels ;β=Ϭ.ϴϮ, t=Ϯ.ϱϱ, p=0.01, R2 change=0.05, F1,96=6.48). As 
haemoglobin levels increased by one unit, the difference in overall healthcare 
utilisation between the intervention and control group increased by 0.82 units. The 
Johnson-Neyman technique indicated that there was a conditional effect of trial arm 
on healthcare usage when participants haemoglobin levels were below 14.26 (β=-0.91, 
t=-1.99, p=0.05). Specifically, when mean haemoglobin levels at baseline were lower 
than 14.26 the intervention decreased the number of overall healthcare visits, as 
participants with haemoglobin of less than 14.26 at the start of the trial assigned to 
the intervention group made less visits to healthcare professionals over the trial period 
than those in the control group (Figure 8.10). 
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Figure 8.10. Moderating effect of haemoglobin on overall healthcare utilisation 
 
 Quality of life 
The only significant moderator of the SF-12v1® MCS was knowledge about 
ŵethotƌeǆate ;β=-0.64, t=-2.15, p=0.04, R2 change=0.06, F1,75=4.63). As knowledge 
about methotrexate increased by one unit, the difference in SF-12v1® MCS between 
the intervention and control group decreased by 0.64 units. The Johnson-Neyman 
technique indicated that there was a conditional effect of trial arm on SF-12v1® MCS 
when participants knowledge about methotrexate was <10.88 (β=ϱ.ϮϮ, t=Ϯ.ϲϱ, 
p=0.05). Specifically, when the mean knowledge score was less than 10.88 at baseline 
the intervention increased SF-12v1® MCS. As participants with scores on less than 
10.88 on knowledge of methotrexate assigned to the intervention group had higher SF-
12v1® MCS at final follow-up than those in the control group. Figure 8.11 does not 
necessarily reflect this, which could be attributed to the fact that 91.14% of the sample 
scored over 10.88 on the scale. Therefore, this region of significance may be less 
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robust as there are not enough participants at this end of the scale to be confident of 
this claim (Hayes, 2013).   
 
 
Figure 8.11. Moderating effect of knowledge on mental health-related QoL 
 
The MeiQ™ active communication ĐoŶstƌuĐt ;β=ϱ.Ϯϭ, t=Ϯ.Ϭϲ, p=0.04, R2 change=0.05, 
F1,96=ϰ.ϮϯͿ aŶd ďaseliŶe E“‘ ;β=Ϭ.ϯϴ, t=Ϯ.Ϯϯ, p=0.03, R2 change=0.06, F1,75=4.96) were 
the only significant moderators of SF-12v1® PCS. As confidence in communicating with 
the rheumatology team increased by one unit at baseline, the difference in SF-12v1® 
PCS between the intervention and control group increased by 5.21 units at final follow-
up. As ESR increased by one unit at baseline, the difference in SF-12v1® PCS between 
the intervention and control group increased by 0.38 units at final follow-up.  
 
The Johnson-Neyman technique indicated that there was a conditional effect of trial 
arm on SF-12v1® PCS ǁheŶ sĐoƌes oŶ the MeiQ™ aĐtiǀe ĐoŵŵuŶiĐatioŶ ĐoŶstƌuĐt 
were <4.14 (β=-6.88, t=-1.99, p=0.05). Specifically, when the mean scores on the 
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MeiQ™ aĐtiǀe ĐoŵŵuŶiĐatioŶ ĐoŶstƌuĐt ǁere less than 4.14 at baseline the 
intervention decreased SF-12v1® PCS, as participants with scores on less than 4.14 on 
the MeiQ™ aĐtiǀe ĐoŵŵuŶiĐation construct assigned to the intervention group had 
lower SF-12v1® PCS at final follow-up than those in the control group (Figure 8.12).  
 
 
Figure 8.12. ModeƌatiŶg effeĐt of MeiQ™ Active Communication on physical health-
related QoL 
 
Probing of the interaction effect for baseline ESR, however, revealed no statistically 
significant transition points within the observed range of ESR levels. Figure 8.13 does, 
however, suggest that for those participants with higher ESR levels at the start of the 
trial allocation to the intervention group is associated with increased SF-12v1® PCS 
scores at final follow-up than those in the control group. 
 
Chapter 8 – Intervention Effectiveness 
 
306 
 
Figure 8.13. Moderating effect of knowledge on physical health-related QoL 
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9. CHAPTE‘ ϵ - INTE‘VENTION EFFECTIVENESS DISCUSSION 
9.1 PROLOGUE 
The aims of this RCT were to establish whether a patient-initiated and self-monitoring 
service for patients with RA or PsA on methotrexate had an impact on healthcare 
utilisation, psychosocial and clinical outcomes in comparison to usual care. An 
additional aim was to explore the mechanisms through which the intervention affected 
healthcare utilization and quality of life and the baseline variables which may have 
altered the strength of these relationships.   
 
This chapter will discuss the results presented in Chapter 8 within the context of these 
aims, along with the strengths and weaknesses of the study. In considering the findings 
of this trial it is important to locate the intervention within the current literature. The 
current intervention included a number of behaviour change techniques, focusing 
primarily on patients self-monitoring clinical information and then using this as part of 
a patient-initiated service. This type of intervention can, therefore, be placed under 
the umbrella of self-management, in that it enabled patients to manage the 
consequences of living with a long-term condition (i.e. accessing care) and 
incorporated patients monitoring their condition (Barlow et al., 2002). Therefore, 
comparisons of the effectiveness of this trial will be made in relation to chronic disease 
and arthritis self-management programmes, interventions in self-monitoring which 
were reviewed in Chapter 3 and other rheumatology based patient-initiated follow-up 
services, which were presented in section 2.5.6.1 (page 82). As the current study is the 
first to combine these approaches for patients with arthritis it is not strictly 
comparable with many previous disease management programmes but this approach 
provides an understanding of how this intervention performs in relation to other 
similar and related programmes. 
9.2 INTERVENTION EFFECTIVENESS AND MECHANISMS OF CHANGE 
9.2.1 Healthcare utilisation 
The primary outcome within this trial was healthcare utilisation, assessed in relation to 
overall arthritis-related visits in both primary and secondary care, as well individual 
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appointments with the CNS, rheumatologist and GP. The intervention had a significant 
effect on outpatient visits to the CNS resulting in fewer visits made by the intervention 
group compared to usual care, but had no effect on visits to the rheumatologist or GP.  
 
The intervention led to 55% fewer visits to the CNS compared to those in the control 
group and hence a 55% saving in regards to the cost of delivering rheumatology 
nursing care. This suggests that a large proportion of follow-up appointments in the 
CNS-led DMARD monitoring clinic were made habitually and may, therefore, not be 
entirely necessary, thus reflecting the findings of Hehir et al., (2001), which found that 
42% of all visits to rheumatologist were deemed unnecessary.  
 
A majority of participants in the intervention group had either no appointments or just 
one appointment to see their CNS over the course of the trial period, whilst control 
group participants were more likely to have either one or two scheduled visits. Whilst 
the current trial focused on reducing the number of follow-up visits scheduled within 
the nurse-led DMARD monitoring clinic all other trials of patient-initiated services in 
arthritis have sought to reduce visits to the rheumatologist (Hewlett et al., 2000; 
Hewlett et al., 2005b; Sands & Adams, 2009). It is, therefore, logical to compare the 
primary outcome in this trial with the primary outcome in these other evaluations 
rather than a comparing like for like visits.  
 
The 55% reduction in follow-up visits to the CNS found within this trial, is greater than 
the 43.8% difference in consultant reviews found by Hewlett et al., (2000) 2 years after 
implementing their patient-initiated outpatient follow-up service and is considerably 
greater than the 38% difference found after 6 years of running the same service 
(Hewlett et al., 2005b). This higher rate could be attributed to the shorter follow-up 
found within the current trial and hence a trial with a longer follow-up would be 
needed in order to compare results at the same time-point. The mean number of visits 
to the CNS in this trial per participant indicated that participants in the control group 
visited their CNS 2.37 times more than intervention participants. This reflects the mean 
number of visits to the consultant found within the trials by Hewlett et al., (2000) and 
Sands and Adams (2009).  
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The intervention did not have any effect on the number of visits patients had with 
their rheumatologist and hence there were no significant cost savings in relation to 
these consultations. In the current trial these visits were measured to ensure that 
patients did not redirect their care to other members of the specialist team and also 
because rheumatologists were not blinded to treatment group it was important to 
ensure that the rheumatologists themselves did not increase the frequency with which 
they offered intervention participants appointments. All participants in the 
intervention group did, however, have between 0 and 4 visits to the rheumatologist 
whilst the control group had between 0 and 7 visits. So although the median number 
of appointments was the same, the spread and the mean number of visits per person 
indicated that more of the intervention group attended less frequently. These effects 
are akin to the changes in nurse visits in the other trials of patient-initiated services. 
The trial by Hewlett et al., (2000; 2003b; 2005b) did not measure the effect of the 
intervention on visits to the rheumatology nurse. Sands and Adams (2009) did, 
however, find that the mean number of times patients attended the specialist nurse 
over a 12 month period was similar in the conventional and patient-initiated group. 
The current thesis, therefore, supports these findings and offers evidence for the 
potential for formal self-monitoring to reduce outpatient visits which was not 
demonstrated in the overview reported in Chapter 3.  
 
Although there were no statistically significant effects on arthritis-related GP visits and 
hence no economic savings, the intervention did lead to 39% fewer appointments with 
the GP than usual care. Despite this large reduction in GP attendance, the study was 
not powered to find an effect on this variable. Again, the aim of the study was not to 
reduce visits to the GP, these were measured to ensure that patients who were not 
scheduled to visit their CNS did not seek additional care from community services. This 
does not appear to be the case and in fact participants in the control group saw their 
GP about their arthritis almost twice as often as those in the intervention group; 
suggesting that intervention participants felt better able to manage their arthritis 
themselves rather than seek help in primary care. The reduction in arthritis-related GP 
visits in the current trial could be associated with patients feeling more empowered to 
manage their problems for longer at home as they know rapid access to the CNS was 
available if necessary, as suggested in a similar service by Pope et al., (2005). Similar 
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findings are reported in the trial by Hewlett and colleagues at both 2 (Hewlett et al., 
2000) and 6 years (Hewlett et al., 2005b) post implementation, for GP visits to the 
surgery, GP home visits and practice and district nurse consultations. The systematic 
review presented in Chapter 3 identified three reviews of self-monitoring that had 
synthesised the evidence in relation to GP attendance. All three reviews also failed to 
find any statistically significant differences in scheduled or unscheduled GP visits 
between usual care and either action planning in COPD or home blood pressure 
monitoring in hypertension (Turnock et al., 2005; Jaana et al., 2007; AbuDagga et al., 
2010).  
 
The lack of any significant indirect effect for changes in clinical or psychosocial 
variables between trial arm and healthcare utilisation in the mediation analysis 
indicated that the trial had a direct effect on healthcare utilisation, rather than via 
another mechanism. Hence simply by removing all scheduled appointments and 
delivering a needs based service, unnecessary appointments can be eliminated. There 
were, however, moderators of this relationship including gender, mental health quality 
of life and baseline haemoglobin levels.  
 
Gender moderated the relationship between trial arm and the number of arthritis-
related GP visits with females randomised to the intervention group attending for 
fewer visits than females in the control group. Men randomised to the intervention 
group, however, attended the GP as much as men in the control group. Evidence 
suggests that men are less likely to attend the GP than women generally (Jatrana & 
Crampton, 2010). An intervention of this nature was unable to alter the frequency with 
which men attend.  
 
Baseline haemoglobin levels also moderated the relationship between trial arm and 
overall arthritis-related healthcare utilisation. Specifically, participants with a 
haemoglobin of less than 14.26 at the start of the trial and assigned to the intervention 
group made fewer visits over the trial period than those in the control group. This 
result is difficult to interpret as the advisable range for haemoglobin for a patient with 
arthritis was between 12 and 17, with a drop of more than one a trigger for contact. 
Mental health quality of life moderated the relationship between trial arm and CNS 
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visits. Specifically participants with a mental health quality of life score on the SF-12© 
of less than 34.64 at the start of the trial and assigned to the intervention group made 
fewer visits to their CNS over the trial period than those in the control group. Hence 
poorer quality of life at baseline was associated with fewer visits over the trial period 
in the intervention compared to control group.  
 
These finding could raise possible concerns about patients experiencing anaemia or 
with poor mental health quality of life taking part in a self-monitoring and patient-
initiated service and attending fewer visits to the CNS. Since nurse-led consultations 
not only treat the clinical aspects of arthritis but also provide a more holistic approach 
to patient care (Goh et al., 2006) these appointments could provide an opportunity to 
address issues of physical as well as mental well-being. It is important to acknowledge, 
however, that mental health quality of life and haemoglobin did not change 
significantly over the trial period either within groups or between groups suggesting 
that not seeing the CNS as often did not have a detrimental impact on either of these 
variables.  
 
It is also worth noting that for every five telephone consultations undertaken in the 
intervention group, two led to a face-to-face outpatient appointment with the CNS. 
This 40% conversion rate is substantially higher than in the activity analysis of a 
telephone helpline by McCabe et al., (2000), in which 2.9% of calls resulted in a 
discussion with a rheumatologist. It is unclear, however, if this ͞disĐussioŶ͟ ǁas a faĐe-
to-face outpatient appointment or another telephone consultation, or if the helpline 
was in addition to usual care or an alternative to follow-up, as within the current trial.  
9.2.2 Healthcare costs 
In order to make equitable comparisons between the current trial and the trial run by 
Hewlett et al., (2000), two models of healthcare costs were analysed. One which 
included the additional costs of running the telephone consultations, as per 
Department of Health recommendations (Health & Social Care Information Centre, 
2014) and one which did not include these costs, akin to the model assessed by 
Hewlett et al., (2000).  
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The comparative model to that of Hewlett et al., (2000) indicated that a self-
monitoring and patient-initiated follow-up service was between 10.88% and 13.88% 
cheaper to run than the control group, depending on whether the estimate was based 
on the lower, upper or average Department of Health figures (Department of Health, 
2011a; Department of Health, 2013a). This was despite the additional costs of running 
the training session, the cost for the patient to travel to the hospital to attend, and the 
associated costs of running the telephone consultations for those patients in need. 
This financial gain, however, was not statistically significant. The overall cost of the 
service for 52 patients over a 256 day period (the length of the trial) was between 
£38,645 and £59,315, resulting in an average cost between £512.17 and £650.15 per 
patient. These figures are substantially higher than those reported by Hewlett et al., 
(2000) which were £208 per patient for running the service over a 12 month period. 
Although Hewlett et al., (2000) did not include outpatient visits to the CNS, they did 
include other allied health professionals appointments including the occupational 
therapist, physiotherapist, orthotist, podiatrists and orthopaedic surgeon. In addition a 
comparison of unit costs since this 2000 publication indicates that the average cost of 
a hospital doctor has almost doubled from £70 in 2000 to £133 in 2012-13. It is, 
however, unclear if the figure of £70 in the Hewlett et al., (2000) trial was specific to a 
rheumatologist or general hospital consultant. The unit cost for a GP visit has also 
quadrupled from £10 in 2000 to £39.50 in 2012-13. The cost of hospital transport has, 
however, decreased from £33.59 to £18. It is, therefore, difficult to understand 
whether these costs are comparable considering the differing times periods.  
 
The economic analysis conducted by Hewlett et al., (2000) costed 0% of the CNS time 
for running the nurse helpline. The cost of running a nurse helpline can be substantial 
depending on the size of the population. The NHS Data Model and Dictionary (Health & 
Social Care Information Centre, 2014) which provides a reference point for assured 
information standards to support health care activities states that a telephone 
consultation which directly supports diagnosis and care planning and replaces either a 
face-to-face outpatient attendance with the rheumatologist or nurse should be costed 
as such. Details of the telephone consultation should also be retained in the patient's 
records. Telephone contact solely for informing patients of results is excluded from 
this definition. It is unclear in the other trials of patient-initiated follow-up services 
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whether the telephone contact between the nurse and patient resulted in any care 
planning and hence should be costed as such. In the current trial the telephone 
consultations provided the CNS with an opportunity to assess the needs of the patient. 
In many cases the consultation was triggered by an abnormal blood test result which, 
after discussion with the CNS, required a ͞watch and wait͟ approach to see if the test 
returned to normal at the next blood test. In this case the consultation did not lead to 
any change in care and, therefore, would not fulfil the above criteria. The outcome of 
these telephone consultations, therefore, ƌaŶged iŶ theiƌ ĐoŵpleǆitǇ fƌoŵ this ͞ǁatĐh 
aŶd ǁait͟ appƌoaĐh to the ďookiŶg of aŶ outpatieŶt appoiŶtŵeŶt. It ǁas, however, 
important to consider how the expenditure on these telephone consultations would 
impact on the overall cost-effectiveness of the service. Inclusion of the telephone 
consultations meant that the self-monitoring and patient-initiated follow-up service 
was between 29.31% and 51.88% more expensive per patient than usual care and this 
difference was statistically significant at the lower, upper and average unit cost. 
Whereas without these costs the service was between 10.88% and 13.88% cheaper to 
run than the control group.  
 
Over the 39 months the trial was running, 231 telephone consultations took place for 
52 patients. That is 71 per year or 1-2 calls per week, just short of the 2.4 average calls 
per week in the Hewlett et al., (2000) trial but is almost double that reported by 
Primdahl et al., (2014). If this service was scaled up to all 450 DMARD patients at UCLH 
this would equate to approximately 12 telephone consultations per week. There are 
currently three CNSs running this clinic and, therefore, these 12 calls could be 
managed within the current roles of these existing CNSs (4 per CNS) and hence would 
not necessarily need to be costed in as an additional expenditure.  
 
Analyses of the cost-effectiveness for self-monitoring across other long-term 
conditions have also found similar effects. In a cost-effectiveness review of different 
models of care for people on long-term anticoagulation therapy Connock et al., (2007) 
found seven studies. Only one was in the UK and this study found that patient self-
management was more expensive than current routine care (£417 versus £122 per 
patient-year). Similar self-monitoring of peak flow in asthma was found to have mixed 
economic effects with some interventions demonstrating cost savings and others that 
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self-monitoring was more expensive to run than usual care or a less intensive 
intervention (Willems, Joore, Hendriks, Wouters, & Severens, 2006).  
 
These findings suggest that more work is required to establish the cost effectiveness of 
these types of interventions and a wider debate needs to take place about the cost of 
running nurse helplines in secondary care. Due to problems with data collection 
information was not available on the exact content of these telephone consultations 
but it is likely that many did not lead to any changes in care planning. There does, 
however, need to be capacity within system to take on these additional tasks. As 
highlighted in the survey by the Royal College of Nurse Rheumatology Forum (2009) 
many rheumatology nurses are being asked to change their usual work pattern or take 
oŶ eǆtƌa ǁoƌk ǁhiĐh Ŷuƌses theŵselǀes haǀe desĐƌiďed as ͞iŶĐƌeased aĐtiǀitǇ ǁithout 
iŶĐƌeased ƌesouƌĐes͟. Therefore, consideration needs to be taken when implementing 
interventions of this nature on the work load of current staff and the real cost of 
resourcing such services.  
 
It is important to acknowledge that the number of contacts patients in the control 
group had with the nurse helpline was not recorded due to problems with data 
collection. At the time of the trial usual care did not require notes to be made about 
telephone contact despite recommendations from the Royal College of Nursing (2006). 
It was likely that many of the control group participants also contacted the nurse via 
the helpline and, therefore, these should have also been included in the cost-
effectiveness analysis. This may have reduced the financial loss of providing the new 
service. Primdahl et al., (2014) did collect this data and found that there were no 
significant differences in the number of telephone consultations which were 
conducted in the shared care compared to rheumatologist-led group. This suggests 
that if the data were collected for the control group in the current trial the number of 
telephone consultations may have been the same and hence the service would more 
likely to have resulted in a cost saving.  
9.2.3 Clinical outcomes 
It was important to ensure that the intervention did not lead to any deterioration in 
clinical outcomes. Analyses of the standardized assessments indicated that a majority 
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of patients did not respond according to the disease-specific treatment response 
criteria and analyses of blood tests indicated no interaction effects between trial arm 
and time, hence confirming that the intervention did not have any detrimental effect 
on the clinical biomarkers of the diseases, or disease activity.  
 
The longitudinal analysis also confirmed no significant differences in pain, fatigue or 
functional disability between the intervention and control group over time. For 
comparison at both the 1 and 2 year follow-up Primdahl et al., (2012; 2014) found that 
there was no difference in DAS28-CRP, functional disability, pain, fatigue or the odds of 
having an out-of-range blood test, between a shared care service and rheumatologist-
led follow-up for patients with RA. Similarly, Hewlett et al., (2000) found no significant 
difference in change in disability, disease activity, CRP and haemoglobin from 0-24 
months post implementation, but did find that the shared care patients experienced 
significantly less pain than those in the control group at 24 months and increase in pain 
was also significantly less in the shared care group (Hewlett et al., 2000). At 4 years 
post implementation there were again no significant differences between the 
intervention and control group on any of these clinical outcomes except levels of pain 
which increased in the patient-initiated service and decreased in the control group 
from 24-48 months, this difference was significant but changes in pain from 0-48 
months were not (Kirwan et al., 2003b). At 6 years post intervention there were no 
significant differences between the two arms on any clinical variables including pain 
(Hewlett et al., 2005b). Although these findings are similar, care must be taken in 
extrapolating results from a short intervention and monitoring procedure as found in 
this trial to the larger time scales of past research. 
 
The evidence from Chapter 3 suggested that self-monitoring of blood tests leads to 
significant reductions in mortality and thromboembolic events for patients on anti-
coagulation therapy and significant reductions in HbA1c in diabetes. Symptom 
monitoring in heart failure also led to a significant reduction in mortality and blood 
pressure for those with hypertension. The primary aim of a majority of the primary 
research studies in Chapter 3 were to improve clinical well-being whereas the primary 
aim of the current study was to maintain clinical status whilst at the same time 
reducing healthcare usage. The failure of the current study to improve clinical well-
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being is, therefore, not unexpected particularly given the short follow-up and the distal 
relationship between observing an abnormal symptom, side effect or blood test 
results, a change in treatment and its impact upon clinical well-being (i.e. the effect for 
example of SMBG on HbA1c is likely to be more immediate). 
 
In the current trial participants in the intervention group attended more frequently for 
their blood tests than control group participants. For those in the intervention group 
this was within the 4-6 week range (average = 5.62 weeks) advised for DMARD 
monitoring, but was on average every 6.8 weeks for control group participants. 
Adherence to DMARD monitoring has rarely been reported in the literature. A 
conference abstract published by Zakout, Pugh and Healey (2009) found that of 100 
consecutive rheumatology outpatients 72% were 100% adherent with their DMARD 
blood monitoring over a 2 month period, 14% were between 80-100% compliant, 11% 
50-80% and 3% less than 50% adherent using BSR guidelines for monitoring individual 
DMARDs. Zakout et al., (2009) found no significant differences between men and 
women; however, only 50% of patients aged 30-40 achieved 100% adherent compared 
with 80% in those over 60. Worse adherence was also associated with a longer disease 
duration. Zakout et al., found that the average level of adherence had improved since 
2004 which the authors attributed to the implementation of DMARD education and 
the supply of pre-filled blood test forms sufficient to allow appropriate monitoring 
until the patients next visit. Primdahl et al., (2014), however, found that significantly 
more participants in the shared care group were less than 90% adherent to their blood 
monitoring schedule than those monitored by a rheumatologist.  
Education and the provision of pre-filled blood test forms were strategies which were 
also employed within the current intervention and could help to explain the more 
frequent attendance of intervention participants for blood monitoring and the 
difference in findings reported by Primdahl et al., (2014). The close monitoring of 
participants in the current trial may also explain these differences. Rather than having 
a set time in which participants were within the trial, the protocol dictated that 
intervention and control group participants were in the trial for a minimum of six blood 
tests. There were two reasons for this; six blood tests were considered a sufficient 
number in which participants could be deemed as being able to safely self-monitor and 
if the trial period was time limited, i.e. 6 or 12 months, it could not be guaranteed that 
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all participants would have the same number of blood tests and hence be given the 
same opportunities to gain the relevant skills. As a result of this, attendance was 
monitored more closely which could have affected adherence behaviour. Alternatively 
taking on the additional responsibility of self-monitoring may have encouraged 
participants to attend more regularly. All of these hypotheses are speculative and 
would require further investigations.  
9.2.4 Psychosocial outcomes 
 Quality of life 
Patient-initiated services are designed to not only to relieve the burden of stable 
patients in clinic but also empower patients to know more about their condition and 
take control of their monitoring and treatment. It was, therefore, hypothesized that 
the intervention group would experience significantly better quality of life post 
intervention compared to control group participants. This hypothesis was not 
supported as the study found no significant interaction effects between group and 
time on either the physical or mental health component scores of the SF-12v1®. The 
results do, however, confirm that the intervention did not have any detrimental effects 
on quality of life and thus supports the findings of other evaluations of patient-
initiated rheumatology services. 
 
Primdahl et al., (2014) is the only other trial of patient-initiated services in 
rheumatology to measure quality of life using the SF-12v1®. In comparison to a 
rheumatologist-led follow-up service Primdahl et al., (2014) also found no significant 
differences in either mental or physical quality of life at either the one and two year 
follow-up. The SF-12v1® has been found to be responsive to changes over time and, 
therefore, a lack of an effect is likely to be due to lack of differences in intervention 
efficacy (Ware Jr, Kosinski, Turner-Bowker, & Gandeck, 2002). Use of generic measures 
of quality of life allow for comparisons across chronic conditions, but may fail to 
capture the specific impact of arthritis and its associated symptoms and may, 
therefore, not be as sensitive to small, but clinically significant, changes in quality of 
life over time. A disease specific measure may have, therefore, been more sensitive to 
any changes and may have been more likely to find an effect for the intervention. 
Despite this hypothesis however, Sands and Adams (2009) assessed quality of life in 
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their evaluation of a patient-initiated follow-up service using the disease specific 
Arthritis Impact Measurement Scales-2 Short Form (AIMS2-SF) (Guillemin et al., 1997) 
and also found no significant differences between the patient-initiated and 
conventional follow-up group, although these differences were between the 
intervention and control group at a single time-point and not over time. Obtaining 
similar results on both these measures may reinforce the validity of the findings in the 
current study and could suggest that patient-initiated follow-up services are unlikely to 
change the quality of life of people with arthritis. It is also possible that quality of life 
may have failed to capture the granularity of the effects of the intervention and may 
have been too broad an outcome measure to be affected by the service. It is 
nevertheless encouraging that an intervention that required patients to pay closer 
attention to their illness and that led to significant reductions in healthcare utilisation 
did not have a detrimental effect on quality of life. 
 
The findings are, however, somewhat in contrast to the literature on self-monitoring 
which tentatively suggested an improvement in quality of life (Chapter 3). Self-
monitoring in COPD was associated with clinically significant improvements in quality 
of life, although again not statistically significant (McLean et al., 2012) and self-
management in thrombophilia, which included patients monitoring their INR values 
and adjusting their dose of anticoagulants have also been linked to enhanced quality of 
life (Siebenhofer et al., 2004; Connock et al., 2007). In contrast to the present study all 
three of these systematic reviews included trials in which participants were required to 
monitor and use this information to adjust their medication regimens. Participants in 
this trial and in other trials of patient-initiated services in rheumatology do not allow 
this level of involvement in medication titration and focus on patients using their 
symptoms and side effects, and in the case of this trial their blood test results to seek 
medical assistance. This enhanced level of self-monitoring which empowers patients to 
make decisions about adjusting their treatment may, therefore, be more likely to lead 
to improvements in quality of life, as opposed to those in which patients are required 
to seek help and decisions to adjust treatment and care remain with healthcare 
professionals. This provides support for the conclusions of the overview presented in 
Chapter 3 that suggested there may be additional benefits to patients using their 
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monitored data to adjust their own medication, lifestyle and help-seeking behaviours, 
but these relationships require further exploration.  
 Mood 
It was hypothesised that intervention participants would report improved levels of 
anxiety and depression compared with those in the control group. This hypothesis was 
not supported in relation to levels of depression or anxiety, demonstrated by the non-
significant differences between the intervention and control group participants over 
time. Both groups did decrease slightly from baseline to follow-up in contrast to the 
trial by Hewlett et al., (2000; 2005b) which reported slight increases in depression 
across their 6 year trial period, although again these differences were not statistically 
significant. It is nevertheless encouraging that an intervention which required patients 
to pay closer attention to their illness and attend fewer visits to their healthcare team 
did not have a detrimental effect on levels of depression or anxiety, replicating the 
results of self-monitoring in diabetes (Simon et al., 2008; O'Kane, Bunting, Copeland, & 
Coates, 2008).  
 
The intervention in the current study did not directly target depression or anxiety and, 
therefore, it may have been unrealistic to expect significant improvements in 
symptoms over the trial. A review of psychological, self-management and educational 
interventions in diabetes (Steed, Cooke, & Newman, 2003) suggested that in order to 
improve depression interventions need to clearly aim to address negative mood. 
Therefore, in order to improve depression the intervention would have needed to 
incorporate techniques that directly address depression. This could have included 
relaxation, biofeedback, cognitive–behavioural therapy and stress management which 
have all been found to improve depression in arthritis (Astin et al., 2002). Baseline 
levels of depression and anxiety were, however, not indicative of clinical caseness and 
in fact 85% of sample were within the normal range for depression and 66% anxiety, so 
it may not have been reasonable to expect a significant change in mood to have 
occurred.   
 
The descriptive statistics and effect size at final follow-up however, do provide 
tentative evidence that participants who received the intervention experienced less 
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anxiety compared to participants in the control group. Whereas levels of anxiety in the 
control group increased very slightly over time, intervention participants experienced a 
decrease in anxiety over the trial period. These changes did, however, occur in the 
context of a mean level of anxiety which was within the normal range. A similarly 
pattern was found by Hewlett et al., (2000; 2005b) in which anxiety levels remained 
stable in the patient-initiated service and increased in the control group, although 
these differences were not statistically significant. Sands and Adams (2009) also 
measured mood using the HADS but reported a sum score for overall negative mood 
rather than the individual subscales for anxiety and depression and found no 
significant difference between the patient-initiated and conventional follow-up service 
for patients with RA. The study was, however, a comparative pragmatic trial collecting 
data retrospectively from two groups of already established patients and hence 
changes over time were not explored.  
 
The higher levels of anxiety found within the control group at final follow-up may be 
contra to expectation as one might assume that increasing patient knowledge, 
understanding and exposure to blood test results and decreasing healthcare utilisation 
could increase levels of anxiety. The impact of self-monitoring on anxiety discussed in 
Chapter 3 suggested inconclusive results. Qualitative work in diabetes does, however, 
indicate that patients feel anxious if blood glucose readings are high and they are 
unable to understand why (Peel et al., 2004). Clinicians have also expressed concerns 
that patients predisposed to anxiety might not be suitable for self-monitoring in heart 
failure (Seto et al., 2010). In rheumatology van der Vaart, Drossaert, Taal and van de 
Laar (2013) conducted a Delphi study with healthcare professionals and also found 
that healthcare providers felt that although online access to electronic medical records 
could improve patient participation and involvement in the treatment process they 
were concerned that access to information which patients did not understand could 
cause fear and distress due to misinterpretation. The training session within the 
current intervention presented information on the meaning of blood test results, why 
results could be outside of the normal range and a specific action plan should 
abnormal results be found. This appears to have given participants reassurance and led 
to reductions in anxiety despite patients seeing their CNS and GP less often.  
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These changes in anxiety from baseline to final follow-up also mediated the 
relationship between trial arm and mental health quality of life. Participants who 
experienced a greater decline in anxiety over the trial period experienced better 
quality of life at final follow-up. Since trial arm did not directly affect mental health 
quality of life independent of its effects on anxiety this analysis demonstrates an 
indirect effect for changes in anxiety. Although both in the original model of quality of 
life by Wilson and Cleary (1995) and the revised version by Ferrans, Zerwic, Wilbur and 
Larson (2005) the individual characteristics of the patient, which include levels of 
mood, are thought to influence quality of life in a unidirectional manner. The 
relationship between mood and quality of life is likely to be somewhat bidirectional in 
that increases in quality of life may improve levels of anxiety, and vice versa (Wilson & 
Cleary, 1995). This relationship, therefore, requires further exploration in this 
population.  
9.2.5 Psychosocial process variables 
 Self-efficacy beliefs 
It was hypothesised that participants in the intervention group would experience 
increased self-efficacy compared with those in the control group. In line with social 
cognitive theory it was further hypothesised that any changes in self-efficacy beliefs 
would mediate the relationship between trial arm and healthcare utilisation and trial 
arm and quality of life at final follow-up. Baseline self-efficacy was also hypothesized to 
moderate the effects of the intervention on these outcomes.   
 
The results indicated that the first hypothesis was not supported as the interaction 
effects between group and time for generalised self-efficacy and paƌtiĐipaŶts͛ 
confidence in their ability to monitor and manage their arthritis as well as actively 
communicate with healthcare professionals, as measured by the MeiQ™ and HeiQ™ 
subscales, were not significant. There was a trend for all measures of self-efficacy to 
increase in the intervention group and either decrease or remain stable in the control 
group; however, these differences were very small. 
 
Other trials of patient-initiated services in rheumatology have also measured self-
efficacy and found differing results. Hewlett et al., (2000) measured self-efficacy using 
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the ASES developed by Lorig et al., (1989) which consists of three subscales: pain, 
function and other symptoms. Hewlett et al., (2000) found that self-efficacy for 
function was significantly higher in the intervention compared to control group at 6, 
15, 18 and 21 months post intervention, but not at 24 months. The results for the 
other subscales are not reported and are, therefore, assumed to be non-significant. 
Changes in all three self-efficacy subscales from 0-24, 24-48, 0-48 months (Kirwan et 
al., 2003b) and 0 to 6 years were not significantly different between the patient-
initiated service and usual care (Hewlett et al., 2005b). Primdahl et al., (2012; 2014) 
also used the ASES along with the RASE scale (Hewlett et al., 2001) which measures 
self-efficacy for performing 28 self-management behaviours. The authors also found 
no significant difference between the patient-initiated service and rheumatologist-led 
follow-up on any of these measures at either 3 months (Primdahl et al., 2012) or 1 and 
2 years post intervention (Primdahl et al., 2014).  
 
The GSES (Schwarzer & Jerusalem, 1995) was selected for use in this trial as in a review 
of three generalised self-efficacy measures (Scherbaum et al., 2006) only the GSES had 
been assessed for comprehensibility, reliability and validity in patients with arthritis 
(Barlow et al., 2005). Generalised self-effiĐaĐǇ ƌepƌeseŶts a peƌsoŶ͛s gloďal ĐoŶfideŶĐe 
iŶ oŶe͛s aďilitǇ to Đope aĐƌoss a ƌaŶge of deŵaŶding situations. It has, however, been 
ĐoŶĐeptualised as a tƌait ŵeasuƌe of ͞optiŵistiĐ self-ďeliefs͟ aŶd assuŵed to ďe 
relatively stable over time and domains of functioning. The lack of change in GSES in 
this study suggests that this concept may be more stable than was originally thought. 
In retrospect it seems unrealistic to have hypothesised that the intervention would 
have led to significant changes in this measure. An arthritis-specific measure of self-
efficacy like the ASES or RASE was not selected for inclusion in this evaluation as the 
intervention was not designed to change behaviour in relation to the specific subscales 
or items within these measures, such as pain or function. This may, therefore, explain 
the lack of effect found within the other evaluations of patient-initiated follow-up 
services. As these interventions were also likely to lack specific content in order to 
bring about a change in for example pain and functional self-efficacy.  
 
Bandura (2006) argued the importance of measuring self-efficacy beliefs tailored to 
specific activity domains. Hence self-effiĐaĐǇ ďeliefs iŶ ƌelatioŶ to paƌtiĐipaŶts͛ aďilitǇ 
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to self-manage and specifically self-monitor their arthritis, along with self-efficacy for 
active communication with healthcare professionals were also measured within the 
current study using the MeiQ™ and HeiQ™. These constructs were selected as they 
mapped specifically on to self-monitoring element of the intervention (i.e. MeiQ™ self-
management ability construct and HeiQ™ self-monitoring and insight construct) and 
initiation of a telephone consultations (i.e. HeiQ™ Active Communication construct) 
whilst still being applicable for participants within the control group. The current study 
found no significant interaction effect between time and group on any of these 
variables. In hindsight, a more specific measure could have been developed in order to 
assess people͛s ĐoŶfideŶĐe iŶ theiƌ aďilitǇ to iŶteƌpƌet theiƌ sǇŵptoŵs and blood test 
results and use these data to initiate a telephone consultation. Although this could 
have only been measured within the intervention group, it would have given some 
indication of whether participants felt confident about performing the specific tasks 
required in the intervention.  
 
The MeiQ™ has yet to be published by the developers, hence there are no reported 
data on how these constructs may change over time as a result of health education or 
self-management interventions and nor have the active communication or self-
management ability constructs from the HeiQ™ been measured over time. Neither 
scales have been used to evaluate self-monitoring or patient-initiated follow-up 
interventions. The original version of the HeiQ™ has, however, been used to evaluate 
general self-management interventions which included the self-monitoring and insight 
construct. Nolte, Elsworth, Sinclair and Osborne (2007) performed secondary analysis 
using data from 142 self-management courses across a range of chronic conditions, 
with osteoarthritis and RA two of the most frequently reported diseases. The authors 
also found that a majority of participants experienced either minimal or no change in 
this construct over time, a large proportion experienced substantial improvement and 
some a substantial decline. The stability found within the intervention group in this 
trial supports the findings of Nolte et al., (2007). Since this publication a number of 
other arthritis self-management interventions have also failed to find any change in 
this outcome over time. This included an evaluation of self-management and peer 
support for people with arthritis on a hospital joint replacement waiting list (Crotty et 
al., 2009), a community-based osteoporosis education and self-management course 
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(Francis, Matthews, Van Mechelen, Bennell, & Osborne, 2009) and a generic self-
management programme for a range of chronic conditions including RA (Packer et al., 
2012).  
 
As reported in Chapter 6, at the beginning of the trial there were significant ceiling 
effects for all measures of self-efficacy. Indicating that participants in both the 
intervention and control group already felt able to cope across a range of demanding 
situations, were confident in their ability to communicate with healthcare 
professionals, perform self-management tasks and monitor their arthritis. Due to these 
ceiling effects, a lack of effect, therefore, does not necessarily mean that the 
intervention could not be effective in improving these outcomes but means it was 
unlikely to happen as this population were already confident in their own abilities. 
These ceiling effects mean any analysis including these variables should be interpreted 
with caution as although the intervention may appear to have no significant impact on 
the variables there was little room for improvement (Hessling, Traxel, & Schmidt, 
2004).  
 
The second hypotheses in relation to self-efficacy beliefs was also not supported as 
changes in self-efficacy beliefs over time failed to mediate the relationship between 
trial arm and healthcare utilisation, or between trial arm and quality of life at final 
follow-up. This is the first evaluation of a patient-initiated service to look at the 
mediating effects of self-efficacy on outcomes. Other trials have considered self-
efficacy as a primary or secondary dependant variable rather than a mechanism 
through which the intervention is effective. In support of social cognitive theory 
(Bandura, 1986; Bandura, 1997) baseline scores on the MeiQ™ active communication 
construct did moderate the relationship between trial arm and physical health related 
quality of life and hence the third hypothesis in relation to self-efficacy beliefs was 
supported. The role of self-efficacy as a moderator rather than mediator for outcomes 
in RA supports the work of Schiaffmo and Revenson (1992) which suggested that 
perceived self-efficacy was a stronger moderational factor between causal attributions 
and depression and disability than mediator.  
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This study found that when participants who felt less confident in their ability to 
communicate with healthcare professionals at baseline were randomised to the 
intervention compared to control group their physical health related quality of life was 
poorer at final follow-up. This suggests that those who were less confident in 
communicating with their rheumatology team found the intervention less beneficial. 
One possible explanation for this finding is that if someone who is already finding it 
difficult to interact and communicate with their clinical team takes part in an 
intervention designed to encourage them to initiate contact with their CNS but the 
intervention fails to increase their confidence in their ability to communicate with 
healthcare professionals (as found in this trial), this may have a detrimental impact on 
their psychological well-being.  
 
As described in section 5.8.1.1 (page 204) the intervention contained a number of 
behaviour change techniques targeting two key behaviours (i) self-monitoring – 
including interpretation of symptoms and blood test results and (ii) initiating a 
telephone consultation with the CNS. The intervention contained instruction on how to 
perform the behaviour i.e. contact the CNS; however, there were no techniques which 
aimed to target people͛s aďilitǇ to ĐoŵŵuŶiĐate ǁith healthĐaƌe pƌofessioŶals ŵoƌe 
generally and at no point were barriers to seeking medical assistance explored. 
General self-management interventions in rheumatology, such as the ASMP have been 
found to significantly iŵpƌoǀe people͛s aďilitǇ to ĐoŵŵuŶiĐate ǁith theiƌ phǇsiĐiaŶ at 
both short and long-term follow-up (Barlow, Turner, & Wright, 1998; Barlow et al., 
2000) but the ASMP includes topics and skills training on how to communicate 
effectively with healthcare professionals in order to facilitate this change in beliefs and 
behaviour. Self-management interventions which include elements of communication 
skills training have also been found to improve the quality of life of patients with 
arthritis (Maisiak, Austin, & Heck, 1996). The quality of the communication patients 
have with their doctor is seen as one of the most important issues for people with 
arthritis (Buckley, Vacek, & Cooper, 1990) and good communication is engrained in 
arthritis treatment guidelines (National Institute for Health and Care Excellence, 
2013b). It, therefore, may have been beneficial to integrate these elements of 
generalised self-management programmes into this intervention in order improve 
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patients confidence and ability to interact and communicate with their healthcare 
team.  
 
In a recent evidence based analysis of self-management support interventions for 
people with chronic disease Franek (2013) conducted a meta-analysis and found a 
small but statistically significant increase in self-efficacy in favour of chronic disease 
self-management programme (CDSMP). When attempting to syntheses the evidence in 
relation to who benefits from CDSMP, of the nine studies that conducted secondary 
analysis on this question, the evidence was difficult to interpret. Many of these studies 
attempted to identify moderators or predictors of response to the CDSMP; however, 
these analyses were not identified a priori, no adjustments were made for multiple 
comparisons, and results were inconsistent across studies and varied according to 
outcome. Whilst some studies found that baseline self-efficacy and change in self-
efficacy were significant predictors of health-related quality of life post intervention 
(Reeves et al., 2008) and healthcare utilisation (Lorig et al., 2001), others failed to 
replicate these findings (Ritter, Lee, & Lorig, 2011; Harrison et al., 2011).  
 
In all of these studies however, the authors explored baseline predictors of 
intervention effectiveness. By conducting the analysis in this way it is unclear if these 
baseline variables are moderators or non-specific predictors (i.e. patient baseline 
characteristics that predict response in both treatment and control groups). 
Moderation analysis, as described by Kenny (2013), provides a complete picture of 
which participant characteristics at baseline interact with the treatment to affect the 
outcome and hence which patients might be most responsive to the treatment and for 
which patients, other, more appropriate treatments may be sought (Kraemer, Wilson, 
Fairburn, & Agras, 2002). Hence the analysis in this thesis provides more robust 
support for self-efficacy as a moderator.  
 
As far back as 1989 researchers in chronic disease self-management have highlighted 
the need to examine the mechanisms by which health education affects health status 
(Lorig et al., 1989). Despite more recent rhetoric highlighting the importance of the 
mediating role of self-efficacy on outcomes in self-management interventions (Taal, 
Rasker, & Wiegman, 1996; Jerant, Friederichs-Fitzwater, & Moore, 2005) there is still a 
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lack of studies which have explored this relationship. The mechanisms at work in 
patient-initiated interventions and self-management interventions are also rarely 
explored and, therefore, there is little evidence on the role of theoretically derived 
concepts such as self-efficacy. This trial is, therefore, one of the first to explore 
mechanisms of change and thus provide insight into who may benefit more from a 
self-monitoring and patient-initiated follow-up service or potential avenues that could 
enhance the effects of the intervention. Further studies of this kind are required to 
establish the mechanisms of action. Future trials that prospectively stratify patients 
based on hypothesized predictors of response should also be conducted to better 
confirm these findings (Franek, 2013). 
 Illness and medication beliefs 
Other variables that were hypothesized to change as a result of the intervention as 
well as have an effect on the outcome of the intervention were the beliefs patients 
held about their arthritis and medication, along with their knowledge about 
methotrexate. It was hypothesised that participants who took part in the intervention 
would experience a significant increase in knowledge about methotrexate and 
personal and treatment control compared with the control group. Intervention 
participants were also predicted to attribute fewer symptoms and consequences to 
their arthritis, experience less treatment burden and have fewer concerns about their 
arthritis and methotrexate. In line with self-regulation theory it was also hypothesised 
that changes in illness and medication beliefs would mediate the relationship between 
trial arm and outcomes, and baseline scores would also moderate this relationship. 
 
The first of these hypotheses was not supported as there were no significant 
interaction effects between trial arm and time in the MLM analyses. In order to 
understand why illness and treatment beliefs remained stable it is important to reflect 
on the content of the intervention and likelihood of change. It is surprising that the 
intervention did not affect treatment burden, concerns about taking methotrexate or 
its necessity, or the negative consequences of living with the condition since the 
content of the training session and the service aimed to teach people about their 
treatment and provide them with the skills that could reduce the burden of attending 
clinic. 
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This is the first evaluation of a self-monitoring or patient-initiated follow-up 
intervention which has explored the impact of the intervention on illness and 
treatment beliefs and whether these beliefs are the mechanisms through which these 
interventions work. Other health education and self-management interventions have 
been found to impact upon beliefs about illness, although the outcomes are not 
entirely consistent and no studies have been undertaken in arthritis. A disease-specific 
expert patient programme for people with bronchiectasis led to no significant 
differences between groups over time on any of the IPQ-R subscales (Lavery, O'Neill, 
Parker, Elborn, & Bradley, 2011) and in a review of illness perceptions in diabetes Mc 
Sharry, Moss-Morris and Kendrick (2011) identified four RCTs that had evaluated 
psychosocial interventions to improve HbA1c in type 1 and 2 diabetes. The four 
interventions consisted of structured education, SMBG or motivational interviewing 
and were found to have mixed effects on illness perceptions. One RCT found no 
significant between-group changes in any of the IPQ subscales, another found that the 
intervention led to a more negative view of diabetes and the two remaining studies 
found positive improvements in illness coherence, personal and treatment control, 
illness concern and identity. Only motivational interviewing, the only intervention to 
have a cognitive component, led to positive changes in both illness perceptions and 
HbA1c lending support to the self-regulatory model (Leventhal et al., 1980). Suggesting 
that in order to change beliefs specific cognitive strategies need to be employed within 
an intervention.  
 
According to self-regulation theory (Leventhal et al., 1980) the beliefs a patient holds 
about their illness and treatment will influence how they respond and in turn this will 
impact upon outcomes. In this trial, however, beliefs about arthritis and methotrexate 
failed to mediate or moderate the relationship between trial arm and either quality of 
life or healthcare utilisation. There is a sizeable amount of literature which has 
explored the link between illness perceptions and quality of life in arthritis. The 
dimensions of the IPQ-R that have been found to predict physical and social quality of 
life include the identity, control and consequences subscales in RA (Scharloo et al., 
1998; Graves et al., 2009; Kotsis et al., 2012) and illness identity subscale in PsA (Kotsis 
et al., 2012). These studies all indicate that more positive beliefs, i.e. attributing fewer 
symptoms to arthritis and perceiving greater control over the condition and fewer 
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negative consequences, are associated with increased quality of life. The link between 
illness and treatment beliefs and healthcare utilisation is less established. There is 
some evidence to suggest that perceiving your health problem as being highly 
symptomatic, believing it will last a long time and have serious consequences are key 
predictors of health care use in primary care (Frostholm et al., 2005). The results from 
this trial, however, fail to suppoƌt these fiŶdiŶgs aŶd to the authoƌ͛s kŶoǁledge is the 
only study which looks at the impact of illness and treatment beliefs on healthcare 
utilisation in secondary and primary care.  
 
Despite illness and treatment beliefs not being significant mediators or moderators of 
intervention outcomes, knowledge about methotrexate was a significant moderator of 
mental health quality of life; but this was not in the expected direction, considering 
knowledge remained stable over the intervention period. The intervention was found 
to be more effective, i.e. led to better mental health quality of life post intervention, 
for those participants with poorer knowledge and more specifically those scoring 
below 10.88 at the beginning of the trial. The lowest possible score on this scale is 
eight and hence 10 represents a very poor level of knowledge; however, it is important 
to consider these results in relation to the percentage of the sample who scored below 
10.88 on this measure. Hayes (2013) suggests that some caution is required when 
interpreting interaction effects. Only 8.86% of the sample or five participants scored 
below 10.88 on the knowledge questionnaire in this study. Hayes (2013) suggests that 
this region of significance may, therefore, be less robust as there are not enough 
participants at this end of the scale to be confident in this claim. The relationship still 
remains but the cut-off of 10.88 should, therefore, not be taken too rigidly. Even when 
considering this caveat as knowledge did not significantly change over time or between 
groups it is important to consider why this relationship exists. Change in anxiety from 
baseline to final follow-up was the only significant mediator of the relationship 
between trial arm and mental health quality of life. Speculatively it could be that for 
participants with poor knowledge at baseline who were randomised to the 
intervention group, their anxiety levels decreased at a greater rate than those in the 
control group and this led to better quality of life at baseline. This is theory is purely 
speculatively and further analyses would be needed to explore this relationship 
further.  
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9.3 STRENGTHS AND WEAKNESSES OF THE TRIAL 
A number of factors contributed to the strength and weaknesses of this study.  
9.3.1 Study design 
Whear et al., (2013) argued that although UK policy was eager to implement patient-
initiated services robust evaluations were still needed in order to provide a quality 
evidence base for this model of care. This was to ensure that the time of both patients 
and healthcare professionals was used efficiently and effectively without 
compromising clinical care or psychological well-being. The results of this study go 
some way to addressing this gap in the literature, and remains the only RCT to 
evaluate the use of self-monitoring of blood tests for patients with arthritis in a CNS-
led DMARD monitoring clinic.  
 
The ‘CT ƌeŵaiŶs the ͞gold͟ staŶdaƌd iŶ sĐieŶtifiĐallǇ ƌoďust ƌeseaƌĐh ŵethodologies, 
by eliminating bias and hence providing evidence for healthcare policy and practice. 
The random allocation of patients, reporting of pre and post-intervention data and 
intention-to-treat analysis all indicate the good methodological rigour of this trial 
(Michie & Abraham, 2004).  
 Random allocation  
Random allocation is undertaken in order to reduce potential bias; however, in this 
trial it was undertaken prior to baseline assessment. This was to enable the researcher 
to assign participants randomised to the intervention group to a training date prior to 
leaving the clinic, with the aim of reducing the likelihood of drop out. Randomisation 
should take place after baseline assessment so that allocation of group does not 
impact on any self-report measures. Brooks et al., (1998) found that patients who 
completed a quality of life questionnaire prior to knowing their randomization 
assignment had significantly better mental health quality of life and lower levels of 
depression compared with those who completed it after knowing their randomization 
assignment. This could indicate that participants in the current trial were significantly 
poorer in psychosocial well-being than if they had been randomised after baseline 
assessment.  
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Randomization was undertaken using a randomization plan generator (Dallall, 2010). 
Randomly permuted blocks of 10 participants were used; this ensured that for every 
10 participants entering into the study, five were randomized to the control and five to 
the intervention group. This prevented serious imbalance should the study have been 
terminated prematurely. The process of random allocation however, consists of two 
steps, generating an unpredictable random sequence and implementing the sequence 
in a way that conceals the treatments until patients have been formally assigned to 
their groups (Dettori, 2010). In the case of this trial the first step was successfully 
achieved however, the researcher was not blinded to this list. This non-concealment 
could have influenced whether a patient was included or excluded and has been found 
to bias treatment effects as much as 37% (Moher et al., 1998). This was unlikely to 
have happened as the researcher would not have known the individual patients and 
hence been able to form an impression about which group they thought they would do 
better in. This would have been of more concern if one of the clinical team had been 
randomizing patients. Central randomization or sequentially numbered sealed, opaque 
envelopes could have overcome this potential bias.  
 Blinding 
The practice of keeping the trial participants, care providers, those collecting data, and 
those analysing data unaware of which intervention is being administered to which 
participant is known as blinding or masking. Blinding is intended to prevent bias on the 
part of study personnel; however, this is a complex issue when evaluating non-
pharmacological interventions. CONSORT have amended their guidelines to recognize 
these difficulties and changed their checklist from assessing whether or not 
participants, those administering the interventions, and those assessing the outcomes 
were blinded to group assignment to whether or not those administering co-
interventions were blinded to group assignment (Boutron et al., 2008).  
 
In the current study one of the conditions of recruiting patients into the trial was 
informing the respective rheumatologist when one of their patients was consented 
and which group they were randomised to. IŶ additioŶ, the patieŶt͛s usual CN“ 
remained in charge of their care, irrespective of which trial arm they were in. 
Therefore, those delivering standard care were not blinded. As the rheumatologists 
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were not blinded to the allocation of participants it was important to ensure that the 
rheumatologists themselves did not increase the frequency with which they offered 
intervention participants appointments in their clinic or the CNS-led clinic, this was 
confirmed in the analyses of healthcare utilisation which in fact indicated a significant 
reduction in CNS visits and no significant difference in rheumatologist visits. 
Differences, however, could have occurred in other aspects of the care delivered to 
intervention participants which were not measured such as performing additional tests 
or referrals to other allied healthcare professionals.  
 Intention-to-treat analysis  
ITT analysis provides a realistic assessment of the effectiveness of the intervention in 
the real world. This means all participants analysed according to the group to which 
they were assigned, whether or not they completed the intervention. ITT analysis 
prevents bias caused by the loss of participants, which may disrupt the baseline 
equivalence established by random assignment and reflect non-adherence to the 
protocol. ITT is now widely recommended as the preferred analysis strategy for RCTs 
(Hollis & Campbell, 1999).  
 
This trial performed an ITT analysis in relation to the primary outcome measures of 
healthcare utilization and secondary clinical outcomes, which did not rely on self-
report. Assessment of baseline differences on all variables were performed according 
to ITT. It was, however, not possible to conduct a comprehensive ITT analysis when 
looking at changes over time in the psychosocial variables as data were missing for 
those participants who failed to complete a questionnaire at follow-up. Analysis as 
received was, however, maintained. In order to provide a suitable sensitivity analysis 
on all outcomes, analysis was conducted on all participants who were randomized and 
who provided data, and again for only those who completed all three self-report 
assessments. There were no significant differences between these analyses, suggesting 
that those who did not complete all assessments were no different to those who did.  
9.3.2 Study outcomes 
 Breadth of outcomes 
The study employed a wide range of study outcomes, including healthcare utilisation, 
clinical and psychosocial well-being and theoretically driven constructs such as illness 
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and treatment beliefs and self-efficacy. This enabled a comprehensive evaluation of 
the effects of the intervention from the service delivery and patient perspective. The 
primary outcomes of healthcare utilisation and quality of life allowed a direct 
comparison with other trials in the field and the measurement of psychosocial process 
variables shed light on the mechanisms through which the intervention was effective.  
 
Michie and Abraham (2004) argue that the choice of outcome is critical to any trial but 
the selection of a health outcome as an index of success is limiting. This is because 
factors other than the targeted behaviour change may affect health status, therefore, 
measuring health as a primary outcome could underestimate the effects of the 
intervention. In this study healthcare utilisation was the primary outcome measure 
and the fact that clinical and many of the psychosocial variables remain unchanged in 
this trial adds credence to this argument. This was also evidenced in the study by 
Primdahl et al., (2014) who failed to find any additional benefit to a patient-initiated 
service in comparison to a rheumatologist-led follow-up clinic; however, success was 
judged primarily in relation to clinical and psychosocial outcomes with very few 
behavioural measures of success relevant to the aims of the intervention measured in 
the trial. Clinical outcomes, however, remain an important outcome when evaluating 
alternative models of care. In order to change health policy and practice, if measures 
of behaviour are primary outcomes then at the very least the intervention should not 
have a detrimental impact on either clinical or psychosocial well-being in order to 
warrant any change in practice.  
 
As highlighted previously it may have been useful to have included a behaviour specific 
measures of self-efficacy in order to reflect the recommendations of Bandura et al., 
(1986; 1997; 2006) and provide a more detailed understanding of how confident 
patients felt in performing specific aspects of the intervention such as understanding 
and interpreting their blood results, calculating change scores and initiating their own 
reviews. Inclusion of an arthritis-specific rather than generalised measure of quality of 
life may have been more sensitive to change and provided a more detailed 
understanding of how the intervention impacted upon specific aspects of arthritis.   
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As with most studies there were a number of measures that were not included in the 
evaluation which could have provided a more detailed picture of the impact of the 
intervention and are, therefore, weaknesses of the study. Although not explored as a 
possible moderator of intervention effects Primdahl et al., (2014) collected data on 
level of education at the start of the trial and as highlighted in section 7.5.4 (page 266) 
level of education and more specifically health numeracy and literacy could have been 
important factors in how effective the intervention was and whether patients took 
part in the trial (section 6.5.1, page 247).  
 
As reported elsewhere clinical measures such as early morning stiffness, range of 
movement and grip strength (Hewlett et al., 2005b; Kirwan et al., 2003b), change in 
medications and arthritis-related complications (Hewlett et al., 2000) may have also 
provided a greater understanding of the interventions impact on clinical well-being. In 
addition outpatient visits to allied health professionals (Hewlett et al., 2000) as well as 
confidence and satisfaction in the system (Hewlett et al., 2005b; Kirwan et al., 2003b; 
Primdahl et al., 2014; Sands & Adams, 2009) could have been explored. Due to 
participant burden, the potential of poorer retention rates as a result of more 
assessments and the capacity of the researcher a decision was taken not to measure 
these outcomes.  
 Self-report  
The self-report nature of some of the measures also introduced bias. For instance the 
number GP visits were collected at each of the follow-up time points and could have 
either been deliberately altered or forgotten by patients. This is a distinct possibility 
given that Ritter et al., (2001) found that participants who took part in a CDSMP 
programme were found to significantly under report the number visits they had with 
their GP over the previous 6 months, and of the sample 61% were patients with 
arthritis. An objective measure of GP visits taken from the GP electronic health records 
would have increased the accuracy and reliability of this data, unfortunately access to 
these data was not possible.  
 Cost-effectiveness analysis  
Clinical trials are often viewed as a suitable method via which an economic analysis can 
be performed (Drummond & Davies, 1991) and MRC guidelines for complex 
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interventions states that part of the evaluation should include an assessment of cost-
effectiveness (Craig et al., 2008). Despite this, and as is typical for many trials designed 
to assess the effectiveness of an intervention, a cost-effectiveness analysis was not 
envisaged at the beginning of this trial and hence was performed post-hoc. All post-
hoc tests should be treated with caution as they could be a chance finding, despite 
being statistical significance (Rothwell, 2005). The sample size required to detect 
statistically significant differences in costs was not determined at the beginning of the 
study and is likely to be larger than those needed for trials of efficacy (Kraemer & 
Thiemann, 1987). These post hoc analyses do not necessarily mean the results are 
invalid, as they do reflect the results of other similarly conducted cost-effectiveness 
analyse (Hewlett et al., 2000) and the p-value was adjusted to 0.001 in order to 
compensate for the number of tests performed.  
A full economic evaluation is, however, complex and should include all the potential 
costs of running an intervention including direct and indirect costs in order to capture 
the impact for the patient, employer and policy maker. This trial only looked at direct 
costs, including the costs of running the service from the perspective of the NHS. By 
only looking at these outcomes the most cost-effective treatment may not always be 
the most effective treatment. In order to establish whether an intervention is both 
effective from the patient and financial perspective a cost-utility analysis is 
recommended, particularly when quality of life is either an important outcome or the 
important outcome of a trial (Cunningham, 2001). This however, was beyond the 
scope of the current study, but is recommended for future research.  
9.3.3 Generalizability 
Pincus and Stein (1996) outlined the limitations of RCTs in depicting accurate long-
term outcomes for patients with RA. The first limitation is the implementation of 
exclusion criteria. As reported in section 6.2.1 (page 229), 24.58% of patients assessed 
were not eligible to take part in the trial due to the limited inclusion criteria. The main 
reasons were: not on methotrexate, did not have RA or PsA, or were not stable. The 
inclusion criteria in this trial were selected so that the sample was a homogenous 
group of patients who were likely to be experiencing similar symptoms and side effects 
and also similar treatment plans. Although this does mean that these specific results 
are not generalizable to other rheumatic conditions or other DMARD therapies 
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hypothetically an intervention of this kind could be effective in reducing healthcare 
utilisation in any long-term conditions which require close monitoring, this has already 
been demonstrated in a range of long-term conditions as found in Chapter 3. 
9.3.4 Implementation 
In addition to the limitations discussed, a further drawback of the study is that the 
researcher rather than the CNS administered parts of the intervention. This included 
the education training session and telephone follow-ups in phase one of the trial. This 
would obviously not be possible in practice and, therefore, these elements of the 
intervention would need to be incorporated into the nurse role. This has implications 
on the generalizability of the results, as the intervention evaluated in this study would 
not be the same as implemented in practice. It is however, unlikely that the nurse 
delivering these aspects of the intervention would differ widely from that delivered by 
the researcher if a detailed protocol was used. Therefore, the influence of this factor is 
likely to be minimal.  
 
A related concern is the acceptability of the intervention by healthcare professionals 
and the potential objection of more intensive patient involvement in monitoring 
laboratory results. Despite this being part of standard care in both diabetes and anti-
coagulation therapy, this process is entirely new in rheumatology and could be 
perceived as being a step too far in patient empowerment. In a Delphi study 
conducted by van der Vaart et al., (2013), healthcare professionals in rheumatology 
felt that online access to electronic medical records could improve patient 
participation and involvement in the treatment process. They were, however, 
concerned that access to information which patients did not understand could cause 
fear and distress due to misinterpretation. Interestingly opinions varied on what 
medical data could be released to patients. According to several healthcare 
professionals information on laboratory results should not be available to patients 
until after the consultation in order to provide more explanation and to put results into 
context. The subsequent quantitative questionnaire suggested that the most 
frequentlǇ agƌeed upoŶ disadǀaŶtage ƌegaƌded patieŶts͛ skills to iŶteƌpret their 
medical information. Despite this a majority of care providers felt that laboratory 
results should be available to patients but this should be done with a lag time so that 
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any consultations came prior to reviewing. Demonstrating effectiveness for an 
intervention is an important step in informing whether an intervention should be 
rolled out across the service, but clearly the views of healthcare professionals could be 
an important barrier to implementation and this requires further exploration.  
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10. CHAPTE‘ ϭϬ - A QUALITATIVE EXPLO‘ATION OF 
INTE‘VENTION PA‘TICIPANTS͛ VIEWS ON SELF-
MONITO‘ING AND INITIATING THEI‘ OWN CA‘E. 
10.1 PROLOGUE 
This chapter outlines the methods and results from the qualitative study which directly 
followed the RCT. The aim of this study was to gain a greater understanding of the 
experiences of receiving training and taking part in the intervention by interviewing a 
consecutive sample of participants from the intervention group on their completion in 
the trial. This was to further explore perceptions of value and acceptability of this 
model of care from the patient perspective.  
10.2 RATIONALE FOR A MIXED METHODS APPROACH 
Mixed methods research has evolved as a result of the paradigm debate between 
ƋuaŶtitatiǀe aŶd Ƌualitatiǀe ƌeseaƌĐh ŵethodologies. This ͞thiƌd ŵethodologiĐal 
ŵoǀeŵeŶt͟ aƌgues that the tǁo appƌoaĐhes aƌe Đoŵpatiďle aŶd ĐaŶ ďe used iŶ 
conjunction with one another to understand an issue or problem from varying 
perspectives (Teddlie & Tashakkori, 2011). Although consensus has now been achieved 
foƌ the laďel ͞ŵiǆed ŵethods ƌeseaƌĐh͟, oǀeƌ ϭϵ diffeƌeŶt defiŶitioŶs haǀe ďeeŶ 
proposed by leading mixed methods researchers (Johnson, Onwuegbuzie, & Turner, 
2007). Based on an analysis of these 19 definitions Johnson et al., (2007) have 
proposed the following general definition: 
 
͞Miǆed ŵethods ƌeseaƌĐh is the tǇpe of ƌeseaƌĐh iŶ ǁhiĐh a ƌeseaƌĐheƌ oƌ 
team of researchers combines elements of qualitative and quantitative 
research approaches (e.g., use of qualitative and quantitative viewpoints, 
data collection, analysis, inference techniques) for the broad purposes of 
ďƌeadth aŶd depth of uŶdeƌstaŶdiŶg aŶd ĐoƌƌoďoƌatioŶ.͟ 
 
This definition refers to mixed methods research as a type of research design, and 
iŶǀolǀes ͞ŵiǆiŶg͟ ǁithiŶ a pƌogƌaŵ of ƌeseaƌĐh oƌ aĐƌoss a ĐloselǇ ƌelated set of 
studies.  
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The mixed method approach has been recommended for the evaluation of complex 
health interventions (Craig et al., 2008). In the context of an RCT designed to evaluate 
a complex intervention, qualitative research may be used before, during or after a trial 
(Simon, Claire, & Andrew, 2009). The current qualitative study was undertaken during 
the trial phase and was used to examine whether the intervention was acceptable to 
patieŶts aŶd to eǆploƌe paƌtiĐipaŶts͛ experiences. This method is known as the 
concurrent embedded strategy (Curry et al., 2013) whereby quantitative and 
qualitative data collection occurs at the same time; however, one component is 
predominant. In the case of this thesis the quantitative element was the predominant 
method and the qualitative study was embedded within this.  
 
O'Cathain, Thomas, Drabble, Rudolph and Hewison (2013) conducted a systematic 
mapping review which identified 296 RCTs that had been combined with qualitative 
research. A majority of the qualitative studies were undertaken at the pre-trial stage 
;Ϯϴ%Ϳ. OŶlǇ ϭ% ǁeƌe ĐoŶduĐted to eǆploƌe patieŶt͛s ǀieǁs aďout the aĐĐeptaďilitǇ of 
the trial in practice. The potential value of conducting research at this stage is to aid 
implementation of the intervention and add relevance and interpretation to the 
findings of the RCT (O'Cathain et al., 2013). By embedding a qualitative study into the 
RCT this thesis aimed to explore this model of care from the patient perspective in 
order to provide a better understanding of the findings of the RCT, whilst enhancing 
the benefits of these individual methods and overcoming their limitations. 
10.3 AIMS AND OBJECTIVES OF THE STUDY 
The attitudes, experiences and expectations of patients are essential to the 
implementation of any new model of care. The aims of this study were, therefore, to 
explore not only the experiences of participation from the patient perspective but 
specifically the value placed on the intervention and implementation of this new 
model of care.  
10.4 ETHICS APPROVAL 
The study received full ethics approval from Camden and Islington Community Local 
Research Ethics Committee (Ref. 09/H0722/91).  
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10.5 STUDY DESIGN  
This qualitative study utilised semi-structured interviews. Individual interviews were 
selected over focus groups primarily because data collection could take place 
immediately following participation rather than waiting for a sufficient number of 
people to complete the trial before a focus group could commence. This allowed the 
experience to be fresh in the minds of the participants and reduced the likelihood of 
recall bias which can be problematic when collecting retrospective data (Hassan, 
2006). 
10.6 PROCEDURE 
10.6.1 Identification of participants and consent  
All intervention group participants who took part in the RCT were eligible for 
participation in the interview study. As part of obtaining consent for the RCT 
participants were asked if they would be willing to be approached to take part in a 
qualitative interview at the end of their participation in the trial. At which point 
participants were written to and asked if they would be willing to be interviewed. 
Additional written consent was obtained before the interview was undertaken 
(Appendix AA). 
10.6.2 Location of the interview 
All interviewees were offered a choice of location either at home, at the hospital or 
university, and at a time convenient for them.  
10.6.3 Topic guide 
The topic schedule was developed by the researcher in collaboration with the 
supervisory team and covered the decision to take part in the trial, questions about 
the training and information received in the education session, the tasks involved and 
their reflections on their experiences, views of standard care and the value they 
attached to the system introduced as part of this study (Figure 10.1). The semi-
structured nature of the interviews meant that rather than using the guide as a strict 
interview schedule questions were used as prompts for discussion.  
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1. Can you tell me the reasons why you decided to take part in this trial? 
2. Can you tell me what expectations you had at the start of the trial? 
3. Was the information we provided to you [in the training session] clear in 
outlining what the study was about in relation to what actually happened? 
4. How useful did you find the training session? 
5. Prompt: information, skills, did you learn anything new 
6. At the end of the training session were you clear about what you had to do? 
7. Was there other information that would have been useful? 
8. What was it like receiving your blood test results?  
9. Prompt: were they on time, what did you do if they did not arrive? 
10. How did you feel about interpreting your results? 
11. How easy or difficult did you find interpreting the blood test results and your 
symptoms? 
12. How did you find the telephone calls with the researcher? 
13. How did your experience compare with your normal care? 
14. Can you describe what it was like not visiting your nurse specialist face to 
face? 
15. Has taking part in the study changed your relationship with the rheumatology 
team? 
16. How did it feel when the programme ended? 
17. Has the programme made you feel differently about your future care? 
18. Are there any changes you would recommend? 
19. Is there anything else you would like to tell us about your experience of the 
pƌogƌaŵŵe that ǁe haǀeŶ͛t Đoǀeƌed? 
20. Would you recommend this way of care to other patients with arthritis?  
Figure 10.1. Interview guide for qualitative study 
 
All interviews were conducted by the researcher, digitally recorded with the 
paƌtiĐipaŶt͛s peƌŵissioŶ aŶd tƌaŶsĐƌiďed ǀeƌďatiŵ, ǁith aŶǇ ideŶtifiaďle data ƌeŵoǀed. 
The researcher made notes after each interview outlining their initial impressions of 
how the iŶteƌǀieǁ ǁeŶt, aŶǇ faĐtoƌs ǁhiĐh ŵaǇ haǀe iŶflueŶĐed the paƌtiĐipaŶts͛ 
responses and any potential themes or sub-themes which emerged. 
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10.7 SAMPLE SIZE 
As opposed to quantitative research which aims to count opinions or beliefs, 
qualitative research is about the richness of the data and hence sample size 
calculations are not conducted in the same way (Kuzel, 1992). The study aimed to 
recruit an initial sample of 10 interviews with a stopping criterion of a further three 
interviews to confirm that data saturation had been achieved, as suggested by Francis 
et al., (2010). Data saturation was defined as the emergence of no new themes in 
relation to the research question. In practice, this meant that the interviewer had a 
sense of when nothing new was emerging from the interviews in relation to the 
research question and then begin coding to explore the reality of this. If saturation is 
not reached this simply means that the phenomenon has not yet been fully explored 
rather than that the findings are invalid (Morse & Field, 1995).  
10.8 ANALYSIS 
The data generated from these semi-structured interviews were analysed using 
thematic analysis (Braun & Clarke, 2006) which is a method for identifying, analysing 
and reporting patterns within data. This method was selected as it is flexible, allows 
themes to be identified across a dataset, is suitable for larger samples and appropriate 
for use in studies with a focused research question, as in the case of this study.  
 
Grounded theory (Glaser & Strauss, 2012) was not selected as this aims to develop a 
theory from the data which was not the overall aim of the study. Interpretative 
Phenomenological Analysis (IPA) was not chosen because thematic analysis focuses 
mainly on patterns of meaning across participants whereas IPA has a dual focus on the 
unique characteristics of individual participants and on patterns of meaning across 
participants (Smith, Flowers, & Larkin, 2009). The current study was not concerned 
with the experience of individuals per se but the experiences across the sample. In 
addition IPA requires a small homogenous sample of between three and six 
participants (Smith et al., 2009) which in the context of this study was not deemed 
appƌopƌiate to eǆploƌe a full ƌaŶge of paƌtiĐipaŶts͛ eǆpeƌieŶĐes. Fƌaŵeǁoƌk aŶalǇsis 
(Ritchie & Spencer, 1994; Ritchie, Spencer, & O'Connor, 2003) a type of thematic 
analysis was considered as a legitimate alternative to the methods outlined by Braun 
and Clarke (2006). As the researcher had experience of thematic analysis in a number 
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of other studies (Griva et al., 2013; Walker, James, & Burns, 2012) this method of 
analysis was deemed most appropriate. 
 
Thematic analysis involves searching across a data set to find repeated patterns of 
meaning. All coding was undertaken manually by the researcher following six steps: 
 
Phase One: Familiarizing yourself with your data – In order to get to know the data, 
the transcripts were first checked for errors by listening to the digital recordings. They 
were then read and re-read and by actively searching for meaning within the text, the 
researcher made some initial notes about possible themes and patterns. The 
researcher did not complete transcription of the interviews and as transcription is seen 
as a key part of the analysis process (Bird, 2005) additional time and focus were placed 
on this phase of the analysis in an attempt to overcome this potential limitation.  
Phase Two: Generating initial codes – Using the preliminary list of themes and 
patterns produced in phase one, the researcher then set about generating an initial set 
of codes from the data. A code is defined as a feature of the data that is interesting to 
the researcher, and is the most basic element of the raw data that can be assessed in a 
meaningful way (Boyatzis, 1998). Relevant parts of the transcripts were highlighted in 
the text and given a code in the margin that best described that excerpt. Text thought 
to be in the same code were highlighted in the same colour in order to indicate 
possible patterns within the data. When overlap occurred, or a piece of text was 
thought to relate to more than one code, this was highlighted in the margin. Additional 
notes were also taken in a separate notebook if any initial themes came to mind.  
Phase Three: Searching for themes – When all the data had been coded, the codes 
were collated into one list and then the process of clustering codes into coherent 
groups began. This was achieved by writing the codes on post-it notes and then using a 
large surface to group codes together.  
Phase Four: Reviewing themes – This phase involved letting go of themes that did not 
have sufficient data, collapsing themes together and breaking others down further. 
This was achieved by going back to the original extracts within each code and reading 
these within a theme to ensure they grouped together meaningfully (internal 
homogeneity), whilst checking that both the themes and codes were distinct from one 
another (external heterogeneity) (Patton, 1990). When there was inconsistency the 
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ƌeseaƌĐheƌ ͞stepped ďaĐk͟ to eǀaluate ǁhether the theme was a problem or a 
particular extract within the theme was better represented elsewhere or dropped 
altogether. When a coherent pattern had formed within a theme these were refined 
using a thematic map which represented the data as a whole.  
Phase Five: Defining and naming themes – Once the thematic map had been finalised 
the themes were renamed where necessary in order to reflect the true meaning of the 
theme and decide what aspect of the data it was aiming to capture. 
Phase Six: Producing the report - The results of this analysis are presented in this 
chapter. The results aim to tell the story of the data in a manner that answers the 
primary research question and includes quotes in order to demonstrate and support 
each of the codes and themes; and is part of an overall analytic narrative which will be 
reviewed in the discussion. 
 
In addition to this six phase process, four validity criteria were employed: 
  Audit Trail: Detailed Ƌuotes fƌoŵ the paƌtiĐipaŶts͛ tƌaŶsĐƌipts pƌoǀided 
evidence for the interpretation of the data.   Peer Panel: An auditor was asked to go through randomly selected sections of 
25% (n=3) of transcripts to confirm the pattern of analysis.   ‘eseaƌĐheƌ ‘efleǆiǀitǇ: This is the ƌeseaƌĐheƌs͛ atteŵpt to ƌeĐogŶize theiƌ oǁŶ 
values, interests and views and the role that they may play in their 
understanding of the transcripts. Doing this can help the reader to interpret the 
ƌeseaƌĐheƌ͛s data aŶd aŶalǇsis. A ƌefleĐtiǀe diary was kept by the researcher, 
where notes were taken about initial thoughts and feelings, the main points 
that arose in the interview and any factors that the researcher felt influenced 
the interviewee. These were taken into account throughout the analysis 
process.   Independent Audit: An independent auditor familiar with thematic analysis was 
asked to ĐheĐk the ǀaliditǇ of the ͞fiŶal ƌepoƌt͟. 
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10.9 RESULTS 
10.9.1 Sample characteristics 
All 52 intervention participants were eligible to take part in the study and agreed to be 
approached to take part in a qualitative interview at the end of their participation in 
the trial. A total of 12 (27.91%) semi-structured interviews were conducted which is 
deemed adequate for mixed methods studies (Sandelowski, 1995; Francis et al., 2010), 
at that point no new themes were emerging. To achieve this sample a total of 43 
participants who completed the trial were approached to take part in an interview. All 
of the interviews took place either in a room at University College London (a location 
Ŷeaƌ to UCLHͿ oƌ at the paƌtiĐipaŶts͛ plaĐe of ǁoƌk. The iŶterviews lasted between 20 
and 38 minutes. Participant characteristics can be found in Table 10.1.
  
3
4
7
 
Table 10.1. Participant characteristics for interviewees 
ID Gender Age Condition 
Disease duration 
(years) 
MTX duration 
(years) 
MTX dose 
;ŵgͿ† DASϮϴ† 
PsARC  
phǇsiĐiaŶ† 
PsARC  
patieŶt† 
PsARC  
teŶder† 
PsARC  
swolleŶ† 
5 Female 76 RA 26 1 12.5 6.13 - - - - 
7 Male 49 RA 8 5 10 3.46 - - - - 
23 Female 44 RA 7 5 7.5 4.20 - - - - 
31 Female 47 RA 22 17 22.5 3.76 - - - - 
53 Male 50 RA 10 5 15 3.42 - - - - 
56 Female 64 RA 22 5 15 5.67 - - - - 
71 Female 58 PsA 3 1 10 - 2 2 3 1 
78 Male 60 PsA 11 10 20 - 2 1 17 2 
80 Male 35 PsA 4 2 15 - 2 2 14 1 
81 Male 27 PsA 6 4 17.5 - 2 1 0 0 
82 Male 66 PsA 31 16 15 - 2 2 21 5 
83 Male 76 RA 7 6 7.5 1.72 - - - - 
ID – Identification Number; MTX – Methotrexate; DAS28 – 28-item Disease Activity Score; PsARC – Psoriatic Arthritis Response Criteria; RA – Rheumatoid Arthritis; PsA – Psoriatic 
Arthritis 
† - at baseline 
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10.9.2 Themes 
The analysis revealed five themes talked about by a majority of participants in relation 
to their experience of and the value they placed on both usual care and the self-
monitoring and patient-initiated service.  
 
Theme One – Burden of usual care 
Sub-theme: Efficiency 
Sub-theme: Impact on work life 
Sub-theme: Normality 
Theme Two – The self-management process 
Sub-theme: Knowledge 
Sub-theme: Control 
Sub-theme: Behavioural adjustment 
Theme Three – Conflict 
Sub-theme: Between laboratory tests and symptoms 
Sub-theme: Between study guidelines and practice 
Theme Four – Anxiety 
Theme Five – A tailored service 
Sub-theme: Right time 
Sub-theme: Right method 
Figure 10.2. Qualitative themes 
 
 Theme one – burden of usual care 
With few exceptions participants described attendance for rheumatology outpatient 
visits prior to the commencement of the trial as ͞ďuƌdeŶsoŵe͟, ͞useless͟ and an 
͞aďsolute ǁaste of tiŵe͟. Patients felt quite strongly that usual care was inconvenient 
and did not meet there desire to lead a ͞Ŷoƌŵal͟ life. Whilst self-monitoring and 
initiating their own care was ͞ŵuĐh ŵoƌe ĐoŶǀeŶieŶt͟ and ͞took aǁaǇ a ďuƌdeŶ͟.  
10.9.2.1.1 Sub-theme – Efficiency 
All participants spoke about their rheumatology outpatient appointments being ͞a 
ǁaste of tiŵe͟ (EK) for both them and the clinical team ͞soŵetiŵes, Ǉou kŶoǁ theǇ aƌe 
a ǁaste of tiŵe foƌ eǀeƌǇoŶe I thiŶk͟ ;A“Ϳ. Many participants described situations in 
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which they had made the journey to hospital, waited in some cases for hours and were 
then seen by the CNS for a matter of minutes. These appointments often consisted of 
discussions around what patients felt were very minor symptoms or were used to 
obtain blood tests forms; activities which could have been dealt with in other ways. 
These appointments often led to no changes to treatment, which patients found 
eǆtƌeŵelǇ fƌustƌatiŶg, uŶŶeĐessaƌǇ aŶd aŶ iŶeffiĐieŶt use of eǀeƌǇoŶe͛s tiŵe. 
 
͞it just seeŵs to ďe ŵoƌe effiĐieŶt use of eǀeƌǇďodǇ's tiŵe, ŵiŶe, [the 
Ŷuƌse’s] aŶd ǁhǇ should the hospital Ŷeed to ďotheƌ ǁith aŶ 
appoiŶtŵeŶt foƌ soŵethiŶg that is ƌeallǇ stƌaight foƌǁaƌd͟ – NP 
 
͞….todaǇ I ŵeaŶ [the Ŷuƌse] ǁas ƌuŶŶiŶg half aŶ houƌ late, ŵǇ 
appointment was at 11.15 and it was in fact at 11.45 but I was out of 
[the Ŷuƌse’s] offiĐe ďǇ ϭϭ.ϱϬ foƌ a ϭϱ ŵiŶute appoiŶtŵeŶt, ďasiĐallǇ ǁe 
doŶ’t haǀe aŶǇthiŶg to saǇ, theƌe aƌeŶ’t aŶǇ issues aŶd ƌeallǇ the ǁhole 
puƌpose ǁas foƌ ŵe to get soŵe ŵoƌe ďlood test foƌŵs.͟ – PN 
 
͞No, I thiŶk that ǁas oŶe of the ƌeasoŶs ǁhǇ I found it quite irritating 
was that when I came to see the rheumatologist you know I waited for 
like two hours sometimes and got seen for two minutes, seeing the 
nurse was better it was pretty quick, but still generally things were ok so 
I just got sent away again it seemed a bit tedious to wait all that time to 
ďe told eǀeƌǇthiŶg ǁas fiŶe Đoŵe ďaĐk iŶ a Đouple of ŵoŶth.͟ – JD 
 
This was not due to the capabilities of the CNS ͞…Ŷo ĐƌitiĐisŵ of [the Ŷuƌse] ďeĐause it’s 
aďsolutelǇ Ŷot͟ ;EKͿ but was due to the perceived lack of value or usefulness of 
appointment. 
  
͞Well, I tƌǇ to ŵake theŵ ĐoiŶĐide ǁith doiŶg a ďlood test so to that 
eǆteŶt it ǁas Ŷot a huge iŵpositioŶ aŶd it’s alǁaǇs ŶiĐe to see [the 
nurse] and she is always friendly, a cheerful kind of persoŶ so it’s Ŷot 
oŶeƌous at all ďut eƋuallǇ I ǁouldŶ’t saǇ it ǁas ǀeƌǇ ǀaluaďle.͟ – VH 
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10.9.2.1.2 Sub-theme – Impact on work life 
For those participants who were in employment, the impact of attending outpatients 
appointments along with juggling the other demands of monitoring their condition 
such as attending for the blood test, obtaining blood test forms and the difficulties 
involved in obtaining prescriptions was a challenge. This led to frustration and was 
hence a driver for taking part in the trial.  
   
͞I thiŶk foƌ me the most burdensome aspects of having to be on this 
medication is the fact that there was a period where I was having to go 
into hospital pretty much every month, probably more than every month 
the combined total of coming to see the nurse, having blood tests done, 
getting your prescription and seeing the rheumatologist quite regularly 
and it was quite inconvenient for me, because I was having to do it 
during work hours most of the time and so the idea of me being able to 
do some part of that at home and, therefore, removing the need to be in 
hospital quite so often I thought was really attractive so it was fairly 
selfish reasons I would have to admit, but, yeah that was kind of 
attƌaĐted ŵe to [the studǇ] I guess͟ – JD 
 
Those in current employment or who had been employed at some point since their 
diagnosis spoke about the frustration of trying to fit in regular appointments around 
their work commitments. Regular reviews with the CNS were described as ͞ĐoŵiŶg at 
a Đost͟, both in terms of time as described above but also financially as a result of 
missed work time particularly for those on an hourly wage. Again participants spoke 
about this in the context of unnecessary appointments which led to little or no changes 
to treatment which further compounded the frustration.  
 
͞You kŶoǁ, aŶd I’ǀe speŶd ϰϱ ŵiŶutes iŶ the ǁaitiŶg ƌooŵ aŶd Ǉou 
kŶoǁ, it Đoŵes at a tiŵe Đost, paƌtiĐulaƌlǇ ǁheŶ Ǉou’ƌe paid ďǇ the houƌ 
it ĐaŶ Đoŵe at a ŵuĐh laƌgeƌ Đost͟ A“ 
͞Yeah, I ŵeaŶ I ǁas ǁoƌkiŶg iŶ those daǇs aŶd I’d haǀe to take time off 
to fit in and go to the hospital and then see either [the nurse] or [the 
consultant] and invariably everything was okay it was just follow ups to 
Chapter 10 – Qualitative Study 
 
351 
make sure that everything was okay. Well now I don't have to do that 
because if I can monitor my own ƌesults, I oŶlǇ go to see theŵ if it’s 
absolutely necessary, saves them time and saves me as well, saves them 
ďotheƌiŶg.͟ – AP 
 
͞AŶd the otheƌ thiŶg ǁas that [the Ŷeǁ seƌǀiĐe] ŵeaŶt oŶe less ǀisit to 
the hospital and because I work full-time I thought that is definitely 
going to benefit me and especially as the nurse starts at 9.30 and 
because I work full-tiŵe it ǁas aŶ issue ďeĐause I ǁasŶ’t gettiŶg iŶ to 
ǁoƌk uŶtil afteƌ the ϭϬ o'ĐloĐk deadliŶe͟ – EK 
10.9.2.1.3 Normality  
Although in all cases employees were understanding, one participant spoke about how 
she did not want to draw attention to her illness by taking time off to attend 
appointments. This participant worried that as a result of being late and taking time off 
colleagues would think that she was not committed to her job. Self-monitoring and 
initiating her own care allowed her to spend less time at the hospital and hence feel 
more ͞Ŷoƌŵal͟. This sense of normality was spoken about by another patient, who 
also felt that attending clinic regularly did not allow him to lead a ͞Ŷoƌŵal͟ life.  
 
͞The number one thing I do is keep my appointments to outside of work 
tiŵe so that Ŷo oŶe kŶoǁs I’ŵ at the hospital͟ – EK 
 
͞ǁell if Ǉou’ƌe ǁell Ǉou doŶ't ǁaŶt to ďe iŶǀolǀed iŶ these tǇpes of thiŶgs 
[attending clinic], you waŶt to ďe gettiŶg oŶ ǁith life like Ŷoƌŵal͟ DW 
 Theme two – the self-management process 
The knowledge gained in the training session paired with the ability to initiate their 
own care allowed patients to obtain greater control over their illness and its 
treatment. It also made the link between taking their medication, lifestyle and the 
impact these were having on the results of their laboratory tests and their symptoms 
more salient, suggesting behavioural adjustment was taking place.  
10.9.2.2.1 Sub-theme - Knowledge  
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All participants felt that the training session increased their knowledge of their 
arthritis, the available treatment options - which in some cases had never been 
explained to them the reasons why they were having regular blood tests and their 
meaning, along with the important symptoms and side effects that needed to be 
monitored.  
 
͞I pƌoďaďlǇ leaƌŶt, Ǉou kŶoǁ, soŵe of the iŶfoƌŵatioŶ that ǁas pƌoǀided 
with the training in terms of the disease and the medication. I mean it 
was actually, quite good to have.͟ A“ 
 
͞I did eŶjoǇ ďeĐause it gaǀe ŵe aŶ iŶsight iŶto ǁhat the hieƌoglǇphs 
were that I was getting for my blood tests and now I know what to look 
foƌ. You kŶoǁ aŶd the ƌaŶges, if ŵǇ ďloods aƌe iŶ ĐeƌtaiŶ liŵits͟ – AP 
 
͞I ǁaŶted to kŶoǁ ŵoƌe aďout the ĐoŶditioŶ aŶd I thought I’d pƌoďaďlǇ 
kŶoǁ ŵoƌe fƌoŵ this pilot thiŶg aŶd I aĐtuallǇ did.͟ – EK 
 
One patient appreciated that we had ͞just put it all iŶ a paĐkage aŶd ƌeŵiŶded ŵe of 
thiŶgs͟ ;EKͿ, as information was often delivered primarily at diagnosis but then 
sporadically throughout the disease course.  
 
This knowledge allowed people to feel more involved in the consultation process, 
which provided them with the ability to ask more relevant questions of their clinical 
team and also to be an active participant in the treatment process. 
 
͞But yes I was probably more knowledgeable and I was able to ask him 
ŵoƌe ƌeleǀaŶt ƋuestioŶs.͟ EK. 
 
͞AŶd so, Ǉou kŶoǁ, if I Đould ďe iŶǀolǀed ǁith this aŶd also that it ǁas a 
little bit with more, you know, taking kind of control and understanding, 
you know, more involved what was actually going on rather than going 
off and getting tests done and not knowing what it means, and waiting 
foƌ soŵeoŶe to tell Ǉou that eǀeƌǇthiŶg is OK.͟ A“ 
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10.9.2.2.2 Sub-theme - Control 
A sense of control was identified as important by all participants. Patients felt that 
their increased knowledge, along with the additional responsibility of initiating their 
own care allowed them to feel more control over their health in general.  
 
͞I guess it's Ƌuite ŶiĐe to haǀe more responsibility for my own health it's 
ŶiĐe͟ – JD 
 
͞AŶd Ǉes that ǁas a ďoŶus as ǁell it ǁas haǀiŶg the ƌespoŶsiďilitǇ foƌ 
Ǉouƌ oǁŶ health as ǁell I thiŶk that helps defiŶitelǇ͟ – EK 
 
As well a general sense of control, many participants spoke about feeling in control of 
their arthritis and specific aspects of living with their condition such as accessing care 
when they wanted to rather than it being dictated by the clinical team and hence the 
ability to manage their own time effectively. This allowed them to take ͞oǁŶeƌship͟ of 
their illness and treatment. 
 
͞…aŶǇthiŶg I ĐaŶ do to gaiŶ ŵoƌe iŶfoƌŵatioŶ, ŵoƌe iŶsight aŶd haǀe 
ŵoƌe ĐoŶtƌol oǀeƌ ŵǇ illŶess the ďetteƌ͟ – JH. 
 
͞BeĐause at the eŶd of the daǇ, if I go to [the Ŷuƌse] aŶd saǇ to heƌ ŵǇ 
hands are sore, whether I say it to her over the phone, the end result is 
same and the one over the phone is me doing it and organizing it myself 
ǁithout haǀiŶg to go iŶto a hospital aŶd do it͟. DW 
 
͞…it’s just ŵoƌe ĐoŶtƌol of ŵǇ oǁŶ tiŵe…..it alloǁs ŵe to ĐoŶtƌol the 
ŵoŶitoƌiŶg to suit ŵǇ ƌeƋuiƌeŵeŶts ƌatheƌ thaŶ the hospital sĐhedule͟ – 
NP 
 
͞I thought it ǁas iŵpoƌtaŶt to oǁŶ Ǉouƌ illŶess, Ǉou kŶoǁ ǁhat I ŵeaŶ 
to take ƌespoŶsiďilitǇ foƌ it ďǇ lookiŶg at the data͟ – PN 
10.9.2.2.3 Sub-theme – Behavioural adjustment 
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A number of participants felt that self-monitoring allowed them to make a connection 
between their behaviour and laboratory results and provided them with the 
opportunity to understand how their condition was changing over time in a more 
systematic manner. It enabled them to see how taking new medications or increasing 
their dose of current medications had an effect on their laboratory results and hence 
see the link between medication and blood results as well as see tangible 
improvements or deteriorations in their arthritis.  
 
͞No pƌoďleŵ, it’s alǁaǇs Ƌuite iŶteƌestiŶg aĐtuallǇ iŶ soŵe ǁaǇs it’s 
better than going to see [the nurse] because she says this was up and 
that was up and you think what does it mean but when I read what the 
iŶitials staŶd foƌ, ǁhat I’ŵ ŵoŶitoƌiŶg aŶd it’s iŶteƌestiŶg to see hoǁ 
theǇ ĐhaŶge fƌoŵ ďlood test to ďlood test͟ – ME 
 
͞…seeiŶg ŵǇ ƌesults has eŶaďled ŵe to uŶdeƌstaŶd ŵǇ ďodǇ aŶd its 
ƌeaĐtioŶs to the disease aŶd to ŵethotƌeǆate.͟ – RG 
  
Having access to their laboratory data was described as being better than 
pharmacological treatments, as having understanding of why they were feeling unwell 
or why their laboratory tests were abnormal enabled them to take control of how they 
managed they arthritis and allowed them to change their behaviour accordingly.  
 
͞iŶfoƌŵatioŶ teŶds to ďe ďetteƌ thaŶ pills soŵetiŵes, Ǉeah ďeĐause if 
Ǉou kŶoǁ ǁhǇ Ǉou aƌe feeliŶg that ǁaǇ oƌ ǁhat’s happeŶiŶg, Ǉou’ƌe iŶ 
ĐoŶtƌol of it theŶ Ǉou’ƌe also iŶ ĐoŶtƌol of ǁhat Ǉou do͟ – DW 
One participant spoke about how his alcohol intake, diet and smoking had an effect on 
his symptoms and laboratory results. As a result he had already made steps to change 
his behaviour including stopping smoking which he felt had led to better control of his 
arthritis. He also pondered on whether changes in his alcohol consumption, either by 
drinking less or by drinking more water after consuming alcohol, would alter his liver 
function tests.  
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͞Yeah I ŵeaŶ if I had a glass oƌ Ϯ oǀeƌ the ϭϬ [uŶits of alĐohol] liŵit [ŵǇ 
liver function test] was fractionally higher, or if I had put on a bit of 
weight it got a bit higher and maybe the fat content of the food. I would 
have thought that there would be a relationship between something, 
ďeĐause if Ǉou ǁeŶt oŶ a dƌiŶkiŶg ďiŶge theŶ it’s goiŶg to go up. “o 
there are obviously some, some kind of causal relationship but is there 
aŶǇthiŶg else I doŶ’t kŶoǁ. You kŶoǁ fiŶished Ǉouƌ dƌiŶk aŶd theŶ Ϯ 
litƌes of ǁateƌ oǀeƌ the Ŷeǆt Ϯ daǇs does it Đoŵe ďaĐk doǁŶ agaiŶ I doŶ’t 
kŶoǁ͟ – PN 
 Theme three - conflict  
10.9.2.3.1 Sub-theme – Between laboratory tests and symptoms 
Patients expressed confusion about the disparity between their laboratory tests and 
the symptoms and side effects they were experiencing. In many interviews participants 
reported excruciating pain and swelling but their inflammation markers failed to 
reflect these symptoms, which they found confusing. One participant attributed this 
lack of concordance to the fact that he had arthritis in many of his joints and he felt 
that his CRP would only go up when his flare was extremely severe and not in the case 
of short periods of ͞feeliŶg ƌough͟. He, therefore, regarded the test as ͞useless͟. 
 
͞Yeah, I doŶ’t kŶoǁ ǁhǇ [CRP is loǁ] I doŶ’t kŶoǁ if it’s ďeĐause, 
because I have the arthritis in so many joints. So actually in many ways 
it’s Ŷot a ďig flaƌe. Theƌefoƌe, CRP doesŶ’t piĐk it up ďut it’s affeĐtiŶg ŵe 
iŶ so ŵaŶǇ plaĐes that its ŵakiŶg ŵe feel ƌough. I siŵplǇ doŶ’t, I doŶ’t 
kŶoǁ ǁhat that it…..ďut iŶ ŵǇ Đase aĐtuallǇ, ǁheŶ ŵǇ aƌthƌitis flaƌes, 
[CRP] doesŶ’t ĐhaŶge ǀeƌǇ ŵuĐh so it’s Ŷot ŵuĐh use to ŵe͟ – AS  
͞I get ĐoŶfused ďeĐause soŵetiŵes the ƌesults ǁould tell ŵe the 
opposite of ǁhat I’ŵ feeliŶg aŶd soŵetiŵes, like Ǉou aƌe loǁ, Ǉou go foƌ 
a test and you got low inflammatory factors but your hands are puffed 
up and you’ƌe iŶ paiŶ͟ – DW 
 
This lack of concordance led one participant to question his diagnosis as even though 
he was experiencing what he described as a flare, his blood test results were normal. 
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͞ďut I still thiŶk soŵetiŵes I haǀeŶ’t got the disease theǇ aƌe talking 
about because when I was really flared up the medical professionals 
ǁho saǁ ŵe said I ǁas fiŶe aĐĐoƌdiŶg to ďlood test. It’s ďizaƌƌe.͟ DW 
 
For others when congruence did happen this was reassuring and helped provide an 
explanation for their symptoms and validate their experiences.  
 
͞To ďe aďle to ƌead ŵǇ oǁŶ ďlood ƌesults aŶd theŶ at least ǁheŶ I aŵ 
feeling particularly ill I could see, oh this is why because this factor has 
goŶe up oƌ this has goŶe doǁŶ͟ – JH 
 
͞I ŶotiĐed that if Ǉouƌ E“R goes up it relates directly to your 
iŶflaŵŵatioŶ ǁhiĐh is good. I thiŶk I’ǀe ŶotiĐed that ŵǇ ǁhite ďlood Đell 
ĐouŶt has goŶe up ǁheŶ I’ǀe had aŶ iŶfeĐtioŶ Ǉou kŶoǁ stuff like that͟ – 
PN 
 
10.9.2.3.2 Sub-theme - Between study guidelines and practice 
The intervention contained clear criteria on the triggers patients should use for contact 
with their CNS. A number of participants however, spoke about the confusion which 
arose when less stringent criteria were implemented by the CNSs during their 
telephone consultations. Participants felt that it was important that these criteria were 
aligned and this was identified as an area for future improvement if the service was to 
be implemented. If addressed participants felt that this could lead to further 
reductions in the number of telephone consultations undertaken.  
͞Just oŶe thiŶg I’ŵ just ƌeŵeŵďeƌiŶg ǁhat ǁe had to look foƌ aŶd ǁhat 
variances we had to look when I rang [the nurse] a couple of times on 
changes she would say, you were using too low a benchmark for when 
someone needed to ring her because every time I phoned her she was 
like Ŷo Ŷo that’s fiŶe Ǉou doŶ’t Ŷeed to ǁoƌƌǇ. “o I thiŶk theǇ ǁould Ŷeed 
to be some kind of liaising with the nurses about changing those 
benchmarks. A couple of times that happened. And she was like no no 
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that’s fiŶe. That’s Ŷot a ǁoƌƌǇ. “o if that ĐhaŶged that ǁould pƌeǀeŶt as 
ŵaŶǇ Đalls to the Ŷuƌse.͟-  EK 
 
͞I thiŶk if Ǉou ǁeƌe doiŶg it loŶg teƌŵ I thiŶk Ǉou ǁould fiŶd that Ƌuite 
diffiĐult, ǁheŶ Ǉou kŶeǁ that a tiŶǇ ĐhaŶge ǁasŶ’t ǁoƌth fussiŶg aďout 
going through the motions when you knew how busy people like [the 
Ŷuƌse] aƌe, I thiŶk that ǁould ďe dileŵŵa͟ – VH 
 
Although a majority of participants did seek help despite there being only small 
deviations in their blood test results, the following quotes suggest that participants 
were experiencing an internal struggle between needing to contact their CNS 
according to the study criteria and either feeling like they knew the outcome of that 
consultation or not valuing these abnormalities. This raises concerns regarding the 
safety of the intervention due to the risk of not appropriately seeking help when 
required. 
 
͞You kŶoǁ Ǉou folloǁ theŵ aĐĐoƌdiŶglǇ aŶd I guess soŵetiŵes, Ǉou 
would see that your figure was just outside the range or just moved by a 
certain amouŶt aŶd Ǉou thiŶk that’s pƌoďaďlǇ Ŷo ďig deal ďut I kŶeǁ 
ǁhat to do͟ A“ 
 
͞I ŵeaŶ haǀiŶg to phoŶe if it’s slightlǇ out of ƌaŶge eaĐh tiŵe ďut as she 
said soŵe of theŵ out of ƌaŶge is Ŷoƌŵal foƌ ŵe aŶǇǁaǇ theǇ’ǀe alǁaǇs 
ďeeŶ that ǁaǇ͟ – ME 
 
One participant who had been living with RA for 22 years described predicting this 
inconsistency when she had received the training. She felt over the course of her 
arthritis and hence she had come to know not only her own condition but the views of 
her CNS.  
 
͞I kŶeǁ theƌe would be some ambiguity and there was because every 
tiŵe I haǀe a ďlood test doŶe alŵost iŶǀaƌiaďle theƌe is soŵethiŶg that’s 
out of range and I am kind of familiar after all these years of how [the 
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nurse] would view it and so minor changes or the minor breaches of the 
limit, I know they are not something to get terribly het up about. There 
were one of the two times when I thought do I need to bother her about 
ďeĐause I kŶeǁ she ǁould ǀieǁ it as soŵethiŶg iŵpoƌtaŶt.͟ – VH 
 Theme four – anxiety 
Some participants spoke of feeling anxious about taking on the responsibility of 
monitoring, this made them extra diligent in checking their laboratory results against 
the criteria given to them during the training session. These participants were 
concerned about the ͞ƌisk͟ of allowing patients to take full responsibility of their 
monitoring, which could lead to mistakes being made and hence serious side effects 
being missed with possible devastating consequences. These participants suggested 
that additional safety nets should be in place to ensure that any serious abnormalities 
were also flagged to the clinical team to ensure that nothing was missed. 
 
͞I thiŶk theƌe ǁas ĐleaƌlǇ a possiďilitǇ foƌ Đaƌeless ŵistakes aŶd iŶ the 
back of my mind it would worry me if the patient had full responsibility 
for identifying if there was a real problem – such as a side effect of 
ŵethotƌeǆate. I did feel Ƌuite Ŷeƌǀous I’d alǁaǇs get the foƌŵs out aŶd 
try not to do it from memory but I think it is quite demanding quite risky 
that aspect of it͟ – VH 
͞ǁhat I ǁould like to ďe aďle to do, is feel ĐeƌtaiŶ at the ďaĐk of ŵǇ ŵiŶd 
that if the thiŶgs aƌeŶ’t goiŶg ǁell it isŶ’t eŶtiƌelǇ left ŵe to deĐide fiŶd 
that’s all. That I do haǀe soŵeoŶe to ĐoŶsult ǁith as I ǁould ǁoƌƌǇ aďout 
that͟ - RG 
Others implied that the intervention may not be appropriate for people who were 
already anxious and worried about their health as they may find it difficult to deal with 
abnormal blood test results.  
 
͞Yes aŶd I thiŶk soŵe people ǁould fiŶd it diffiĐult to Đope with if they 
had a rather nervous disposition or [if they were] a worrying sort 
aŶǇǁaǇ͟ – RG 
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But whilst some expressed concern others acknowledged the seriousness of 
iŶteƌpƌetiŶg theiƌ ďlood tests ďut ǁeƌeŶ͛t ǁoƌƌied aďout the additioŶal ƌespoŶsiďilities. 
One participant attributed this lack of anxiety to being more comfortable with his 
treatment regimen. This particular patient had recently started on Enbrel which had 
controlled his debilitating nausea and hence was happier with his treatment regimen 
and current disease status.  
 
͞I doŶ’t thiŶk I was ever blasé about them I was reading them and 
takiŶg theŵ seƌiouslǇ ďut theǇ didŶ’t ǁoƌƌǇ ŵe at all͟ – EK 
 
͞I didŶ't feel aŶǇ aŶǆietǇ aďout the pƌoĐess at all that’s ŵoƌe ďeĐause I 
feel comfortable with the tƌeatŵeŶt aŶd ǁhat’s happeŶiŶg͟ – NP 
  Theme five – a tailored service 
There was an underlying narrative across all of the interviews that the services offered 
in rheumatology outpatients should be tailored to the needs of the individual and 
delivered at an appropriate time and via the most convenient method. Many 
participants spoke about usual care being a mismatch between delivery of care and 
disease status. The fluctuating nature of the disease often meant patients were seen at 
times when they were well, which led patients to describe the service as ͞iŶeffiĐieŶt͟, 
as described above. Patients described the desire for a tailored service, with care and 
education delivered at the right time and via the right method.   
10.9.2.5.1 Sub-theme - Right time 
Participants described usual care as being a ͞sŶap shot͟ in the disease course and that 
between their outpatient appointments significant changes in their disease status 
often occurred but were not known to the clinical team. This was frustrating for 
patients as in many cases by the time their appointment had arrived their symptoms 
had subsided.  
 
͞thiŶgs ĐaŶ ĐhaŶge so ŵuĐh oǀeƌ a ϲ ŵoŶth peƌiod ďǇ the tiŵe I Đoŵe to 
the hospital to see them things might have changed dramatically and so 
something that was really bad 3 months ago is Ŷo loŶgeƌ ďad͟ – JD 
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͞BeĐause the thiŶgs ǁeƌe so sŶap shottǇ, it’s iŵpossiďle foƌ people, foƌ 
three months you could be really ill but the whole care is based on how 
Ǉou ǁeƌe theƌe aŶd theŶ. That's fƌustƌatiŶg.͟ – DW 
 
One participant went to on to describe how this approach made him feel that his 
eǆpeƌieŶĐes ǁeƌeŶ͛t ďelieǀed aŶd that soŵeoŶe ͞seeiŶg hiŵ ill͟ was an important part 
of validating his experiences. In his case this was friends.  
 
͞It ǁas like theǇ ǁoŶ’t ďelieǀe I’ŵ ill, I’ǀe got oŶe oƌ two friends who 
haǀe seeŶ ŵe ƌeallǇ ill aŶd that kiŶd of helped ďeĐause theǇ kŶoǁ Ǉou’ƌe 
ill. WheŶ Ǉou’ƌe doiŶg that ϯ ŵoŶth thiŶg aŶd Ǉou’ƌe iŶ the ŵiddle aŶd 
Ǉou’ƌe theŶ ďeiŶg told that Ǉou’ƌe alƌight that’s Ƌuite distƌessiŶg ǁheŶ 
Ǉou’ǀe just haǀe Ǉouƌ life turned up side and down. So just realizing that 
doesŶ't ŵeaŶ that aŵ Ŷot ill ďut it’s good that soŵeoŶe else has seeŶ 
it.͟  DW 
 
As a result of this lack of alignment between ill health and delivery of care all 
participants described an ͞ideal͟ service which is tailored to the needs of the patient 
and their current disease state. The tailored service offered in the trial allowed 
patients to access care when they needed it rather than the prescriptive model of care 
driven by healthcare professionals currently delivered and this was highly valued by 
participants. Self-monitoring and initiating their own reviews was recognised as 
particularly important when they were well and their disease was stable. A majority of 
participants recognised that if their condition deteriorated, they were experiencing a 
flare or a laboratory test was considered abnormal, they needed to make contact with 
their clinical team as a matter of urgency and at that point wanted to have more 
regular face to face contact with their CNS.  
 
͞Yeah I ŵeaŶ as loŶg as ŵǇ ƌesults ǁeƌe ǁithiŶ the ƌaŶges speĐified, I 
ǁas Ƌuite happǇ Ŷot to see aŶǇďodǇ͟. – AP 
 
͞if I had a seƌies of ƌesults that shoǁed deteƌioƌatioŶ that ŵight ĐhaŶge 
thiŶgs, that’s a diffeƌeŶt thiŶg it’s sepaƌate fƌoŵ the ŵoŶitoƌiŶg, the 
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monitoring is one thing the outcome is another so as long as the 
monitoring and the results are fine then I would imagine things would 
just ĐoŶtiŶue as theǇ aƌe.͟ – NP 
 
͞…saǇiŶg that ŵǇ psoƌiatiĐ aƌthƌitis is ƌelatiǀelǇ uŶdeƌ ĐoŶtƌol, Ŷoǁ if 
ŵiŶe ǁasŶ’t under control I think I might not be saying that. I think I 
ǁould like, if thiŶgs ǁeƌeŶ’t uŶdeƌ ĐoŶtƌol aŶd I ǁas iŶ paiŶ all the tiŵe, 
related to the arthritis I think I would feel more comfortable seeing 
soŵeoŶe oŶ a ŵoƌe ƌegulaƌ ďasis….I’ŵ goiŶg to ďe in pain more in that 
sĐeŶaƌio fƌoŵ ŵǇ aƌthƌitis, theŶ I thiŶk iŶ faĐt that’s fiŶe, that’s ǁhat I 
ǁould eǆpeĐt aŶd that’s ǁhat theǇ ǁould eǆpeĐt, to see ŵe. But ǁheŶ 
eǀeƌǇthiŶg’s ok aŶd I get the oĐĐasioŶal Ŷiggle theǇ doŶ’t ƌeallǇ Ŷeed to 
see people͟. – PN 
 
Participants also spoke about this need for more appropriate access to the 
rheumatology team from not only their perspective but also other patients. 
Participants acknowledge that self-monitoring and initiating their own care could also 
benefit newly diagnosed patients and established patients who were unwell which 
they felt was hugely beneficial and important.  
 
͞that ǁas pƌettǇ ŵuĐh ǁhat it ǁas like this ŵoƌŶiŶg, ǁhiĐh is also a 
ǁaste of [the Ŷuƌse’s] tiŵe. I doŶ’t ŵiŶd ďut it’s a ǁaste of ŵǇ tiŵe as 
well. [The Ŷuƌse’s] tiŵe Đould ďe ďetteƌ off seeiŶg people ǁho ƌeallǇ 
need it and there were one or two people in [the clinic] who looked as if 
theǇ Ŷeeded to ďe seeŶ.͟ – PN 
 
͞I ŵeaŶ I thiŶk this idea foƌ fƌeeiŶg up speĐialist Ŷuƌse’s tiŵe to see 
people who really need to be seen just seems to be to be incredible 
iŵpoƌtaŶt aŶd I thiŶk Ǉou should pƌess ahead ǁith that͟ – VH 
 
͞I just feel it ǁas ƌeallǇ good thiŶg to take paƌt iŶ ďeĐause it’s ƌeallǇ 
worthwhile and if it cuts down unnecessary appointments and frees up 
appointments so that newly diagnosed patients do not have to wait as 
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long as I did it to the point where I could not make it and ended up for 
siǆ ǁeeks iŶ hospital theŶ that ĐaŶ oŶlǇ ďe a good thiŶg.͟- JH 
 
Participants also spoke more generally about receiving education and information at 
the right time. In usual care information and education seemed to come at times when 
it was not relevant to their needs and they were unable to apply the knowledge to 
their specific situation. Those with longer disease duration had, however, learnt how 
to select information that was relevant to them and filter other information out.  
 
͞….it’s just Ǉou ĐaŶ get all the iŶfoƌŵatioŶ Ǉou ǁaŶt. But uŶtil it’s 
applied, it’s a little haƌd to gƌasp͟ – AS 
 
͞to ďe hoŶest ǁheŶ I first got the arthritis I just wanted to be pain free 
and thinking of long term wasn't something that was in my mind I just 
Ŷeeded to get ďetteƌ, so Ŷoǁ that I aŵ ďetteƌ it’s ǁhat aƌe the loŶg teƌŵ 
issues foƌ ŵe͟ – EK 
͞“o Ǉou seek it out ǁheŶ Ǉou get fuƌther in to it you know the forest 
opens up you and know when the information is not going to be of any 
use to Ǉou.͟- DW 
 
͞The more information you get, at first I read everything I could get my 
hands on and didn't understand any of it but now I can see what’s useful 
to ŵe aŶd ǁhat isŶ't.͟ – DW 
10.9.2.5.2 Sub-theme - Right method 
All participants spoke about the benefits of having direct access to the CNS via 
telephoŶe, as this pƌoǀided the ͞oppoƌtuŶitǇ to applǇ foƌ help͟ when ͞aŶǇthiŶg ǁas 
ǁoƌƌǇiŶg͟ them. Despite not seeing the CNS face-to-face, telephone contact was 
considered equal in regards to the amount of access participants had to their 
rheumatology team and was, therefore, an acceptability method of both accessing 
urgent care and undertaking follow-up consultations.  
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͞I did aĐĐess [the Ŷuƌse] a Đouple of tiŵes thƌough this peƌiod I just 
phoned her up if there was something on the reading that I needed 
ĐlaƌifiĐatioŶ oŶ. “o I’ǀe had aĐĐess, I feel as if I’ǀe had as ŵuĐh aĐĐess to 
her during that period as I did befoƌe aŶd just it’s ďǇ aŶotheƌ ŵethod, 
it’s aďsolutelǇ Ŷot ŶeĐessaƌǇ foƌ go foƌ speĐial appoiŶtŵeŶts.͟  – EK 
 
͞I kŶeǁ that if I had a pƌoďleŵ that if I felt uŶǁell, ƌeallǇ uŶǁell theŶ I 
would phone [the nurse] anyways and I knew I could always speak to 
her. So I did not feel I was just put in the study and shipped out and left 
on my own to deal with it I felt there was support there in place for me if 
I Ŷeeded it.͟ – JH 
10.10 DISCUSSION 
The aim of this study was to understand the experiences of the participants who were 
randomised to the intervention arm of the trial and to explore the value they placed 
on this new model of care. The overall narrative indicated that participants were 
positive about the new service, valuing its efficiency and tailored approach. The service 
enabled knowledge and a sense of control to grow; however, some participants 
expressed worry and concern about aspects of the intervention. Each of these themes 
will now be discussed in relation to previous research, the implications of these 
findings will then discussed in more detail in Chapter 11 in combination with the 
findings from the overview in Chapter 3 and the quantitative results of the RCT.  
10.10.1 Burden of usual care 
Participants weighed the advantages of self-monitoring and initiating their own care 
against usual care. A majority of participants spoke about usual care within the context 
of ďeiŶg ͞a complete waste of time͟ ǁith the Ŷeǁ seƌǀiĐe thought to ďe a ŵoƌe 
efficient use of their time as well as that of the CNS. This, the patients felt, would 
enable the CNSs to see more urgent cases such as patients with newly diagnosed 
arthritis and established patients who were unwell. Many participants described 
occasions on which they travelled to the hospital for their appointment, often having 
to take time away from work, waiting in clinic and then to be seen by the CNS for a 
matter of minutes to be told everything was ok. This patients found frustrating and 
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reflects the findings of both Mitchell (2000) and Hehir et al., (2001) who found that 
follow-up appointments for patients with arthritis who are feeling well often result in 
little or no intervention and are often deemed inappropriate by rheumatologists. The 
current findings also support qualitative work by Primdahl et al., (2011b) in their trial 
of shared care. Three months after the implementation of the service for patients with 
RA, Primdahl et al., (2011b) conducted focus groups with patients who took part in 
each of the three trial arms. Participants in the shared care setting appreciated the 
time saved by not having to attend planned consultations and felt relieved they no 
longer had to negotiate the practical problems experienced when they did have to 
attend.  
 
Data from the current trial suggests this was particularly salient for people in 
employment, which may explain why people with arthritis who are employed are more 
likely to prefer an evening or weekend appointment than those not in employment 
(Douglas et al., 2005). The difficulties participants reported in terms of managing their 
arthritis-related appointments and monitoring schedule alongside their work 
commitments reflects findings from a survey conducted by Gignac et al., (2008). 
Gignac et al., (2008) found that a significant proportion of patients with arthritis 
experienced work transitions such as occasional loss of work hours. This was either in 
the form of interruptions of greater than 20 minutes experienced by 38.2% of patients, 
taking more than three days absence from work due to their arthritis - experienced by 
26.8% of patients and use of holiday for arthritis-related reasons experienced by 9.6% 
of patients. Although Gignac et al., (2008) did not specify the reasons for these work 
transitions, it is reasonable to assume given the intensive monitoring of the condition 
that a proportion of this was due to attendance in outpatients. Gignac et al., (2008) 
also found that more arthritis-related work transitions were associated with being 
younger, increased levels of depression, greater workplace limitations such as the 
ability to get to work and perform work-related activities, and an increased perception 
of the impact of arthritis on their capacity and goals. Work disability not only 
constitutes a financial burden for patients and their families and an economic burden 
for society but has a negative impact on self-esteem (MacKinnon & Miller, 2003) and is 
associated with poorer quality of life (Chorus, Miedema, Boonen, & van der Linden, 
2003). The findings from the qualitative study in this thesis and the survey by Gignac et 
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al., (2008) suggest that it is not just a complete inability to work that may be 
associated with poor psychological well-being but also frequent interruptions to work 
life.  
10.10.2 The self-management process 
One of the only otheƌ Ƌualitatiǀe studies to eǆploƌe patieŶts͛ ǀieǁs of theiƌ folloǁ-up 
care in a trial of a patient-initiated service was that of Sands and Adams (2009). The 
authors interviewed 12 participants who took part in their comparative pragmatic 
study. They sampled six participants from the intervention and six from the group who 
received conventional care. This qualitative study generated four themes, one of which 
ǁas ͞pƌoǀisioŶ of iŶfoƌŵatioŶ aŶd ŵaŶagiŶg theiƌ ĐoŶditioŶ͟ iŶ ǁhiĐh patieŶts 
described the importance of information provision which enabled them to take control 
of their symptoms and access their own hospital reviews in times of needs. This theme 
directly reflects ͞the self-ŵaŶageŵeŶt pƌoĐess͟ theŵe fouŶd ǁithiŶ the ĐuƌƌeŶt studǇ 
which indicated that patients not only valued the information provided in the 
intervention training sessions but felt that the training increased their knowledge. This 
they described as enabling them to be a more active participant in the consultation 
process and gain more control over their health in general and specific aspects of their 
arthritis including accessing care when they needed to.  
 
This pƌoĐess alloǁed patieŶts to gaiŶ ͞ownership͟ oǀeƌ theiƌ aƌthƌitis, aŶ uŶdeƌ 
researched concept in the context of chronic illness (Karnilowicz, 2011). These findings 
support the work of Winkelman, Leonard and Rossos (2005), a qualitative exploration 
of how patients with chronic IBD valued internet-based access to their electronic 
patient records. Winkelman et al., (2005) found that illness ownership was an 
important part of gaining control over the condition. Having access to their own test 
results, and explanatory information about relevant laboratory and disease markers 
promoted illness ownership by allowing patients with IBD to take an active role in 
managing disease exacerbations and complications, arranging appointments and 
performing some autonomous decision making. 
 
The findings in the current study also tentatively suggested that behavioural regulation 
was taking place as a result of patients self-monitoring laboratory results. Participants 
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were able to see how their behaviour was affecting their blood test results. This 
included the link between taking their methotrexate and improvements in their 
inflammatory markers. As well as making a connection between their lifestyle 
behaviours including alcohol intake, diet and weight and their clinical well-being. This 
connection provided a basis on which to change behaviour and make healthier lifestyle 
choices. This self-regulatory process is central to both social cognitive theory (Bandura, 
1986; Bandura, 1997) and self-regulation theory (Leventhal et al., 1980); therefore, 
providing support for the use of these two theories in grounding of this thesis.  
10.10.3 Conflict 
This study found that frustration and confusion arose when there was conflict between 
laďoƌatoƌǇ tests aŶd the paƌtiĐipaŶt͛s eǆpeƌieŶĐe of sǇŵptoŵs, foƌ eǆaŵple the 
presence of intense pain and swelling in the absence of elevated inflammatory 
markers. Research has demonstrated discordance between objective and subjective 
measures of functional disability (van den Ende, Hazes, Le Cessie, Breedveld, & 
Dijkmans, 1995) and hand function (O'Connor et al., 1999) in RA and it is now well 
established that the association between subjective reports of pain with radiographic 
damage are modest at best (Sarzi-Puttini et al., 2002). This discordance has been linked 
to both psychological and social determinants of the illness experience, reflected in 
development of the bio-psychosocial model of chronic illness. Nevertheless, this lack of 
relationship confused and frustrated patients suggesting that these relationships have 
not been adequately communicated. This corresponds to the findings of Winkelman et 
al., (2005) that suggested when the reality of living with IBD was not captured in 
laboratory tests or consultant reports patients found it difficult to recognize their 
illness experience represented in the records and hence the record became 
meaningless to the patient and as a result, less useful. In the context of the current 
trial this may mean that patients placed less value on the meaning of their blood test 
results when they did not correspond to how they felt, which is supported by the views 
of one patient who felt that his CRP test was ͞useless͟ as it did not reflect his 
symptoms.  
 
The legitimization and validation of the fluctuating nature of arthritis was viewed as an 
important factor. Patients felt their symptoms were validated when there was 
Chapter 10 – Qualitative Study 
 
367 
consistency between symptoms and laboratory tests. Validation focuses on expressing 
aĐĐeptaŶĐe of the patieŶt͛s eǆpeƌieŶĐe as ďeiŶg ƌeal aŶd ͞ǀalid͟ ǁithout judgŵeŶt 
(Epstein et al., 2005; Epstein et al., 2006). Legitimization of symptoms is acknowledged 
as important part of the diagnosis of arthritis (Undeland & Malterud, 2007; Brand, 
Claydon-Platt, McColl, & Bucknall, 2010) but has not been explored to the same extent 
in the experience of patients with established arthritis beyond diagnosis. Being ͞seeŶ͟ 
during a flare was important to the validation pƌoĐess, ǁhiĐh ǁasŶ͛t oĐĐuƌƌiŶg ǁheŶ 
hospital reviews were taking place at inappropriate times. Main, Buchbinder, 
Porcheret and Foster (2010) recognized that in primary care one of the main reason for 
patients seeking helping is legitimization of symptoms and in order to maximise the 
effectiveness of the consultation this should be acknowledged from the outset. 
Validation of pain in particular appears to be important to psychological well-being 
(Linton, Boersma, Vangronsveld, & Fruzzetti, 2012) and is, therefore, key to our 
understanding of arthritis since this is the most frequently reported symptom (Carr et 
al., 2003). Employing more validating responses has been associated with greater 
positive affect and less worry in patients (Linton et al., 2012) and hence could have 
been used during any communication between the CNS and patient to address the 
frustration and confusion people felt in relation to the conflict between laboratory 
tests and symptoms. By providing a service which allows patients to access care at the 
time they need it could also overcome some of these frustrations as control is placed 
back in the hands of the patient who can then contact services during a flare and 
hence receive the validation they require.  
10.10.4 Anxiety 
The current study found that a number of participants experienced worry and anxiety 
about being given full responsibility for monitoring their blood test results. Slight 
increases in anxiety have been found in quantitative evaluations of patient-initiated 
services (Hewlett et al., 2000), although not statistically significant. It is, therefore, 
important to recognise that access to laboratory results could negatively impact upon 
mood. Whilst this has been attributed to a lack of understanding about abnormal 
readings (van der Vaart et al., 2013; Peel et al., 2004) it could also reflect a clear 
understanding and genuine concern about the underlying advancement of the 
condition.  
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10.10.5 A tailored service 
All interviews contained an underlying narrative that reflected the patients need to be 
able to access a rheumatology service which was tailored to their current needs. There 
was an incongruence between usual care which was directed and dictated by the 
healthcare professional and the ͞ideal seƌǀiĐe͟ in which they could access services in 
times of need and not need to be reviewed when they were feeling well. This desire 
for personalised care was also expressed in relation to information provision and being 
given information at relevant times rather than just at diagnosis which was an already 
complex time or sporadically throughout the disease course. As a result of the 
untimely nature of information provision, patients felt that they had become apt in 
filtering out irrelevant information. It was also important to participants that they were 
able to access the CNS via the most convenient method and a majority of patients felt 
that the nurse helpline and telephone consultations were an acceptable model of care. 
This service enabled them to seek help at appropriate times and quickly. Hence 
supporting for the findings of Pal (1998) and Hennell et al., (2005), who both found 
high levels of patient satisfaction with rheumatology telephone follow-up clinics held 
by CNSs, and that the advantages of saving time and money, less stress and greater 
convenience outweighed the disadvantages. 
10.11 STRENGTHS AND WEAKNESS OF THE STUDY 
In all research settings there are issues of power between the researcher and 
participant and this can be particularly problematic in qualitative research which has 
the potential to magnify these issues due to the close intense nature of the data 
collection process. In the context of this study there is potential for bias as the 
interviewer also delivered the intervention which raises concerns about social 
desirability and researcher bias. Social desirability occurs when respondents give the 
answers that they believe the researcher wants to hear (Stevenson, Britten, Barry, 
Barber, & Bradley, 2000). In the context of the current study this may have led 
participants to be wary of reporting anything that might appear critical of the 
intervention, as it may have been perceived as a criticism of the researcher. Although 
some qualitative researchers consider their interviewees as collaborators (Collins, 
Shattell, & Thomas, 2005) the direction of the interview is most certainly steered by 
the iŶteƌǀieǁeƌ ǁho deĐides ǁhat paƌtiĐulaƌ paƌt of the paƌtiĐipaŶt͛s aŶsǁeƌs to 
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pursue (Rapley, 2001). Hence it is possible that the researcher was able to bias the 
results of the study by actively pursuing and encouraging dialogue which suggested a 
more positive response to the intervention. This would have been overcome to a 
certain extent by the interview guide, along with making a conscious effort to explore 
all avenues not just those which were positive. The fact that the analysis reports both 
positive and negative aspects of the service supports this latter hypothesis. 
 
A sample of 12 participants were interviewed as part of this study which could be 
criticised as being too small to be generalizable. The sample were, however, diverse in 
their age, disease duration and length of time on methotrexate, as well as being a mix 
of genders and disease types. Qualitative research, however, aims for conceptual 
rather than statistical generalizability (Stevenson et al., 2000). Therefore, the focus is 
to draw inferences from one setting to another rather than on the statistical 
representativeness of the sample.  
 
The clearly outlined phases in thematic analysis provided rigour to the study and the 
four validity checks undertaken, including providing detailed quotes from the 
paƌtiĐipaŶt͛s tƌaŶsĐƌipts to suppoƌt the iŶteƌpƌetatioŶ offeƌed, a pƌopoƌtioŶ of the 
transcripts being analysed by an independent auditor to confirm the pattern of 
analysis and the overall results and discussion being reviewed by the supervisory team 
increased the validity of the study. In addition the researcher kept a reflective diary in 
an attempt to understand the role they played in directing the interviews and 
understanding the transcripts which was used during the analysis.  
10.12 SUMMARY 
The aim of this study was to understand the experiences of the participants who were 
randomised to the intervention arm of the RCT and to explore the value they placed on 
the rheumatology outpatient service they experienced. The overall narrative indicated 
that participants were positive about the new service, valuing its efficiency and 
tailored approach. The service allowed patients to gain new knowledge and use this 
information along with the skills they obtained to take control of their health and 
arthritis. For some participants, however, there were feelings of conflict and anxiety, 
which concerned participants and would need to be addressed prior to any 
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widespread implementation of the service. The following chapter will now bring 
together these findings, along with the results of the overview in Chapter 3 and RCT in 
order to discuss the areas of new knowledge and the implications for research, theory 
and practice. 
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11. CHAPTE‘ ϭϭ - OVE‘ALL DISCUSSION 
11.1 PROLOGUE 
This final chapter considers the results of the literature review and overview of reviews 
reported in Chapters 2 and 3, and the quantitative and qualitative findings of the RCT 
and qualitative study reported in Chapters 6 to 10, in order in provide an 
understanding of the findings of this thesis. The overall aims of the thesis will be 
discussed in relation to how the studies make a novel contribution to the literature. 
The chapter will conclude with a discussion on the recommendations for future 
research and practice along with the overall strengths and weaknesses of this thesis. 
11.2 THESIS AIMS 
This thesis sought to establish whether a self-monitoring and patient-initiated service 
for patients with RA or PsA on methotrexate could be effective in reducing healthcare 
utilisation, improve psychosocial well-being as well as being acceptable to patients. 
The specific aims of this thesis were: 
  To establish the current evidence for patient-initiated services in rheumatology 
in comparison to other models of care.  To understand the benefits, to healthcare utilisation and psychosocial well-
being, of formal self-monitoring across a range of long-term conditions.  To design a self-monitoring and patient-initiated service that could be 
delivered in rheumatology outpatients.  To evaluate the effectiveness and safety of the intervention in relation to usual 
care.  To identify the mediators and moderators of intervention effectiveness.  To establish patient acceptability and the value placed on this model of care. 
11.3 NOVEL CONTRIBUTIONS TO THE LITERATURE 
This thesis has led to a number of novel contributions to the literature, specific findings 
in relation to previous research have been discussed in greater detail within Chapters 
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7, 9 and 10. This section aims to bring the contributions made by the research in this 
thesis together and highlights the distinctness of the findings.  
11.3.1 Novel intervention 
This intervention drew on the evidence base derived from evaluations of patient-
initiated services in rheumatology and the broader self-monitoring literature in other 
long-term conditions. As a result, this thesis presents the first attempt either in 
research or service redesign to involve patients with arthritis in the monitoring of their 
own blood test results. In addition, although many of the interventions presented in 
section 2.5.6.1 (page 82Ϳ aƌe desĐƌiďed as ͞patieŶt-iŶitiated͟ seƌǀiĐes, the ŵajoƌitǇ 
included an element of shared care with the GP. This intervention is, therefore, one of 
very few studies which has not integrated primary care services into this model of care 
and is, therefore, truly patient driven. Consequently, both the quantitative and 
qualitative findings from this thesis represent the first evaluation of effectiveness and 
acceptability of this model of care. In addition, use of a concurrent embedded 
experimental mixed methods design and within that, novel statistical techniques in 
health psychology (Marques & Hamilton, 2014), underlies the unique approach 
adopted in this thesis.  
 
This model of care led to clear reductions in healthcare utilisation in relation to CNS 
outpatient visits and arthritis-related GP appointments. These, in combination, led to 
statistically significant reductions in overall healthcare utilisation, despite no changes 
in visits to the rheumatologist. The results in relation to economic benefits were, 
however, less persuasive. This could in part be due to the post-hoc nature of the 
analysis, which meant the study was not powered to find an effect on this outcome, 
but also because of the lack clarity in how elements of service delivery should be 
accounted for. This issue has been fully discussed in section 9.2.2 (page 311). 
Importantly there was no negative impact on clinical or psychosocial well-being as a 
result of taking part in the intervention. The results of this study in relation to previous 
research have been discussed at length in Chapter 9. In summary, these findings reflect 
those of other evaluations of patient-initiated services in rheumatology, particularly in 
relation to reductions in healthcare utilisation (Hewlett et al., 2000; Hewlett et al., 
2005b; Kirwan et al., 2003b; Adams & Sands, 2009; Chattopadhyay & Hickey, 2008) 
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and no significant detrimental effect on clinical or psychosocial well-being (Kirwan et 
al., 2003b; Hewlett et al., 2005b; Primdahl et al., 2012; Primdahl et al., 2014; Adams & 
Sands, 2009; Sands & Adams, 2009).  
11.3.2 Mechanisms of effectiveness 
This is the first trial of patient-initiated services which has explored, using appropriate 
analytical techniques, the mechanisms of effectiveness. Under more traditional 
methods of testing mediation the lack of effect of the intervention on consultant visits, 
arthritis-related GP visits and quality of life would have precluded an investigation of 
mediation. More contemporary methods of mediations analysis, however, such as 
those used within this thesis, state that the existence of an effect of the intervention 
on the study outcomes is no longer necessary for mediation to be possible (Collins et 
al., 1998; Hayes, 2009).   
 
The analysis, however, identified no significant mediating variables indicating that the 
intervention was having no effect on quality of life, consultant visits or arthritis-related 
GP visits either direct or indirectly. The significant impact on CNS outpatient visits was, 
therefore, a direct effect of not having any pre-scheduled appointments. A number of 
moderators were identified suggesting that female participants, those with poorer 
mental health-related quality of life, poorer knowledge about methotrexate, lower 
haemoglobin levels and higher ESR at baseline would benefit more from the 
intervention (i.e. used less health services and had better quality of life post 
intervention) than control group. Those with poorer self-efficacy for active 
communication at baseline, however, experienced better quality of life if they were 
allocated to the control group.  
 
By identifying moderators of the intervention this provides useful information on the 
type of patient who may benefit more from a self-monitoring and patient-initiated 
service and those who would benefit more from remaining within standard care. This 
information has two potential uses, the first and most obvious is identifying which 
patients are likely to be more responsive to this new model of care and could, 
therefore, be used to guide referrals into the service. The second is to help guide 
researchers in the best choice of inclusion and exclusion criteria for future evaluations 
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(Kraemer et al., 2002). As the study was not powered for mediation or moderation 
analysis however, these findings should be considered as hypothesis generating.  
11.3.3 Predictors of help-seeking 
An important element of establishing whether patients could safely monitor their own 
blood tests results was to establish the accuracy with which they made decisions about 
contacting the CNS. The results from this thesis indicated that, with training, 
participants were able to make safe help-seeking decisions, and this improved over the 
trial period. There were, however, a small proportion of patients who were unable to 
self-monitor safely and these participants returned to standard care according to 
criteria defined in the study protocol. The findings of this thesis provides unique insight 
into the drivers of appropriate help-seeking, under experimental conditions, and 
identified that rather than symptoms or clinical status being associated with help-
seeking, self-efficacy played an important role, as did age and the presence of co-
morbidities.  
 
Little is known about help-seeking in patients with established arthritis. Much of the 
literature has to date focused on help-seeking during the initial phases of the disease, 
and the delay found in reporting symptoms to a healthcare professional prior to 
diagnosis (Stack et al., 2012). Outside of experimental conditions patients with arthritis 
seek help when they become more certain that they are experiencing a disease flare 
often after a number of failed self-management attempts (Hewlett et al., 2012). It 
appears that patients during this process either decide to access services early in a 
flare in order to stop symptoms having a more serious and widespread impact on their 
life or they wait in the belief that they may be wasting the medical teaŵ͛s tiŵe (Flurey, 
2014). This thesis extends this model by suggesting a possible role of self-efficacy, 
speĐifiĐallǇ iŶ ƌelatioŶ to patieŶts͛ ĐoŶfideŶĐe iŶ ĐoŵŵuŶiĐatiŶg ǁith theiƌ 
rheumatology team and their ability to self-manage.  
 
The findings presented in Chapter 7 suggest that the more confident participants were 
about self-managing their arthritis and the less confident they were about 
communicating with healthcare professionals the more safe help-seeking decisions 
they made. As these findings are within the context of an experimental study which 
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aimed to manipulate help-seeking behaviour it is difficult to compare them to the work 
of Hewlett et al., (2012) and Flurey (2014), particularly as the intervention failed to 
increase self-efficacy over time. These results could, however, suggest that seeking 
help is considered an element of self-management rather than as a consequence of 
failed self-management attempts as suggested in the model by Hewlett et al., (2012). 
Hence when someone is more confident about their ability to manage their arthritis 
they are able to seek help more appropriately. It could also indicate that the 
intervention gave patients who were less confident about communicating with their 
rheumatology team with a structured approach to seeking help and clear guidelines on 
the triggers for contacting the CNS. In this interpretation although the intervention did 
not improve self-effiĐaĐǇ foƌ ĐoŵŵuŶiĐatioŶ it gaǀe the paƌtiĐipaŶts the ͞peƌŵissioŶ͟ 
they needed to make contact, without fear of time wasting. These explanations are, 
however, purely speculative and do require further exploration.  
11.3.4 Conceptualisation of self-monitoring 
By synthesising the evidence in relation to self-monitoring, across a range of long-term 
conditions, the overview of reviews presented in Chapter 3 has provided the basis for a 
schematic representation how self-monitoring is implemented within these 
interventions. This conceptualisation recognises that self-monitoring interventions run 
on a continuum from less patient involvement to those in which patients are full and 
active participants in the monitoring and interpretation of their data and making of 
autonomous decisions to adjust their lifestyle and treatment plans. This latter 
intervention can be defined as purely patient self-management, according to Barlow et 
al., (2002) and the former clinical monitoring. The common thread between them is 
their aim to change behaviour, and both target similar outcomes i.e. clinical or 
psychosocial well-being, and/or healthcare utilisation.
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Figure 11.1. A schematic representation of self-monitoring interventions in long-term conditions 
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However, those that are patient-self-management directly target the behaviour of 
patients whilst the latter initially aim to change the behaviour of healthcare 
professionals by enabling tighter disease control but make either an explicit or implicit 
assumption that patient behaviour will need to change in order for outcomes to 
improve. Other self-monitoring interventions, including the one evaluated within this 
thesis, lie somewhere in the middle of these two approaches, whereby patients use 
their monitored data to make decisions about help-seeking in accordance with pre-
defined clinical criteria. Healthcare professionals then make the decisions to change 
either a treatment plan or lifestyle behaviour, but again this assumes that patients 
then make these recommended changes.  
 
This conceptualisation provides a structure in which interventions that include patient 
self-monitoring can be classified, evaluated and synthesised, and also provides a 
clearer understanding of the mechanisms through which these intervention may affect 
outcomes. The results from the overview of reviews and this schematic representation 
could provide an alternative explanation for why the current intervention failed to 
change psychosocial outcomes. Participants randomised to the intervention arm in this 
thesis were required to seek help from their CNS who then made all decisions in 
regards to any necessary lifestyle or treatment changes. The inability of participants to 
make autonomous decisions about lifestyle and treatment changes may have hindered 
the effects of the intervention on psychosocial outcomes as patients still heavily relied 
on the rheumatology team to manage their condition.  
 
The distinction between these three types of self-monitoring interventions is not well 
represented in the literature. These interventions have often been grouped together in 
systematic reviews making a synthesis of their effectiveness difficult, as evidenced in 
Chapter 3. The conclusions of the overview of reviews in this thesis, however, proposes 
that there may be additional clinical and psychological benefits to self-monitoring 
untaken in the context of patient self-management as opposed to clinical monitoring. 
Allowing patients with a long-term condition to make autonomous decisions about 
necessary treatment and lifestyle adjustments may empower patients to implement 
and adhere to these behaviours. In contrast adjustment decisions made by a 
healthcare professional may allow for a more passive patient and lead to 
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comparatively poorer outcomes due to a lack of awareness between behaviour and 
outcome. Anti-coagulation therapy appears to be the only chronic condition to have 
made this clear distinction, and have hence designed and evaluated interventions in 
order to compare these two distinct conceptualisations of self-monitoring, but with 
somewhat mixed results (for a full discussion see section 3.7.4, page 155). Only more 
recently has this distinction been recognised in diabetes (Ng et al., 2013), which is 
particularly surprising given that SMBG is part of standard care in diabetes 
management (National Collaborating Centre for Chronic Conditions, 2008). It was not 
possible in the overview in Chapter 3 to distinguish between these types of 
intervention; hence further work would need to be conducted to test this hypothesis. 
11.3.5 Behaviour change theory 
This is one of the first studies under the umbrella of chronic disease self-management 
to utilise the recently published behaviour change taxonomy (BCTv1) (Michie et al., 
2013) to describe the content of the active intervention and is certainly the first within 
patient-initiated services to do so. The intervention contained a total of 13 behaviour 
change techniques that can be directly linked to social cognitive theory (Bandura, 
1997) and self-regulation theory (Leventhal et al., 1980). By defining the current 
intervention in terms of behaviour change techniques this has identified the active 
ingredients within the intervention, which will allow for easier replication of the study 
(Michie & Johnston, 2013). It is, however, important to recognise that the behaviour 
change techniques contained within the current intervention could be techniques that 
are delivered within standard care, along with other behavioural strategies. The effects 
of the intervention, therefore, cannot be attributed to these techniques until the 
content of usual care is assessed in accordance with the BCTTv1; however, this was 
outside of the scope of this thesis. 
11.4 SYNTHESIS OF THE QUANTITATIVE AND QUALITATIVE FINDINGS 
The following section will present the primary similarities and differences between the 
results of the RCT and qualitative study in order to establish the degree to which 
triangulation of study findings were achieved. Triangulation is one of the primary 
benefits of a mixed methods approach and is discussed in more detail in section 11.7 
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(page 389). As well as providing an opportunity to cross-check data from multiple 
sources, mixed methods research brings to light inconsistencies in the study data. 
Embedding a piece qualitative research nuanced the findings of the RCT and provided 
ǀaluaďle iŶsights iŶto paƌtiĐipaŶts͛ peƌĐeptioŶs of the ďenefits of this model of care.  
11.4.1 Acceptability 
As monitoring of laboratory results is a novel activity for patients with arthritis there 
was some uncertainty about whether patients would find this model of care 
acceptable. Acceptability was assessed in a number of ways in this thesis including 
uptake and drop-out rates, reasons for refusing participation and the findings from the 
qualitative study. These sources indicated a mixed picture in terms of the acceptability 
of this model of care for patients with RA or PsA on methotrexate. This supports the 
rhetoric of Trappenburg et al., (2013) who highlighted that a ͞one size fits all͟ 
approach to helping patients manage their chronic illness is not appropriate and, 
therefore, consideration must be made to those who would prefer the more 
traditional model of care.  
 
This thesis found uptake rates of approximately 60%, reflecting the findings of Hewlett 
et al., (2000; 2003b; 2005b) and van der Vaart et al., (2011); significantly higher than 
Primdahl et al., (2012; 2014) who had a 26% response rate. The current trial found that 
around 30% of those approached to take part preferred the more traditional system of 
having regular scheduled visits to the CNS. Of the 63% who consented into the study, 
22% failed to enter the trial despite consenting to take part. There was, however, no 
difference between the intervention and control group on drop-out rates at this point, 
indicating that it was not necessarily the intervention itself but possibly the research in 
general which was unappealing. Despite 30% preferring face-to-face contact with their 
CNS, once in the trial, participants were committed to this model of care. This was 
evidenced by the responses of those who took part in the qualitative interviews and 
the fact that no intervention participants requested to return to usual care and in fact 
were disappointed at the end of their participation in the trial. The qualitative 
narratives indicated that overall participants were positive about the new service, 
valuing its efficiency and tailored approach. In comparison to usual care it was deemed 
͞ŵuĐh ŵoƌe ĐoŶǀeŶieŶt͟ and ͞less ďuƌdeŶsoŵe͟ and allowed them to develop self-
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management strategies, which patients valued, such as increased knowledge and a 
sense of control. Overall this suggests that a majority of patients with RA or PsA on 
methotrexate may deem this model of care acceptable and could, therefore, be a 
suitable way in which patients could be followed-up.   
11.4.2 Treatment burden 
Disparate findings were evidenced in relation to treatment burden. Whilst the RCT 
failed to find any statistically significant differences between the intervention and 
control group on treatment burden, participants in the qualitative study emphasised 
the burden of usual care and described this new model as a more efficient use of their 
time. The self-report measure of burden used within the RCT was, however, a one-
item general measure of treatment burden, which participants could have 
conceptualised as meaning medication rather than the care they received in 
outpatients. Greater specificity in the quantitative measurement may have led to more 
consistent findings between the qualitative and quantitative findings. Another possible 
explanation is that participants saw this concept as being on a continuum from 
burdensome to convenient, but the quantitative measure failed to capture this full 
spectrum.  
11.4.3 Time and cost saving 
The results of the RCT suggested that a significant proportion of outpatient visits made 
to the CNS-led DMARD monitoring clinic may not be necessary. Fifty-five percent fewer 
appointments with the CNS in the intervention compared to control group suggests 
that even when abnormal blood tests or symptoms do occur they can be sufficiently 
addressed in a telephone consultation rather than face-to-face visit. The time saved by 
healthcare professionals and patients evidenced in these quantitative findings, were 
corroborated by patients in the qualitative study some of whom described usual care 
as a ͞complete waste of time͟. 
 
͞it just seeŵs to ďe more efficient use of everybody's time, mine, [the 
Ŷuƌse’s] aŶd ǁhǇ should the hospital Ŷeed to ďotheƌ ǁith aŶ 
appoiŶtŵeŶt foƌ soŵethiŶg that is ƌeallǇ stƌaight foƌǁaƌd͟ – NP 
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Telephone contact was considered equal in regards to the access participants had to 
their rheumatology team and was, therefore, an acceptable method of both accessing 
urgent care and undertaking follow-up consultations. 
 
͞I kŶeǁ that if I had a pƌoďleŵ that if I felt uŶǁell, ƌeallǇ uŶǁell theŶ I 
would phone [the nurse] anyways and I knew I could always speak to 
her. So I did not feel I was just put in the study and shipped out and left 
on my own to deal with it I felt there was support there in place for me if 
I Ŷeeded it.͟ – JH 
 
The results of the RCT with regards to cost-effectiveness were mixed dependant on the 
model evaluated and the level at which the cost was estimated (i.e. lower, mean, 
upper limit). There was, however, potential for this service to be cost saving for the 
health service and this was also reflected by patients in the qualitative interviews. 
Regular reviews with the CNS were described as ͞ĐoŵiŶg at a Đost͟, both in terms of 
being a waste time or not a valuable use of time due to little changes to treatment, but 
also financially as a result of missed work. The findings of the RCT do, however, 
indicate that agreement needs to be reached on how telephone contact with patients 
is costed and integrated into the CNS role. In addition a full cost analysis with indirect 
as well as direct costs may have provided a more complete picture of the benefits 
described by patients in the qualitative interviews.   
11.4.4 Knowledge 
The qualitative data suggested that patients felt that the intervention increased their 
knowledge and gave them greater control over their arthritis and its treatment. This 
enabled them to feel more involved in the consultation process and change their 
lifestyle behaviours accordingly.  
 
͞AŶd so, Ǉou kŶoǁ, if I Đould ďe iŶǀolǀed ǁith this aŶd also that it ǁas a 
little bit with more, you know, taking kind of control and understanding, 
you know, more involved what was actually going on rather than going 
off and getting tests done and not knowing what it means, and waiting 
foƌ soŵeoŶe to tell Ǉou that eǀeƌǇthiŶg is OK.͟ A“ 
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Despite this qualitative evidence, the quantitative findings found only a very small non-
sigŶifiĐaŶt iŶĐƌease iŶ paƌtiĐipaŶts͛ kŶoǁledge aďout ŵethotƌeǆate. The folloǁiŶg 
quote could shed light on these conflicting results. 
 
͞I did eŶjoǇ ďeĐause it gaǀe ŵe aŶ iŶsight iŶto ǁhat the hieƌoglǇphs 
were that I was getting for my blood tests and now I know what to look 
foƌ. You kŶoǁ aŶd the ƌaŶges, if ŵǇ ďloods aƌe iŶ ĐeƌtaiŶ liŵits͟ – AP 
 
The knowledge scale utilised within the trial evaluated knowledge specific to 
methotrexate and although the training session presented information about 
methotrexate and its side effects it appears possible from this quote that the 
knowledge improvements spoke about by people in the qualitative study were 
associated with the specifics of laboratory results rather than a broader understanding 
of methotrexate.  
11.4.5 Conflict between study and CNS criteria 
The results from the RCT revealed that all participants made some errors when 
monitoring their own blood test results and symptoms, often choosing not to contact 
their CNS when their results were either outside of the specified range or had changed 
significantly since their last blood test. The qualitative data illuminated this issue and 
provided a possible explanation for these findings.  
 
A number of the participants who took part in a semi-structured interview reported an 
internal conflict between the criteria outlined in the study protocol and the less 
stringent criteria implemented by the CNS during their telephone consultations.  
 
͞I kŶeǁ theƌe ǁould ďe soŵe aŵďiguitǇ aŶd theƌe ǁas because every 
tiŵe I haǀe a ďlood test doŶe alŵost iŶǀaƌiaďle theƌe is soŵethiŶg that’s 
out of range and I am kind of familiar after all these years of how [the 
nurse] would view it and so minor changes or the minor breaches of the 
limit, I know they are not something to get terribly het up about. There 
were one of the two times when I thought do I need to bother her about 
ďeĐause I kŶeǁ she ǁould ǀieǁ it as soŵethiŶg iŵpoƌtaŶt.͟ – VH 
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Participants felt that it was important that these criteria were aligned and this was 
identified as an important area for improvement if the service was to be implemented. 
If this issue was addressed some participants felt that this could lead to further 
reductions in the number of telephone consultations required.  
 
͞Just oŶe thiŶg I’ŵ just ƌeŵeŵďeƌiŶg ǁhat ǁe had to look foƌ aŶd ǁhat 
variances we had to look when I rang [the nurse] a couple of times on 
changes she would say, you were using too low a benchmark for when 
someone needed to ring her because every time I phoned her she was 
like no no that’s fiŶe Ǉou doŶ’t Ŷeed to ǁoƌƌǇ. “o I thiŶk theǇ ǁould Ŷeed 
to be some kind of liaising with the nurses about changing those 
benchmarks. A couple of times that happened. And she was like no no 
that’s fiŶe. That’s Ŷot a ǁoƌƌǇ. “o if that changed that would prevent as 
ŵaŶǇ Đalls to the Ŷuƌse.͟-  EK 
11.4.6 Communication between patient and rheumatology team 
PatieŶts͛ ĐoŶfideŶĐe iŶ theiƌ aďilitǇ to ĐoŵŵuŶiĐate ǁith theiƌ ƌheuŵatologǇ teaŵ ǁas 
both a predictor of appropriate help-seeking and was a significant moderator of the 
effeĐt ďetǁeeŶ tƌial aƌŵ aŶd patieŶts͛ post iŶteƌǀeŶtioŶ ƋualitǇ of life. The Ƌualitatiǀe 
data elaborated on these findings and suggested that patients valued legitimization of 
their symptoms and that this was primarily found when laboratory results were 
congruent with the symptoms they experienced but was also achieved when patients 
ǁeƌe ͞seeŶ͟ during a flare or when the fluctuating nature of their arthritis was 
validated during the consultation process. The importance of good communication 
between the rheumatology team and patient has be found to be important part of the 
consultation process (Thorne et al., 2004) and legitimization of symptoms is not only 
central to that process but a significant driver of help-seeking (Main et al., 2010).   
11.4.7 Anxiety 
Whilst the RCT found no statistically significant differences in levels of anxiety between 
the intervention and control group overtime, the qualitative interviews revealed that 
some participants experienced anxiety and worry about self-monitoring whilst others 
were not concerned. In fact the estimated marginal means indicated that participants 
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in the intervention group experienced a small decrease in anxiety overtime and the 
control group an increase. These contradictory findings support the conclusions of the 
systematic review presented in Chapter 3 which found that many articles were unable 
to make definite conclusions about the impact of self-monitoring on anxiety as some 
primary research studies found significant improvements whilst others failed to find 
any effects.  
 
There could be a number of explanations for the contrasting findings found within this 
thesis. The most obvious is that the study was not powered to find an effect for 
anxiety, although the use of MLM allowed for trajectories of change to be estimated 
within a participant rather than pooled at a group level, therefore, individuals were 
represented more accurately within the statistical model. Nevertheless it is likely that 
there was a combination of people within the intervention group who experienced a 
decline in anxiety, stability or an improvement across the trial period, as demonstrated 
by the mixed responses of those within the qualitative study.  
 
Another possible explanation relates to the RCT measuring generalised anxiety whilst 
those in the qualitative study were reflecting on anxiety specific to self-monitoring. So 
whilst generalised anxiety may have improved over time, this does not necessarily 
mean that anxiety specific to self-monitoring would follow the same pattern. It is, 
however, important to acknowledge that the anxiety and concern expressed by 
participants in the qualitative could be a legitimate concern about a deteriorating 
disease state. 
 
Although anxiety was thought to be a possible moderator of the effects of the 
intervention in the qualitative study: 
 
͞Yes aŶd I thiŶk soŵe people ǁould fiŶd it diffiĐult to Đope ǁith if theǇ 
had a rather nervous disposition or [if they were] a worrying sort 
aŶǇǁaǇ͟ – RG 
 
The results of the RCT did not demonstrate that anxiety moderated the relationship 
between trial arm and either healthcare utilisation or quality of life. Anxiety did, 
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however, mediate the relationship between trial arm and quality of life, suggesting 
that participants who experienced a greater decline in anxiety over the trial period 
reported higher levels of quality of life at final follow-up.   
11.5 RECOMMENDATIONS FOR FUTURE RESEARCH 
There are a number of clear avenues for research which have been identified from the 
results of the RCT and qualitative study, as well as the literature review and overview 
of reviews found within Chapters 2 and 3 of this thesis. Each of these will now be 
discussed in order of their appearance within the thesis, and not in order of 
importance.  
11.5.1 Community-based rheumatology services 
Given the current Government͛s desire to shift hospital-based care of long-term 
conditions into the community, there is a need to establish the best way in which this 
can be delivered and a sufficient evidence base to suggest that it is at least equitable to 
current standard care, if cost savings are demonstrated. The literature review 
presented in section 2.5.4 (page 74) suggests that there is a lack of methodological 
robust evaluations of GP-led and community based rheumatology services within the 
UK. The evidence that is presented suggests neither an equitable or beneficial effect 
for the patient or health service. The publication of a systematic review would be 
beneficial in order to establish more thoroughly the evidence base, including a formal 
evaluation of study quality. The literature review in section 2.5.4 (page 74) does, 
however, suggest that more robust RCTs need to be conducted in order to establish 
the effectiveness of community led rheumatology services in comparison to specialist-
led care.  
11.5.2 Self-monitoring in long-term conditions 
As the articles included in the overview of reviews in Chapter 3 suffered from poor 
reporting it was not possible to establish whether self-monitoring was taking place in 
the context of self-management or purely as a tool for clinical monitoring. As 
acknowledged by Ng et al., (2013) and Clar et al., (2010) it is important to establish 
whether self-monitoring which takes place within patient self-management has 
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differing effects on clinical, psychosocial and healthcare utilisation in comparison to 
interventions which use self-monitoring as a clinical tool. This could be achieved by 
classifying the 321 primary research studies identified within the overview of reviews 
according to the three types of intervention conceptualised in Figure 11.1 and 
assessing whether these different interventions lead to differing effects.  
11.5.3 Predictors of help-seeking in established arthritis 
Given that self-efficacy for self-management and communicating with healthcare 
professionals appeared to play an important role in the ability of patients to 
appropriately seek help from their specialist nurse, future research would benefit from 
exploring how these factors impact on help-seeking outside of experimental 
conditions. There is generally a lack of research exploring help-seeking in established 
arthritis. Building on the findings of this thesis and the work of Hewlett et al., (2012) 
and Flurey (2014), a longitudinal study to explore predictors of help-seeking in RA 
would be a valuable contribution to the literature.   
11.5.4 Acceptability from the healthcare professional perspective 
Although the intervention was successful in reducing healthcare utilisation and had the 
potential for economic benefits to the health service more generally, the thesis failed 
to explore this model of care from the perspective of healthcare professionals in 
rheumatology. This service could have implications on the role of the CNS, in terms of 
their identity within the rheumatology team and a possible change in work load and 
the manner in which they work i.e. a transfer from face-to-face to telephone 
consultations. It would be important to explore the experiences of the CNSs who were 
part of the research team to understand their views and acceptability of the service 
and that of the rheumatologists within the wider team. This could provide important 
information on the value placed on this model of care and the likelihood and manner 
in which it may be integrated into standard care. A general understanding of the views 
of healthcare professionals in rheumatology and those commissioning services within 
rheumatology on this model of care would also shed further light on the potential for 
implementation.  
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11.5.5 Overall lack of literature on PsA 
This thesis was focused on patients receiving methotrexate and, therefore, those with 
RA were assumed to experience similar symptoms and side effects to those with PsA, 
and were not expected to have different outcomes in relation to the intervention. This 
was confirmed in both the quantitative and qualitative findings. A general finding from 
this thesis, however, was a distinct lack of literature relating to patients with PsA, from 
a lack of prevalence estimates in the UK, through to the design of interventions to 
enable patients with PsA to self-manage their condition. Although the incidence rate of 
PsA is significantly lower than that of RA the combination of both arthritis and psoriasis 
brings with it the complexities of managing both conditions, from both a clinical and 
psychological perspective. Hence future research would benefit from exploring the 
impact of this condition and how formal self-management programmes could help 
patients adjust to the psychosocial effects of both the skin condition and arthritis.  
11.6 RECOMMENDATIONS FOR PRACTICE 
There are a number of important issues when considering whether a new model of 
care should or could be implemented in practice, this includes its impact on the clinical 
and psychological well-being of patients and staff, the implications to the health 
service including healthcare utilisation and economic impact, and the acceptability of 
the intervention from a patient and healthcare professional perspective. Individually 
these issues have been discussed in relation to the strengths and weakness of each 
study in section 9.3 (page 330) and section 10.11 (page 368).  
An intervention of this nature would contribute towards Domain 4 of the NHS 
Outcomes Framework (Department of Health, 2013f) which looks to ensure that 
patients have a positive experience of the care that they receive in outpatients. 
Implementation of the service in UCLH, however, would require careful consideration 
as a consequence of changes in usual care at UCLH since the start of this thesis. As 
highlighted in section 2.6 (page 93) in 2013 NHS Camden CCG, the local CCG for UCLH, 
published their key interests. One of these was to ensure that patients were seen in 
the appropriate setting of their choice in a timely manner whilst ensuring that best 
value for money is achieved (Camden Clinical Commissioning Group, 2013). Since the 
completion of the RCT more concerted steps have been taken to move the monitoring 
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of DMARDS from the CNS-led rheumatology clinics held at the hospital to individual 
GPs.  
 
Although at the start of this thesis UCLH had shared-care guidelines which included 
GPs (Appendix A) an overwhelming majority of GPs refused to take on these additional 
responsibilities. Despite this resistance, the CNSs running the hospital based clinics are 
now being asked to refer patients with arthritis on a stable dose of methotrexate back 
to their GPs for ongoing monitoring. Anecdotal evidence suggests this has not been 
welcomed by patients, although more formal evaluation needs to be conducted. This 
does not necessarily mean that the model of care evaluated within this thesis could 
not be implemented, but the views of GPs would also need to be considered carefully 
as their commitment to any change would be critical. There would also need to be 
greater clarity on how future services are likely to run in order to understand how a 
self-monitoring and patient-initiated service could be integrated within the planned 
framework. This would make the service evaluated by Hewlett et al., (2000; 2003; 
2005) and Primdahl et al., (2012; 2014), which was a shared-care approach between 
the patient, GP and rheumatology team, a more applicable option; with the additional 
element of patients monitoring their blood test results as well as their symptoms and 
side effects. Any implementation would need to consider the triggers for patients 
contacting the service, so that discrepancies did not occur between the service 
protocol and the views of the healthcare professionals administering the telephone 
consultations. This discrepancy identified within the current trial caused some 
confusion and potentially led to mistakes being made by the patient about when to 
make contact.   
 
Although the RCT identified potential mediators and moderators, and hence the 
mechanisms of action and type of patient who may benefit more from the 
intervention. These results are at present considered to be hypothesis generating as 
the study was not powered adequately to identify all possible moderators and 
mediators. Therefore, offering the service to only those patients in which it appeared 
to be more beneficial would at this stage be inappropriate as this question requires 
further research.  
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The findings from the RCT and qualitative study suggest that the ability and confidence 
patients have in communicating with their rheumatology team plays an important role 
in their help-seeking behaviour and quality of life. This highlights a wider issue about 
healthĐaƌe pƌofessioŶals͛ ĐoŵŵuŶiĐatioŶ stǇles aŶd the possiďilitǇ of pƌeǀious 
eŶĐouŶteƌs affeĐtiŶg patieŶts͛ futuƌe help-seeking behaviour (Stack et al., 2012). 
Therefore, healthcare professionals in rheumatology should be aware of how they 
interact and communicate with their patients, particularly in regards to the 
legitimization and validation of the fluctuating nature of arthritis which is important to 
patients and could have a potential impact on their reluctance to contact health 
services in times of need. 
11.7 STRENGTHS AND WEAKNESS 
The strengths and weakness of each study have been discussed in their respective 
chapters. The primary weaknesses being the lack of power, the number of statistical 
tests performed, ecological validity, social desirability and lack of a full health 
economic evaluation. The primary strengths of the trial include the robust study 
designs and analytical techniques; however, the overall strength of this thesis lies in its 
mixed methods approach. The concurrent embedded experimental strategy, whereby 
the quantitative and qualitative data collection were collected at the same time but 
with the RCT as the predominant study (Curry et al., 2013) addressed a number of the 
benefits of mixed methods research as outlined by Doyle et al., (2009). These benefits 
will now be discussed within the context of this thesis. 
  Triangulation – Methodological triangulation indicates that two research 
methods have been used in order to check the overall conclusions of a study 
(Denzin, 2006). The idea is that one can be more confident with a result if 
different methods lead to the same conclusions. By seeking corroboration 
between quantitative and qualitative data this thesis has increased the validity 
of the findings. The embedding of the qualitative study within the RCT has 
highlighted both similarities and differences between the effectiveness of this 
intervention each of which have been discussed in section 11.4 (page 378). 
Synthesis of the results from the two methodologies has highlighted a number 
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of consistent findings particularly in relation to the acceptability of the 
intervention and the time and cost-saving benefits to both patients and the 
health system. There were, however, inconsistencies in the conclusions of the 
two studies specifically in relation to a number of the psychosocial outcomes 
and this is likely due to the lack of specificity of the quantitative measures. 
Although the RCT failed to find any effects on psychosocial outcomes, the 
iŶfoƌŵatioŶ ĐolleĐted oŶ patieŶts͛ eǆpeƌieŶĐes ŶuaŶĐed these fiŶdiŶgs aŶd 
pƌoǀided ǀaluaďle iŶsights iŶto paƌtiĐipaŶts͛ peƌĐeptioŶs of the value of this 
model of care.   Completeness - By using an RCT and embedded qualitative approach this thesis 
provides a more complete picture of the impact and experience of a self-
monitoring and patient-initiated service for patients with RA or PsA on 
methotrexate. This could have been further enhanced by undertaking 
additional qualitative interviews with healthcare professionals delivering and 
those commissioning services in order to explore their views and acceptability 
of this model of care which could have provided useful insight into the 
potential for wider implementation.  Offsetting weaknesses and providing stronger inferences – Both quantitative 
and qualitative methods have their strengths and weaknesses. Therefore, by 
combining these approaches the limitations of each method are diminished 
whilst the strengths preserved. In this thesis, the RCT was able to explore the 
overall effectiveness of the intervention and the qualitative study an insight 
into the personal experiences of individual participants which could not have 
been captured or represented within an RCT.   Answering different research questions - Creswell and Clark (2007) argue that 
mixed methods research helps answer the research questions that cannot be 
answered by quantitative or qualitative methods alone particularly in complex 
interventions, such as the one evaluation within this thesis. As stated above the 
RCT evaluated the effects of the intervention at a group level, whilst the 
qualitative study explored the acceptability of the intervention in order to 
understand how the target population experienced this new model of care. 
Questions of this nature are best suited to qualitative research designs as they 
are able to explore experiences in greater depth (Ayala & Elder, 2011).  
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 Illustration of data – By using the findings of the qualitative research to 
illustrate the findings of the RCT it has helped paint a better picture of how 
patients experience this new model of care and the potential benefits to both 
them and the health service.  
11.8 OVERALL CONCLUSIONS 
The current study has made a number of novel contributions to the literature 
particularly in regards to the unique nature of the intervention. The RCT demonstrated 
that a self-monitoring and patient-initiated service can lead to significant reductions in 
healthcare utilisation, whilst maintaining clinical and psychosocial well-being. The 
economic benefits, however, require further investigation. Patients were able to safely 
self-monitor and use this information to seek appropriate help from their CNS. More 
in-depth investigation of patient acceptability using qualitative interviews indicated 
that patients found usual care inconvenient and burdensome, which the new service 
was able to overcome. It also enabled patients to gain knowledge about their 
laboratory results and provided a link between their medications and disease status. 
Participants also reported increased control over the impact of their condition on their 
lives. The implementation of this intervention now needs to be considered in light of 
the move in parts of the UK towards GP-led DMARD monitoring.  
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APPENDIX A. UCLH SHARED CARE GUIDELINES 
Shared Care Guideline  
METHOTREXATE  
Treatment of moderate to severe active rheumatoid 
arthritis or  
Treatment of severe psoriasis  
  
Dear GP,  
  
Progressing to a stable, optimal dose usually takes about three months. Once 
achieved, a Shared Care arrangement with you will be requested. It will clarify 
responsibilities between the specialist and general practitioner (GP) for managing the 
prescribing of methotrexate such as:  
  Who will prescribe;   Who will monitor;   How often blood tests will be conducted and in which location;   Which clinician will be responsible for receipt and review of the results;   Who will communicate any necessary changes in dose to the patient and the 
GP;   Who will record test results in the Patient-Held Monitoring and Dosage Record 
booklet.    
 
 GPs are invited to participate. If the GP is not confident to undertake these roles, the 
total clinical responsibility for the patient for the diagnosed condition remains with the 
specialist.    
  
Sharing of care assumes communication between the specialist, GP and patient. The 
intention to share care should be explained to the patient by the Consultant / specialist 
nurse when treatment is initiated. It is important that patients are consulted about 
treatment and are in agreement with it.  
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Shared Care Criteria  
  
Patients who are stabilised on methotrexate and have been monitored appropriately 
at baseline and after initiation of treatment with no problems identified during this 
period.  
RESPONSIBILITIES and ROLES  
  
Consultant and Specialist Nurse  
1. Perform baseline tests (FBC, LFTs, U&Es, creatinine, chest X-ray).  
2. Initiate and stabilise treatment with methotrexate and continue to prescribe until the 
GP formally agrees to shared care.  
3. Discuss the benefits and side effects of treatment with the patient. Provide the patient 
with a Patient Information Leaflet, explain it and ensure that the patient understands 
that dosing is at weekly intervals. Issue a Methotrexate Monitoring Booklet to the 
patient and explain monitoring schedule.  
4. Write to the GP with a standard letter asking whether he or she is willing to participate 
in shared care.  
5. Discuss the shared care arrangement with the patient.  
6. Provide results of baseline tests and recommend frequency of monitoring to GP. Record 
ƌesults iŶ the patieŶt͛s Methotƌeǆate MoŶitoƌiŶg Booklet aŶd ĐoŶtiŶue to do so uŶtil GP 
agrees to shared care. Recommend dose and timing of concomitant folic acid.   
7. PeƌiodiĐallǇ ƌeǀieǁ the patieŶt͛s ĐoŶditioŶ aŶd ĐoŵŵuŶiĐate pƌoŵptlǇ ǁith the GP 
when treatment is changed. Counsel the patient on any dose changes that are made 
during clinic appointments.   
8. Inform GP of blood test results, actions to take in case of abnormal results, and advise 
the GP on when to adjust the dose, stop treatment, or consult with specialist.  
9. Evaluate adverse effects reported by GP or patient.  
10. Report adverse events to the MHRA and GP.  
11. Ensure that clear backup arrangements exist for GPs to obtain advice and support.  
  
Written by Jay Pang – Royal Free Hospital and Balram Malhotra – University 
College London Hospitals, Rheumatology and Dermatology Pharmacists.  
  
Agreed with lead commissioning PCT, NHS Camden: May 2009.      
Date of next review: April 2011.  
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General Practitioner   
1. Reply to the request for shared care as soon as practicable by completing standard 
letters to the Consultant and Primary Care Trust accepting or declining shared care.   
2. MoŶitoƌ patieŶt͛s oǀeƌall health aŶd ǁellďeiŶg.  
3. Prescribe methotrexate at the dose recommended and ensure patient understands the 
number of tablets and strength of tablets to take. Only 2.5 mg tablets should be 
prescribed. 10 mg tablets SHOULD NOT be prescribed. Prescriptions should specify 
͞oŶĐe a ǁeek͟ aŶd the daǇ of adŵiŶistƌatioŶ. The teƌŵ ͞as diƌeĐted͟ SHOULD NOT 
be used.  
4. Ensure that the patient understands that dosing is at weekly intervals.  
5. Ensure that the patient knows that he/she must report the warning symptoms as listed 
uŶdeƌ ͞Adǀeƌse EffeĐts͟.  
6. Ensure compatibility with other concomitant medication.  
7. Monitor blood counts, hepatic and renal function at recommended frequencies as 
desĐƌiďed ;see ͞MoŶitoƌiŶg͟Ϳ, aŶd iŶfoƌŵ ĐoŶsultaŶt if aďŶoƌŵal. All test results to be 
ƌeĐoƌded iŶ patieŶt͛s Methotƌeǆate MoŶitoƌiŶg Booklet.   
8. ‘eĐoƌd the date of the Ŷeǆt ďlood test iŶ the ͞PatieŶt-Held Monitoring and Dosage 
‘eĐoƌd͟, aŶd aƌƌaŶge it.  
9. Adjust the dose as advised by the specialist and counsel patient on any dose changes. 
‘eĐoƌd dose ĐhaŶges iŶ the ͞PatieŶt-Held MoŶitoƌiŶg aŶd Dosage ‘eĐoƌd͟.    
10. Stop treatment on the advice of the specialist or immediately if an urgent need to stop 
treatment arises.  
11. Report adverse events to the specialist and MHRA.  
12. All requests for repeat prescriptions should be reviewed individually prior to issuing.   
13. Offer annual influenza vaccination to the patient.  
  
Patient  
1. Report to the specialist or GP if he or she does not have a clear understanding of the 
treatment.  
2. Share any concerns in relation to treatment with methotrexate.  
3. Inform specialist or GP of any other medication being taken, including over-the-
counter products.  
4. Report any adverse effects or warning symptoms (sore throat, bruising, mouth ulcers, 
nausea, vomiting, abdominal discomfort, dark urine, shortness of breath) to the 
specialist or GP whilst taking methotrexate.  
5. Bring the Methotrexate Monitoring Booklet to all appointments and when collecting 
supply of tablets.  
  
Primary Care Trust  
1. To support GPs to decide whether or not to accept clinical responsibility for 
prescribing.  
2. To support Trusts in resolving issues that may arise as a result of shared care.  
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SUPPORTING INFORMATION  
  
1. Licensed indications  
• Methotrexate is licensed for the treatment of adults with severe, active, classical or 
definite rheumatoid arthritis who are unresponsive to or intolerant of conventional 
therapy.  
• Methotrexate is licensed for the treatment of severe, uncontrolled psoriasis, which 
is not responsive to other therapy.  
  
2. Dosage and Administration  
Rheumatoid Arthritis  
Methotrexate is started at a dose of 7.5mg orally once weekly. The schedule may be 
adjusted gradually to achieve an optimal response (licensed maximum weekly dose is 
25mg although some patients may require higher doses on advice of the specialist).  
Psoriasis  
Patients are given a small test dose of methotrexate (usually 5mg) orally once weekly. 
If after 7 days the full blood count (FBC) is stable methotrexate is continued. The 
schedule may be adjusted gradually (usually in 2.5-5mg steps) to achieve an optimal 
response. The licensed maximum weekly dose is 25mg, although few patients require 
more than 20mg, and some patients may require higher doses (up to 30mg) on advice 
of the specialist.  
  
The lowest possible effective dose should be used. Methotrexate should be used with 
extreme caution in elderly patients and a lower dose should be considered.  
  
Regular folic acid supplements should be given to reduce the risk of toxicity. 
Please follow the regime detailed in the handover summary. Folic acid 
should not be taken on the same day as methotrexate  
  
Methotrexate will be issued as 2.5mg tablets. Patients should consistently receive the 
same strength of tablets to avoid confusion with the 10mg strength and, therefore, the 
risk of overdose. All patients should be fully counselled regarding the strength and 
number of tablets to take as a single weekly dose.   
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Patients will be issued with a Methotrexate Monitoring Booklet from the hospital. All 
blood results and dose or change in dose should be recorded in this booklet.  
  
Patients should be offered annual influenza vaccination.  
 
3. Cautions and Contraindications   Profound impairment of renal or hepatic function or haematological 
impairment    Liver disease including fibrosis, cirrhosis, recent or active hepatitis; active 
infectious disease; and overt or laboratory evidence of immunodeficiency 
syndrome(s)    Serious cases of anaemia, leucopenia, or thrombocytopenia    Pregnancy or breast-feeding   Patients with a known allergic hypersensitivity to methotrexate   Exposure to chicken pox – patients who have had significant exposure to 
chicken pox but do not know if they have had chicken pox in the past, will 
need to have their varicella zoster antibody titre checked. If it is low, the 
patient will need varicella zoster immunoglobulin within 10 days of the initial 
exposure. If this is necessary, please contact the appropriate specialist nurse 
or specialist registrar or consultant   Localised or systemic infection – including hepatitis B or C  
  
Immunisations - live vaccines should be avoided. Influenza vaccine is safe. For a full list 
of cautions and contraindications, refer to the Summary of Product Characteristics.  
  
The National Patient Safety Agency has published actions to reduce the risks 
associated with oral methotrexate (www.npsa.nhs.uk).  
 
4. Monitoring  
Regular monitoring according to the BSR/BHPR guideline for disease-modifying anti-
rheumatic drug (DMARD) therapy in consultation with the British Association of 
Dermatologists1 during treatment is essential to detect adverse reactions at an early 
stage and patients should be counselled about the risk factors and to report all signs 
and symptoms of toxicity.   
   FBC, U&Es, creatinine, LFTs and chest X-ray should be measured before starting 
treatment.    FBC, U&Es and LFTs should then be monitored fortnightly until dose of 
methotrexate and monitoring is stable for 6 weeks, then monthly thereafter 
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until the dose and disease is stable for 1 year. Thereafter, the monitoring may 
be reduced in frequency to every two to three months, based on clinical 
judgement with due consideration for risk factors including age, comorbidity, 
renal impairment, etc.  
  
(NB. The frequency of monitoring advised by the specialist to the GP may vary from 
the above recommendations depending on patient factors.)  
  
The following threshold laboratory values and symptoms require action as detailed in 
the table below.  
  
Monitoring parameter  Action to be taken if changed  
WBC <3.5x10^9/l  Withhold methotrexate until discussed 
with rheumatologist / dermatologist  
Neutrophils<2.0x10^9  Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
Platelets<150x10^9 /l  Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
>2-fold rise in AST, ALT (from upper 
limit of reference range)  
Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
Unexplained fall in albumin (in absence 
of active disease)  
Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
Rash or oral ulceration, nausea and 
vomiting, diarrhoea  
Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
New or increasing dyspnoea or dry 
cough  
Withhold methotrexate until discussed 
with rheumatologist / dermatologist 
MCV>105fl  Withhold and check serum B12, folate and 
TFT and discuss with specialist team if 
necessary  
Significant deterioration in renal 
function  
Withhold methotrexate until discussed 
with rheumatologist / dermatologist  
Abnormal bruising or severe sore 
throat  
Immediate FBC and withhold 
methotrexate until FBC result available  
  
Appendix A 
 
459 
The specialist may conduct additional investigations as required e.g. CRP, ESR, (and 
PIIINP and liver biopsy for psoriatic patients). The results will be sent to the GP.  
  
5. Adverse Effects  
Possible adverse effects and what to do if they occur:  
  
1. Nausea and diarrhoea – these will be minimised by the folic acid therapy. 
Some patients benefit by taking their NSAID (if they are on one) a few hours 
before or after, rather than at the same time as their methotrexate dose. If 
severe despite these measures, the methotrexate must be stopped, and the 
specialist nurse or specialist registrar or Consultant, contacted.  
2. Mouth ulcers, hair loss, and skin rash – these usually respond to omitting a 
dose and resuming at a dose reduced by 2.5mg. Topical hydrocortisone may be 
used for skin rash. If any are severe (particularly stomatitis), the methotrexate 
must be stopped, and the specialist nurse or specialist registrar or Consultant, 
contacted.  
3. Recurrent sore throat, infections and fevers – these may indicate neutropenia, 
so the methotrexate must be stopped, the FBC checked, and the specialist 
nurse or specialist registrar or Consultant, contacted.  
4. Unexplained bruising or bleeding – if severe, the APTT and FBC should be 
ĐheĐked. If theǇ aƌe Ŷoƌŵal ;see ͞MoŶitoƌiŶg͟Ϳ, ŵethotƌeǆate ŵaǇ ďe 
continued and the specialist nurse or specialist registrar or Consultant, 
contacted. If they are abnormal, the methotrexate should be stopped, and the 
specialist nurse or specialist registrar or Consultant, contacted.   
5. Unexplained cough or shortness of breath – these may indicate pneumonitis 
or pulmonary fibrosis, so the methotrexate should be stopped and the 
specialist nurse or specialist registrar or Consultant, contacted.  
6. Jaundice, abdominal discomfort, or dark urine – these may indicate liver 
damage, so the methotrexate should be stopped and the specialist nurse or 
specialist registrar or Consultant, contacted.    
 Methotrexate was launched in 1989 and no longer has black triangle status. Serious 
suspected reactions (even if well recognised or causal link uncertain) should be 
reported to the CHM.  
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6. Drug Interactions  
  
Methotrexate is extensively protein-bound and may be displaced by other protein-
bound drugs (e.g. diuretics, salicylates, hypoglycaemics), with a potential for increased 
toxicity.   
  
NSAIDs can be continued whilst on methotrexate. The NSAID or its dose should not be 
changed without discussion with the Consultant. All patients should be regularly 
advised to avoid over-the-counter medications including aspirin and ibuprofen without 
the knowledge of the specialist team.  
  
Concomitant use of other drugs with nephrotoxic or hepatotoxic potential should be 
avoided. Folate antagonists such as trimethoprim and co-trimoxazole should not be 
given concomitantly.   
  
For a full list of drug interactions, refer to the Summary of Product Characteristics.   
7. Pregnancy and Lactation   All patients, male and female, should be advised to avoid conception and 
pregnancy during treatment with methotrexate as it is an abortificient as well 
as a teratogenic drug.   Patients and their partners should be advised to continue contraception for at 
least 3 months after cessation of methotrexate therapy.   Patients should not breastfeed whilst taking methotrexate.  
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CONTACT DETAILS  
  
Royal Free Hospital - Rheumatology  
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Royal Free Hospital switchboard:              0207 794 
0500  
Consultants: Professor C Denton, Dr R Stratton, Dr H Beynon, Dr A Kaul, Dr G 
Brough  
ext  
Rheumatology sister: Olanike Akinsulire             ext  
Rheumatology Pharmacist: Jay Pang           
   
  
Royal Free Hospital - Dermatology  
bleep  
Royal Free Hospital switchboard:              0207 794 
0500  
Consultants: Drs E Seaton, M Rustin, F Child, C Orteu, S McBride, V 
Swale, J Jones  
ext  
Dermatology sister: Annie Waite               ext  
Dermatology Pharmacist: Nisha Patel           
   
bleep  
  
University College London Hospitals - Rheumatology  
Centre for Rheumatology, University College London Hospitals, 3rd Floor Central, 250 
Euston Road, London, NW1 2PG. Switchboard telephone number: 0845 155 5000  
Further information and support: Monday to Friday, 8 a.m. to 5 p.m., 
rheumatology helpline (Rheumatology Clinical Nurse Specialist) on tel. 
 At all other times, a rheumatology specialist registrar can 
be paged by the hospital switchboard, on 0845 155 5000.  
  
University College London Hospitals - Dermatology  
Department of Dermatology, University College London Hospitals, 3rd Floor Central, 
250 Euston Road, London, NW1 2PG. Switchboard telephone number: 0845 155 5000  
Further information and support: Monday to Friday, 8 a.m. to 5 p.m., 
dermatology helpline (Dermatology Clinical Nurse Specialist) on tel.  
. At all other times, a dermatology specialist registrar can be 
paged by the hospital switchboard, on 0845 155 5000.    
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APPENDIX B. PRISMA 2009 CHECKLIST 
Section/topic  # Checklist item  
Reported 
on page #  
Notes 
TITLE    
Title  1 Identify the report as a systematic review, meta-analysis, or both.  99  
ABSTRACT    
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
No Not a 
published 
review (but 
will be 
undertaken 
for 
publication) 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  99-101   
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
101  
METHODS    
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
No  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
104  
  
4
6
4
 
Section/topic  # Checklist item  
Reported 
on page #  
Notes 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched.  
103  
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
Appendix C  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
106  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, 
in duplicate) and any processes for obtaining and confirming data from investigators.  
106, 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) 
and any assumptions and simplifications made.  
106  
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
No Quality was 
assessed not 
risk of bias. 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  102 NB: data 
were not 
meta-
analysed 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
102  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
No Quality was 
assessed not 
risk of bias. 
  
4
6
5
 
Section/topic  # Checklist item  
Reported 
on page #  
Notes 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
n/a  
RESULTS    
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram.  
107, Figure 
3.2 
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
108-140, 
Table 3.1 
 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
No Quality was 
assessed not 
risk of bias. 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
Appendix H, 
I, J 
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
n/a  
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  No Quality was 
assessed not 
risk of bias. 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
n/a  
  
4
6
6
 
Section/topic  # Checklist item  
Reported 
on page #  
Notes 
DISCUSSION    
Summary of evidence  24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
140   
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
163  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
152  
FUNDING    
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply 
of data); role of funders for the systematic review.  
No Will be 
provided for 
publication 
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APPENDIX C. SYSTEMATIC REVIEW SEARCH STRATEGY 
1. Cochrane Library (Title, abstract or keywords) 
self care  
self monitor*  
self administer*  
self examin* 
self medicat*  
self inject* 
self evaluat* 
self test* 
self manage* 
self adjust* 
self measure* 
patient participation  
patient monitor*  
patient manage*  
patient adjust*  
patient administer* 
patient control* 
patient cent?d  
telemedicine  
telehealth 
telecare 
telemonitor* 
telemetry  
home monitor* 
 
2. DARE & HTA 
self care  
self monitor*  
self administer*  
self examin* 
self medicat*  
self inject* 
self evaluat* 
self test* 
self manage* 
self adjust* 
self measure* 
patient participation  
Monitoring, Physiologic[Mesh] 
patient manage* 
patient adjust* 
patient administ* 
patient control* 
patient centered 
patient centred   
telemedicine  
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telehealth 
telecare 
telemonitor* 
home monitor* 
 
3. Pub med 
self care[Mesh]  
self monitor*  
self administration[Mesh]  
self examination[Mesh] 
self medication[Mesh] 
self inject* 
self test* 
self management[Mesh] 
self adjust* 
self evaluat* 
self measure* 
patient-centered care[Mesh]  
patient participation[Mesh] 
Monitoring, Physiologic[Mesh] 
patient manage* 
patient adjust* 
patient administ* 
patient control* 
telemedicine[Mesh] 
telecare 
telehealth 
telemonitor* 
home monitor* 
 
AND 
 
Meta-Analysis[Publication Type][Mesh] 
Review[Publication Type][Mesh] 
overview 
narrative review 
 
5, 6, 7 & 8. AMED, HMIC, EMBASE & PsycINFO 
Self Care/  
self monitor$.mp. 
self administer$.mp. 
self examin$.mp. 
self medicat$.mp. 
self inject$.af 
self evaluat$.mp. 
self test$.af. 
self management.mp. 
self adjust$.mp. 
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self measure$.mp 
Patient participation/ 
Patient monitor$.mp. 
Patient manage$.mp. 
Patient adjust$.mp. 
Patient administer$.mp. 
Patient control$.mp. 
Patient centred.mp. 
Telemedicine/ 
Telehealth.mp. 
Telecare.mp. 
telemonitoring.ab. or telemonitoring.ti. 
telemetry.mp. 
home monitor* 
 
4. CINAHL plus 
MH Self Care+ 
self monitor*  
MH Self Administration+ 
self examine* 
MH Self Medication 
self inject* 
self evaluat* 
self test* 
self manage* 
self adjust* 
self measure* 
MH Health Services+ 
MH Monitoring, Physiologic+ 
patient manage*  
patient adjust*  
patient administer* 
patient control* 
MH Telehealth+ 
telecare 
telemonitor* 
home monitor* 
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APPENDIX D. DATA EXTRACTION FORM 
Reference. 
 
Title 
 
Aim 
 
 
Objective 
 
 
Type of review 
 
Literature search 
 
Level of self-monitoring 
 
Inclusion/exclusion criteria 
Design 
 
Participants 
 
Interventions 
 
Outcomes 
 
Other 
 
Study selection procedure 
 
Methods 
Statistical analysis 
 
Quality assessment tool 
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Quality assessment procedure 
 
Data extracted from primary studies 
 
Data extraction procedure 
 
How were studies combined in the review 
 
How was bias assessed 
 
How was heterogeneity assessed 
 
Was a sensitivity analysis conducted? 
 
 
Results 
Number of studies included in the review 
 
Number of participants 
 
Results of quality assessment 
 
Main outcome 
 
Secondary outcome 
 
Publication bias 
 
Heterogeneity & sensitivity 
 
Conclusions and Interpretations 
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Authors interpretation 
 
Conclusion 
 
Implications for research 
 
Implication for practice 
 
Reviewers comments  
 
 
 
 
 474 
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APPENDIX E. AMSTAR CRITERIA FOR REVIEW QUALITY 
1. Was an a priori design provided? 
The research question and inclusion criteria should be established before the conduct 
of the review. 
2. Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus procedure 
for disagreements should be in place. 
3. Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g. Central, EMBASE, and MEDLINE). Key words and/or MESH terms 
must be stated and where feasible the search strategy should be provided. All 
searches should be supplemented by consulting current contents, reviews, textbooks, 
specialized registers, or experts in the particular field of study, and by reviewing the 
references in the studies found. 
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
The authors should state that they searched for reports regardless of their publication 
type. The authors should state whether or not they excluded any reports (from the 
systematic review), based on their publication status, language etc. 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
6. Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should be 
provided on the participants, interventions and outcomes. The ranges of 
characteristics in all the studies analysed e.g. age, race, sex, relevant socioeconomic 
data, disease status, duration, severity, or other diseases should be reported. 
7. Was the scientific quality of the included studies assessed and documented? 
A priori methods of assessment should be provided (e.g., for effectiveness studies if 
the author(s) chose to include only randomized, double-blind, placebo controlled 
studies, or allocation concealment as inclusion criteria); for other types of studies 
alternative items will be relevant. 
8. Was the scientific quality of the included studies used appropriately in 
formulating conclusions? 
The results of the methodological rigor and scientific quality should be considered in 
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the analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. 
9. Were the methods used to combine the findings of studies appropriate? 
For the pooled results, a test should be done to ensure the studies were combinable, 
to assess their homogeneity (i.e. Chi-squared test for homogeneity, I2). If 
heterogeneity exists a random effects model should be used and/or the clinical 
appropriateness of combining should be taken into consideration (i.e. is it sensible to 
combine?). 
10. Was the likelihood of publication bias assessed? 
An assessment of publication bias should include a combination of graphical aids (e.g., 
funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test). 
11. Was the conflict of interest stated? 
Potential sources of support should be clearly acknowledged in both the systematic 
review and the included studies. 
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APPENDIX F. SYSTEMATIC REVIEW - EXCLUDED STUDIES 
Excluded at stage 2 – included children 
Centre for Reviews and Dissemination. The effect of nurse-led diabetes self-management education on glycosylated hemoglobin 
and cardiovascular risk factors: a meta-analysis (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. The value of self-monitoring of blood glucose: a review of recent evidence (Structured 
abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. The impact of telemedicine interventions involving routine transmission of blood glucose 
data with clinician feedback on metabolic control in youth with type 1 diabetes: a systematic review and meta-analysis (Provisional 
abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Electronic media-based health interventions promoting behavior change in youth: a 
systematic review (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. A systematic review of internet-based self-management interventions for youth with 
health conditions (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Health technologies for monitoring and managing diabetes: a systematic review 
(Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Do school-based asthma education programs improve self-management and health 
outcomes? (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. The socio-economic impact of telehealth: a systematic review (Provisional abstract). 
Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in 
type 1 diabetic patients: systematic review and meta-analysis of randomized trials (Structured abstract). Database of Abstracts of 
Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Efficacy of continuous glucose monitoring in improving glycemic control and reducing 
hypoglycemia: a systematic review and meta-analysis of randomized trials (Provisional abstract). Database of Abstracts of Reviews 
of Effects 4. 2013.  
Ref Type: Abstract 
Coster S., Gulliford, M.C., Seed, P.T., Royle, P., & Swaminathan, R. 2000. Monitoring blood glucose control in diabetes mellitus:a 
systematic review. Health Technology Assessment, 4, (12) 
Cox, N.S., Alison, J.A., Rasekaba, T., & Holland, A.E. Telehealth in cystic fibrosis: A systematic review. Journal Of Telemedicine And 
Telecare, 18, (2) March 
Farmer, A., Gibson, O.J., Tarassenko, L., & Neil, A. 2005. A systematic review of telemedicine interventions to support blood 
glucose self-monitoring in diabetes. Diabetic Medicine, 22, (10) 1372-1378 
George, M. & Topaz, M. 2013. A systematic review of complementary and alternative medicine for asthma self-management. The 
Nursing Clinics Of North America, 48, (1) 53-149 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=23465447&site=ehost-live  
Hailey, D., Ohinmaa, A., & Roine, R. 2014. Evidence for the benefits of telecardiology applications: a systematic review (Structured 
abstract). Health Technology Assessment Database (1) 
Jaana, M. & Pare, G. 2007. Home telemonitoring of patients with diabetes: A systematic assessment of observed effects. Journal of 
Evaluation in Clinical Practice, 13, (2) 242-253 
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Jaana, M., Pare, G., & Sicotte, C. 2009. Home telemonitoring for respiratory conditions: A systematic review. American Journal of 
Managed Care, 15, (5) 313-320 
Labre, M.P., Herman, E.J., Dumitru, G.G., Valenzuela, K.A., & Cechman, C.L. Public health interventions for asthma: An umbrella 
review, 1990-2010. American Journal of Preventive Medicine, 42, (4) April 
Lefevre, F., Piper, M., Weiss, K., Mark, D., Clark, N., & Aronson, N. 2002. Do written action plans improve patient outcomes in 
asthma? An evidence-based analysis. The Journal of Family Practice, 51, (10) 842-848 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2002-04648-004&site=ehost-live;f-lefevre@northwestern.edu  
Marcano Belisario, J.S., Huckvale, K., Greenfield, G., Car, J., & Gunn, L.H. 2013. Smartphone and tablet self management apps for 
asthma. Cochrane Database of Systematic Reviews, 11, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010013.pub2/pdf  
McIntosh, B., Yu, C., Lal, A., Chelak, K., Cameron, C., Singh, S., & Dahl, M. 2010. Efficacy of self-monitoring of blood glucose in 
patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Medicine, 4, (2) 
e102-e113 available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116681/pdf/OpenMed-04-e102.pdf  
McLean, S., Chandler, D., Nurmatov, U., Liu, J., Pagliari, C., Car, J., & Sheikh, A. 2011. Telehealthcare for asthma: A Cochrane 
review. CMAJ, 183, (11) 09-E742 
Montori, V.M., Helgemoe, P.K., Guyatt, G.H., Dean, D.S., Leung, T.W., Smith, S.A., & Kudva, Y.C. 2004. Telecare for patients with 
type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care, 27, 1088-1094 
Pare, G., Jaana, M., & Sicotte, C. 2007. Systematic review of home telemonitoring for chronic diseases: the evidence base. Journal 
of the American Medical Informatics Association, 14, (3) 269-277 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=2009592387&site=ehost-live;Publisher URL: 
www.cinahl.com/cgi-bin/refsvc?jid=2362&accno=2009592387  
Pare, G., Moqadem, K., Pineau, G., & St-Hilaire, C. 2010. Clinical effects of home telemonitoring in the context of diabetes, asthma, 
heart failure and hypertension: a systematic review. Journal of medical Internet research, 12, (2) e21 
St John, A., Davis, W.A., Price, C.P., & Davis, T.M.E. 2010. The value of self-monitoring of blood glucose: a review of recent 
evidence. Journal of Diabetes and its Complications, 24, (2) 129-141 
Sutcliffe, P., Martin, S., Sturt, J., Powell, J., Griffiths, F., Adams, A., & Dale, J. 2011. Systematic review of communication 
technologies to promote access and engagement of young people with diabetes into healthcare. BMC Endocrine Disorders, 11, 
Yeh, H.-C., Brown, T.T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y.D., Wilson, L.M., Haberl, E.B., Brick, J., Bass, E.B., & Golden, 
S.H. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A 
systematic review and meta-analysis. Annals of Internal Medicine, 157, (5) 16 
 
Excluded at stage 2 – not a systematic review 
Agarwal, R., Bills, J.E., Hecht, T.J.W., & Light, R.P. 2011. Role of home blood pressure monitoring in overcoming therapeutic inertia 
and improving hypertension control: A systematic review and meta-analysis. Hypertension, 57, (1) January-38 
Aldcroft, S.A., Taylor, N.F., Blackstock, F.C., & O'Halloran, P.D. 2011. Psychoeducational rehabilitation for ealth behavior change in 
coronary artery dsease: A systematic review of controlled trials. Journal of Cardiopulmonary Rehabilitation and Prevention, 31, (5) 
September-October 
Alonso-Coello, P., Zhou, Q., & Guyatt, G. Home-monitoring of oral anticoagulation vs. dabigatran: An indirect comparison. 
Thrombosis and Haemostasis, 108, (4) September 
Anderson, E. & Esper, G. 2012. A systematic review of teleneurology. Neurology.Conference: 64th American Academy of Neurology 
Annual Meeting New Orleans, LA United States.Conference Start: 20120421 Conference End: 20120428.Conference Publication: 
(var.pagings), 78, (1 Meeting Abstract) 22 
Ann, M.K., Lokker, C., Handler, S.M., Dolovich, L.R., Holbrook, A.M., O'Reilly, D., Tamblyn, R., Hemens, B.J., Basu, R., Troyan, S., & 
Roshanov, P.S. 2012. The effectiveness of integrated health information technologies across the phases of medication 
management: A systematic review of randomized controlled trials. Journal of the American Medical Informatics Association, 19, (1) 
January/February-30 
Arad, Y., Fonseca, V., Peters, A., & Vinik, A. 2011. Beyond the monofilament for the insensate diabetic foot: A systematic review of 
randomized trials to prevent the occurrence of plantar foot ulcers in patients with diabetes. Diabetes Care, 34, (4) April-1046 
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Aspry, K.E., Furman, R., Karalis, D.G., Jacobson, T.A., Zhang, A.M., Liptak, G.S., & Cohen, J.D. Effect of health information 
technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials. Journal of 
Clinical Lipidology, 7, (6) November-December 
Avery, L., Flynn, D., Van, W.A., Sniehotta, F.F., & Trenell, M.I. Changing physical activity behavior in type 2 diabetes: A systematic 
review and meta-analysis of behavioral interventions. Diabetes Care, 35, (12) December 
Aziz, K.M.A. Management of type-1 and type-2 diabetes by insulin injections in diabetology clinics - a scientific research review. 
Recent Patents on Endocrine, Metabolic and Immune Drug Discovery, 6, (2) May 
Baradaran, H.R.S. 2010. Effectiveness of diabetes educational interventions in Iran: A systematic review. Diabetes Technology and 
Therapeutics, 12, (4) 317-331 
Beatty, L. & Lambert, S. 2013. A systematic review of internet-based self-help therapeutic interventions to improve distress and 
disease-control among adults with chronic health conditions. Clinical Psychology Review, 33, (4) 609-622 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=23603521&site=ehost-live  
Bentsen, S.B., Langeland, E., & Holm, A.L. Evaluation of self-management interventions for chronic obstructive pulmonary disease. 
Journal of Nursing Management, 20, (6) September 
Birns, J., Roots, A., & Bhalla, A. Role of telemedicine in the management of acute ischemic stroke. Clinical Practice, 10, (2) 2013 
Bliziotis, I.A., Destounis, A., & Stergiou, G.S. 2012. Home versus ambulatory and office blood pressure in predicting target organ 
damage in hypertension: A systematic review and meta-analysis. Journal of Hypertension, 30, (7) July-1299 
Boland, M.R.S., Tsiachristas, A., Kruis, A.L., Chavannes, N.H., & Rutten-Van Molken, M.P.M.H. The health economic impact of 
disease management programs for COPD: A systematic literature review and meta-analysis. BMC Pulmonary Medicine, 13, (1) 40 
Bonner, K., Mezochow, A., Roberts, T., Ford, N., & Cohn, J. Viral load monitoring as a tool to reinforce adherence: A systematic 
review. Journal of Acquired Immune Deficiency Syndromes, 64, (1) 01 
Boren, S.A., Wakefield, B.J., Gunlock, T.L., & Wakefield, D.S. 2009. Heart failure self-management education: A systematic review 
of the evidence. International Journal of Evidence-Based Healthcare, 7, (3) 159-168 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-12861-002&site=ehost-
live;borens@health.missouri.edu  
Bourbeau, J. 2003. Disease-specific self-management programs in patients with advanced chronic obstructive pulmonary disease: 
a comprehensive and critical evaluation (Structured abstract). Disease Management and Health Outcomes, 11, 311-319 
Boyde, M., Turner, C., Thompson, D.R., & Stewart, S. 2011. Educational interventions for patients with heart failure: a systematic 
review of randomized controlled trials. The Journal of cardiovascular nursing, 26, (4) 2011-2Aug 
Boyers, D., McNamee, P., Clarke, A., Jones, D., Martin, D., Schofield, P., & Smith, B.H. 2013. Cost-effectiveness of self-management 
methods for the treatment of chronic pain in an aging adult population: a systematic review of the literature. The Clinical Journal 
Of Pain, 29, (4) 366-375 available from: 
http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=23042472&site=ehost-live  
Breland, H.L. & Kamen, D.L. Lupus patient education: An examination of approaches. International Journal of Clinical 
Rheumatology, 7, (5) October 
Brewster, L.B. 2010. Systematic Review of the Use of Spot and Overnight Urine for Assessment of Sodium Excretion: 5D.05. Journal 
of Hypertension, Conference, (var.pagings) June 
Brouwer, W., Kroeze, W., Crutzen, R., de, N.J., de Vries, N.K., Brug, J., & Oenema, A. 2011. Which intervention characteristics are 
related to more exposure to internet-delivered healthy lifestyle promotion interventions? A systematic review. Journal of medical 
Internet research, 13, (1) 2011 
Bryant, J., McDonald, V.M., Boyes, A., Sanson-Fisher, R., Paul, C., & Melville, J. Improving medication adherence in chronic 
obstructive pulmonary disease: A systematic review. Respiratory Research, 14, (1) 109 
Bussey-Smith, K.L. & Rossen, R.D. 2007. A systematic review of randomized control trials evaluating the effectiveness of interactive 
computerized asthma patient education programs (Structured abstract). Annals of Allergy, Asthma and Immunology, 98, 507-516 
Carlier, I.V.E., Meuldijk, D., Van Vliet, I.M., Van, F.E., Van Der Wee, N.J.A., & Zitman, F.G. Routine outcome monitoring and 
feedback on physical or mental health status: Evidence and theory. Journal of Evaluation in Clinical Practice, 18, (1) February 
Carnes, D., Homer, K.E., Miles, C.L., Pincus, T., Underwood, M., Rahman, A., & Taylor, S.J.C. Effective delivery styles and content for 
self-management interventions for chronic musculoskeletal pain: A systematic literature review. Clinical Journal of Pain, 28, (4) 
May 
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Castrejon, I., Silva-Fernandez, L., Bombardier, C., & Carmona, L. 2011. Clinical composite measures of disease activity for diagnosis 
and followup of undifferentiated peripheral inflammatory arthritis: A systematic review. Journal of Rheumatology, 38, (SUPPL.#87) 
March-53 
Catalani, C., Philbrick, W., Fraser, H., Mechael, P., & Israelski, D.M. mHealth for HIV treatment & prevention: A systematic review 
of the literature. Open AIDS Journal, 7, (1) 2013 
Centre for Reviews and Dissemination. Communication-related behavior change techniques used in face-to-face lifestyle 
interventions in primary care: a systematic review of the literature (Structured abstract). Database of Abstracts of Reviews of 
Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Computer-based education for patients with hypertension: a systematic review (Structured 
abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Telehealth interventions for the secondary prevention of coronary heart disease: a 
systematic review (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Pharmacist interventions to enhance blood pressure control and adherence to 
antihypertensive therapy: review and meta-analysis (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. A systematic review of randomized trials of disease management programs in heart failure 
(Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Nurse-led telephone interventions for people with cardiac disease: a review of the research 
literature (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. A systematic review of psychosocial outcomes following education, self-management and 
psychological interventions in diabetes mellitus (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. A systematic review of community-based health interventions on depression for older 
adults with heart disease (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Systematic review of the chronic care model in chronic obstructive pulmonary disease 
prevention and management (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Systematic review: self-management support interventions for irritable bowel syndrome 
(Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Self-monitoring and other non-pharmacological interventions to improve the management 
of hypertension in primary care: a systematic review (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Effectiveness of chronic obstructive pulmonary disease-management programs: systematic 
review and meta-analysis (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Effectiveness of chronic care model-oriented interventions to improve quality of diabetes 
care: a systematic review (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
Centre for Reviews and Dissemination. Educational interventions for migrant South Asians with type 2 diabetes: a systematic 
review (Structured abstract). Database of Abstracts of Reviews of Effects 4. 2013.  
Ref Type: Abstract 
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Centre for Reviews and Dissemination. Effectiveness of web-based interventions on patient empowerment: a systematic review 
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APPENDIX H. HEALTHCARE UTILISATION OUTCOMES - OVERVIEW 
First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Hypertension      
Jaana, 2007 BP TM SR  14(1119) Office visits – 1 RCT found no significant  difference between groups 
AbuDagga, 
2010 
TM SR 15(3192) Office visits – 5 RCTs found no significant differences between groups 
COPD      
Turnock, 2005 Action planning  MA  3(367) No. hospital admissions in past 12 months - No significant difference between groups in 2 RCTs (WMD=0.16, 95% CI -
0.09 to 0.42).  
Visits to GP or practice nurse in 6 months – No significant difference between groups in 2 RCTs (WMD=1.00, 95% CI -
0.57 to 2.57) 
No. of scheduled visits to GP in 12 months - No significant difference between groups in 1 RCT (MD=-0.50, 95% CI -4.06 
to 3.06) 
No. of emergency visits to GP for COPD in 12 months - No significant difference between groups in 1 RCT (MD=-0.20, 
95% CI -1.55 to 1.15) 
No. of ED visits in 12 months - No significant difference between groups in 2 RCTs (WMD=-0.01, 95% CI -0.12 to 0.10). 
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First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
McLean 2011 Telehealthcare  MA  10(1307) ED visits - A meta-analysis of 3 RCTs patients with telehealthcare were much less likely to attend the emergency 
department than patients in the control group: OR 0.27 (95% CI 0.11 to 0.66). 1 additional RCT had too few cases of 
hospitalisation to conduct an analysis. Another RCT recorded the average number of visits per patient over a three 
month period as greater in the control group, OR 0.17 (95% CI 0.04 to 0.67). Another RCT reported that the average 
number of ED visits per patient was greater in the intervention compared to control group but no statistical tests were 
performed.  
Hospitalisation - A meta-analysis of 4 RCTs suggested that the number of patients with one or more hospital 
admissions during the 12 month period was significantly greater in the control compared to telehealthcare (OR=0.46, 
95% CI 0.33 to 0.65, p<0.00001). 1 additional RCT found no significant difference between the telephone and the 
control group in hospitalisation rates at three months: p=0.182. 
Discharge to higher levels of care - 1 RCT found that telehealthcare patients have a lower odds of being discharged to 
a higher level of care than usual care patients (OR=0.29, 95% CI 0.08 to 1.05).  
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First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Heart failure      
Louis, 2003 TM  SR  24(3643) Hospitalisation - 7 non-randomised studies report reduced hospitalisation rates as a result of the intervention 
however, only 1 of these studies reports that the difference was significant.   
Readmissions - 2 RCTs found lower readmission rates as a result of the intervention; however, only 1 of these reports 
this as a significant difference. Another RCT found no significant difference in readmission rates. 5 non-randomised 
studies also found reduced readmission rates as a result of the intervention however, only 2 of these trials report 
significant differences.  
Length of stay - 1 RCT reported significantly reduced length of stay in the intervention compared to a nurse visit group. 
4 non-randomised studies found reductions in the length of stay and hospital days however, only 1 of these studies 
reports that the difference is significant.   
ER visits - 4 non-randomised studies report reductions in the number of visits as a result of the intervention; however, 
1 of these is not significant and the others do not report significance.  
Jovicic 2006 Self-management  MA  6(857) All-cause readmission - Results indicate a significant decrease in all-cause readmission (OR=0.59; 95% CI 0.44 to 0.80) 
in favour of self-management.    
HF-related readmission - Results indicate a significant decrease in HF-related readmission (OR=0.44; 95% CI 0.27 to 
0.71) in favour of self-management.    
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First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Martinez, 
2006 
Home-monitoring  SR  42(2303) Readmission - 11 studies found significantly fewer admissions as a result of the intervention. The other 11 studies 
found no significant difference between the 2 groups.    
Length of stay - 12 of 15 studies found a significantly shorter length of stay in the intervention compared to control 
group. 3 studies failed to find a significant difference.   
Chaudhry, 
2007 
TM SR  9(3582) HF-related hospitalization - 4 studies found a significant decrease in HF-related hospitalisation in favour of the 
intervention group. 2 studies failed to find a difference and 1 reports a reduction but does not state if it is significant.  
All-cause hospitalization - 2 studies found a significant decrease in all-cause hospitalisation in favour of the 
intervention, 4 found no significant differences.  
Clark, 2007 TM or STS  MA 14(4264) All-cause hospital admission - No statistically significant differences between the intervention and control group for 
STS (RR=0.94, 95% CI 0.87 to 1.02, p=0.15) or TM (RR=0.98, 95% CI 0.84 to 1.15, p=0.83). 
HF-related hospitalization – There was statistically significant differences between the intervention and control group 
in favour of STS (RR=0.78, 95% CI 0.68 to 0.89, p=0.0003). 1 study of TM failed to find a significant effect on HF-related 
hospitalisation.  
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Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Dang, 2009 Home telehealth 
remote monitoring  
SR  9(2017) All-cause admissions - 4 studies found no significant difference between the groups. 4 studies found a significant 
reduction in favour of the intervention group at varying time points and another study reported a trend towards an 
increase as a result of the intervention however, significance is not reported.    
CHF-related admissions - 2 studies found no significant difference between groups. 2 studies report significantly fewer 
admissions in the intervention compared to control group and another 2 report a trend but no significance test.  
ED visits - 2 studies found a significant reduction in the intervention compared to control group. 4 other studies failed 
to find a difference between groups.   
Length of stay - 2 studies found a significant reduction as a result of the intervention compared to controls. The other 
4 studies found no significant difference.   
Klersy, 2009 Remote patient 
monitoring  
MA  32(8612) All-cause hospitalisation - RPM was associated with significantly fewer hospitalisations (RCTs: RR=0.93; 95% CI 0.73 to 
0.95; p=0.030, Cohort: RR=0.52; 95% CI 0.28 to 0.96; p<0.001) when compared with usual care  
CHF-related hospitalisations - RPM was associated with significantly fewer CHF-related hospitalisations (RR=0.71; 95% 
CI 0.64 to 0.80; p<0.001) when compared with usual care.  
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First author, 
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Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Maric, 2009 TM SR  56(NR) Length of stay - 7 studies found reductions in the length of hospital stay; however, 3 of these studies failed to report 
if the differences were significant  
ER visits - 6 studies found reductions in the number of ER visits; however, 1 of these studies failed to report if the 
differences were significant.  
Readmissions - 4 studies found reductions in the number of readmissions; however, 1 of these studies failed to report 
if the difference was significant.  
Home visits - 1 study found a reduction when compared to data prior to intervention implementation; however, it is 
unclear if this is significant.  
Hospitalisation - 15 studies found reductions or low numbers of hospitalisation as a result of TM; however, 7 studies 
failed to report if these differences were significant. 2 studies found a significant increase in the hospitalisation as a 
result of the intervention.  
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First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Polisena, 
2010 
TM MA & 
SR  
22(3028) No. of patients hospitalised all-cause - TM had significantly fewer patients hospitalised than usual care (RR=0.77; 
95%CI 0.65 to 0.90).  
No. of patients hospitalised CHF-related - Significantly lower rates in TM compared with usual care in 1 study.  
All-cause hospitalisations - 6 studies reported a lower number of hospitalisations per patient in TM than in usual care. 
2 pre/post studies report reductions at the end of the intervention compared to baseline. However, it is unclear if 
these reductions were significant.   
CHF-related hospitalisations - 2 studies found higher rates of the CHF-related hospitalisation in the TM compared to 
usual care and 1 RCT and 1 OB study found the reverse. However, it is unclear if these changes were significant.   
All-cause ED visits - 7 studies found a lower mean no. of ED visits per patient in TM compared with usual care. 1 pre-
post study found a reduced mean no. of ED visits compared with the baseline period. 1 RCT found a higher no. of ED 
visits in the TM group and 1 study found no difference between groups. However, it is unclear if these differences 
were significant.   
CHF-related ED visits - Lower mean in the TM group compared with usual care in 1 study. However, it is unclear if 
these differences were significant.   
All-cause BDOC - 2 OB studies reported a lower mean BDOC per patient in the TM group. 2 pre-post studies reported 
a reduction in the mean BDOC at the end of the study compared with baseline. 1 RCT reported a slightly higher mean 
BDOC in the TM group compared with usual care. However, it is unclear if these reductions were significant.   
. 
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First author, 
year 
Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Polisena, 
2010 (cont.) 
TM MA & 
SR  
22(3028) CHF-related BDOC - 2 RCTs reported a lower mean BDOC in TM compared to usual care. 1 pre-port study reported a 
reduced mean per patients at the end of the study period compared with the baseline. However, it is unclear if these 
reductions were significant.   
No. of outpatient visits - 2 RCTs reported a greater no. of outpatients visits for TM compared with usual care. 2 OB 
studies found a lower mean no. in TM compared with usual care. However, it is unclear if these reductions were 
significant.   
Home care visits - 2 RCTs reported a greater no. of home care visits for TM compared with usual care. However, it is 
unclear if these reductions were significant 
Inglis, 2010 Telephone 
support or TM  
  
MA & 
SR  
30(10490) All-cause hospitalisation - Significant reductions in the intervention compared to control group for telephone support 
(RR=0.91; 95% CI 0.85 to 0.99; p=0.02) and TM (RR=0.92; 95% CI 0.84 to 0.99; p=0.02)  
CHF-related hospitalisation – Significant reductions in the intervention compared to control group for telephone 
support (RR=0.77; 95% CI 0.68 to 0.87; p<0.0001) and TM (RR=0.79; 95% CI 0.67 to 0.94; p=0.008)  
Length of stay - 1 of 6 studies looking at telephone support reported significant reduction in length of stay in the 
intervention compared to control group, the 5 other studies found no significant differences.1 study in TM found a 
large difference in the total no. of days in hospital per patients (no details on if this was significant) and another 
study reported no significant differences.   
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First author, 
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Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Clarke, 2011 TM MA & 
SR 
13(NR) All-cause hospital admission - MA of 6 studies found no significant reduction as a result of TM (RR=0.99, 95% CI 0.88 
to 1.11, p=0.84). 
CHF-related hospital admission - MA of 6 studies found a significant reduction as a result of TM (RR=0.73, 95% CI 0.62 
to 0.87, p=0.0004). 
All-cause emergency visits - A meta-analysis of 4 of 7 studies showed no significant reduction (RR=1.04, 95% CI 0.86 
to 1.26, p=0.67). 
Length of hospital stay - 7 of 9 studies reported no difference between the groups on CHF-related to all-cause length 
of stay. 2 studies found a reduction in CHF-related length of stay for patients in the TM group.  
Giamouzis, 
2012 
TM  SR 12(3877) Hospitalization rates - 4 RCTs reported significantly reduced hospitalization rates in TM group compared to controls. 
8 RCTs failed to find a significant difference between groups in hospitalization rates. 
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First author, 
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Type of 
intervention  
Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Pandor, 
2013 
TM or STS (human 
to 
human/machine)  
MA & 
SR 
21(6317) All-cause hospitalisation - TM interventions with medical support during office hours or 24/7 were associated with a 
25% (HR: 0.75, 95% CrI: 0.49 to 1.10) and 19% (HR: 0.81, 95% CrI: 0.33 to 2.00) reduction in all-cause hospitalisation 
respectively. STS HM or HH did not have a major effect on all-cause hospitalisation (HR: 1.06, 95% CrI: 0.44 to 2.53; 
HR: 0.97, 95% CrI: 0.70, 1.31 respectively).  
CHF-related hospitalisation - There were no major effects on HF-related hospitalisation for TM with medical support 
during office hours (HR: 0.95, 95% CrI: 0.70, 1.34). STS HM did not have a major effect on HF-related hospitalisation 
(HR: 1.03, 95% CrI: 0.66, 1.54). STS HH was associated with a 23% reduction in HF-related hospitalisations (HR: 0.77, 
95% CrI: 0.62, 0.96). 
Length of hospital stay - Three studies found no significant between-group differences at 180 days or in the 1st year 
post-discharge on length of stay for TM interventions. Only 1 of 7 studies reported a statistically significant reduction 
in the length of hospital stay among the STS group. 
BP – blood pressure; BDOC – Bed Days Of Care; COPD – chronic obstructive pulmonary disease; CHF – Chronic Heart Failure; CI – Confidence Interval; ED – Emergency Department; 
ER – Emergency Room; GP - general practitioner; HF – Heart Failure; HR – hazard ratio; MA – meta-analysis; OB – Observational; OR – Odds Ratio; TM – Telemonitoring; RCT – 
Randomized Controlled Trial; RR – Relative Risk; SR – Systematic Review; STS – structured telephone support;  WMD – weighted mean difference
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APPENDIX I. PATIENT-REPORTED OUTCOME MEASURES - OVERVIEW 
First author, 
year 
Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Hypertension      
Jaana, 2007 TM SR  14(1119) Disease knowledge - 1 study found significant improvements as a result of the intervention.   
Satisfaction - 2 studies reported high satisfaction with the technology.  
Ease of use - 2 studies report measuring ease of use of device but fail to report results.   
Awareness of health benefits - 1 study found 54% of participants acknowledged the benefits of TM.   
QoL - 1 study reported no significant change in QoL.  
AbuDagga, 
2010 
TM SR 15(3192) QoL - 3 RCTs & 1 single group study found no significant effects. 
Satisfaction - 3 studies reported high satisfaction. 
Acceptability - 1 study reported anecdotal information on high rates of technology acceptance among participants. 
COPD     
Turnock, 2005 Action planning MA & 
SR  
3(367) Mood - 1 RCT found no significant difference between groups.  
Self-management knowledge - 1 RCT found a significant difference in participant knowledge in favour of 
intervention.   
QoL - A MA of 3 RCTs found no statistically significant differences in QoL at 6 (MD=2.37, 95% CI -1.96 to 6.70, 
p=0.28) or 12 months (MD=-0.39, 95% CI -3.48 to 2.70, p=0.80) post intervention between the intervention & 
control group.  
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First author, 
year 
Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
McLean, 2012 Telehealthcare MA & 
SR 
10(1307) QoL - A meta-analysis of 2 RCTs found a MD of -6.57 (95% CI -13.62 to 0.48, p=0.15) in favour of telehealthcare, 
which is more than the minimally clinical significant difference. 
Patient satisfaction - 3 RCTs report high levels of satisfaction with telehealthcare. 
Heart failure      
Louis, 2003 TM  SR  24(3643) Acceptability - 2 OB studies report good acceptability ranging from 86-95%.   
QoL - 1 RCT & 1 OB study found improved QoL as a result of TM; however, it is unclear if this change was 
significant.  
Patient satisfaction - 1 RCT & 1 OB report high satisfaction with TM.   
Jovicic, 2006 Self-
management 
SR  6(857) QoL - No significant effect in 3 RCTs  
Martinez, 2006 Home 
monitoring  
SR  42(2303) Acceptability - All 17 studies reported a high level of acceptance with home monitoring & no evidence of rejection 
by the patients of this kind of system.  
QoL - 11 studies (study design unclear) found a significant impact on QoL as a result of home monitoring when 
compared to a control group & pre-intervention period at 3 months post intervention. 5 RCTs & 2 non-controlled 
studies found no significant impact.  
Anxiety - 1 study (design unclear) found a significant reduction in anxiety in the intervention compared to control 
group.  
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Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Clark, 2007 TM or STS  SR  14(4264) QoL - 3 RCTs report a significant improvement between the groups in favour of the intervention. 3 RCTs found no 
significant effect.  
Acceptability - 1 RCT found acceptability to be higher & another did not consider the intervention useful.  
Depression - 1 RCT found no significant effect.  
Health distress - 1 RCT found no significant effect.  
Satisfaction - 1 RCT reports significantly higher satisfaction in the intervention compared to control group. 2 other 
RCTs report high levels of satisfaction in the intervention group.  
Ease of use - 1 RCT found that 97% of patients found TM easy to use.  
Maric, 2009 TM SR  56(NR) QoL - 3 RCTs report significant changes over time as a result of device-based TM but it was unclear if there were 
between group differences. 2 studies found significant improvements in QoL as a result of device-based TM 
compared to pre-intervention period. 1 pre-post study of website-based TM found significant differences on 3 QoL 
subscales when comparing participants to a pre intervention period. It is unclear if these differences were positive 
or significant. 1 non-RCT examined a number of TM modalities found no significant effect on QoL & another study 
found improvements but no significance test.  
Self-care skills - 1 RCT found no significant differences between device-based monitoring & usual care.  
Self-efficacy - 1 RCT found significant improvements in self-efficacy as a result of device-based monitoring 
compared with usual care. 1 RCT examining several TM modalities found that a telephone group reported a  
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First author, 
year 
Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Maric, 2009 
(cont.) 
TM SR  56(NR) significant decrease in self-efficacy whilst the other groups reported a significant increase. It is unclear if there 
were any between group differences.   
Mood - 1 RCT of device-based TM found no significant effect on anxiety or depression. 1 study of teleconsultation 
based TM found that mood ratings (sleeplessness, fatigue, depression & appetite) significantly improved in some 
instances & deteriorated in others, when comparing the intervention to a pre-intervention period.   
Stress - 1 study found significantly lower stress in device-based monitoring compared with usual care 
Polisena, 2010 TM SR  22(3028) QoL, satisfaction, drug adherence - 7 studies reported no significant differences between groups in QoL or patient 
satisfaction. 6 studies reported a better QoL, higher satisfaction or drug adherence in the intervention compared 
with usual care (not possible to separate the outcomes). 
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First author, 
year 
Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Inglis, 2010 STS/TM  
 
SR  30(10490) QoL - 8 RCTs evaluating STS/TM reported statistically significant improvements in QoL in the intervention 
compared to control group. However, 7 failed to find a significant difference between groups.  
Health perceptions - 1 RCT found that TM significantly increased health perceptions; however, it unclear if 
between group differences were significant.  
Satisfaction - 4 RCTs of STS/TM found high levels of satisfaction. 1 RCT of STS found no significant differences 
between video & telephone self-monitoring. 1 RCT of STS found significant differences in favour of the 
intervention group compared to usual care. A video over telephone line was not considered to be useful in 1 RCT. 
1 RCT reported consistently high levels of treatment satisfaction in the TM group.  
Knowledge - 2 RCT of TM/STS found that knowledge significantly increased; however, it is unclear if this was within 
or between groups.   
Depression - 1 RCT of STS found no significant effect.   
Acceptability/ease of use - 4 RCTs of both STS & TM found good to very high levels of acceptance & ease of use.  
Self-efficacy - 1 RCT of STS found significant improvements however, it is unclear if this is between or within 
groups.  
Self-care behaviour - 1 RCT of STS found significant improvements however, it is unclear if this is between or within 
groups.  
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Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Ciere, 2012 Telehealth SR  12(943) Knowledge - 1 RCT found that telehealth was associated with significantly higher HF knowledge at 3-months 
compared to a control group in 2 hospitals but there were no group differences in a third hospital. Another RCT 
found no significant differences in knowledge about medications at 90- & 180-days.  
Self-efficacy - 1 RCT found that telehealth improved self-efficacy compared to the control group. 4 RCTs found no 
significant benefits for telehealth compared to the control group. 1 case control study found no change in self-
efficacy overtime.  
Self-care - 5 RCT & 1 CCT suggesting that telehealth improves self-care behaviour over timeframes from 4 weeks to 
12 months; however, significance levels are not provided. 3 further RCTs failed to find any significant 
improvements in self-care behaviour for telehealth relative to alternative treatment or control groups. 
Pandor, 2013 TM or STS SR  21(6317) QoL - 5 studies found significant improvements in QoL as a result of TM/STS. 3 other studies failed to find any 
significant differences between groups in QoL.  
Satisfaction - 2 studies report very high levels of patient satisfaction with TM, which was significantly higher than 
controls in 1 study. 3 studies report high levels of satisfaction with STS. 
Acceptability – 1 RCT reported high levels of patient acceptance for STS.  
Thrombophilia      
Siebenhofer, 
2004 
PSM  SR  4(1547) QoL - 2 studies reported significant differences in QoL in favour of self-management.   
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Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Connock, 2007 PST/PSM SR  24(5567) QoL - 2 RCTs found significant improvements in QoL in favour of the intervention group. Improvements were 
reported in another RCT; however, it is unclear if these were significant. 3 further RCTs found no significant 
differences between groups.  
Garcia-
Alamino, 2010 
PST/PSM SR  18(4723) Satisfaction – 4 RCTs found significant differences in treatment satisfaction over time; however, it is unclear if 
there were significant between group differences.  
Bloomfield, 
2011 
PST/PSM SR  29(8413) Satisfaction – 5 RCTs found significantly greater satisfaction in the intervention compared to usual care. 3 RCTs 
found no significant effects on patient satisfaction.   
Self-efficacy - 4 RCTs found significantly greater self-efficacy in the intervention compared to usual care.   
Distress & hassles - 4 RCTs found significantly less distress & hassles in the intervention compared to usual care.   
Preference for care - 3 RCTs found that participants in the intervention group had a preference for self-testing & 
wanted to continue the program.  
QoL - 1 RCT found that QoL was significantly higher in the intervention compared to usual care. 1 RCT found 
significant improvements over time in the intervention group & no improvement in usual care but no between 
group comparisons were conducted. 3 RCTs found no significant effects. 
Diabetes      
Welschen, 
2005b 
SMBG SR  6(1285) QoL, well-being, satisfaction - No significant effect in 2 RCTs on any variables. 
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year 
Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
McGeoch, 2007 SMBG SR  17(81901) Treatment satisfaction - 1 RCT found equal increases in both intervention & control groups; however, it is unclear 
if these were significant changes.   
Well-being - Improved markedly in 1 RCT for the intervention group, but no details on analysis or significance.  
Kleefstra, 2009 SMBG SR  9(2532) QoL/well-being - 6 RCTs found no significant differences in overall QoL/well-being between groups. 3 of these RCTs 
found significant reductions in depression & lack of well-being in favour of the intervention. 3 RCTs found 
significant reductions in QoL as a result of intensive SMBG when compared to controls. 1 RCT found that well-
being (depression) was significantly reduced as a result of SMBG when compared to controls.   
Treatment satisfaction - 6 RCTs found no significant difference between the 2 groups.   
Attitudes to diabetes - 1 RCT found no significant differences in the diabetes attitude scale.   
Clar, 201 SMBG SR  66(146148) QoL - 1 RCT found significantly lower QoL for SMBG compared to controls. 1 RCT found no significant differences 
between groups.  
Well-being - 2 RCTs found no significant effect.   
Mood/Affect - 1 RCT found no significant effect on anxiety but patients in SMBG were significantly more depressed 
than controls. 2 RCTs found that participants in the intervention were significantly less depression/negative affect 
than controls.  
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Intervention Type of 
review 
N primary 
research 
studies(n 
participants) 
Results 
Malanda, 2012 SMBG SR  12(3170) QoL - 2 studies found no significant differences between groups on overall QoL. 1 of these studies did find a 
significant between group differences in health change (SF-ϯϲ™ suďsĐaleͿ iŶ faǀouƌ of the ĐoŶtƌol gƌoup. ϭ fuƌtheƌ 
study found a significant improvement in QoL in the intervention compared to controls group.   
Treatment Satisfaction - No significant between group differences were found in 4 RCTs.   
Well-being - 4 RCTs found no significant differences between groups.  
Depression - 1 study found a significant increase & another significant decrease in depression as a result of SMBG.   
CCT – case controlled trial; CI – confidence interval; COPD – chronic obstructive pulmonary disease; MA – Meta-Analysis; MD – mean difference; QoL – Quality of Life; SMBG – Self-
Monitoring of Blood Glucose; SR – Systematic Review; OB – Observational; RCT – Randomised Controlled Trial; PSM – patient self-management; PST – patient self-testing; SMBG – 
self-monitoring of blood glucose; STS – structured telephone support; TM – telemonitoring 
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APPENDIX J. CLINICAL OUTCOMES - OVERVIEW 
First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
Hypertension     
Jaana, 2007 BP TM SR Gender: NR 
Age: Mean range 43.6-76 
Condition: Chronic hypertension 
Treatment: NR 
SBP - 2 of 6 RCTs found a significant reduction in SBP compared to controls. 1 
RCT and 1 pre- post-test study found no significant effect and 1 post-test study 
found a higher number of participants experiencing a weekly decrease in SBP as 
a result of HBPM but it was unclear if this was significant. 
DBP - 3 RCTs found a significant reduction as a result of TM when compared to 
controls, 1 pre-post found significant reductions overtime as a result of TM. 
Ambulatory BP - 1 RCT found a significant reduction as a result of TM.  
BP outliers - 1 post-test study found a significant decrease in the rate of 
occurrence at the end of the study period (1 month). 
Medication adherence - 1 RCT found a significantly greater increase in the 
intervention compared to controls. 2 studies suspected improvements but there 
was no clear evidence or statistical analysis. 1 study found no difference. 
Weight - 1 pre-post study found a significant improvement in weight for those in 
the intervention group. 
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First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
AbuDagga, 2010 TM SR Gender: NR 
Age: Mean range 51-76yrs 
Condition: Uncontrolled 
hypertension 
Treatment: Range of anti-
hypertensive medications 
Ambulatory BP - 2 RCTs & 1 single group study found significant reductions 
ranging from 2.8 to 11.9mm Hg for SBP. DBP reductions ranged from 2.0 to 
6.6mm Hg. 1 RCT found no significant difference between intervention and 
control group.  
SBP - 2 RCTs found a significant reduction in SBP compared to controls. 2 single 
group studies and 1 quasi-experimental found significant reductions from pre to 
post intervention ranging from 3.9 to 13.0mm Hg. 
DBP - 2 RCTs found a significant reduction in DBP compared to controls. 2 single 
group and 1 quasi-experimental study found significant reductions from pre to 
post intervention ranging from 2.0 to 8.0mm Hg. 
% of participants with normal BP - 1 RCT and 1 single group studies found a 
favourable impact of TM.  
Adjusted BP improvement - 1 RCT found greater percentage of participants who 
improved in the intervention compared to control groups.  
% uncontrolled BP - 1 RCT found no significant difference between the 
intervention and control group. 
No. of medications or medication compliance - reported in 2 studies but no 
results documented. 
Medications altered - reported in 3 studies but no results documented. 
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First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
AbuDagga, 2010 
(cont.) 
TM SR Gender: NR 
Age: Mean range 51-76yrs 
Condition: Uncontrolled 
hypertension 
Treatment: Range of anti-
hypertensive medications 
Medication class - reported in 2 studies but no results documented. 
COPD     
Turnock, 2005 Action planning MA & SR Gender: % female range 16-67 
Age: Mean range 68-72.1 
Condition: COPD 
Treatment: NR 
Medication usage: 1 RCT found a significant increase in the use of antibiotics by 
the intervention group but no difference in the use of corticosteroids. 2 other 
RCT also found no significant difference in either antibiotics or oral 
corticosteroids.  
Mortality: No significant difference (OR=1.01; 95% CI 0.32 to 3.24). 
FEV1: At 6 months MD=50ml, 95% CI -29.86 to 129.86 in 1 RCT. At 12 months 
MD=43ml, 95% CI -63.30 to 149.30 in 1 study. 
% predicted FEV1: At 6 months WMD=1.83%; 95% CI -1.05 to 4.71 (2 studies). At 
12 months MD=2%, 95% CI -1.89 to 5.89 (1 study). 
Symptoms - No significant change in symptoms in 1 RCT. 
No. of days with respiratory symptoms – In 1 RCT MD=-16.00 days, 95% CI -
45.65 to 13.65.. 
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First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
Turnock, 2005 (cont.) Action planning MA & SR Gender: % female range 16-67 
Age: Mean range 68-72.1 
Condition: COPD 
Treatment: NR 
Subjective breathing status - No significant differences in the percentage of days 
recorded as mild, moderate or severe in 1 RCT. 
Exacerbations: 1 study found a significantly greater number of participants 
treated for exacerbation of COPD in the intervention group. 
Functional capacity: No significant difference in 1 RCT 
McLean, 2011 Telehealthcare MA & SR Gender: NR 
Age: NR 
Condition: Clinician diagnosed 
COPD 
Treatment: NR 
Mortality - A MA of 4 studies found no significant effect on mortality (OR=1.05, 
95% CI 0.63-1.75, p=0.86). 1 multi-group RCT (in which patients with COPD 
could not be separated from CHF patients) found no significant difference in 
mortality rate. There were no further deaths in any other study.  
Total exacerbations - 1 RCT found no significant difference between the 
intervention and control group.  
Mean no. of exacerbations/month - 1 RCT found that the mean no. of 
exacerbations/month was significantly greater in the control compared to 
intervention group.  
Time free from exacerbations - 1 RCT found that more intervention participants 
were free of an exacerbation in a 1 year period than in the control group.   
FEV1 - 1 RCT reported no significant change overtime within the intervention or 
control group. 1 RCT found no significant difference in FEV1 between the 
intervention and control group. 
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intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
McLean, 2011 (cont.) Telehealthcare MA & SR Gender: NR 
Age: NR 
Condition: Clinician diagnosed 
COPD 
Treatment: NR 
FVC - 1 RCT found no significant change overtime within the intervention or 
control group. 
Heart failure     
Louis, 2003 TM SR Gender: NR 
Age: Mean range 53-82 
Condition: HF 
Treatment: NR 
Mortality - 1 study found a significant reduction (study design NR). 
Jovicic, 2006 Self-management  MA & SR Gender: % female range 24-47 
Age: Mean range 56-76 
Condition: HF  
Treatment: NR 
Mortality - MA found no significant effect (OR 0.93; 95% CI 0.57 to 1.51, 
p=0.76). 
Adherence - Patients in the intervention group were significantly more likely to 
adhere to sodium and fluid restriction, exercise and not smoke in 1 study. 1 
study found a significant improvement in adherence to general medical advice, 
but no significant improvement in medication adherence. 
  
5
1
8
 
First author, year Type of 
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Method of 
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Martinez, 2006 Home monitoring  SR Gender: NR 
Age: Mean range 48-83 
Condition: HF  
Treatment: NR 
Mortality - 3 large RCTs found significant reductions in the intervention group 
compared to controls. 1 study (design NR) found no incidence of death in the 
intervention group. 2 studies found no significant differences between the 
groups (design NR). 
Chaudhry, 2007 TM 
 
SR Gender: % men range 37-78 
Age: Mean range 59-72 
Condition: HF 
Treatment: Patients at baseline 
on; beta-blockers ranged 17-62%, 
ACE/ARB inhibitors ranged 54-
93% 
Mortality - In 5 RCTs comparing telephone-based symptom monitoring with 
controls the RR ranged from 0.59 (95% CI 0.20-1.71) to 1.17 (95% CI 0.36-3.84). 
1 RCT comparing automated monitoring of signs and symptoms versus controls 
found a RR of 0.44 (95% CI 0.22-0.85). 1 RCT found RR of 0.66 (95% CI 0.40-1.11) 
when comparing nurse telephone support with usual care, 0.71 (95% CI 0.42-
1.18) when comparing home TM with usual care and 1.07 (95% CI 0.66-1.73) 
when comparing home TM with nurse telephone support. The final RCT 
comparing video conferencing with nursing and usual care was unable to 
calculate RR due to small numbers. 
Clark, 2007 TM or STS MA Gender: NR 
Age: Mean range 57-75 
Condition: HF  
Treatment: NR 
All-cause mortality - Significant 20% reduction (95% CI 8% to 31%) in the 
intervention group compared to controls. The benefits were greater with TM 
(RR=0.62, 95% CI 0.45 to 0.85, p=0.003), than with STS (RR=0.85, 95% CI 0.72 to 
1.01, p=0.06), although the difference was not significant (p=0.18). 
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First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
Dang, 2009 Home telehealth 
remote 
monitoring 
SR Gender: NR 
Age: Mean range 53.2-79 
Condition: HF  
Treatment: NR 
Mortality - 1 study found significant within group reductions in mortality for the 
intervention group, but no between group comparisons. Another study also 
failed to report analysis for group comparisons. 2 studies found a significant 
reduction in mortality in the intervention compared to control group at 1 year.  
1 study found no significant differences. 
Klersy, 2009 Remote patient 
monitoring 
MA Gender: Mean % female 36-40 
Age: Median 70 (RCTs), 66 
(cohort) 
Condition: HF  
Treatment: NR 
Mortality - RPM was associated with significantly fewer deaths compared to 
controls in the RCTs (RR=0.83; 95% CI 0.73 to 0.95) and in cohort studies 
(RR=0.53; 95% CI 0.29 to 0.96). 
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First author, year Type of 
intervention 
Method of 
summarising 
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Maric, 2009 Device 
based/telephone 
touch- 
pad/combination 
of TM 
modalities 
SR Gender: NR 
Age: NR 
Condition: HF  
Treatment: NR 
Mortality - 1 RCT comparing device-based TM with controls reports significantly 
fewer deaths in the intervention compared to control group. 1 RCT comparing 
telephone touch-pad TM with controls found combined hospitalisation and 
mortality events to be significantly lower in the intervention group compared 
with controls. 1 RCT reported in 3 articles comparing usual care with monthly 
telephone calls and home TM including nurse calls reported decreased mortality 
in the intervention groups compared to controls, but no differences between 
interventions. 
Exercise adherence - 1 RCT comparing device-based TM with controls found 
significantly higher levels of exercise adherence in the intervention group 
compared to routine care. 
Functioning (definition unclear) - 1 RCT comparing device-based TM with 
controls found significant improvements in levels of functioning in the 
intervention compared to control. 
BP, weight, shortness of breath - 1 pre-post study found significant 
improvements in BP, weight and shortness of breath over time. 
Time to target dose - 1 RCT reported in 2 articles reported a significantly shorter 
time to achieve the target dose of carvedilol in the intervention group 
compared to controls. 
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Method of 
summarising 
the effect 
Participant characteristics Results 
Maric, 2009 Device 
based/telephone 
touch- 
pad/combination 
of TM 
modalities 
SR Gender: NR 
Age: NR 
Condition: HF  
Treatment: NR 
LVEF, NYHA class - A pre-post study found increased left injection fraction and 
improved NYHA class compared with baseline although does not report 
significance. 
Polinsena, 2010 TM MA & SR Gender: NR 
Age: Mean 55 
Condition: HF  
Treatment: NR 
All-cause Mortality - TM decreased the risk of death significantly more than 
usual care in a MA of 5 RCTs (RR=0.64; 95% CI 0.48 to 0.85) 
CHF-related Mortality: 2 RCTs found significantly fewer deaths in the 
intervention group compared to usual care. 
Inglis, 2010 Telephone 
support/ 
TM 
MA & SR Gender: Mean % men 
64 (range 35-99) 
Age: Mean range 44.5-78 
Condition: HF  
Treatment: NR 
Mortality - Significant reduction in risk of all-cause mortality (RR=0.66, 95% CI 
0.54 to 0.81; p<0.0001) when comparing telephone support with usual care. 
The MA comparing TM with usual care found no significant difference in all-
cause mortality. 
NYHA class - 3 RCTs comparing telephone support with usual care and 1 RCT 
comparing TM with usual care found significant improvements in NYHA 
classification in favour of the intervention. 
Function - 2 RCTs comparing telephone support with usual care found 
significant improvements in the 6 minute walk test. 
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Inglis, 2010 (cont.) Telephone 
support/ 
TM 
MA & SR Gender: Mean % men 
64 (range 35-99) 
Age: Mean range 44.5-78 
Condition: HF  
Treatment: NR 
Adherence - Improvements or high levels of adherence to diet, treatment and 
medications for the intervention group were reported in 4 RCTs comparing 
STS/TM with usual care However, it is unclear if these analyse were within or 
between group comparisons and for some the significance levels were not 
reported.   
Renal function - 1 RCT found significant improvements overtime in the 
intervention group. Unclear if there were any between group differences.   
Weight - 1 RCT found significant improvements over time in the intervention 
group. Unclear if there were any between group differences. 
Clarke, 2011 TM MA Gender: Mean % men 64% (range 
35-99%) 
Age: Mean ranged from 44.5 to 
78 
Condition: HF 
Treatment: NR 
Mortality - A MA of 10 studies found an overall reduction in all-cause mortality 
(RR=0.77, 95% CI 0.61 to 0.97, p=0.02). 
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Giamouzis, 2012 TM SR Gender: NR 
Age: Mean ranged from 57 to 
78.1 
Condition: CHF 
Treatment: NR 
All-cause mortality - 3 RCTs reported significantly fewer deaths in the 
intervention compared to control group. 4 RCTs no significant differences and 1 
a lower % in the intervention group but no significance test.  
Pandor, 2013 Remote monitoring MA Gender: NR 
Age: Mean ranged from 57 to 
78.1 
Condition: CHF 
Treatment: NR 
All-cause mortality - TM interventions with medical support during office hours 
or 24/7 were associated with mortality reductions of 24% (HR=0.76, 95% CrI 
0.49 to 1.18) and 51% (HR=0.49, 95% CrI 0.20 to 1.18), respectively. STS HH was 
associated with a 23% reduction (HR=0.77, 95% CrI 0.55 to 1.08). No beneficial 
effect on mortality was observed with STS HM. The interventions exhibiting the 
greatest effects were TM 24/7 (HR=0.49, 95% CrI 0.26 to 0.88), TM during office 
hours (HR=0.62; 95% CrI: 0.42 to 0.89,) and STS HH (HR=0.75, 95% CrI 0.59 to 
0.96). 
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Thrombophilia     
Siebenhofer, 2004 PSM SR Gender: NR 
Age: Mean range 42-63 
Condition: Mixed indication 
Treatment: Phenprocoumen or 
acenocoumarol  
% INR in range - 1 study found no significant difference between groups. 3 
found that the intervention group had more INR values within range than the 
control group; this was significantly different in 2 studies but unclear in the 
other.    
% mean time in range - 2 studies found that the deviation of the INR value from 
the mean of the INR target range was shown to be significantly lower in the 
intervention compared to control group. 
Major haemorrhage - 1 study found no significant differences between groups. 
The other 3 studies report too few events in both groups for analysis.  
Thromboembolism - 1 study found a significant reduction in major 
thromboembolism in the intervention group; however, it is unclear if this was 
significantly different to the control group. The other 3 studies report too few 
events in both groups for analysis. 
Connock, 2007 PST/PSM MA Gender: % male range 43-76 
Age: Mean ranged 42-75 
Condition: Mixed indication 
Treatment: NR 
% time in range - The pooled estimate for the RCTs was 67.4% in the 
intervention group and 63.4% in the control group. The pooled estimate for the 
non-RCTs was 69.5% in the control group and 82.9% in the PSM group. No 
statistical analysis was performed. 
 
  
5
2
5
 
First author, year Type of 
intervention 
Method of 
summarising 
the effect 
Participant characteristics Results 
Connock, 2007 PST/PSM MA Gender: % male range 43-76 
Age: Mean ranged 42-75 
Condition: Mixed indication 
Treatment: NR 
No. of patients below, within & above range - For the RCTs more patients in the 
intervention group were within range than those in the control group. 
Conversely, more patients in the control groups were outside of range 
compared to the intervention group. For the non-RCTs the pooled values below 
range were 18.4% and 10.1% in the control and intervention group respectively 
and above the range 10.0 and 7.1% respectively. No statistical analysis was 
performed. 
Major haemorrhagic - No significant effect in either an MA of RCTs or non-RCTs 
(RD=–0.0039, 95% CI –0.0154 to 0.0077) 
Thromboembolic events - Significantly fewer events in favour of the 
intervention group for RCTs (RD=-0.0224; 95%CI -0.03 to -0.01) and non-RCTs 
(RD=-0.0199; 95% CI -0.03 to -0.01). 
Mortality - Significantly reduced risk of death in favour of the intervention 
group for RCTs (RD=-0.0170; 95% CI -0.03 to -0.01) and non-RCTs (RD=-0.01; 
95% CI -0.03 to -0.004). 
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Garcia-Alamino, 2010 PST/PSM SR & MA Gender: NR 
Age: Mean range 42-75 
Condition: Mixed indication 
Treatment: Various 
anticoagulants 
Thromboembolic event - The intervention halved thromboembolic events 
(RR=0.50; 95% CI 0.36 to 0.69, p<0.0001). 
Mortality - The intervention was associated with an overall significant reduction 
in all-cause mortality (RR 0.64; 95% CI 0.46 to 0.89, p=0.007) 
Major haemorrhage - No significant effect (RR=0.87, 95% CI 0.66 to 1.16, 
p=0.34). 
Minor haemorrhage - The intervention resulted in significant reduction in minor 
haemorrhage (RR=0.64; 95% CI 0.54 to 0.77, p<0.00001).   
% mean INR within range - 6 studies reported significant improvements in 
favour of the intervention group. 7 studies found no significant differences. 
% time within range - 3 studies reported a significant improvement in the 
intervention group. 8 studies found no significant differences. 
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Bloomfield, 2011 PST/PSM MA Gender: Mean % men 75 (range 
43-98)  
Age: Mean 65 (range 42-75) 
Condition: Mixed indication 
Treatment: Various 
anticoagulants 
Thromboembolic events - Significantly fewer events in the intervention 
compared with control group (OR=0.58; 95% CI 0.45 to 0.75, p<0.001).   
Major haemorrhage - No significant effect (OR=0.89, 95% CI 0.75-1.05, p=0.169) 
Mortality - Significantly lower risk of death in the intervention group compared 
to control (OR=0.74; 95% CI 0.63 to 0.87, p<0.001)  
% mean time within range - No significant difference between PSR or PSM and 
usual care in a MA of RCTs (WMD=1.50%, 95% CI -0.63% to 3.63%, p=0.17). 
% INR results in range - No significant difference between PSR or PSM and usual 
care in a MA of RCTs (WMD=5.9%, 95% CI -0.18% to 12%, p=0.06). 
Diabetes     
Welschen, 2005b SMBG MA & SR Gender: NR 
Age: Mean range 49.8-60.9 
Condition: T2DM 
Treatment: Not using  insulin 
HbA1c - 0.39% (95% CI -0.56 to -0.21, p<0.0001) decrease in HbA1c in favour of 
SMBG. 
FBG - No significant effects in 2 RCTs.   
Hypoglycaemia - 1 RCT found a significant difference in the number of patients 
who reported at least one episode of asymptomatic hypoglycaemia during the 
study. However, it was not possible for the control group to experience this 
type of hypoglycaemia. 
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McGeoch, 2007 SMBG SR Gender: % male range 26-100 
Age: Mean range 50.3-68 
Condition: T2DM 
Treatment: Any 
HbA1c - 2 RCTs reported a statistically significant lower HbA1c with SMBG. The 
other RCT found no significant effect. Mean reduction in HbA1c for SMBG was 
1%, with a decrease of 0.5% more in patients who used SMBG than those who 
did not. 4 OB studies found an association between SMBG and lowering of 
HbA1c. 4 other OB studies found no association. 
Morbidity & Mortality - 1 OB study found that those undertaking SMBG 
compared to no SMBG had a significant reduction in both outcomes. 
Adherence - 1 RCT found no difference in the proportion exercising but more 
were following dietary advice in the intervention group, no details on 
significance. 
Kleefstra, 2009 SMBG SR Gender: % male range 26-100 
Age: Mean range 50-65.7  
Condition:T2DM 
Treatment: Any 
HbA1c: 3 RCTs found a beneficial effect on HbA1c for the intervention when 
compared to controls. No significant effect for the remaining 6 RCTs. 
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Clar, 2010 SMBG MA & SR Gender: NR 
Age: Mean range 50-68.4 (RCTs 
only) 
Condition: T2DM 
Treatment: Any 
HbA1c: A MA of 10 RCTs found a significant reduction of 0.21% in HbA1c (95% 
CI -0.31 to -0.10; p<0.001) in favour of the intervention group. 18 OB and non-
randomised experimental studies found no favourable changes in HbA1c with 
SMBG, while 18 did.   
Hypoglycaemia: 2 RCTs found significant reductions as a result of the 
intervention. 2 found no significant difference and the results of the other 2 
studies are not reported. 
Weight: 13 RCTs found no significant difference between groups in weight/BMI. 
Lipid parameters: 6 RCTs reported inconsistent results in terms of lipid 
parameters, with most finding no significant differences between groups. 
BP - There was no significant effect on BP in 4 RCTs. 
Morbidity/Mortality: 1 OB study found SMBG to be related to lower morbidity 
and mortality and another did not. 
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Malanda, 2012 SMBG MA Gender: NR 
Age: Mean range 48.7-65.6 
Condition: T2DM 
Treatment: NIDDM 
HbA1c: In a meta-analysis of SMBG versus control the overall effect for short-
term f/u (up to 6 months) in those with a diabetes duration of greater than 1 
year, was a statistically significant decrease of 0.26% in HbA1c (95% CI -0.39 to -
0.13, p<0.0001) in favour of SMBG. For medium term f/u (between 6 & 12 
months) analysis revealed no significant decrease in HbA1c of 0.13% (95% CI -
0.31 to 0.04, p=0.13). The pooled analysis for short term f/up in newly 
diagnosed patients could not be undertaken due to high heterogeneity. For 
medium-term f/u in the newly diagnosed there was a statistically significant 
decrease in HbA1c of 0.52% (95% CI -0.89 to -0.14, p=0.007). 
ACE - angiotensin-converting-enzyme; ARB - angiotensin receptor blockers; BMI – body mass index; BP – Blood Pressure; CI – Confidence Interval; COPD - Chronic Obstructive 
Pulmonary Disease; CHF – Chronic Heart Failure; DBP – Diastolic Blood Pressure; FBG – Fasting Blood Glucose; FEV - Forced Vital Capacity; HbA1c - Glycated haemoglobin; HBPM – 
Home Blood Pressure Monitoring; HF – heart failure; HR – hazards ratio; INR – International Normalised Ratios; LVEF – Left Ventricle Injection Fraction; MA – meta-analysis; MD – 
mean difference; NIDDM – Non Insulin Dependent Diabetes Mellitus; NR – not reported; NYHA – New York Heart Association; PSM – Patient Self-Management; PST – Patient Self-
Testing; RCT – Randomised Controlled Trial; RD – Risk Difference; RR – Relative Risk; SBP – Systolic Blood Pressure; SMBG – Self-Monitoring of Blood Glucose; SR – Systematic 
Review; T2DM – Type 2 Diabetes Mellitus; TM – Telemonitoring; STS – Structured Telephone Support; WMD – Weighted Mean Difference 
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APPENDIX K. RCT INFORMATION SHEET 
 
UCLH Project ID number 09/H0722/91     
 
 CONFIDENTIAL 
PATIENT INFORMATION SHEET 
 
Title of Project:  Self-monitoring of treatment with methotrexate alone or in 
combination with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis 
 
Investigators:     Hayley James  Tel.  
         Dr Michael Shipley Tel.  
   Abigail Olaleye Tel. 
 
You are being invited to take part in a research study. Before you decide we think it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Please take your own time to decide whether or not you wish to take 
part. 
 
Part 1 
 
1. What is the purpose of the study? 
We are a research team looking at alternatives to the traditional outpatient 
appointment procedure for patients with arthritis on the medication Methotrexate 
taken with and without an anti-TNF agent.  
 
We know from previous research that attending outpatient appointments for your 
blood results to be checked can be inconvenient and often results in no changes to 
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your treatment or care. We are, therefore, investigating an alternative way of 
managing your treatment. 
 
The aim of the study is to assess whether individuals on Methotrexate alone or with an 
anti-TNF agent can self-monitor part of their treatment and initiate their own 
outpatient appointments. This involves an intervention which teaches you how to read 
and interpret your own blood test results and symptoms and as a result book your own 
outpatient appointments. We are particularly interested in the factors which may 
predict success when it comes to deciding about whether to arrange an out-patient 
appointment or not. 
 
Your participation in the study will help us uŶdeƌstaŶd ŵoƌe aďout hoǁ patieŶt͛s 
understand and manage their medication. We hope that this information will enable 
us to develop a better and more efficient Rheumatology Service at University College 
Hospital London (UCLH). The research will be conducted over 3 years and is taking 
place at UCLH in conjunction with University College London (UCL).  
 
2. Why have I been invited? 
You are being invited to participate because you are a patient attending the Centre for 
Rheumatology at UCLH, you have arthritis and you have been receiving Methotrexate 
treatment for at least 6 months or Methotrexate with an anti-TNF agent for at least 3 
months. We are seeking a total of 140 people over the age of 18 to take part in this 
study.   
 
3. Do I have to take part? 
No, taking part is voluntary. It is up to you to decide to join the study. If you agree to 
take part you will be given this information sheet to keep and be asked to sign a 
consent form.  
 
If you decide to take part you are free to withdraw at any time and without giving a 
reason. Nobody will be upset if you do decide not to take part. Please be reassured 
that deciding to withdraw at any time, or choosing not to take part at all, will not affect 
the standard of care you receive at any time, either now or in the future.  
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4. What will happen to me if I take part? 
If you decide to take part, you will be asked to complete a questionnaire booklet that 
asks questions about how you feel about having arthritis and taking Methotrexate or 
Methotrexate with anti-TNF treatment. We do not anticipate that this will take you 
more than 40 minutes to complete.  
 
To test whether the self-monitoring approach works we need to compare people who 
are managed in this new way with people are managed normally. We can do this by 
putting people into two different groups by chance (randomly). Therefore, if you agree 
to take part you have a 50% chance of being allocated to group 1 (usual management) 
and a 50% of being allocated to group 2 (self-monitoring). 
 
Group 1. You will continue to receive the same care that you normally receive, 
according to a strict plan agreed with your Rheumatologist. 
 
Group 2. You will receive a 2 hour self-monitoring training session in which you will be 
told what self-monitoring is and how it works, how to interpret your blood tests and 
how to monitor any physical side effects related to the treatment and illness. You will 
practice interpreting blood test results and physical side effects and on the basis of all 
of this, how to decide whether you require an outpatient appointment.  
 
Being part of group 2 will involve attending the hospital for your blood tests on a 
regular basis, but instead of attending a clinic appointment to have these blood tests 
interpreted we will train you to be able to do this at home and ask for an appointment 
if necessary. You will continue to see your Consultant Rheumatologist and GP when 
you see fit. You will of course be able to contact the nurse helpline if you are 
concerned at any time. 
 
At the end of your participation in the study which maybe after the 6th blood test or 
earlier if you no longer wish to take part in the study, we will ask if you would be 
prepared to be interviewed at a place and time convenient for you. During the 
interview you will asked about how it was to take part in the study and what if there 
was anything you would change. If you do agree, we would like to tape record the 
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interview which will then be transcribed. At the end of the study, all the tape 
recordings will be destroyed. 
 
If you tick the box on the consent form about further participation and provide your 
contact details we will contact you to discuss this in more detail. We assure you that 
ticking the box at this stage does not mean you have to take part in an interview – you 
are free to change your mind at any time in the future, without influencing the care 
you receive. You do not have to give a reason for changing your mind or for choosing 
not to take part in the research at all.  
 
5. What will I have to do? 
For those participants who are randomly allocated to Group 1 you will continue to 
receive the same care that you normally receive and will be asked to complete a 
questionnaire booklet at the beginning of the study, after your 3rd and 6th blood test. 
You will be given a freepost envelope to send these back to the research team. 
 
For those participants who are randomly allocated to Group 2 after taking part in the 
training you will need to inform the Rheumatology Nurse Specialist once you have had 
your blood test. Your results will then be sent to you by your preferred method - this 
could be by post or email.  
 
The training will give you the knowledge to understand these results and for the first 3 
blood tests the Researcher will call you once you have had a chance to look at them to 
ask whether you blood results fall within the normal range, if you feel you need an 
outpatient appointment based on these results and how confident you feel about your 
decision. If you accurately interpret 2 consecutive blood tests you will then be able to 
independently interpret the results of your next 3 blood tests with no telephone call 
from the Researcher. If you feel you require an appointment based on the results of 
these blood tests you will be given a telephone number to speak to the Rheumatology 
Nurse Specialist. As in Group 1 you will be asked to complete a questionnaire at the 
beginning of the study and after the 3rd and 6th blood test. 
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The research team will also ask if you would be willing to take part in an interview after 
your participation in the study, this is entirely voluntary and taking part in the main 
study does not mean you have to take part in the interview. 
 
6. What are the possible disadvantages and risks of taking part? 
We are always required to tell you about any risks to you should you agree to take part 
in research; however, in this instance we are not aware of there being any such risks to 
you. For those people who are randomly put into group 2 and receive the training you 
will be given the contact details of the Rheumatology Nurse Specialist involved in the 
study whom you can contact at any time. Your safety is of utmost concern to the 
research and clinical team and, therefore, throughout the intervention period you will 
be closely monitored and contacted if deemed essential. 
 
7. What are the possible benefits of taking part? 
Not only will the intervention be more convenient for patients being monitored in this 
way, but it will also reduce wasted clinic visits and waiting times. Findings from the 
pilot study we conducted suggest that participants may experience increases in patient 
satisfaction and confidence.  
 
Those who took part in the pilot study also expressed the wish to continue being 
monitored in this way, describing it as a positive experience, allowing them to take 
control of their condition. In taking part we expect that the information we get from 
this study will help us to provide more appropriate support to people with arthritis 
receiving Methotrexate treatment. 
 
8. What happens when the research stops? 
On completion of the study those within group 2 will return to usual care that they 
received before taking part in the research.  
 
9. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2. 
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10. Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
This completes part 1. 
 
If the information in Part 1 has interested you and you are considering taking part, 
please read the additional information in Part 2 before making any decision. 
 
 
 
Part 2 
 
1. What will happeŶ if I doŶ͛t waŶt to ĐarrǇ oŶ with the studǇ? 
If you decide at any point in your participation in the study that you wish to withdraw 
from the study you can contact the research or clinical team to discuss this. It would be 
useful for us to use the information you have given us up until that point in the study; 
however, if you wish us to destroy this data this can also be arranged. 
 
2. What if there is a problem? 
If you have a concern about any aspect of this study you should speak to the 
researchers who will do their best to answer your questions either at your next 
appointment or on or via email . If you 
remain unhappy and wish to complain formally you can do this through the Complaints 
Manager, UCLH, 2nd Floor West, 250, Euston Road, London NW1 2PQ. Please quote the 
UCLH project number at the top of this information sheet. 
 
3. Will my taking part in this study be kept confidential? 
We need permission to access your medical records which relate directly to this study. 
All the information collected during the study will be held securely and in the strictest 
confidence and will only be used for research purposes.   
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If you agree, we would like to inform your GP that you are taking part. This is as a 
matter of courtesy, but rest assured that they will not know what information you 
have given to us.  
 
The data that we collect will be kept anonymously on password protected computers 
and in locked filing cabinets. Only members of the research team will see this 
anonymous information, the researcher Ms Hayley James will be the only person who 
will have access to identifiable data. 
 
If you take part in an interview we will ask your permission to audio-tape it, this will 
then be transcribed with any identifying information removed from the transcript. The 
audio-tape will then be destroyed.   
 
4. What will happen to the results of the research study? 
The findings of this research will be reported in professional publications or at 
meetings but you will not be identified in any report or publication. For those 
participants who take part in an interview any information which would allow 
someone to identify you will be removed from the transcribed interviews. The 
transcripts may also be used for teaching purposes with your permission. 
 
If at any point during the study you lose capacity to take part the data you have 
provided up until that point will remain within the study, but only with the permission 
of your next of kin. 
 
5. Who is organising and funding the research? 
This research is being paid for by The Shipley-Rudge Fund for Rheumatology and the 
Otto Beit Fund both of which are held by the UCLH Charity and are specifically 
dedicated to rheumatology research. It is being organized by researchers at University 
College London and staff in the Centre for Rheumatology at UCLH. 
6. Who has reviewed the study? 
This study has been reviewed and approved by the Camden and Islington Community 
Research Ethics Committee and by the funders before they agreed to provide the 
funding.  
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7. Further Information and contact details 
If you want some general information about taking part in research please contact the 
Patient Advice Liaison Service (PALS) at UCLH who are found in the Ground Floor 
Atrium of University College Hospital between 9 and 4pm or on . 
 
If you have any questions about this study and what you are being asked to consider, 
please contact one of the research team.  
 
If you would like any further information about this research or if you have any queries 
at any time in the future, please contact Hayley James in the Department of Health 
Services Research at City University on or via email 
. 
 
Thank you for reading this information sheet.  
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APPENDIX L. RCT CONSENT FORM 
 
UCLH Project ID number 09/H0722/91    
Patient Identification Number for this study:     
 
 CONFIDENTIAL  
CONSENT FORM (RCT) 
 
Title of Project:  Self-monitoring of treatment with Methotrexate alone or in 
combination with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis 
 
Name of Principal Investigator: Professor Stanton Newman 
Please initial box 
1. I confirm that I have read and understand the information sheet 
dated 08.10.10 (version 3) for the above study and have had the 
opportunity to ask questions 
 
 
2.  I confirm that I have had sufficient time to consider whether or not 
want to be included in the study  
 
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
   
4. I understand that sections of any of my medical notes may be looked 
at by responsible individuals of the research team where it is relevant 
to my taking part in research. I give permission for these individuals to 
have access to my records. 
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5. 
 
I understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals 
to haǀe aĐĐess to ŵǇ ƌeĐoƌds͟. 
 
 
6. 
 
I agree to take part in the above study. 
 
 
 
7. I give my permission for my GP to be informed that I am taking 
part in this research.   
 
  
8. I understand that taking part in this research project will 
involve completing a questionnaire on one or more occasions 
and that I might also be asked to take part in an interview. At 
this stage I am giving my consent to complete the 
questionnaire study and I understand that the researchers 
will only contact me about the interview study if I give them 
permission to do so.   
 
  
9. I would like to received feedback about the findings of the 
study 
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CONSENT FORM 
 
Title of Project:  Self-monitoring of treatment with methotrexate alone or in 
combination with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis 
 
Name of Principal Investigator: Professor Stanton Newman 
 
 
 
__________________________ _________________ _______________________ 
Name of patient   Date         Signature 
 
 
 
__________________________ _________________ _______________________ 
Name of Person taking consent Date      Signature 
(If different from researcher) 
 
 
__________________________ _________________ _______________________ 
Researcher (to be contacted   Date      Signature 
if there are any problems)  
         
 
 
Comments or concerns during the study  
If you have any comments or concerns you may discuss these with the 
investigator. If you wish to go further and complain about any aspect of the 
way you have been approached or treated during the course of the study, you 
should write or get in touch with the Complaints Manager, UCL hospitals.  
Please quote the UCLH project number at the top this consent form 
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APPENDIX M. RCT STUDY QUESTIONNAIRES 
 
 
 
  UCLH Project ID number: 09/H0722/91   
 
Patient Identification Number for this study: 
 
Date:    
 
Self-monitoring of treatment with methotrexate alone or in combination 
with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis 
 
Thank you for agreeing to take part in this project. This booklet contains 
questions which will help us find out more about your thoughts and feelings 
about Rheumatoid Arthritis (RA) and Methotrexate. Please read each 
question carefully and answer them as honestly as you can. If you have any 
queries please contact a member of the research team. 
 
This ƋuestioŶŶaiƌe asks Ǉouƌ ǀieǁs aďout ‘A. It is Ŷot a ͚ test͛ of kŶoǁiŶg the 
͚ĐoƌƌeĐt͛ aŶswer, but about what you personally think and feel about your 
RA. Please ask if anything is unclear.                    
 
 
UCL Hospitals is an NHS Foundation Trust comprising: The Eastman Dental Hospital, The Heart 
Hospital, Hospital for Tropical Diseases, National Hospital for Neurology and Neurosurgery, The 
Royal London Homoeopathic Hospital and University College Hospital (incorporating the former 
Middlesex and Elizabeth Garrett Anderson Hospitals). 
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SEX (please circle  
Male   Female 
AGE: _________ 
 
YOUR LIVING STATUS (please circle the option closest to your situation) 
 
Married/Living with partner               
Living alone         
Living with relatives/friends 
 
YOUR ETHNIC BACKGROUND (please circle) 
Bangladeshi      Black – African                   Black - Caribbean                   Chinese  
Indian       Pakistani                           White            
Other (please specify) _____________________________________________ 
 
When were you first diagnosed with RA? 
 
 
 
 
 
 
When did you begin taking methotrexate? 
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We are interested in learning whether or not you are affected by FATIGUE. Please 
circle the number below that describes your fatigue in the past 2 weeks: 
 
  
           
 
  
 
No fatigue  
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Severe fatigue  
 
 
We are interested in learning whether or not you are affected by PAIN. Please circle 
the number below that describes your pain in the past 2 weeks: 
 
  
           
 
 
  
 
No pain  
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Severe pain  
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Listed below are a number of symptoms that you may or may not have experienced 
since having treatment for RA. Please circle YES or NO if you have experienced them 
and YES or NO if you think the symptom is related to RA.  
 I have experienced this 
symptom since my RA 
This symptom is related to my 
RA 
Pain YES NO YES NO 
Sore Throat YES NO YES NO 
Nausea YES NO YES NO 
Breathlessness YES NO YES NO 
Weight loss YES NO YES NO 
Fatigue YES NO YES NO 
Stiff Joints YES NO YES NO 
Sore Eyes YES NO YES NO 
Wheeziness YES NO YES NO 
Headaches YES NO YES NO 
Upset stomach YES NO YES NO 
Sleep difficulties YES NO YES NO 
Dizziness YES NO YES NO 
Loss of strength YES NO YES NO 
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We are interested in your own personal views of how you see your RA. Please indicate 
how much you agree or disagree with the following statements about RA by circling 
the appropriate number.  
 
Your views about 
Rheumatoid Arthritis: 
Strongly 
Disagree 
Disagree 
Neither 
Agree or 
Disagree 
Agree 
Strongly 
Agree 
My RA is a serious 
condition. 
1 2 3 4 5 
My RA has major 
consequences on my 
life 
1 2 3 4 5 
My RA does not have 
much effect on my life 
1 2 3 4 5 
My RA strongly affects 
the way others see me 
1 2 3 4 5 
My RA has serious 
financial 
consequences 
1 2 3 4 5 
My RA causes 
difficulties for those 
who are close to me 
1 2 3 4 5 
There is a lot which I 
can do to control my 
symptoms 
1 2 3 4 5 
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Your views about 
Rheumatoid Arthritis: 
Strongly 
Disagree 
Disagree 
Neither 
Agree or 
Disagree 
Agree 
Strongly 
Agree 
What I do can 
determine whether 
my RA gets better or 
worse 
1 2 3 4 5 
The course of my RA 
depends on me 
1 2 3 4 5 
Nothing I do will affect 
my RA 
1 2 3 4 5 
I have the power to 
influence my RA 
1 2 3 4 5 
My actions will have 
no effect on the 
outcome of my RA 
1 2 3 4 5 
There is very little that 
can be done to 
improve my RA 
1 2 3 4 5 
My treatment will be 
effective in curing my 
RA 
1 2 3 4 5 
The negative effects 
of my RA can be 
prevented (avoided) 
by my treatment 
1 2 3 4 5 
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Your views about 
Rheumatoid Arthritis: 
Strongly 
Disagree 
Disagree 
Neither 
Agree or 
Disagree 
Agree 
Strongly 
Agree 
My treatment can 
control my RA 
1 2 3 4 5 
There is nothing which 
can help my condition 
1 2 3 4 5 
The symptoms of my 
condition are puzzling 
to me 
1 2 3 4 5 
My RA is a mystery to 
me 
1 2 3 4 5 
I doŶ͛t uŶdeƌstaŶd ŵǇ 
RA 
1 2 3 4 5 
MǇ ‘A doesŶ͛t ŵake 
any sense to me 
1 2 3 4 5 
I have a clear picture 
or understanding of 
my condition 
1 2 3 4 5 
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We would like to ask you about your personal views of Methotrexate. These are 
statements other people have made about their medicines. Please indicate the extent 
to which you agree or disagree by circling the appropriate number. There are no right 
or wrong answers. We are interested in your personal views. 
Your views about 
Methotrexate: 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
My health at present, 
depends on my 
Methotrexate  
1 2 3 4 5 
Having to take my 
Methotrexate worries 
me 
1 2 3 4 5 
My life would be 
impossible without 
my Methotrexate 
1 2 3 4 5 
Without my 
Methotrexate I would 
be very ill 
1 2 3 4 5 
I sometimes worry 
about the long-term 
effects of 
Methotrexate 
1 2 3 4 5 
My Methotrexate is a 
mystery to me 
1 2 3 4 5 
My health in the 
future will depend on 
my  Methotrexate 
1 2 3 4 5 
Appendix M 
 
551 
Your views about 
Methotrexate: 
Strongly 
Agree 
Agree Uncertain Disagree 
Strongly 
Disagree 
Methotrexate disrupts 
my life 
1 2 3 4 5 
I sometimes worry 
about becoming too 
dependent on my 
Methotrexate 
1 2 3 4 5 
My Methotrexate 
protects me from 
becoming worse 
1 2 3 4 5 
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This part of the questionnaire asks you about how you generally approach problems or 
challenges in life. Please read each statement carefully and circle the number which 
you feel is most true for you. 
 
 Not at all 
true 
Hardly True 
Moderately 
True 
Exactly True 
I can always manage to 
solve difficult problems if 
I try hard enough 
1 2 3 4 
If someone opposes me, I 
can find ways and means 
to get what I want 
1 2 3 4 
It is easy for me to stick 
to my aims and 
accomplish my goals 
1 2 3 4 
I am confident that I 
could deal with 
unexpected events 
1 2 3 4 
Thanks to my 
resourcefulness, I know 
how to handle 
unforeseen situations 
1 2 3 4 
I can solve most 
problems if I invest the 
necessary effort 
1 2 3 4 
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 Not at all 
true 
Hardly True 
Moderately 
True 
Exactly True 
I can remain calm when 
facing difficulties because 
I can rely on my coping 
abilities 
1 2 3 4 
When I am confronted 
with a problem, I can 
usually find several 
solutions 
1 2 3 4 
If I am in trouble, I can 
usually think of 
something to do 
1 2 3 4 
No matter what comes 
ŵǇ ǁaǇ, I͛ŵ usuallǇ aďle 
to handle it. 
1 2 3 4 
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 Please read each item below and then place a tick in the box next to the reply which 
comes closest to how you have been feeling in the past week. Try to give your first 
reaction. This will probably be more accurate than spending a long time thinking about 
an answer.  
1) I feel tense or wound up  2) I feel as if I am slowed down  
Most of the time [     ] Nearly all the time [      ] 
A lot of the time [     ] Very often [      ] 
Time to time, occasionally  [     ] Sometimes [      ] 
Not at all [     ] Not at all [      ] 
    
3) I still enjoy the things I used to 
enjoy 
 4) I get a sort of frightened feeling like  
 
  "butterflies" in my stomach  
Definitely as much [     ] Not at all [      ] 
Not quite so much [     ] Occasionally [      ] 
Only a little [     ] Quite often [      ] 
Hardly at all [     ] Very often [      ] 
    
5) I get a sort of frightened feeling as 
if 
 6) I have lost interest in my appearance 
 
something awful is about to happen    
Very definitely and quite badly [     ] Definitely [      ] 
Yes, but not too badly [     ] 
I don't take as much care as I 
should 
[      ] 
A little, but it doesn't worry me  [     ] 
I may not take quite as much 
care 
[      ] 
Not at all [     ] I take just as much care as ever [      ] 
    
7) I can laugh and see the funny side  
of things 
 8) I feel restless as if I have to be on the 
move  
of things    
As much as I always could  [     ] Very much indeed [      ] 
Not quite so much now [     ] Quite a lot [      ] 
Definitely not so much  [     ] Not very much [      ] 
Not at all [     ] Not at all [      ] 
    
9) Worrying thoughts go through my   10) I look forward with enjoyment to things  
mind    
A great deal of the time [     ] As much as I ever did [      ] 
A lot of the time [     ] Rather less than I used to [      ] 
From time to time but not often [ [     ] Definitely less than I used to [      ] 
Only occasionally  [     ] Hardly at all [      ] 
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11) I feel cheerful  12) I get sudden feelings of panic  
Not at all [     ] Very often indeed  
Not often [     ] Quite often [      ] 
Sometimes [     ] Not very often [      ] 
Most of the time [     ] Not at all [      ] 
 
 
 
 
[      ] 
13) I can sit at ease and feel relaxed   
14) I can enjoy a good book or TV 
programme  
Definitely [     ] Often  
Usually [     ] Sometimes [      ] 
Not often [     ] Not often [      ] 
Not at all [     ] Very seldom [      ] 
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The following statements are about methotrexate and RA. Please mark whether you think 
these statements are true or false. These questions are testing the quality of the information 
you have been given. We, therefore, ask that if you do not know the answer to a question you 
mark "don't know" rather than trying to guess the answer or looking it up. Please answer all 
of the questions. 
 
At present there is no cure for 
rheumatoid arthritis 
TRUE  
 
FALSE  
 
DON'T 
KNOW 
 
 
Methotrexate is effective at relieving 
joint stiffness 
TRUE  FALSE  DON'T 
KNOW 
 
Taking regular folate tablets (also 
known as folic acid or megafol) lessens 
the chance of getting side effects from 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Rheumatoid arthritis affects people of 
all ages 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause mouth ulcers 
TRUE  FALSE  DON'T 
KNOW 
 
It takes many years for rheumatoid 
arthritis to cause joint damage 
TRUE  FALSE  DON'T 
KNOW 
 
The low dose of methotrexate used to 
treat rheumatoid arthritis has the 
same risks and side effects as the 
higher doses used to treat other 
conditions 
TRUE  FALSE  DON'T 
KNOW 
 
Rheumatoid arthritis often goes away 
by itself 
TRUE  FALSE  DON'T 
KNOW 
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Alcohol use increases the chance of 
getting liver damage from 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
If you forget a dose of methotrexate, 
you can still take it the next day 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate tablets are white 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate is also used to treat 
cancer 
TRUE  FALSE  DON'T 
KNOW 
 
Trimethoprim (which is an antibiotic 
also known as Alprim and Triprim) can 
be safely taken while on methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Most people can safely continue taking 
methotrexate long-term 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause a rare type of 
lymphoma (tumour of the lymph 
glands) 
TRUE  FALSE  DON'T 
KNOW 
 
Rheumatoid arthritis causes joint 
inflammation  
TRUE  FALSE  DON'T 
KNOW 
 
Regular folate tablets (also known as 
folic acid or megafol) should be taken 
by everyone who is taking 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
The benefits of methotrexate should 
be noticeable within a few days of 
starting it 
TRUE  FALSE  DON'T 
KNOW 
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Methotrexate does not slow the joint 
damage caused by rheumatoid arthritis 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause serious 
problems with your breathing 
TRUE  FALSE  DON'T 
KNOW 
 
Nausea is a common side effect of 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Daily low dose aspirin (one tablet or 
less a day) should not be taken while 
on methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Treatment of rheumatoid arthritis with 
medications can prevent joint damage 
TRUE  FALSE  DON'T 
KNOW 
 
You should seek medical attention if 
you have a  cough that does not go 
away while taking methotrexate  
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause women to 
have irregular periods 
TRUE  FALSE  DON'T 
KNOW 
 
Taking regular folate tablets (also 
known as folic acid or megafol) 
improves joint pain and swelling 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate is a commonly used 
treatment for rheumatoid arthritis 
TRUE  FALSE  DON'T 
KNOW 
 
Treatment for rheumatoid arthritis is 
more effective it if is started early 
TRUE  FALSE  DON'T 
KNOW 
 
Having untreated rheumatoid arthritis 
increases your chance of having a 
heart attack 
TRUE  FALSE  DON'T 
KNOW 
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You need to continue having regular 
blood tests as long as you keep taking 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Anti-inflammatory medications (for 
example Voltaren or Celebrex) should 
not be used while taking methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
At present, joint damage caused by 
rheumatoid arthritis cannot be 
reversed 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause stomach 
ulcers 
TRUE  FALSE  DON'T 
KNOW 
 
Methoblastin is another name for 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
If you forget a dose of methotrexate, 
you should double the dose next time 
to make up for it 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate is often combined with 
other medications that treat 
rheumatoid arthritis 
TRUE  FALSE  DON'T 
KNOW 
 
You should not have the flu vaccine 
while on methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate is safe to take if you are 
breastfeeding 
TRUE  FALSE  DON'T 
KNOW 
 
Both men and women taking 
methotrexate should use reliable birth 
control (contraception) 
TRUE  FALSE  DON'T 
KNOW 
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Anti-inflammatory medications (for 
example Voltaren or Celebrex) can 
slow joint damage caused by 
rheumatoid arthritis 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate should be stopped if 
your rheumatoid arthritis flares up 
(becomes worse) 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can cause thinning of 
the hair 
TRUE  FALSE  DON'T 
KNOW 
 
All medications used to treat 
rheumatoid arthritis can cause side 
effects 
TRUE  FALSE  DON'T 
KNOW 
 
It is safe to become pregnant 3 weeks 
after methotrexate has been stopped 
TRUE  FALSE  DON'T 
KNOW 
 
You should restrict your alcohol intake 
while taking methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
You should take Methotrexate daily 
(tablets or injections) 
TRUE  FALSE  DON'T 
KNOW 
 
Scarring of the liver is a common side 
effect of methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate can reverse joint 
damage caused by rheumatoid arthritis 
TRUE  FALSE  DON'T 
KNOW 
 
You should keep taking methotrexate 
even when your joints are not painful 
TRUE  FALSE  DON'T 
KNOW 
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People who already have joint damage 
from rheumatoid arthritis will not get 
any better with methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate is effective at relieving 
joint swelling 
TRUE  FALSE  DON'T 
KNOW 
 
Treatment for newly diagnosed 
rheumatoid arthritis often includes 
methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Taking methotrexate more often than 
what was prescribed increases the 
chance of side effects 
TRUE  FALSE  DON'T 
KNOW 
 
You should not have any vaccinations 
while on methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
If you are unable to eat or drink you 
should still try to take your 
methotrexate 
 
TRUE 
  
FALSE 
  
DON'T 
KNOW 
 
Methotrexate should not be taken 
during pregnancy 
TRUE  FALSE  DON'T 
KNOW 
 
Blood tests are done to pick up side 
effects caused by methotrexate 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate treatment will be 
stopped once your  arthritis is under 
control 
TRUE  FALSE  DON'T 
KNOW 
 
Methotrexate should be stopped if you 
develop a cold 
TRUE  FALSE  DON'T 
KNOW 
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Methotrexate tablets come in two 
different strengths 
TRUE  FALSE  DON'T 
KNOW 
 
 
My treatment so far has been... 
Not 
burdensome 
   Extremely 
burdensome 
1 2 3 4 5 
Please check the response which best describes your usual abilities over the past week.   
 
 
Are you able to: 
Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With 
MUCH 
difficulty 
UNABLE to 
do 
Go up two or more flights of 
stairs 
1 2 3 4 
Walk outdoors on flat ground 1 2 3 4 
Stand up from a straight chair 1 2 3 4 
Lift heavy objects 1 2 3 4 
Move heavy objects 1 2 3 4 
Wait in line for 15 minutes 1 2 3 4 
Do outside work (such as garden 
work) 
1 2 3 4 
Get on and off the toilet 1 2 3 4 
Reach and get down a 5lb object 
from above your head 
1 2 3 4 
Open car doors 1 2 3 4 
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Please indicate how strongly you disagree or agree with the following statements by 
circling the number which best describes you now.  
 
 Strongly 
disagree 
Disagree Agree 
Strongly 
Agree 
As well as seeing my doctor, I 
regularly monitor changes in my 
health 
1 2 3 4 
I know what things can trigger 
my health problems and make 
them worse 
1 2 3 4 
I have a very good 
understanding of when and why 
I am supposed to take my 
medication 
1 2 3 4 
When I have health problems, I 
have a clear understanding of 
what I need to do to control 
them 
1 2 3 4 
I carefully watch my health and 
do what is necessary to keep as 
healthy as possible 
1 2 3 4 
With my health in mind, I have 
realistic expectations of what I 
can and cannot do 
1 2 3 4 
 
 
 
 
Appendix M 
 
564 
The following statements relate to your experiences while starting methotrexate 
treatment for your arthritis. They are about the care and information you received as 
well as your feelings and attitude to your diagnosis and treatment. Please indicate how 
strongly you disagree or agree with the following statements by circling the response 
which best describes you. Answer each of these questions based on your feelings 
about Methotrexate, your arthritis and the care and information you received when 
starting methotrexate treatment. 
 
 Disagree 
strongly 
Disagree 
Disagree 
Slightly 
Agree 
Slightly 
Agree 
Agree 
Strongly 
I am confident in 
my ability to 
communicate 
with my doctors 
1 2 3 4 5 6 
I am able to 
have good 
discussions with 
my doctors 
about my 
treatment 
1 2 3 4 5 6 
Overall I feel 
that I am able to 
ask my doctors 
questions 
1 2 3 4 5 6 
I feel 
comfortable 
about asking my 
doctors for more 
information 
1 2 3 4 5 6 
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 Disagree 
strongly 
Disagree 
Disagree 
Slightly 
Agree 
Slightly 
Agree 
Agree 
Strongly 
I feel that I am 
able to make an 
educated 
decision about 
taking this 
medication 
1 2 3 4 5 6 
I feel I have 
enough 
knowledge to 
choose between 
treatment 
options 
1 2 3 4 5 6 
I understand the 
risks of taking 
this medication 
1 2 3 4 5 6 
I am able to 
assess how well 
I am responding 
to treatment 
1 2 3 4 5 6 
I am confident 
that I can 
recognise side 
effects caused 
by my 
medication 
1 2 3 4 5 6 
 
Appendix M 
 
566 
 Disagree 
strongly 
Disagree 
Disagree 
Slightly 
Agree 
Slightly 
Agree 
Agree 
Strongly 
I know what I 
need to do to 
improve my 
condition 
1 2 3 4 5 6 
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INSTRUCTIONS: This questionnaire asks for your views about your health. Please 
answer every question by circling the relevant answer. If you are unsure how to 
answer please give the best answer you can. 
 
1. In general, would you say your health is:  
 
1 2 3 4 5 
Excellent Very good Good Fair Poor 
 
The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so how much? 
 
2a. Moderate 
activities such as 
moving a table, 
pushing a vacuum 
cleaner, bowling or 
playing golf. 
Yes, limited a lot Yes, limited a little 
No, not limited at 
all 
2b. Climbing several 
flights of stairs 
Yes, limited a lot Yes, limited a little No, not limited at 
all 
 
During the past 4 weeks have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 
  
3a. Accomplished less than you would 
like? 
Yes No 
3b. Were limited in the kind of work or 
activities? 
Yes No 
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During the past 4 weeks have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 
4a. Accomplished less than you would like Yes No 
4b. Didn't do work or other activities as 
carefully as usual  
Yes No 
 
5. During the past 4 weeks how much did pain interfere with your normal work 
(including work both outside the home and housework)? 
 
1 2 3 4 5 
Not at all A little bit Moderately Quite a bit Extremely 
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please indicate the one answer that comes closest to 
the way you have been feeling.  
 
6a. Have you felt calm and peaceful? 
1 2 3 4 5 6 
All the time Most of the 
time 
A good bit 
of the time 
Some of the 
time 
A little of 
the time 
None of the 
time 
 
6b. Did you have a lot of energy? 
1 2 3 4 5 6 
All the time Most of the 
time 
A good bit 
of the time 
Some of the 
time 
A little of 
the time 
None of the 
time 
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6c. Have you felt downhearted and blue? 
1 2 3 4 5 6 
All the time Most of the 
time 
A good bit 
of the time 
Some of the 
time 
A little of 
the time 
None of the 
time 
 
7. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)?  
 
1 2 3 4 5 
All the time Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
 
 
 
 
 
 
 
 
 
Thank you very much for completing this questionnaire. Please return the 
questionnaire to the researcher.  
 
By taking part in this research you have contributed to a study that we anticipate will 
benefit many people.  
 
If, at any point you wish to talk to someone regarding this project please do not 
hesitate to call Hayley James the Researcher in Health Services Research at City 
University, Tel (0207) 040 0870 or e-mail hayley.james.1@city.ac.uk 
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APPENDIX N. INTERVENTION MATERIALS - TRAINING SLIDES 
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APPENDIX O. CRITERIA FOR PATIENT ACTION 
CRITERIA FOR PATIENT ACTION 
 
The following criteria will help you decide if your blood test results or symptoms and 
side effects you are experiencing require further attention from your Clinical Nurse 
Specialist. 
Blood Results 
When completing the questionnaire if either of the following occurs, this would 
require further attention from your Clinical Nurse Specialist. 
 
1. A blood test result is out of the normal range 
or 
2. A blood test result changes significantly from the previous test 
 
Test Normal range Significant Change Defined As. 
Haemoglobin 12.0 – 17.0 Fall of more than 1.0 
White Blood Cell Count 3.0 - 10.0 A fall of more than 2 
Neutrophils 2.0 – 7.5 Two readings in a row each with a fall of 
more than 1.0 
Platelets 150 - 400 Two readings in a row with falls of more 
than 50 
ALP 35 - 104 A result which doubles from the 
previous blood test or rises 208 
ALT 10 - 35 A results which doubles from the 
previous blood test or rises above 70 
ESR 0 – 20 A rise of more than 20 from the previous 
blood test results 
CRP 0 - 5 A rise of more than 20 from the previous 
blood test results 
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Symptoms & Side Effects 
When completing the questionnaire if either of the following occurs, this would 
require further attention from your Clinical Nurse Specialist. 
 
1. The appearance of any new symptom or side effect since your last blood test 
or 
2. A symptom or side effect you have been experiencing has significantly 
worsened since your last blood test 
 
In between blood tests: 
Symptom or Side Effect What action to take 
Nausea No contact necessary 
Vomiting Contact Nurse – if persists over 24 hours  
Diarrhoea Contact Nurse – if persists over 48 hours 
Mouth Ulcers Contact Nurse – if symptoms, causing discomfort and 
interference with normal eating 
Skin problems Contact –Nurse – if unexplained rash or itching occurs 
Bruising Contact Nurse – if unexplained bruising occurs 
Bleeding Contact Nurse – if frequent nose bleeds or excessive 
bleeding following minor injury 
Sore Throat Contact Nurse – if episodes requiring treatment occur 
within a 4 week period 
Fever Contact Nurse – if fever persist for over 24 hours 
Breathlessness Contact Nurse – if breathlessness occurs in the 
absence of physical exertion 
Dry Cough Contact Nurse 
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Chicken pox/shingles Contact Nurse – if been exposed to the chicken pox 
or shingles virus 
Pregnancy Contact Nurse – if pregnancy is suspected 
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APPENDIX P. CONTACT DETAILS FOR THE RESEARCH TEAM 
Contact details 
 
 
Ms. Hayley James    Telephone number: 
Researcher     Email:   
 
Ms. Abigail Olaleye     Telephone number: 
Rheumatology Nurse Specialist  Email: 
 
Ms. Sam Moore             Telephone number: 
Rheumatology Nurse Specialist  Email: 
 
Ms. Nicola Daly    Telephone number: 
Rheumatology Nurse Specialist  Email: 
 
Dr. Mike Shipley                            Telephone number:  
Consultant Rheumatologist   Email: 
 
 
IF YOU CONTACT ANY OF THE ABOVE PEOPLE VIA EMAIL PLEASE PUT ͚SELF-
MONITORING INTERVENTION – U‘GENT͛ IN THE SUBJECT HEADING 
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APPENDIX Q. BLOOD RECORD SHEET FORM 
 
PERSONAL BLOOD RESULTS SHEET 
When you receive your blood test letter enter your blood results in the table below. Please compare these with YOUR acceptable baseline range. 
This will help you decide whether your results fall within your normal range and will then help you make a decision about whether you require an 
out-patient appointment.  
 Date:  
 
Date: 
 
Blood Test 1 
Date:  
Blood Test 2 
Date: 
Blood Test 3 
Date: 
Blood Test 4 
Date: 
Blood Test 5 
Date: 
Blood Test 6 
Date: 
Haemoglobin         
White Blood Cell Count          
Neutrophils         
Platelets         
ALP         
ALT         
ESR         
CRP         
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APPENDIX R. PRACTICE DOCUMENTS 
PRACTICE NUMBER 1 
 Last ŵoŶth’s 
blood test 
results 
This ŵoŶth͛s 
blood test results 
Difference 
between the 
two results 
Are these results 
outside of the normal 
range? 
Has there been a 
significant 
change? 
Do I need further 
advice? 
Haemoglobin 11.3 10.0     
White Blood Cell Count 6.4 4.8     
Neutrophils 4.6 4.3     
Platelets 220 305     
ALP 88 95     
ALT 30 35     
ESR 25 53     
CRP 12 12     
Instructions:  
1. Calculate the change in blood test results between this month and last month  
2. Using the Criteria for Patient Action sheet are the results within the normal range, has there been a significant change in the results 
On the basis of these blood results do you need to speak with the Rheumatology Nurse Specialist?  
Yes                             No 
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PRACTICE NUMBER 2 
 Last ŵoŶth’s 
blood test 
results 
This ŵoŶth͛s 
blood test results 
Difference 
between the 
two results 
Are these results 
outside of the normal 
range? 
Has there been a 
significant 
change? 
Do I need further 
advice? 
Haemoglobin 10.4 10.8     
White Blood Cell Count 7.3 8.2     
Neutrophils 4.2 4.2     
Platelets 235 260     
ALP 65 220     
ALT 39 126     
ESR 19 22     
CRP 4.0 5.0     
 
Instructions:  
1. Calculate the change in blood test results between this month and last month  
2. Using the Criteria for Patient Action sheet are the results within the normal range, has there been a significant change in the results 
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PRACTICE NUMBER 3 
 Last ŵoŶth’s 
blood test 
results 
This ŵoŶth͛s 
blood test results 
Difference 
between the 
two results 
Are these results 
outside of the normal 
range? 
Has there been a 
significant 
change? 
Do I need further 
advice? 
Haemoglobin 12.0 12.5     
White Blood Cell Count 7.6 8.0     
Neutrophils 5.9 6.1     
Platelets 355 320     
ALP 50 43     
ALT 40 32     
ESR 12 15     
CRP 2.0 2.3     
 
Instructions:  
1. Calculate the change in blood test results between this month and last month  
2. Using the Criteria for Patient Action sheet are the results within the normal range, has there been a significant change in the results 
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PRACTICE NUMBER 4 
 
 
Last ŵoŶth’s 
blood test 
results 
This ŵoŶth͛s 
blood test results 
Difference 
between the 
two results 
Are these results 
outside of the normal 
range? 
Has there been a 
significant 
change? 
Do I need further 
advice? 
Haemoglobin 11.0 10.2     
White Blood Cell Count 7.0 8.1     
Neutrophils 4.2 4.5     
Platelets 235 460     
ALP 65 70     
ALT 39 52     
ESR 19 55     
CRP 4.0 25     
 
Instructions:  
1. Calculate the change in blood test results between this month and last month  
2. Using the Criteria for Patient Action sheet are the results within the normal range, has there been a significant change in the results 
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APPENDIX S. SAMPLE BLOOD TEST RESULTS 
 
 
31st January 2nd April  Difference 
between the 
two results 
Are these results 
outside of the 
normal range? 
Has there been a 
significant 
change? 
Do I need 
further 
advice? 
Haemoglobin 15.7 14.2 
    
White Blood Cell Count 6.34 6.20 
    
Neutrophil 2.90 3.19 
    
Platelets 275 265 
 
  
 
ALP 62 54 
    
ALT 31 48 
    
ESR 31 4 
    
CRP 5.7 6.3 
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Instructions:  
1. Calculate the change in blood test results between this month and last month  
2. Using the Criteria for Patient Action sheet are the results within the normal range and has there been a significant change in the results 
3. Complete the questionnaire overleaf
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On the basis of these blood results do you need to speak with the Rheumatology Nurse Specialist?  
 
 
                                        Yes                             No 
        
 
Please tick whether you have experienced any of these symptoms or side effects since you last blood test.  
 
If you have please indicate whether this is a new symptom or side effect. If it is something you have experienced before please indicate whether it 
has got worse, better or remained the same. 
 
Symptom (side effect) 
Yes No New  Worse Better Same 
Morning stiffness       
Pain       
Fatigue       
  
5
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Symptom (side effect) 
Yes No New  Worse Better Same 
Nausea       
Vomiting        
Diarrhoea       
Mouth Ulcers       
Skin problems       
Bruising       
Joint swelling       
Bleeding        
Sore throat        
Fever        
  
5
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Symptom (side effect) 
Yes No New  Worse Better Same 
Breathlessness       
Dry cough       
Hair loss       
Chicken pox/shingles       
  
5
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On the basis of these symptoms do you need to speak with the Rheumatology Nurse Specialist? 
 
                                        Yes                             No 
      
Are there any other reasons why you think you may need to speak with the Rheumatology Nurse Specialist? 
Yes                             No 
If yes, please give brief details:  
 
 
Have you seen your GP regarding your arthritis or its treatment since your last blood test?  
    Yes   No 
If yes, how many times and please give reasons why: 
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Please contact the Researcher or your Clinical Nurse Specialist if any of the following has happened;   Any of your blood test results are out of range  Any of your blood test results have significantly changed since your last blood test  You have experienced a new symptom or side effect since your last blood test  A symptom or side effect you have experience before has become worse since your last blood test 
 
If none of the above has happened there is no need to contact us, unless there is something else that you need to discuss.  
 
 
 598 
Appendix T 
 
599 
APPENDIX T. MISSING DATA 
Variable 
% of 
missing 
data 
 
Variable 
% of 
missing 
data 
T3 DAS28 48.44  BT4 ALT 10.00 
T3 PsARC physician 43.48  BT4 CRP 10.00 
T3 PsARC patient 43.48  BT6 Hb 9.20 
T3 PsARC tender 39.13  BT6 Neutrophils 9.20 
T3 PsARC swollen 39.13  BT6 Platelets 9.20 
T1 MCS final 30.00  BT6 ESR 9.20 
T1 PCS final 30.00  BT5 Hb 8.99 
BT7 Hb 20.00  BT5 Neutrophils 8.99 
BT7 Neutrophils 20.00  BT5 Platelets 8.99 
BT7 Platelets 20.00  BT5 CRP 8.99 
T1 PsARC patient 17.24  BT4 ESR 8.89 
T1 DAS28 16.90  T3 Knowledge Total 8.86 
BT3 ESR 14.58  BT3 ALT 8.33 
T3 MCS final 13.92  BT3 CRP 8.33 
T3 PCS final 13.92  BT2 ALP 8.16 
T1 PsARC physician 13.79  BT2 ALT 8.16 
T1 PsARC swollen 13.79  BT2 ESR 8.16 
T1 PsARC tender 13.79  BT6 WCC 8.05 
T1 Knowledge Total 12.00  BT5 ALP 7.87 
BT1 ESR 12.00  BT5 ESR 7.87 
T2 Knowledge Total 11.90  BT4 ALP 7.78 
T2 MCS final 10.71  BT3 Hb 7.29 
T2 PCS final 10.71  BT3 WCC 7.29 
BT2 CRP 10.20  BT3 Neutrophils 7.29 
BT5 ALT 10.11  BT3 Platelets 7.29 
BT1 ALT 10.00  BT3 ALP 7.29 
T2 IPQ PC 7.14  BT4 Platelets 5.56 
BT1 CRP 7.14  T3 HAQ Total 5.06 
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Variable 
% of 
missing 
data 
 
Variable 
% of 
missing 
data 
BT2 Hb 7.14  Years on MTX 5.00 
BT2 WCC 7.14  T1 IPQ C 5.00 
BT2 Neutrophils 7.14  T2 IPQ TC v2 4.76 
BT2 Platelets 7.14  T2 IPQ IC 4.76 
BT1 Hb 7.00  T2 HADS anxiety 4.76 
BT1 WCC 7.00  T2 HAQ Total 4.76 
BT1 Neutrophils 7.00  T3 Fatigue 3.80 
BT1 Platelets 7.00  T3 Pain 3.80 
BT1 ALP 7.00  T2 Burden 3.57 
BT6 ALP 6.90  T2 IPQ C 3.57 
BT6 ALT 6.90  Disease duration 3.00 
BT6 CRP 6.90  T1 IPQ IC 3.00 
BT5 WCC 6.74  T1 SE Total 3.00 
T1 IPQ PC 6.00  T3 Burden 2.53 
T1 HAQ Total 6.00  T3 IPQ C 2.53 
PreBT Hb 6.00  T2 Fatigue 2.38 
PreBT WCC 6.00  T2 Pain 2.38 
PreBT Neutrophils 6.00  T2 BMQ Concern v2 2.38 
PreBT Platelets 6.00  T2 SE Total 2.38 
PreBT ALP 6.00  T1 Fatigue 2.00 
PreBT ALT 6.00  T1 Pain 2.00 
PreBT ESR 6.00  T1 IPQ TC V2 2.00 
PreBT CRP 6.00  T1 BMQ Necessity 2.00 
BT4 Hb 5.56  T1 HADS depression 2.00 
BT4 WCC 5.56  T3 IPQ IC 1.27 
BT4 Neutrophils 5.56  T3 BMQ Concern v2 1.27 
T3 BMQ Necessity 1.27  Cimzia 0.00 
T3 SE Total 1.27  Topical preparations 0.00 
T2 BMQ Necessity 1.19  Amitriptyline 0.00 
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Variable 
% of 
missing 
data 
 
Variable 
% of 
missing 
data 
T2 HADS depression  1.19  Chondroitin 0.00 
T2 SM 1.19  Steroids 0.00 
T2 SMA 1.19  Raloxifene 0.00 
T1 Burden 1.00  Codeine phosphate 0.00 
T1 BMQ Concern v2 1.00  Maxepa 0.00 
T1 HADS anxiety 1.00  Ranitidine 0.00 
T1 SM 1.00  Fosamax 0.00 
No. of comorbidities 0.00  Homeopathic remedy 0.00 
Total no. of drugs 0.00  Salazopyrin 0.00 
MTX dose 0.00  Chondroitin 0.00 
Age 0.00  Piroxicam 0.00 
T1 IPQ I 0.00  Meloxicam 0.00 
T1 AC 0.00  Tramadol 0.00 
T1 SMA 0.00  Strontium ranelate 0.00 
Retinitis pigmentosa 0.00  Aspirin 0.00 
Ulcerative colitis 0.00  Etanercept 0.00 
Epilepsy 0.00  Hydroxychloroquine 0.00 
Respiratory 0.00  Vitamin supplements 0.00 
Hypertension 0.00  Finasteride 0.00 
Hyperthyroidism 0.00  Humira 0.00 
Hypercholesterolemia 0.00  Ferrous sulphate 0.00 
Diabetes 0.00  Cocodamol 0.00 
Osteoporosis 0.00  Adcal 0.00 
Mental health 0.00  Bendroflumethiazide 0.00 
Bisphosphonate 0.00  Levothyroxine 0.00 
Fish oils 0.00  Simivastin 0.00 
Omeprazole 0.00  Gliclazide 0.00 
Enbrel 0.00  Glyceryl trinitrate 0.00 
Diclofenac 0.00  Diprobase cream 0.00 
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Variable 
% of 
missing 
data 
 
Variable 
% of 
missing 
data 
Folic acid 0.00  Perindopril 0.00 
Paracetamol 0.00  Atorvastatin 0.00 
Gabapentin 0.00  Acrivastine 0.00 
Adalimumab 0.00  Bisoprolol 0.00 
Sulphasalazine 0.00  Montelukast 0.00 
Prednisolone 0.00  Desloratadine 0.00 
Naproxen 0.00  Leveitiarcetam 0.00 
Ibuprofen 0.00  Chlorphenamine 0.00 
Calcium 0.00  Nebrivlol 0.00 
Pamidronate 0.00  Risperidone 0.00 
Arthrotec 0.00  Aripiprazole 0.00 
Glucosamine 0.00  Carbimazole 0.00 
Alendronic acid 0.00  Citalopram 0.00 
Lansoprazole 0.00  Felodipine 0.00 
Codydramol 0.00  Inhalers 0.00 
Amlodipine 0.00  Diagnosis 0.00 
Ramipril 0.00  Gender 0.00 
Metformin 0.00  Living status 0.00 
Atenolol 0.00  Ethnicity 0.00 
Fosinopril 0.00  T2 IPQ I 0.00 
Warfarin 0.00  T2 AC 0.00 
HRT 0.00  T3 IPQ I 0.00 
T3 IPQ PC 0.00  T3 HADS anxiety 0.00 
T3 IPQ TC v2 0.00  T3 HADS depression 0.00 
T3 SM 0.00  BT8 Hb 0.00 
T3 AC 0.00  BT8 WCC 0.00 
T3 SMA 0.00  BT8 Neutrophils 0.00 
BT7 WCC 0.00  BT8 Platelets 0.00 
BT7 ALP 0.00  BT8 ALP 0.00 
Appendix T 
 
603 
Variable 
% of 
missing 
data 
 
Variable 
% of 
missing 
data 
BT7 ALT 0.00  BT8 ALT 0.00 
BT7 ESR 0.00  BT8 ESR 0.00 
BT7 CRP 0.00  BT8 CRP 0.00 
 Total % of missing data 3.65%    
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APPENDIX U. DIFFERENCES BETWEEN COMPLETE CASES AND NON-COMPLETE CASES 
Variable Completed 
n=79 
Non-completed 
n=21 
Statistic 
No. of years on MTX, median(range) 4(1-20) 3.70(1-20)  U=753.50, z=-0.65, p=0.52, r=-0.06  
Total no. of medications, median(range) 4(1-11) 5(2-8) U=811.50, z=-0.15, p=0.88, r=-0.02   
Dose of MTX, median(range) 15(5-25) 15(7.5-20) U=747.00, z=-0.71, p=0.48, r=-0.07  
DAS28, mean(SD) 3.41(1.36) 3.13(1.01) t(69)=0.75, p=0.53, =0.01 
PsARC physician global assessment, median(range) 2(0.82-3.20) 2.16(1-3.51) U=59.50, z=-0.55, p=0.62, r=-0.05   
PsARC patient global assessment, median(range) 1.41(0.92-3) 1.95(1.01-3.06) U=43.70, z=-1.43, p=0.23, r=-0.14   
PsARC swollen joint count, median(range) 1.48(0-9.25) 3.89(0-13) U=44.00, z=-1.36, p=0.21, r=-0.14   
PsARC tender joint count, mean(SD) 8.52(7.33) 10.90(6.11) t(27)= -0.71, p=0.54, =0.01 
Age, mean(SD) 58.30(12.11) 50.71(8.46) t(27)= 2.70, p=0.01, =0.07 
Disease duration in years, median(range) 8.50(1-54) 4(1-35) U=621.40, z=-1.77, p=0.08, r=-0.18   
Fatigue, mean(SD) 4.11(2.63) 4.86(2.77) t(98)=-1.14, p=0.26, =0.01 
Pain, median(range) 3(0-9) 3.50(0-8)   U=759.10, z=-0.60, p=0.55, r=-0.06  
Treatment burden, median(range) 2(1-5) 2(1-4)  U=764.40, z=-0.58, p=0.57, r=-0.06  
IPQ Illness identity, mean(SD) 5.11(2.10) 5.48(3.01) t(98)=25.40, p=060, <0.001 
IPQ Consequences, mean(SD) 20.04(4.73) 19.24(4.44) t(98)=0.70, p=0.48, <0.001 
IPQ Personal control, mean(SD) 20.96(4.36) 20.46(3.68) t(98)=0.49, p=0.63, <0.001 
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Variable Completed 
n=79 
Non-completed 
n=21 
Statistic 
IPQ Treatment control, mean(SD) 16.01(2.11) 15.10(2.49) t(98)=11.69, p=0.09, =0.03 
IPQ Illness Coherence, mean(SD) 18.64(4.28) 19.05(4.70) t(98)=-0.38, p=0.71, <0.001 
BMQ Specific concern, mean(SD) 11.92(2.78) 13.85(2.90) t(98)=-2.80, p=0.01, =0.07 
BMQ Specific necessity, mean(SD) 16.71(3.08) 16.41(2.41) t(98)=0.41, p=0.68, <0.001 
Generalised self-efficacy, mean(SD) 31.41(3.66) 33.28(3.94) t(98)=-2.05, p=0.04, =0.04 
Anxiety, median(range) 5(0-17) 6(2-15) U=783.20, z=-0.39, p=0.69, r=-0.04  
Depression, median(range) 3(0-12) 4.50(0-11)  U=751.85, z=-0.66, p=0.51, r=-0.07   
Knowledge, mean(SD) 18.01(4.83) 18.74(4.46) t(98)=-0.63, p=0.53, <0.001 
Functional disability, median(range) 0.49(0-2.20) 0.23(0-1.91) U=698.35, z=-1.12, p=0.29, r=-0.11   
HeiQ Self-monitoring & insight, mean(SD) 3.09(0.42) 3.00(0.41) t(98)=0.89, p=0.39, =0.01 
MeiQ Active Communication, median(range) 5(1-6) 5.5(2.75-6)   U=784.00, z=-0.40, p=0.69, r=-0.04 
MeiQ Self-management ability, median(range) 4.83(2.50-6) 4.83(3.33-6)  U=744.50, z=-0.72, p=0.47, r=-0.07   
SF-12v1® MCS, mean(SD) 30.78(5.68) 30.49(4.97) t(98)=0.21, p=0.83, <0.001 
SF-12v1® PCS, mean(SD) 45.95(9.64) 46.10(8.52) t(98)=-0.07, p=0.95, <0.001 
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APPENDIX V. CRONBACH'S ALPHAS 
Variable Number of 
items 
Baseline First f/u Final f/u 
Functional disability 10 0.92 0.92 0.92 
Anxiety 7 0.85 0.83 0.86 
Depression 7 0.80 0.80 0.77 
Generalised self-efficacy 10 0.87 0.94 0.93 
HeiQ™ Self-monitoring & insight 6 0.78 0.79 0.80 
MeiQ™ Active Communication 4 0.93 0.89 0.95 
MeiQ™ Self-management ability 6 0.87 0.85 0.85 
IPQ Consequences 6 0.84 0.85 0.86 
IPQ Illness Coherence 5 0.92 0.90 0.92 
IPQ Personal control 6 0.86 0.82 0.86 
IPQ Treatment Control 5 0.48 0.57 0.54 
BMQ Specific Necessity 5 0.76 0.85 0.75 
BMQ Specific Concern 5 0.63 0.68 0.7 
Knowledge 60 0.72 0.80 0.76 
f/u – follow-up 
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APPENDIX W. CHANGES OVER TIME ON CLINICAL, PSYCHOSOCIAL OUTCOME AND PROCESS VARIABLES IN COMPLETE CASES ONLY 
Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
Fatigue Intervention 4.20(2.98) 4.56(2.99) 4.37(3.00) F1,76.28 = 0.19, p=0.67 F2,102.22 = 0.87, p=0.42 F2,102.22 = 0.52, p=0.60 
Control 3.94(3.08) 4.11(3.08) 4.37(3.10) 
Pain Intervention 3.65(2.68) 3.57(2.71) 3.69(2.68) F1,77.34 < 0.001, p=0.98 F2,147.62 = 0.44, p=0.64 F2,147.62 = 0.54, p=0.59 
Control 3.36(2.76) 3.86(2.76) 3.72(2.81) 
Functional disability Intervention 0.64(0.68) 0.60(0.68) 0.60(0.68) F1,75.06 = 0.21, p=0.65 F2,98.23 = 0.08, p=0.92 F2,98.23 = 1.32, p=0.27 
Control 0.64(0.69) 0.70(0.69) 0.68(0.69) 
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Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
SF-12v1® MCS Intervention 30.51(8.30) 29.35(8.14) 31.03(8.19) F1,73.40 = 0.08, p=0.78 F2,74.65 = 0.77, p=0.47 F2,74.65 = 1.33, p=0.27 
Control 30.37(9.42) 29.92(8.25) 29.39(8.60) 
SF-12v1® PCS Intervention 46.26(12.69) 45.92(12.56) 44.75(12.57) F1,74.89 = 0.09, p=0.76 F2,87.40 = 0.07, p=0.93 F2,87.40 = 0.78, p=0.46 
Control 44.68(14.10) 44.69(12.78) 45.45(13.21) 
Anxiety Intervention 5.50(4.71) 5.64(4.72) 4.86(4.70) F1,76.06 = 1.97, p=0.17 F2,100.11= 0.87, p=0.42 F2,100.11 = 1.74, p=0.18 
Control 6.42(4.87) 6.64(4.87) 6.75(4.87) 
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Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
Depression Intervention 4.76(3.64) 4.56(3.64) 4.26(3.63) F1,76.03 = 0.64, 
p=0.43 
F2,120.33 = 0.11, 
p=0.90 
F2,120.33 = 1.23, 
p=0.30 
Control 3.81(3.76) 4.03(3.76) 4.11(3.76) 
Generalised self-efficacy Intervention 31.50(5.12
) 
31.45(5.17
) 
32.26(5.12
) 
F1,73.77 = 1.13, 
p=0.29 
F2,125.68= 0.22, 
p=0.81 
F2,125.68 = 1.76, 
p=0.18 
Control 30.89(5.34
) 
30.81(5.32
) 
30.46(5.34
) 
HeiQ™ self-monitoring & insight Intervention 3.00(0.46) 3.07(0.46) 3.10(0.46) F176.54 = 2.70, 
p=0.11 
F2,104.48 = 0.65, 
p=0.52 
F2,104.48 = 1.98, 
p=0.14 
Control 3.21(0.47) 3.22(0.47) 3.14(0.47) 
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Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
MeiQ™ aĐtiǀe 
communication 
Intervention 5.26(0.75) 5.21(0.71) 5.14(0.91) F1,75.03 = 0.14, 
p=0.72 
F2,105.36 = 0.20, 
p=0.82 
F2,105.36 = 1.84, 
p=0.16 
Control 5.02(1.03) 5.14(0.79) 5.13(0.91) 
MeiQ™ self-
management ability 
Intervention 4.68(0.85) 4.80(0.85) 4.81(0.85) F1,76.00 = 0.09, 
p=0.77 
F2,117.97 = 0.76, 
p=0.47 
F2,117.97 = 0.69, 
p=0.51 
Control 4.81(0.89) 4.79(0.89) 4.84(0.89) 
IPQ-R Identity Intervention 5.02(2.55) 4.48(2.55) 4.14(2.55) F1,75.91 = 2.87, 
p=0.09 
F2,129.01= 1.22, 
p=0.30 
F2,129.01 = 2.24, 
p=0.11 
Control 5.25(2.65) 5.17(2.65) 5.42(2.65) 
IPQ-R Consequences Intervention 19.76(5.70) 18.90(5.70) 18.81(5.69) F1,75.91 = 0.86, 
p=0.36 
F2,105.86 = 4.04, 
p=0.02 
F2,105.86= 0.08, 
p=0.92 
Control 20.72(5.99) 20.07(5.99) 19.74(5.95) 
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Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
IPQ-R Personal Control Intervention 20.54(4.86) 21.23(4.85) 21.21(4.84) F1,76.38 = 1.00, 
p=0.32 
F2,101.92 = 1.89, 
p=0.16 
F2,101.92 = 0.01, 
p=0.99 
Control 21.50(5.08) 22.08(5.12) 22.11(5.02) 
IPQ-R Treatment Control Intervention 15.67 (2.46) 15.57(2.43) 16.02(2.04) F1,77.02 = 0.22, 
p=0.64 
F2,102.24 = 0.90, 
p=0.41 
F2,102.24 = 2.01, 
p=0.14 
Control 16.36(2.51) 15.82(2.55) 15.64(2.51) 
IPQ-R Illness Coherence Intervention 18.42(4.62) 19.60(4.63) 19.45(4.57) F1,76.20 = 0.58, 
p=0.45 
F2,98.68 = 3.42, 
p=0.04 
F2,98.68 = 2.33, 
p=0.10 
Control 18.69(4.77) 19.09(4.76) 17.83(4.77) 
BMQ Concern Intervention 11.67(3.32) 11.64(3.32) 11.12(3.32) F1,77.74 = 1.35, 
p=0.25 
F2,95.47 = 1.12, 
p=0.33 
F2,95.47 = 0.17, 
p=0.84 
Control 12.31(3.44) 12.20(3.48) 11.99(3.47) 
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Variable  Trial arm Baseline 
Mean(SD) 
First f/u 
Mean(SD) 
Final f/u 
Mean(SD) 
Group Time Time*Group  
BMQ Necessity Intervention 16.21(3.39) 16.60(3.39) 16.69(3.39) F1,77.27 = 0.95, 
p=0.33 
F2,96.71 = 0.48, 
p=0.62 
F2,96.71 = 1.10, 
p=0.34 
Control 17.25(3.52) 17.27(3.54) 16.74(3.54) 
Treatment burden Intervention 2.19(1.12) 1.92(1.14) 2.05(1.12) F1,74.93 = 0.30, 
p=0.59 
F2,128.85 = 1.58, 
p=0.21 
F2,128.85 = 0.68, 
p=0.51 
Control 2.00(1.16) 1.94(1.16) 1.89(1.17) 
Knowledge about 
methotrexate 
Intervention 18.58(5.90) 19.89(5.87) 20.43(5.88) F1,7510 = 2.54, 
p=0.12 
F2,84.55 = 4.63, 
p=0.01 
F2,84.55 = 0.90, 
p=0.41 
Control 17.45(6.33) 17.70(6.30) 18.39(6.29) 
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APPENDIX X. GRAPHICAL REPRESENTATION OF CHANGES OVER TIME (WITH 99% CI) ON CLINICAL VARIABLES (N=100) 
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APPENDIX Y. GRAPHICAL REPRESENTATION OF CHANGES OVER TIME (WITH 99% CI) ON THE PSYCHOSOCIAL OUTCOME VARIABLES (N=100) 
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APPENDIX Z. GRAPHICAL REPRESENTATION OF CHANGES OVER TIME (WITH 99% CI) ON THE PSYCHOSOCIAL PROCESS VARIABLES (N=100) 
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Appendix AA 
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APPENDIX AA. QUALITATIVE CONSENT FORM 
UCLH Project ID number 09/H0722/91    
Patient Identification Number for this study:     
 CONFIDENTIAL  
CONSENT FORM (INTERVIEW STUDY) 
Title of Project:  Self-monitoring of treatment with methotrexate alone or in 
combination with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis. 
 
Name of Principal Investigator: Professor Stanton Newman 
    Please initial box 
1. I confirm that I have read and understand the information sheet 
dated 08.10.10 (version 3) for the above study and have had the 
opportunity to ask questions 
 
   
2.  I confirm that I have had sufficient time to consider whether or not I 
want to be included in the study  
 
   
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
   
4. I agree to take part in the above study.  
   
5. I understand that all the information I provide will be treated as 
confidential    
 
   
6. I understand that the interview will be tape recorded                  
   
7. I understand that at the end of the study, the tape recording will be          
destroyed but an anonymous written copy of my interview will be kept 
for research purposes and potentially for teaching.     
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CONSENT FORM 
 
Title of Project:  Self-monitoring of treatment with methotrexate alone or in 
combination with a self-injecting anti-tumour necrosis factor agent by patients with 
arthritis 
 
Name of Principal Investigator: Professor Stanton Newman 
 
 
 
__________________________ _________________ _______________________ 
Name of patient   Date         Signature 
 
 
 
__________________________ _________________ _______________________ 
Name of Person taking consent Date      Signature 
(if different from researcher) 
 
 
 
__________________________ _________________ _______________________ 
Researcher (to be contacted   Date      Signature 
if there are any problems)  
         
Comments or concerns during the study  
If you have any comments or concerns you may discuss these with the 
investigator. If you wish to go further and complain about any aspect of the 
way you have been approached or treated during the course of the study, you 
should write or get in touch with the Complaints Manager, UCL hospitals. 
Please quote the UCLH project number at the top this consent form. 
 
  
 
